Gliomen
Deze richtlijn is tot stand gekomen op initiatief van Nederlandse Vereniging voor Neurologie
 
© 2012 - 2025
 
Richtlijnendatabase is een product ondersteund door het 
Kennisinstituut van de Federatie van Medisch Specialisten
1
2
4
6
10
29
48
59
67
86
94
113
134
153
183
206
225
238
258
277
296
321
342
364
383
405
426
448Inhoudsopgave
Gliomen
Inhoudsopgave
Startpagina - Gliomen
Epidemiologie
Diagnostiek bij Gliomen
Beeldvormende diagnostiek bij Gliomen
Beeldvorming ter nadere differentiatie
Beeldvorming ten behoeve van chirurgie/radiotherapie
Neuropathologie bij Gliomen
Typering/gradering diffuse gliomen
Behandeling Laaggradig glioom
Klinisch prognostische factoren laaggradig glioom
Neurochirurgie bij laaggradig glioom
Resectie versus watchful waiting bij laaggradig glioom
Minimale mate van resectie bij laaggradig glioom
Radio-/chemotherapie bij laaggradig glioom
Behandeling bij nieuw gediagnosticeerd laaggradig glioom
Recidief laaggradig glioom
Behandeling Hooggradig glioom
Neurochirurgie bij hooggradig glioom
Chirurgische behandelingsstrategie hooggradig glioom
Minimale mate van resectie hooggradig glioom
Waarde en mate van re-resectie glioblastoom
Radiotherapie bij hooggradig glioom
Indicatie radiotherapie anaplastisch glioom
Indicatie radiotherapie glioblastoom
Radiotherapie bij progressie hooggradig glioom/recidief
Chemotherapie/systeemtherapie bij hooggradig glioom
467
488
508
530
554
577
583
596
617
636
655
676
695
715
735
756
775
804
828
849
869
888
912
932
952
Chemotherapie nieuw gediagnostiseerd anaplastisch glioom
Chemotherapie recidief anaplastisch glioom
Chemotherapie nieuw gediagnostiseerd glioblastoom
Chemotherapie recidief glioblastoom
Behandeling van ouderen bij glioblastoom
Indicatie geriatrisch assessment
Behandeling ouderen/kwetsbaren
Behandeling Gliomatosis cerebri
Behandeling Recidief gliomen
Medicamenteuze symptoombestrijding bij gliomen
Corticosteroïden bij gliomen
Anti-epileptica bij gliomen
Rol van anti-epileptica bij de behandeling van gliomen
Invloed van anti-epileptica op de behandeling van gliomen
Medicatie in de terminale fase bij gliomen
Cognitie, revalidatie en begeleiding bij gliomen
Revalidatie en begeleiding bij gliomen
Signalering en behandeling cognitieve en emotionele gevolgen na glioom
Voorlichting bij gliomen
Rol verpleegkundige/verpleegkundig specialist bij gliomen
Follow-up na gliomen
Onderscheiden tumorprogressie en therapie-effect bij gliomen
Radiologische follow-up tijdens behandeling bij het glioblastoom
Postoperatieve scan bij gliomen
Radiologische follow-up na afronden behandeling bij glioblastoom
Startpagina - Gliomen
Waar gaat deze richtlijn over?
De richtlijn is van toepassing op alle volwassen patiënten met een glioom. De richtlijn gaat in op astrocytomen
en oligodendrogliomen. Ependymomen, gliomen op ruggenmergniveau en gliomen die vooral op de
kinderleeftijd voorkomen, zoals het pilocytair astrocytoom, worden buiten beschouwing gelaten.
De richtlijn gliomen geeft aanbevelingen over diagnostiek, behandeling, nazorg en organisatie van zorg bij
patiënten met een (mogelijk) glioom. De richtlijn beoogt hiermee de kwaliteit van de zorgverlening te
verbeteren, het klinisch handelen meer te baseren op wetenschappelijk bewijs dan op ervaringen en
meningen, de transparantie te vergroten en de diversiteit van handelen door professionals te verminderen.
 
Voor wie is deze richtlijn bedoeld?
De richtlijn is bestemd voor zorgverleners in de tweede (of derde) lijn die betrokken zijn bij de diagnostiek,
behandeling en begeleiding van patiënten met een (verdenking op een) glioom. Deze zorg vereist een
multidisciplinaire aanpak waarbij neuroloog, neurochirurg, radioloog, patholoog, radiotherapeut, internist-
oncoloog, verpleegkundigen, verpleegkundig specialisten, klinisch neuropsychologen, huisartsen, IKNL-
consulenten palliatieve zorg en het palliatief consult team betrokken kunnen zijn.
 
Voor patiënten
Het grootste deel van de kwaadaardige tumoren die in de hersenen ontstaan zijn tumoren van het
steunweefsel. De cellen (de glia-cellen) die het steunweefsel vormen, steunen, voeden, beschermen en
isoleren de zenuwcellen. Een tumoren van het glia-weefsel heten gliomen, deze zijn meestal kwaadaardig.
Deze richtlijn heeft betrekking op patiënten met gliomen, die in de tweede of derde lijn behandeld worden.
De richtlijn richt zich op diagnostiek, behandeling en nazorg. Patiënteninformatie over gliomen is te vinden op
de website van Thuisarts via: 
[in ontwikkeling]
 
Status van de richtlijn
In de laatste herziening (2023) zijn de volgende modules herzien/ontwikkeld:
Epidemiologie
Typering/gradering diffuse gliomen
Beeldvorming ter nadere differentiatie
Indicatie geriatrisch assessment
Behandeling van ouderen/kwetsbaren
Beeldvorming ten behoeve van behandeling
De werkgroep heeft ook bekeken of de overige modules konden worden aangepast aan de laatste WHO-
classificatie. Dit is niet haalbaar gebleken omdat de onderliggende literatuur berust op eerdere WHO-
classificaties.
Verantwoording
Laatst beoordeeld
 : 11-07-2023
Laatst geautoriseerd
 : 11-07-2023
Gliomen
PDF aangemaakt op 
23-01-2025
4
/
971
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Gliomen
PDF aangemaakt op 
23-01-2025
5
/
971
Epidemiologie
Gliomen zijn een relatief zeldzame vorm van kanker. Jaarlijks krijgen ongeveer 1300 volwassen patiënten in
Nederland de diagnose diffuus glioom (grafiek 1), waarvan 1000 bevestigd door weefselonderzoek. De
incidentie is al jaren stabiel en ligt gestandaardiseerd voor de Europese bevolking rond 6 per 100.000
inwoners voor tumoren bevestigd door weefselonderzoek, en rond 8 per 100.000 als klinisch verdachte
gevallen worden meegerekend. Deze laatste groep betreft patiënten die niet zijn geopereerd, bijvoorbeeld
vanwege hun slechte conditie.
 
Diffuse gliomen komen vaker voor bij mannen (Ostrom, 2022). Hoewel verschillende risicofactoren zijn
onderzocht, heeft alleen therapeutische, ioniserende straling een duidelijke etiologische invloed. Vooral
degenen die als kind radiotherapie ondergingen, bijvoorbeeld vanwege leukemie, hebben een hogere kans
op het ontwikkelen van een glioom (Ohgaki, 2005).
 
Gliomen worden geclassificeerd volgens de Wereldgezondheidsorganisatie (WHO, 2021), zie tabel 1.
 
Tabel 1. WHO-classificatie (2021) van diffuse gliomen
 
Van de door weefselonderzoek bevestigde diffuse gliomen betreft het merendeel (75%) een glioblastoom
(grafiek 2).
 
Gliomen groeien vaak uitgebreid in het omliggende hersenweefsel, wat adequate behandeling bemoeilijkt.
Metastasering naar andere delen van het lichaam komt vrijwel niet voor. Afhankelijk van het tumortype en de
tumorgraad krijgen vrijwel alle patiënten te maken met recidiefgroei na een eerste behandeling.
 
Gliomen
PDF aangemaakt op 
23-01-2025
6
/
971
De overleving van patiënten met een glioom is sterk afhankelijk van de WHO-graad: in de periode 2012–2021
in Nederland was de 1-jaarsoverleving van patiënten met een door weefselonderzoek bevestigd WHO graad
2 glioom 90%, van degenen met een WHO graad 3 glioom 69%, en van degenen met een WHO graad 4
glioom 42% (grafiek 3). De 5-jaarsoverleving van deze patiënten bedroeg respectievelijk 70%, 38% en 5%.
 
Grafiek 1. Aantal nieuwe gevallen van diffuse gliomen per incidentiejaar (Nederland) in de periode 2012–
2021, absoluut (staaf) alsmede gestandaardiseerd voor de leeftijdsopbouw van de Europese bevolking
(ESR; lijn)
 
Grafiek 2. Subtypes diffuse gliomen door weefseldiagnostiek bevestigd in de periode 2012–2021, in
Nederland.
Gliomen
PDF aangemaakt op 
23-01-2025
7
/
971
 
Grafiek 3. De 1-, 3-, 5-jaarsoverleving voor de diagnose diffuus glioom per WHO gradering ( (WHO graad
2, 3 en 4) in Nederland.
Gliomen
PDF aangemaakt op 
23-01-2025
8
/
971
Verantwoording
Laatst beoordeeld
 : 11-07-2023
Laatst geautoriseerd
 : 11-07-2023
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Gliomen
PDF aangemaakt op 
23-01-2025
9
/
971
Diagnostiek bij Gliomen
Deze module is onderverdeeld in de volgende submodules en sub-submodules:
Beeldvormende diagnostiek
Initiële beeldvorming
Aanvullende beeldvorming
Neuropathologie
Typering/gradering diffuse gliomen
Moleculaire veranderingen diffuse gliomen
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
Gliomen
PDF aangemaakt op 
23-01-2025
10
/
971
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
Gliomen
PDF aangemaakt op 
23-01-2025
11
/
971
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
Gliomen
PDF aangemaakt op 
23-01-2025
12
/
971
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
Gliomen
PDF aangemaakt op 
23-01-2025
13
/
971
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
14
/
971
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
Gliomen
PDF aangemaakt op 
23-01-2025
15
/
971
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
Gliomen
PDF aangemaakt op 
23-01-2025
16
/
971
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
Gliomen
PDF aangemaakt op 
23-01-2025
17
/
971
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
Gliomen
PDF aangemaakt op 
23-01-2025
18
/
971
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
Gliomen
PDF aangemaakt op 
23-01-2025
19
/
971
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Gliomen
PDF aangemaakt op 
23-01-2025
20
/
971
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
Gliomen
PDF aangemaakt op 
23-01-2025
21
/
971
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
Gliomen
PDF aangemaakt op 
23-01-2025
22
/
971
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Gliomen
PDF aangemaakt op 
23-01-2025
23
/
971
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
Gliomen
PDF aangemaakt op 
23-01-2025
24
/
971
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
Gliomen
PDF aangemaakt op 
23-01-2025
25
/
971
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
Gliomen
PDF aangemaakt op 
23-01-2025
26
/
971
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
Gliomen
PDF aangemaakt op 
23-01-2025
27
/
971
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
28
/
971
Beeldvormende diagnostiek bij Gliomen
Deze submodule is onderverdeeld in de volgende sub-submodules:
Initiële beeldvorming
Aanvullende beeldvorming
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
Gliomen
PDF aangemaakt op 
23-01-2025
29
/
971
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
30
/
971
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
Gliomen
PDF aangemaakt op 
23-01-2025
31
/
971
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
32
/
971
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
Gliomen
PDF aangemaakt op 
23-01-2025
33
/
971
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
Gliomen
PDF aangemaakt op 
23-01-2025
34
/
971
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
Gliomen
PDF aangemaakt op 
23-01-2025
35
/
971
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
Gliomen
PDF aangemaakt op 
23-01-2025
36
/
971
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
Gliomen
PDF aangemaakt op 
23-01-2025
37
/
971
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
Gliomen
PDF aangemaakt op 
23-01-2025
38
/
971
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
Gliomen
PDF aangemaakt op 
23-01-2025
39
/
971
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Gliomen
PDF aangemaakt op 
23-01-2025
40
/
971
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Gliomen
PDF aangemaakt op 
23-01-2025
41
/
971
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
42
/
971
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
Gliomen
PDF aangemaakt op 
23-01-2025
43
/
971
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
Gliomen
PDF aangemaakt op 
23-01-2025
44
/
971
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
Gliomen
PDF aangemaakt op 
23-01-2025
45
/
971
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
Gliomen
PDF aangemaakt op 
23-01-2025
46
/
971
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
47
/
971
Beeldvorming ter nadere differentiatie
Uitgangsvraag
Wat is de gewenste beeldvorming bij patiënten met een verdenking glioom ter vaststelling van de diagnose?
Aanbeveling
Overweeg het gebruik van DWI en perfusie MRI voor het onderscheid tussen glioom en lymfoom of
hersenmetastase.
 
Overweeg perfusie MRI voor het onderscheid tussen hoog- en laaggradig glioom.
 
Overleg bij klinische consequenties en twijfel in een neuro-oncologisch MDO met aanwezigheid van terzake
kundig radioloog.
Overwegingen
Voor- en nadelen van de interventie en de kwaliteit van het bewijs
Het doel van deze uitgangsvraag was om de aanvullende waarde van geavanceerde beeldvorming bij
patiënten met een verdenking op een glioom (bij wie al iets is gezien op beeldvorming), in vergelijking met
alleen conventionele beeldvorming te beoordelen. Er is één systematische review (Dunet, 2016), waarin FET-
PET vergeleken werd met FDG-PET. Naast methodologische beperkingen werd de vergelijking niet
getrokken met conventionele beeldvorming alleen (indirect bewijs). Bewijskracht voor de kritieke
uitkomstmaten was zeer laag. Dit betekent dat andere studies kunnen leiden tot nieuwe inzichten. Er kunnen
op basis van enkel de literatuur geen sterke aanbevelingen geformuleerd worden over de aanvullende waarde
van geavanceerde beeldvorming vergeleken met conventionele beeldvorming alleen voor patiënten een
verdenking op een glioom.
 
Meest relevante studies ter beschrijving
Diverse systematische/meta-analyses werden niet meegenomen in de literatuursamenvatting omdat deze niet
voldeden aan de PICO. Deze studies betroffen over het algemeen onderzoeken waarbij de geavanceerde
techniek niet werd vergeleken met conventionele MRI als controle. Daarnaast hadden veel studies een
geselecteerde populatie met reeds bevestigd glioom (danwel andere laesie) waarbij retrospectief of in een
case-control /two gate design de techniek werd onderzocht. Aangezien de literatuursamenvatting slechts één
van de geavanceerde beeldvormende techniek beschrijft, zijn beknopt in tabel 1 en 2 de resultaten van
studies naar andere geavanceerde technieken uitgelicht. Voor het onderscheid tussen gliomen en andere
laesies (lymfoom, metastasen) zijn perfusie MRI met DSC en ASL, MRS en DTI/DWI onderzocht (tabel 1).
Hooggradig glioom en lymfoom werden met hoge sensitiviteit en specificiteit onderscheiden middels DSC
(Liang, 2014). Metastase en hooggradig glioom konden eveneens met hoge sensitiviteit en specificiteit van
elkaar worden onderscheiden middels perfusie MRI met DSC, ASL of DCE (Suh, 2018), ASL (Fu, 2019) en MRS
(Wang, 2017). Zhang et al (2020) rapporteert hoge sensitiviteit en specificiteit in het onderscheiden van
glioblastoom, metastase en lymfoom met DWI en DTI. Overigens werd bij deze laatste studie geen
referentietechniek gerapporteerd. Mede gezien het gehanteerde studie-design in veel van deze studies
dienen deze resultaten met voorzichtigheid te worden geïnterpreteerd.
Gliomen
PDF aangemaakt op 
23-01-2025
48
/
971
Ook in het onderscheid tussen hoog- en laaggradige gliomen (tabel 2) wordt er een hoge sensitiviteit en
specificiteit gerapporteerd van diverse perfusie MRI technieken en parameters (DSC, ASL, DCE). De
gerapporteerde sensitiviteit en specificiteit van MRS is iets lager, hoewel nog steeds >70% (Wang, 2019). Een
directe vergelijking tussen perfusie MRI en MRS is in deze studies overigens niet verricht. Ook hier geldt dat
de resultaten met voorzichtigheid geïnterpreteerd dienen te worden.
In de studie door Shaw (2019) werd onderzocht of FDG-PET-CT alleen, of in combinatie met MRI kan
bijdragen aan het differentiëren tussen hooggradige histologie (WHO
IV glioblastoom, WHO III glioom en metastasen) en laaggradige histologie (WHO II glioom en benigne
afwijkingen). De studiepopulatie bestond voor een deel uit patiënten die diagnostiek voor verdenking glioom
ondergingen en voor een deel uit patiënten met reeds vastgesteld glioom. Vanwege beperkte sensitiviteit en
negatief voorspellende waarde, concludeerden de auteurs dat een negatieve FDG-PET-CT alleen of in
combinatie met MRI, niet leidend moet zijn in de beslissing voor observatie waar anders chirurgie aanbevolen
zou worden.
 
Tabel 1 Differentiatie gliomen ten opzichte van niet gliomen
Study
ID
N studies
(totaal
patiënten)
Differentieert
tussen
Techniek
(interventie)
Conventionele
beeldvormende
techniek
(controle)
Techniek
(referentie)
Diagnostische
accuratessemaat
(95% CI)
QUADAS
beoordeeld
Liang,
2014
3 (79)
Hooggradig/
lymfoom
DSC-MRI
(rCBV)
-
Histopathologie
Sensitiviteit:
0.90 (0.76 tot
0.97)
Ja
Specificiteit:
0.98 (0.89 tot
1.00)
Zhang,
2020
19 (1558)
Glioblastoom/
lymfoom/
metastasen
DTI
-
NR
Sensitiviteit:
0.87 (0.78 tot
0.93)
Nee
Specificiteit:
0.91 (0.83 tot
0.96)
AUC: 0.95 (0.93
tot 0.97)
DWI
-
NR
Sensitiviteit:
0.81 (0.71 tot
0.88)
Specificiteit 0.84
(0.78 tot 0.89)
AUC: 0.90 (0.87
tot 0.92)
Gliomen
PDF aangemaakt op 
23-01-2025
49
/
971
Suh,
2018
18 (900)
Glioom/
metastasen
Perfusie
MRI: DSC
(13), ASL (4),
DCE (2) –
m.n.
peri
tumorale
rCBV/rCBF
-
Histopathologie
Sensitiviteit:
0.90 (0.84 tot
0.94)
Ja
Specificiteit:
0.91 (0.84 tot
0.95)
AUC: 0.96 (0.94
tot 0.98)
Fu,
2019
5 (346)
Hooggradig/
metastasen
ASL
-
Histopathologie/
klinische follow-
up
Sensitiviteit:
0.88 (0.65 tot
0.96)
Ja
Specificiteit:
0.85 (0.74 tot
0.92)
AUC: 0.92 (0.89
tot 0.94)
Wang,
2017
7 (261)
Hooggradig/
metastasen
MRS
-
Histopathologie
en/of klinische
follow-up
Sensitiviteit:
0.85 (0.79 tot
0.90)
Ja
Specificiteit:
0.84 (0.75-0.90)
AUC: 0.90 (NR)
 
Tabel 2 Differentiatie hooggradige /laaggradige gliomen
Study ID
N studies
Techniek
(interventie)
Conventionele
beeldvormende
techniek
(controle)
Techniek
(referentie)
Diagnostische
accuratessemaat
QUADAS
beoordeeld
Luan,
2020
20
ASL (rCBF)
-
Pathologie
Sensitiviteit: 0.88
(0.83 tot 0.92)
Ja
Specificiteit: 0.91
(0.84 tot 0.94)
AUC: 0.95 (0.93 tot
0.97)
22
DSC-MRI (rCBV)
-
Pathologie
Sensitiviteit: 0.92
(0.83 tot 0.96)
Gliomen
PDF aangemaakt op 
23-01-2025
50
/
971
Specificiteit: 0.81
(0.73 tot 0.88)
AUC: 0.91 (0.89 tot
0.94)
Liang,
2018
13
DCE-MRI ) K
 )
-
Pathologie
Sensitiviteit: 0.88
(0.81 tot 0.93)
Ja
Specificiteit: 0.80
(0.72 tot 0.86)
AUC: 0.90 (0.87 tot
0.92)
6
DCE-MRI (V
)
-
Pathologie
Sensitiviteit: 0.85
(0.73 tot 0.92)
Specificiteit: 0.84
(0.75 tot 0.91)
AUC: 0.88 (0.85 tot
0.91)
5
DSC-MRI (rCBF)
-
Pathologie
Sensitiviteit: 0.88
(0.77 tot 0.94)
Specificiteit: 0.68
(0.56 tot 0.77)
AUC: 0.73 (0.69 tot
0.77)
Abrigo,
2018
7
DSC-MRI (rCBV ()
(n= 6)
DCE-MRI (K
 )
(n= 1)
-
Histopathologie
Sensitiviteit: 0.83
(0.66 tot 0.93)
Ja
Specificiteit: 0.48
(0.09 tot 0.90)
Wang,
2016
19
MRS (Cho/Cr)
 
-
Histopathologie
en/of klinische
follow-up
Sensitiviteit: 0.75
(0.71 tot 0.79)
Ja
Specificiteit: 0.60
(0.55 tot 0.66)
AUC: 0.83 (NR)
16
MRS(Cho/NAA)
 
-
Histopathologie
en/of klinische
follow-up
Sensitiviteit: 0.80
(0.76 tot 0.84)
Specificiteit: 0.76
(0.70 tot 0.82)
AUC: 0.87 (NR)
trans
e
trans
Gliomen
PDF aangemaakt op 
23-01-2025
51
/
971
11
MRS NAA/Cr)
-
Histopathologie
en/of klinische
follow-up
Sensitiviteit: 0.71
(0.65 tot 0.77)
Specificiteit: 0.70
(0.61 tot 0.78)
AUC: 0.78 (NR)
Abbreviations: ASL, arterial spin labeling; CBV, cerebral blood flow; DCE-MRI, Dynamic Contrast Enhanced-
MRI; DSC-MRI, dynamic susceptibility contrast--MRI; DTI, diffusion tensor imaging; DWI, diffusion weighted
imaging; MK, mean kurtosis; MRS, Magnetic resonance spectroscopy; NR, not reported
 
Waarden en voorkeuren van patiënten (en evt. hun naasten/ mantelzorgers)
Geavanceerde MRI-technieken zijn relatief weinig belastend voor de patiënt, aangezien deze over het
algemeen worden toegevoegd aan de standaard MRI scan. Een PET-scan is meer belastend, aangezien dit
een separaat en – de voorbereidingstijd in ogenschouw nemend – meer langdurig onderzoek is. Daarnaast
gaat dit gepaard met (beperkte) stralenbelasting, hetgeen sommige patiënten als meer ingrijpend
beschouwen. Niet alle geavanceerde technieken zijn overal allemaal beschikbaar. Het kan zijn dat patiënten
wel een bepaalde voorkeur hebben voor een bepaalde techniek. Omdat er geen eenduidig bewijs is dat een
specifieke techniek beter is dan een andere, is er geen reden om te denken dat de topografische variatie
invloed heeft op de behandeling of uitkomst. 
 
Kosten (middelenbeslag)
Het aantal nieuwe patiënten met een glioom in Nederland bedraagt ±1300 per jaar.
 
De kosten van geavanceerde MRI zullen over het algemeen met name betrekking hebben op een verlenging
van het standaard uitgevoerde MRI-onderzoek. Deze verlenging is relatief beperkt (5-15 min), maar is gezien
de schaarste van MRI-capaciteit wel van belang. PET betreft een geheel additioneel onderzoek dat duurder is
dan MRI, en waarvoor de tracer (FET) niet standaard overal beschikbaar is. Bij de werkgroep zijn geen studies
naar kosteneffectiviteit voor deze geavanceerde technieken bekend.
 
Aanvaardbaarheid, haalbaarheid en implementatie
DWI en DSC MRI zijn in Nederland breed beschikbaar en geïmplementeerd. De overige geavanceerde MRI-
technieken (ASL, DCE, MRS) zijn niet in alle centra beschikbaar. PET is minder toegankelijk en de tracer (FET)
is niet standaard overal beschikbaar.
 
De werkgroep is van mening dat bij klinische consequenties en twijfel de patiënt besproken dient te worden
in een neuro-oncologisch multidisciplinair overleg met aanwezigheid van een terzake kundig radioloog. Zie
document ‘
Kwaliteitscriteria neuro-oncologie
’ (LWNO, 2022 voor de kwaliteitseisen van terzake kundig
radioloog.
 
Rationale van de aanbeveling: weging van argumenten voor en tegen de diagnostische procedure
Er is onvoldoende bewijs dat PET-onderzoek bijdraagt aan de differentiële diagnostiek bij patiënten met een
verdenking op glioom. Hierbij is de sensitiviteit van FDG-PET beduidend lager (en onder de norm) dan FET-
PET.
Gliomen
PDF aangemaakt op 
23-01-2025
52
/
971
De breed beschikbare geavanceerde MRI-technieken DWI en perfusie MRI lijken van waarde bij het
differentiëren tussen hooggradig glioom, metastase en lymfoom en voor het onderscheid tussen hoog- en
laaggradig glioom, maar bij het ontbreken van goede studies valt niet te zeggen wat de daadwerkelijke
diagnostische kracht van deze technieken is. MRS lijkt iets minder goed te zijn voor het onderscheid tussen
hoog- en laaggradig glioom.
Onderbouwing
Achtergrond
Nadat er een afwijking in de hersenen is vastgesteld die zou kunnen passen bij een glioom (middels CT dan
wel MRI) blijft de diagnose soms onzeker. Belangrijke differentiële diagnosen zijn andere maligne
aandoeningen (zoals metastase of lymfoom), demyelinisatie, abces, een infectie anderszins, of vasculaire
aandoeningen. Deze vereisen alle een andere behandeling, die soms met spoed moet worden ingezet.
Daarnaast is het type en graad van een vermoedelijk glioom van belang. Onzekerheid omtrent de diagnose
leidt nu soms tot onnodig of onvolledig operatief ingrijpen en zou kunnen worden voorkomen met betere
niet-invasieve, beeldvormende diagnostiek. Het is echter de vraag of en welke aanvullende beeldvormende
technieken een toegevoegde waarde hebben boven de conventionele, structurele beeldvorming die
routinematig wordt verricht, bestaande uit T2-gewogen (al dan niet met vochtonderdrukking: FLAIR) en pre-
en post-contrast T1-gewogen sequenties.
Conclusies
1. Sensitivity (glioma or non-glioma) (critical)
Very low
GRADE
It is unclear whether add-on FET-PET is more sensitive compared to add-on FDG-PET in
discriminating between glioma and non-glioma lesions in patients suspected of glioma.
 
Source: Dunet, 2016
 
2. Specificity (glioma or non-glioma) (critical)
Very low
GRADE
It is unclear whether add-on FET-PET is more specific compared to add-on FDG-PET in
discriminating between glioma and non-glioma lesions in patients suspected of glioma.
 
Source: Dunet, 2016
 
3. Positive predictive value, negative predictive value (PPV, NPV) (important)
No GRADE
No information was found regarding the effect of initial imaging followed by add-on
advanced imaging on positive predictive value or negative predictive value when
compared with initial imaging only in patients suspected of glioma.
 
Source: -
 
4. Area under the curve (important) (glioma or non-glioma)
Gliomen
PDF aangemaakt op 
23-01-2025
53
/
971
Very low
GRADE
It is unclear whether add-on FET-PET had a higher discriminative value compared to add-
on PDG-PET in discriminating between glioma and non-glioma lesions in patients
suspected of glioma.
 
Source: Dunet, 2016
 
Effect of initial imaging followed by add-on advanced imaging (any outcome)
No GRADE
No information was found regarding the effect of initial imaging followed by add-on
advanced imaging on any outcome when compared with initial imaging only in patients
suspected of glioma.
 
Source: -
Samenvatting literatuur
Description of studies
In the systematic review with meta-analysis by Dunet (2016), five diagnostic accuracy studies were included
(190 patients). Eligible studies used both 
F-fluoro-ethyl-L-tyrosine (FET) positron emission tomography (PET)
and 
F-fluoro-deoxy-glucose (FDG)-PET and compared both with histology (reference). Patients were newly
diagnosed with brain lesions or suspected of a recurrent brain tumor and did not undergo treatment before
diagnostics. The available data from the five studies were combined in the meta-analysis (n= 119), resulting in
a pooled AUC for FDG-PET and for FET-PET separately. Histology was used as a reference, distinguishing
between glioma and non-glioma and between low-grade and high-grade glioma. In 3 studies (Floeth, 2006;
Lau, 2010;Pichler, 2010), histology as reference standard was not possible in all patients, thus longitudinal
observation (clinical follow-up, imaging) was used as reference in some cases. In three studies, not all patients
were included in the analysis (Floeth, 2006; Lau, 2010; Pichler, 2010). A more elaborate explanation is
provided in the risk of bias tables.
 
Table 1. Description of included studies in Dunet (2016)
18
18
Gliomen
PDF aangemaakt op 
23-01-2025
54
/
971
Study
Study characteristics
 
 
 
 
n
Gender
(F:M)
Mean age in
years (SD)
Patients with
a tumor
Diagnostic trajectory
Prevalence of
glioma
Floeth, 2006
14
0:11
54 (12)
 
4
Contrast enhanced MRI à
FET-PET and FDG-PET à
histology (biopsies or
clinical follow-up)
4/14 (29%)
Pauleit, 2009
52
16:36
46 (14)
45
MRI à FET-PET and FDG-
PET à histology (biopsy)
43/52 (83%)
Lau, 2010
21
5:13
 42 (16)
 
12
Contrast enhanced MRI à
FET-PET and FDG-PET à
histology (surgical or
clinical/imaging course)
10/21 (48%)
Plotkin, 2010
15
9:6
44 (11)
15
MRI à FET-PET and FDG-
PET à histology (surgical)
15/15 (100%)
Pichler, 2010
88
NR
NR
14
MRI à FET-PET and FDG-
PET à histology (surgical) or
longitudinal observation
10/88 (11%)
Abbreviations: 
F-fluoro-deoxy-glucose; FDG, 
F-fluoro-ethyl-L-tyrosine; FET, NR; not reported
 
Results
1. Sensitivity (glioma or non-glioma) (critical)
For the sensitivity of FET-PET in discriminating between glioma and non-glioma lesions, data from four
studies (Floeth, 2006; Pauleit, 2009; Lau, 2010 and Pichler, 2010) could be combined in meta-analysis. Pooled
sensitivity was 0.92 (95% CI 0.75 to 0.98). For sensitivity of FDG-PET, pooling the same studies led to a
sensitivity of 0.35 (95% CI 0.11 to 0.71).
 
2. Specificity (glioma or non-glioma) (critical)
For the specificity of FET-PET in discrimination between glioma and non-glioma lesions, data from four
studies (Floeth, 2006; Pauleit, 2009; Lau, 2010 and Pichler, 2010) could be combined in meta-analysis. Pooled
specificity was 0.62 (95% CI 0.43 to 0.79). For specificity of FDG-PET, pooling the same studies led to a
specificity of 0.65 (95% CI 0.48 to 0.79).
 
3. Positive predictive value, negative predictive value (PPV, NPV) (important)
Neither positive predictive value nor negative value were reported.
 
4. Area under the curve (important) (glioma or non-glioma)
Data from all five studies could be combined in the meta-analysis for a pooled AUC. The AUC for FET-PET in
discriminating between glioma and non-glioma lesions was 0.76 (95% CI 0.67 to 0.84) and for FDG-PET 0.49
(95% CI 0.40 to 0.58).
 
18
18
Gliomen
PDF aangemaakt op 
23-01-2025
55
/
971
Level of evidence of the literature
1. Sensitivity (glioma or non-glioma) (critical)
The level of evidence regarding the outcome measure sensitivity was downgraded by three levels because
not all study participants were included in the analyses and inclusion of participants with a confirmed
diagnosis of a brain tumor or suspected recurrence of a known low-grade glioma (Plotkin, 2010) (-2 risk of
bias) and conflicting results within studies for FDG-PET compared with histology (-1, inconsistency).
 
2. Specificity (glioma or non-glioma) (critical)
The level of evidence regarding the outcome measure specificity was downgraded by two levels because not
all study participants were included in the analyses and inclusion of participants with a diagnosis of a brain
tumor or suspected recurrence of a known low-grade glioma (Plotkin, 2010) (-2, risk of bias); and two
additional advanced imaging techniques were compared (-1, indirectness).
 
3. Positive predictive value, negative predictive value (PPV, NPV) (important)
The level of evidence regarding the outcome measure PPV and NPV could not be graded.
 
4. Area under the curve (important) (glioma or non-glioma)
The level of evidence regarding the outcome measure AUC was downgraded by three levels because not all
study participants were included in the analyses and inclusion of participants with a diagnosis of a brain tumor
or suspected recurrence of a known low-grade glioma (Plotkin, 2010) (-2, risk of bias); two additional
advanced imaging techniques were compared (-1, indirectness).
Zoeken en selecteren
A systematic review of the literature was performed to answer the following question: is initial imaging
followed by advanced imaging recommended versus initial imaging or additionally imaging techniques only in
patients suspected of glioma?
 
Patients:
 Patients suspected of glioma in whom a lesion has been seen with imaging (CT or
conventional MRI)
Intervention:
 Initial imaging followed by advanced imaging technique
Comparator
: Initial imaging (CT, conventional MRI, structural MRI, pre- and post-contrast,
T1w, T2w and/or FLAIR)
Reference:
 Clinical course, histopathology
Outcomes:
 Diagnostic accuracy (sensitivity, specificity, positive predictive value, negative
predictive value, Area Under the Curve (AUC))
 
Timing and setting: Outpatient clinic (neurology/neurosurgery/oncology)
Timing: Advanced imaging after initial imaging (term: <4 weeks)
 
Relevant outcome measures
The guideline development group considered sensitivity and specificity as a critical outcome measure for
decision making; and negative predictive value, positive predictive value and AUC as important outcome
measures for decision making.
1
Gliomen
PDF aangemaakt op 
23-01-2025
56
/
971
 
A priori, the working group did not define the outcome measures listed above but used the definitions used
in the studies.
 
The working group defined minimal clinically (patient) important thresholds for accuracy measures as ≥70%
 
Search and select (Methods)
The databases Medline (via OVID) and Embase (via Embase.com) were searched with relevant search terms
from 2014 until January 24
, 2022. The detailed search strategy is depicted under the tab Methods. The
systematic literature search resulted in 248 hits. Studies were selected based on the following criteria:
Systematic review (searched in at least two databases, and detailed search strategy, risk of bias
assessment and results of individual studies available) or observational study;
Full-text English language publication;
Studies according to PICO.
A total of 29 studies were initially selected based on title and abstract screening. After reading the full text,
28 studies were excluded (see the table with reasons for exclusion under the tab Methods), and one studies
was included (Dunet, 2016).
 
Results
One study was included in the analysis of the literature (Dunet, 2016). Important study characteristics and
results are summarized in table 1 and the evidence tables. The assessment of the risk of bias is summarized in
the risk of bias tables.
Verantwoording
Laatst beoordeeld
 : 11-07-2023
Laatst geautoriseerd
 : 11-07-2023
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Dunet V, Pomoni A, Hottinger A, Nicod-Lalonde M, Prior JO. Performance of 18F-FET versus 18F-FDG-PET for the
diagnosis and grading of brain tumors: systematic review and meta-analysis. Neuro Oncol. 2016 Mar;18(3):426-34. doi:
10.1093/neuonc/nov148. Epub 2015 Aug 4. PMID: 26243791; PMCID: PMC4767236.
2
 - Jansen NL, Graute V, Armbruster L, Suchorska B, Lutz J, Eigenbrod S, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la
Fougère C. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? Eur J Nucl Med Mol Imaging. 2012
Jun;39(6):1021-9. doi: 10.1007/s00259-012-2109-9. Epub 2012 Apr 11. PMID: 22491781.
3
 - LWNO,2014 
https://richtlijnendatabase.nl/uploaded/docs/IKNL_in_ontw/Kwaliteitscriteria_Gliomen_def_mei2014.pdf
4
 - Shaw TB, Jeffree RL, Thomas P, Goodman S, Debowski M, Lwin Z, Chua B. Diagnostic performance of 18F-
fluorodeoxyglucose positron emission tomography in the evaluation of glioma. J Med Imaging Radiat Oncol. 2019
Oct;63(5):650-656. doi: 10.1111/1754-9485.12929. Epub 2019 Aug 1. PMID: 31368665.
5
 - Wang S, Kim S, Chawla S, Wolf RL, Knipp DE, Vossough A, O'Rourke DM, Judy KD, Poptani H, Melhem ER. Differentiation
between glioblastomas, solitary brain metastases, and primary cerebral lymphomas using diffusion tensor and dynamic
th
Gliomen
PDF aangemaakt op 
23-01-2025
57
/
971
susceptibility contrast-enhanced MR imaging. AJNR Am J Neuroradiol. 2011 Mar;32(3):507-14. doi: 10.3174/ajnr.A2333. Epub
2011 Feb 17. PMID: 21330399; PMCID: PMC8013110
Gliomen
PDF aangemaakt op 
23-01-2025
58
/
971
Beeldvorming ten behoeve van chirurgie/radiotherapie
Uitgangsvraag
Wat is de plaats van nieuwe radiologische technieken bij patiënten met een glioom t.b.v. planning van
chirurgie/radiotherapie?
Aanbeveling
Overweeg het gebruik van neuronavigatie tijdens resectie van een glioom.
 
Overweeg bij (verdenking op) een glioom in of nabij eloquente gebieden functie localiserende beeldvorming
te gebruiken zoals DTI en/of fMRI voorafgaand aan de resectie.
 
Overweeg voor het identificeren van de meer maligne tumorcomponenten gebruik te maken van aanvullende
beeldvorming zoals PET, perfusie MRI (ASL, DSC, DCE) of MRS.
 
Overweeg voor een (supra)maximale resectie de infiltratie beter af te beelden door bijvoorbeeld PET,
perfusie MRI, MRS of intra-operatieve echografie.
Overwegingen
Voor- en nadelen van de interventie en de kwaliteit van het bewijs
Het doel van deze uitgangsvraag was om te achterhalen wat de waarde van geavanceerde beeldvorming
(DTI, fMRI, MRS, CEST, ASL DSC, DCE, MRS, intra-operatieve echografie, neuronavigatie, PET) is bij het
plannen van de lokale behandeling bij patiënten met een verdenking op een glioom, in vergelijking met
conventionele beeldvorming. Er is voor neurochirurgie één gerandomiseerde trial beschreven (Willems, 2006),
waarin resectie met neuronavigatie vergeleken werd met resectie zonder neuronavigatie. Naast
methodologische beperkingen was de studiepopulatie zeer klein en divers (zowel glioblastoom als
metastase). Bewijskracht voor de kritieke uitkomstmaten was zeer laag. Dit betekent dat andere studies
kunnen leiden tot nieuwe inzichten. Er kunnen op basis van enkel de literatuurgeen sterke aanbevelingen
geformuleerd worden over de waarde van geavanceerde beeldvorming vergeleken met conventionele
beeldvorming voor lokale behandeling van patiënten een verdenking op een glioom.
 
Ondanks de uitkomst van deze underpowerde RCT is neuronavigatie voor vermoedelijke glioom chirurgie
wereldwijd als standaard geaccepteerd en wordt deze techniek ook wereldwijd toegepast. De werkgroep is
niet bekend met eventuele lopende studies naar deze techniek. In alle Nederlandse klinieken wordt
neuronavigatie toegepast en door vele neurochirurgen als effectief en veilig ervaren voor glioomchirurgie.
 
Voor andere geavanceerde beeldvormende technieken (PET, DTI, fMRI, MRS, CEST, ASL DSC, DCE, intra-
operatieve echografie)werden geen artikelen gevonden die aan de PICO voldeden. Wel zijn er twee
systematische reviews over dit onderwerp gepubliceerd, alle in het kader van het plannen van een operatie.
Caras et al (2020) includeerden uit 435 geïdentficeerde artikelen drie studies over DTI, vijf studies over fMRI
en 21 over intra-operatieve MRI. Intra-operatieve MRI wordt in deze richtlijn buiten beschouwing gelaten,
omdat deze faciliteit niet in Nederland beschikbaar is noch verwacht te zullen komen. Geen van deze studies
Gliomen
PDF aangemaakt op 
23-01-2025
59
/
971
betrof een RCT. Hoewel patiënten met deze geavanceerde technieken vaker een totale resectie en minder
permanente neurologische uitval leken te hebben, was er geen statistisch significant verschil in vergelijking
met neuronavigatie. In een Cochrane review (Barone, 2016) werden vier RCT’s geïncludeerd met elk een
andere geavanceerde beeldvormende techniek: intra-operatieve MRI, 5-ALA fluorescentie, neuronavigatie (de
hierboven beschreven RCT van Willems et al 2006), DTI. Alle studies hadden een groot risico op bias,
metname de DTI-studie. Vanwege de grote heterogeniteit was een meta-analyse niet mogelijk. Ook in deze
review was er in de individuele studies een grotere mate van resectie met geavanceerde beeldvorming
(behoudens neuronavigatie), maar de bewijskracht was zeer laag. Er was geen bewijs voor verbeterde
overleving. Op basis van de beschikbare literatuur is er geen bewijs dat het al dan niet toepassen van een van
deze beeldvormende technieken zou leiden tot een verandering van operatierisico. Desalniettemin acht de
werkgroep het verstandig om bij (verdenking op) een glioom in of nabij eloquente gebieden functie
localiserende beeldvorming te gebruiken zoals DTI of fMRI als extra informatie tijdens de resectie. Het kan
daarnaast verstandig zijn om voor het identificeren van de meer maligne tumorcomponenten gebruik te
maken van aanvullende beeldvorming zoals PET, perfusie (ASL, DSC, DCE) of MRS. De werkgroep is
eveneens van mening dat het verstandig kan zijn voor een (supra)maximale resectie de infiltratie beter af te
beelden door bijvoorbeeld PET, MRS of intra-operatieve echografie. Eenduidig bewijs voor een individuele
aanvullende vorm van beeldvorming naast conventionele MRI ontbreekt echter.  
Over het gebruik van geavanceerde beeldvormende technieken ten behoeve van het bepalen van het
doelgebied voor bestraling is geen afdoende literatuur beschikbaar en acht de werkgroep dat er hiervoor
geen indicatie is.
 
Waarden en voorkeuren van patiënten (en evt. hun naasten/ mantelzorgers)
Veel patienten zullen het advies van het neurochirurgisch en radiotherapeutisch team volgen, dat ingevuld
wordt naar overtuiging, lokale beschikbaarheid en middelen. Neuronavigatie, DTI en intraoperatieve
echografie lijken niet extra belastend voor de patiënt. Het uitvoeren van CEST, fMRI en ASL neemt meer tijd
in beslag, maar wordt door de werkgroep als vergelijkbaar belastend voor de patiënt ingeschat. PET (-CT)
wordt door de werkgroep ingeschat als zijnde extra belastend.
 
Een deel van deze beeldvorming kan bijdragen aan het localiseren van functionele structuren (DTI, fMRI), een
ander deel kan bijdragen aan het localiseren van de meest maligne tumorcomponenten (PET, CEST, perfusie,
MRS) of aan het localiseren van de infiltratieve tumorzone (MRS, intraoperatieve echografie). Deze technieken
zijn niet overal beschikbaar en worden niet altijd toegepast, zonder dat dit betekent dat de kwaliteit van de
behandeling hiermee vermindert.
 
Kosten (middelenbeslag)
Naar inschatting van de werkgroep gaan kosten gepaard met pre-therapeutische MRI-scan met apparatuur.
Het is onduidelijk of onder de streep een van de technieken leidt tot hogere danwel lagere kosten.
 
Aanvaardbaarheid, haalbaarheid en implementatie
DSC-MRI, intra-operatieve echografie en neuronavigatie zijn alle breed beschikbaar, aanvaardbaar en
haalbaar. MRI-beeldvorming met ASL, CEST, fMRI, DTI, DCE en MRS behoren niet tot de diagnostische
standaard, en zijn niet overal geïmplementeerd in de MRI protocollen. Wel zijn ASL, fMRI, DTI, DCE en MRS
Gliomen
PDF aangemaakt op 
23-01-2025
60
/
971
in de academische centra beschikbaar. CEST bevindt zich nog overwegend in het onderzoeksdomein, maar is
potentieel wel implementeerbaar op bestaande MRI-scanners.  PET, en met name met aminozuur tracers, is
daarnaast niet overal beschikbaar.
Onderbouwing
Achtergrond
Momenteel wordt neurochirurgische en radiotherapeutische behandeling van een (verdenking op) glioom
gebaseerd op structurele, conventionele beeldvorming met MRI, bestaande uit pre- en post-contrast T1-
gewogen beelden en T2-gewogen (al dan niet met vochtonderdrukking: FLAIR) beelden. Het is bekend dat
de afwijkingen die hiermee zichtbaar worden gemaakt niet volledig overeenkomen met de microscopische
tumoruitbreiding, noch met de meest agressieve delen van de tumor. Daarnaast verschaffen structurele,
conventionele MRI-beelden geen informatie over functionele hersengebieden, noch over het verloop van
essentiële witte stofbanen. Ten derde is het de vraag of beeldvorming tijdens een operatie de resectie kan
ondersteunen en daarmee de uitkomst voor de patiënt kan verbeteren.
Met meer geavanceerde beeldvormende technieken kan meer informatie worden verkregen over
tumoruitbreiding en functioneel relevante hersenstructuren. Het is echter de vraag of deze daadwerkelijk
kunnen of zouden moeten worden ingezet voor het plannen van behandeling, zoals het bepalen van de
uitgebreidheid van operatie in relatie tot eloquente hersengebieden, het identificeren van het optimale
target voor een biopt, of het bepalen van doelgebied van bestraling.
Conclusies
1. Overall survival (critical)
No GRADE
No sufficient information was found regarding the effect of an advanced imaging
technique on overall survival when compared with non-neuronavigation surgery in patients
suspected of glioblastoma for whom a treatment is planned.
 
Source: -
 
2. Extent of resection (critical)
Very low
GRADE
The evidence is very uncertain about the effect of neuronavigation on extent of resection
when compared with standard surgery in patients suspected of glioblastoma in whom
gross total resection is planned.
 
Source: Willems (2006)
 
3. Quality of life (critical)
Very low
GRADE
The evidence is very uncertain about the effect of neuronavigation on quality of life when
compared with standard surgery in patients suspected of glioblastoma in whom gross total
resection is planned.
 
Source: Willems (2006)
Gliomen
PDF aangemaakt op 
23-01-2025
61
/
971
 
4. Progression free survival and (intracranial) response (important)
No GRADE
No information was found regarding the effect of an advanced imaging technique on
progression free survival and (intracranial) response when compared with using only
conventional imaging in patients suspected of glioblastoma for whom a treatment is
planned.
 
Source: -
 
5. Neurological/cognitive deterioration (important)
Very low
GRADE
The evidence is very uncertain about the effect of neuronavigation on
neurological/cognitive deterioration when compared with non-neuronavigation surgery in
patients 
suspected
 of glioblastoma in whom gross total resection is planned.
 
Source: Willems (2006)
 
6. PET, DTI, fMRI, MRS, CEST, ASL DSC, DCE, intra-operative ultrasound
No GRADE
No information was found regarding the effect of advanced imaging techniques on any
outcome when compared with conventional, structural MRI in patients suspected of glioma
for whom a local treatment (surgery/radiotherapy) is planned.
 
Source: -
Samenvatting literatuur
Description of study
In the RCT by Willems (2006), 45 participants were randomly assigned to either surgery involving
neuronavigation (n= 23) or ‘standard’ surgery (n= 22), between 11-1999 and 12-2002. Patients with a solitary
intracerebral space-occupying lesion with (partial) contrast enhancement, eligible for surgical debulking with
intention of gross-total resection were included. Patients who already received surgical treatment, or with
other known primary tumors elsewhere in the body, were excluded. All included participants were
preoperatively evaluated using 0.5T MRI. In participants assigned to surgery involving neuronavigation, a
surgical plan was made by localizing the fiducial markers, determination of surgical trajectories and
segmentation of the tumor boundaries on the MR image. Neuronavigational equipment could include (when
applicable) an infrared pointer device and a mechanically tracked operating microscope with heads-up
display. In participants assigned to ‘standard’ surgery, no use was made of the MR images during surgery.
Final diagnosis in patients receiving ‘standard’ and neuronavigation surgery was glioblastoma in 16
respectively 15, anaplastic glioma in 5 respectively 3, and metastasis in 1 respectively 5. No subgroup
analyses by diagnosis were performed. Relevant outcome measures included extent of resection, (subjective)
cognitive deterioration and quality of life.
 
Table 1. Description of included studies
Gliomen
PDF aangemaakt op 
23-01-2025
62
/
971
Studie
Intervention
Comparator
Follow-up
Outcomes
 
Characteristics
Interventie
type/ dose
Characteristics
Type of
usual care
 
 
Willems
(2006)
Arm 1 (n= 23)
Mean age (SD):
60.6 (12.1)
Female
: 74%
Mean total
tumor volume
in cm
 (SD):
54.2 (31.4)
Mean KPS (SD):
77.4 (19.4)
Median KPS:
80 (IQR not
reported)
Surgery
involving
neuronavigation
Arm 2 (n= 22)
Mean age
(SD):
 60.8
(12.1)
Female:
 64%
Mean total
tumor volume
in cm
(SD):
68.4 (48.9)
Mean KPS
(SD):
 78.6
(15.5)
Median KPS:
80 (IQR not
reported)
Standard
surgery
72-hours
postoperative (extend
of resection)
 
3-month
postoperative
((subjective)
neurological/cognitive
deterioration, quality
of life)
Extent of
resection
(%),
(subjective)
cognitive
deterioration
(EORTC
QLQ-C30
(cognitive
functioning
subscale)),
quality of life
(EORTC
QLQ-C30
(global
health
status))
Abbreviations: EORTC QLQ-C30; European organization for Research and Treatment of Cancer quality of life
questionnaire C30
 
Results
Since no dispersion measures were reported, bar graphs for all outcomes were analyzed using the web-
application WebPlotDigitizer.
 
Surgery with neuronavigation versus conventional MRI without neuronavigation
1. Overall survival (critical)
Median survival time was 5.6 months for participants in the group assigned to surgery involving
neuronavigation, and 9 months for participants in the group assigned to ‘standard’ surgery. The
corresponding hazard ratio was 1.6, however measures of dispersion were not reported.
 
2. Extent of resection (critical)
Willems (2006) reported on extent of resection using a bar graph showing the change between preoperative
and 72-hours postoperative tumor volumes (range 0%-100%). In the group assigned to surgery involving
neuronavigation (n= 15), a mean of 13.6% (SD 27.7) of the preoperative tumor volume was left. In the
‘standard’ surgery group (n= 18), a mean of 28.7% (SD 63.5) of the preoperative tumor volume was left. The
mean difference between these residual volumes was -15.10 (95% CI -47.61 to 17.41). This difference was not
clinically relevant.
 
3. Quality of life (QoL) (critical)
3
3 
Gliomen
PDF aangemaakt op 
23-01-2025
63
/
971
Willems (2006) measured quality of life using the EORTC QLQ C30, reported as the difference between pre-
operative and 3-months’ post-operative QoL. Results for global health status were extracted for the purpose
of this chapter (range 0-100, higher scores indicating a higher quality of life). In the group assigned to surgery
with neuronavigation (n=8), the mean difference score was 4.8 (SD 24.7). In the ‘standard’ surgery group
(n=11), the mean difference score was 8.5 (SD 53.7). The mean difference between the groups was -3.7 (95%
CI -39.76 to 32.36). This difference was not clinically relevant.
 
4. Progression free survival and (intracranial) response (important)
These outcomes were not assessed in the study by Willems (2006).
 
5. Neurological/cognitive deterioration (important)
Willems (2006) measured subjective cognitive status with the European organization for Research and
Treatment of Cancer quality of life questionnaire (EORTC QLQ C30) cognitive subscale (range 0-100, higher
scores indicating a higher level of cognitive functioning), reported as the difference between pre-operative
and 3-months’ post-operative cognitive status. In the group assigned to surgery with neuronavigation (n=8),
the mean difference score was 3.9 (SD 27.3). In the ‘standard’ surgery group (n=11), the mean difference
score was 5.6 (SD 45.9). The mean difference between the groups was -1.70 (95% CI -34.77 to 31.37). This
difference was not clinically relevant.
 
In the group assigned to surgery involving neuronavigation, 4 participants (18.2%) exhibited new or worsened
neurological deficits, compared with 10 participants (45%) in the ‘standard surgery’ group. This resulted in an
RR of 0.38 (95% CI 0.14 to 1.04). In 1 participant in the neuronavigation surgery group, and in 8 participants in
the ‘standard surgery’ group, these deficits subsequently subsided either completely or partially. It is not
reported how neurological deficits were defined in the study.
 
Level of evidence of the literature
1. Overall survival (critical)
The level of evidence regarding the outcome measure overall survival was not assessed due to lack of
measures of dispersion.
 
2. Extent of resection (critical)
The level of evidence regarding the outcome measure extent of resection started as high as it was based on
an RCT and was downgraded by three levels to very low because lack of blinding, incomplete outcome data
(Willems, 2006) (-2 risk of bias), and confidence interval includes both harm and benefit (-1 imprecision).
 
3. Quality of life (critical)
The level of evidence regarding the outcome measure quality of life started as high as it was based on an RCT
and was downgraded by three levels to very low because lack of blinding, incomplete outcome data (Willems,
2006) (-2 risk of bias), and confidence interval includes both harm and benefit (-1 imprecision).
 
4. Progression free survival and (intracranial) response (important)
The level of evidence regarding the outcome measures progression free survival and (intracranial) response
was not assessed.
Gliomen
PDF aangemaakt op 
23-01-2025
64
/
971
 
5. Neurological/cognitive deterioration (important)
The level of evidence regarding the outcome measure neurological/cognitive deterioration started as high as
it was based on an RCT and was downgraded by three levels to very low because lack of blinding, incomplete
outcome data (Willems, 2006) (-2 risk of bias), and confidence interval includes both harm and benefit (-1
imprecision).
Zoeken en selecteren
A systematic review of the literature was performed to answer the following question: What is the effectivity
of advanced imaging for the benefit of treatment planning (radiotherapy, neurosurgery), compared to
conventional MRI in patients with glioma?
 
Patients:
 Patients with glioma or suspected of glioma for whom a treatment is planned
Intervention:
 Advanced imaging technique
[1]
: PET, DTI, fMRI, MRS, CEST, ASL DSC, DCE, intra
operative ultrasound, neuronavigation
Comparitor:
 Conventional MRI, structural MRI
Outcomes:
 Overall survival, progression free survival, (intracranial) response, neurological/cognitive
deterioration, extent of resection, quality of life
 
[1]
 DTI = diffusion tensor imaging; PET = positron emission tomography; fMRI = functional MRI; MRS = MR
spectroscopy; CEST = chemical exchange saturation transfer; ASL = arterial spin labeling; DSC = dynamic
susceptibility contrast; DCE = dynamic contrast enhanced.
 
Relevant outcome measures
The guideline development group considered overall survival, extent of resection and quality of life as a
critical outcome measure for decision making; and progression free survival and neurological/cognitive
deterioration as important outcome measures for decision making.
 
The working group defined the following minimal clinically (patient) important differences:
Survival (progression-free, or overall): hazard ratio < 0.7
Intracranial response: 0.5 SD
Extent of resection: 0.5 SD
Neurological/cognitive deterioration: EORTC cognitive functioning subscale ≥10 points
Quality of life: The minimum important difference (MID) has been estimated to be a difference of 0.08 or
more points for the EQ-5D utility index, seven or more points for the EQ-5D VAS (Pickard, 2007), or EORTC
global health status subscale ≥10 points
 
In all other cases, the working group defined the GRADE-standard limit of 25% difference for dichotomous
outcomes (RR < 0.8 or > 1.25), and 0.5 SD for continuous outcomes as a minimal clinically (patient) important
difference.
 
Search and select (Methods)
Gliomen
PDF aangemaakt op 
23-01-2025
65
/
971
The databases Medline (via OVID) and Embase (via Embase.com) were searched with relevant search terms
from 2014 until January 24
, 2022. The detailed search strategy is depicted under the tab Methods. The
systematic literature search resulted in 248 hits. Studies were selected based on the following criteria:
Systematic review (searched in at least two databases, and detailed search strategy, risk of bias
assessment and results of individual studies available), randomized controlled trial or observational
study comparing advanced imaging technique (PET, DTI, fMRI, MRS, CEST, ASL DSC, DCE, intra-
operative ultrasound) with conventional MRI/structural MRI);
Full-text English language publication;
Studies according to PICO.
A total of 29 studies were initially selected based on title and abstract screening. After reading the full text,
28 studies were excluded (see the table with reasons for exclusion under the tab Methods), and one study
was included (Willems, 2006). One systematic review matched the predefined PICO (Barbosa, 2014). This
review reported on six studies including Willems (2006), however only the randomized controlled trial by
Willems et al. (2006) matched the predefined PICO.
 
Results
One study was included in the analysis of the literature (Willems, 2006). Important study characteristics and
results are summarized in table 1 and the evidence tables. The assessment of the risk of bias is summarized in
the risk of bias tables.
Verantwoording
Laatst beoordeeld
 : 11-07-2023
Laatst geautoriseerd
 : 11-07-2023
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Barone, D. G., Lawrie, T. A., & Hart, M. G. (2014). Image guided surgery for the resection of brain tumours. Cochrane
Database of Systematic Reviews, (1).
2
 - Caras, A., Mugge, L., Miller, W. K., Mansour, T. R., Schroeder, J., & Medhkour, A. (2020). Usefulness and impact of
intraoperative imaging for glioma resection on patient outcome and extent of resection: a systematic review and meta-
analysis. World neurosurgery, 134, 98-110.
3
 - Willems, P. W., Taphoorn, M. J., Burger, H., van der Sprenkel, J. W. B., & Tulleken, C. A. (2006). Effectiveness of
neuronavigation in resecting solitary intracerebral contrast-enhancing tumors: a randomized controlled trial. Journal of
neurosurgery, 104(3), 360-368.
th
Gliomen
PDF aangemaakt op 
23-01-2025
66
/
971
Neuropathologie bij Gliomen
Deze submodule is onderverdeeld in de volgende sub-submodule:
Typering/gradering diffuse gliomen
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
Gliomen
PDF aangemaakt op 
23-01-2025
67
/
971
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
Gliomen
PDF aangemaakt op 
23-01-2025
68
/
971
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
Gliomen
PDF aangemaakt op 
23-01-2025
69
/
971
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
Gliomen
PDF aangemaakt op 
23-01-2025
70
/
971
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
Gliomen
PDF aangemaakt op 
23-01-2025
71
/
971
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
Gliomen
PDF aangemaakt op 
23-01-2025
72
/
971
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
Gliomen
PDF aangemaakt op 
23-01-2025
73
/
971
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
Gliomen
PDF aangemaakt op 
23-01-2025
74
/
971
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
Gliomen
PDF aangemaakt op 
23-01-2025
75
/
971
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
Gliomen
PDF aangemaakt op 
23-01-2025
76
/
971
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
Gliomen
PDF aangemaakt op 
23-01-2025
77
/
971
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
Gliomen
PDF aangemaakt op 
23-01-2025
78
/
971
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
Gliomen
PDF aangemaakt op 
23-01-2025
79
/
971
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
Gliomen
PDF aangemaakt op 
23-01-2025
80
/
971
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
Gliomen
PDF aangemaakt op 
23-01-2025
81
/
971
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
Gliomen
PDF aangemaakt op 
23-01-2025
82
/
971
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Gliomen
PDF aangemaakt op 
23-01-2025
83
/
971
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
Gliomen
PDF aangemaakt op 
23-01-2025
84
/
971
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
85
/
971
Typering/gradering diffuse gliomen
Uitgangsvraag
Op welke wijze dient typering/gradering van diffuse gliomen plaats te vinden?
Aanbeveling
Typeren en graderen van gliomen dient te worden gedaan conform de meest recente WHO-classificatie.
 
Bepaal de mutatiestatus van IDH bij alle gliomen. Bij patiënten van 55 jaar of jonger met negatieve
immuunhistochemie dient dit gevolgd te worden door sequencing voor IDH1 en 2 mutaties.
 
Onderzoek bij alle gliomen met IDH-mutatie de aan- of afwezigheid van 1p/19q-codeleties. Dit dient
onderzoek van de hele arm 1p en 19q te betreffen. Indien verlies van ATRX-expressie of een ATRX-mutatie is
aangetoond kan dit achterwege blijven.*
 
Verricht uitgebreide moleculaire karakterisering bij twijfel over de diagnose en verdenking op een glioom.
 
Onderzoek op de aanwezigheid van H3F3-K27-mutatie bij patiënten met een glioom in de midline, met name
in de thalamus, hersenstam, cerebellum of ruggenmerg.
 
Bepaal tenminste de MGMT-methyleringsstatus bij oudere patiënten en/of patiënten met een slechte
conditie met een glioblastoom (zie module Behandeling ouderen/kwetsbaren).
Overwegingen
In de in 2016 uitgebrachte, gereviseerde WHO-uitgave ‘WHO Classification of Tumors of The Central Nervous
System’ is een belangrijke verandering aangebracht in de definitie van de verschillende tumoren (Louis, 2016).
Waar in voorgaande edities de definities van de representanten van de diffuus infiltrerende gliomen steeds
gebaseerd waren op morfologische aspecten, zijn deze sinds de editie van 2016 bepaald door
discriminerende genetische mutaties die constant voorkomen en prognostische waarde vertegenwoordigen.
Dit betreft mutaties van het isocitraat-dehydrogenase-gen (IDH-mutant) en het gecombineerde verlies van de
chromosoomarmen 1p en 19q (1p/19q-codeletie). IDH-mutatie (IDHmut) is een prognostisch gunstig teken bij
astrocytaire tumoren en is diagnostisch voor de zogeheten IDHmut-astrocytomen (Wick, 2009; Eckel-Passow,
2015; Louis, 2016). Codeletie van 1p/19q tezamen met een IDH-mutatie is diagnostisch voor een
oligodendroglioom (Cairncross, 2013; van den Bent, 2015; Louis, 2016). Ook voor zeldzaam voorkomende
tumoren is de genetische handtekening definiërend geworden. Subsets van tumoren zoals het bij kinderen
voorkomend ‘diffuse midline glioma’ met een H3F3AK27M-mutatie gelden als een aparte diagnose.
 Het
voorkomen van de H3K27M-mutatie zonder de klinische context van een tumor op een midlinelocatie is
echter onvoldoende om de diagnose te stellen (Louis, 2016; Meyronet, 2017; Louis, 2018).
 
Het gaat om mutaties positie K27 van de histon-coderende genen H3F3A, HIT1H3B of HIST1H3C. De
mutatie H3F3A (kortweg H3.3 K27M) komt echter het meest voor en is als zodanig opgenomen in de WHO).
 
1
1
Gliomen
PDF aangemaakt op 
23-01-2025
86
/
971
Ook voor de gliomen uit de ‘circumscripte’ groep (pilocytair astrocytoom, ganglioglioom) hebben moleculaire
karakteristieken een belangrijke klinische betekenis verworven. Het pilocytair astrocytoom wordt genetisch
gekenmerkt door mutaties in de genen geassocieerd met mitogen-activated proteïne kinase (MAPK), in het
bijzonder het BRAF-gen. Afgezien van relevantie voor tumorclassificatie zijn bepaalde mutaties ook
geassocieerd met de tumormaligniteitsgraad. Zo zijn mutaties in astrocytaire IDH-wildtype (wt) tumoren van
TERT, PTEN of EGFR indicatief voor de diagnose glioblastoom.
 
In 2021 werd een herziene editie van de WHO-classificatie uitgebracht, waarin nieuwe inzichten in
tumornomenclatuur en gradering worden geïntroduceerd, en er een nog grotere rol voor moleculaire
diagnostiek is weggelegd. Het is belangrijk zich te realiseren dat de diagnostiek op basis van de thans in de
classificatie opgenomen mutaties op DNA-niveau een ‘moving target’ is. Het is goed mogelijk dat
toekomstige classificaties niet alleen andere mutaties zullen includeren, maar ook zullen worden uitgebreid
met karakteristieke expressiepatronen op RNA- en eiwitniveau en vooral op basis van verschillen in
methyleringsprofiel.
 
De transitie van de voorgaande WHO-edities naar de edities uit 2016 en 2021 waarin genetische definities
worden gehanteerd, is gecompliceerd. De problemen die zich kunnen voordoen zijn:
De aansluiting van de oude op de nieuwe terminologie; in het verleden op morfologie / immunohistochemie
gebaseerde diagnoses kunnen op basis van huidig moleculaire diagnostiek veranderen. Zo is de diagnose
oligoastrocytoom in essentie verdwenen.
In de herziene editie van de WHO-classificatie van hersentumoren wordt de term ‘NOS’ (not otherwise
specified) en ‘NEC’ (not elsewhere classified) toegepast. Indien moleculair onderzoek niet is verricht (om
welke reden dan ook) of indien het technisch niet mogelijk was, zou ‘niet anders omschreven’ (NOS) moeten
worden toegevoegd aan de diagnose, bijvoorbeeld: astrocytoom, WHO graad 2, NOS. Indien moleculair
onderzoek wel is verricht en valide resultaten opleverde, maar er geen diagnose binnen de WHO classificatie
aan kan worden gehangen, zou ‘niet elders te classificeren’ (NEC) moeten worden toegevoegd aan de
diagnose, bijvoorbeeld histologisch een oligodendroglioom, maar zonder IDH-mutatie: oligodendroglioom,
WHO graad 2 (of 3), NEC (Louis, 2018)
 
Diagnostische groepen
In onderstaande figuur worden de verschillende groepen diffuse gliomen weergegeven (Figuur 1). (kopie uit
Weller, 2021)
Gliomen
PDF aangemaakt op 
23-01-2025
87
/
971
 
Gradering van gliomen
Gliomen
PDF aangemaakt op 
23-01-2025
88
/
971
In de WHO-classificatie wordt bij de gliomen allereerst onderscheid gemaakt tussen diffuse en circumscripte
gliomen. Circumscripte gliomen betreffen bijvoorbeeld pilocytaire astrocytomen met een essentieel andere
genetische opmaak (geen IDH-mutaties, wel vaak andere mutaties zoals BRAF-KIAA), pleomorf
xanthoastrocytoma (PXA) en subependymale reuscel astrocytoma (SEGA). Deze richtlijn betreft alleen de
diffuse astrocytaire en oligodendrogliale tumoren; de circumscripte blijven gezien de zeer lage prevalentie
buiten beschouwing. De verschillende diagnostische categorieën zijn weergegeven in tabel 1.
 
De diffuse gliomen worden allereerst onderverdeeld in gliomen met en zonder IDH-mutatie; de IDH-
gemuteerde tumoren worden vervolgens onderverdeeld in astrocytomen of oligodendrogliomen op basis van
1p/19q-status. Oligodendrogliale tumoren zijn per definitie IDH-gemuteerd, dit geldt in de nieuwe
classificatie ook voor astrocytomen. IDH-mutant astrocytomen worden verder onderverdeeld in verschillende
tumorgraderingen op basis van CDKN2A/B status en histologische kenmerken (microvasculaire proliferatie en
necrose). IDH-wildtype gliomen worden glioblastoom genoemd. Patiënten met een graad 4, IDH-mutant
astrocytoom hebben een significant betere overleving dan patiënten met een IDH-wildtype glioblastoom.
(Shirahata 2018).
 
Tabel 1 Hoofdgroepen gliomen, conform WHO classificatie 2021
Diagnose
Moleculaire karakteristieken
Oligodendroglioom WHO graad
2
IDH mutant, 1p/19q codeletie
Oligodendroglioom WHO graad
3
IDH mutant, 1p/19q codeletie
Astrocytoom, IDHmut, WHO
graad 2
IDH mutant, CDKN2A/B wildtype, frequent ATRX en/of TP53 mutatie
Astrocytoom, IDHmut, WHO
graad 3
IDH mutant, CDKN2A/B wildtype, frequent ATRX en/of TP53 mutatie
Astrocytoom, IDHmut, WHO
graad 4
IDH mutant, CDKN2A/B homozygote deletie, frequent ATRX en/of TP53
mutatie
Glioblastoom, IDHwt
IDH wildtype, vaak TERT mutatie, EGFR amplificatie, +7/-10
Diffuus ‘midline’ glioom
IDH wildtype, H3K27 mutatie
Diffuus hemisferisch glioom
H3 G34-mutant
 
Astrocytoom, IDHmut, WHO graad 2, 3 en 4
In de vorige classificatie (2016) werden er twee soorten diffuse astrocytomen gedefinieerd: astrocytomen
IDHmut en astrocytomen IDHwt. In de huidige classificatie is er voor gekozen om alle IDH-mutante diffuse
astrocytomen onder dezelfde noemer te scharen (astrocytoom, IDH mutant) en binnen deze groep te
graderen als WHO graad 2, 3 of 4. De term glioblastoom is daarmee voor IDH-mutant astrocytomen in
onbruik geraakt en alleen nog gereserveerd voor IDH wildtype WHO graad 4 astrocytomen.
 
IDHmut astrocytomen bestaan uit cellen die de voor astrocyten typische cytoplasmatische uitlopers of een
meer afgeronde cytoplasmatische contour hebben (gemistocytair fenotype). De celkern is daarbij vaak
Gliomen
PDF aangemaakt op 
23-01-2025
89
/
971
vergroot en kan een abnormale vorm hebben. Zodra de polymorfie en pleomorfie van de cellen sterker zijn
en de astrocytaire kenmerken van astrocyten minder duidelijk zijn, veelal in combinatie met een hogere
celrijkdom en tevens het frequent voorkomen van mitosen, is de diagnose astrocytoom graad 3 morfologisch
van toepassing. Met name de morfologische afgrenzing tussen astrocytoom WHO-graad 2 en astrocytoom
WHO-graad 3 is subjectief.
 
Moleculaire veranderingen
De meeste diffuse astrocytomen hebben naast de kenmerkende IDH-mutaties ook mutaties in TP53 en ATRX.
In de context van een astrocytaire tumor met zowel IDH-mutatie als verlies van ATRX-expressie en/of sterke
p53-positiviteit kan de diagnose diffuus astrocytoom, IDH-mutant ook gesteld worden zonder testen van
1p/19q (Louis, 2018). Een homozygote deletie van CDKN2A/B is een belangrijke diagnostische en
prognostische marker in IDH-mutant astrocytomen. Omdat gebleken is dat een homozygote CDKN2A/B
deletie een zeer slechte prognose met zich meebrengt, rechtvaardigt de aanwezigheid van deze mutatie een
WHO graad 4 toekenning (astrocytoom, IDH-mutant, WHO graad 4), onafhankelijk van de histologische
gradering. (Brat, 2020) Indien dit type tumor geen mutatie in CDKN2A/B heeft, maar histologisch wel
microvasculaire proliferaties en/of necrose laat zien, is het nog steeds een graad 4 tumor, maar is de
prognose beter dan wanneer er wel een homozygote CDKN2A/B deletie aanwezig is. (Shirahata, 2018)
 
Oligodendroglioom
Het oligodendroglioom wordt gedefinieerd als een glioom met zowel een IDH-mutatie als het verlies van
zowel de hele korte arm van chromosoom 1 en de gehele lange arm van chromosoom 19 (gecombineerd
1p/19q-verlies). De klassieke morfologie bestaat uit cellen met ronde kernen waar omheen cytoplasma,
waarin geen intermediaire filamenten voorkomen, en dat door fixatie meestal verdwenen is. Hierdoor ontstaat
een honingraatstructuur van het tumorweefsel.
 
Oligodendrogliomen worden onderverdeeld in WHO-graad 2 en WHO-graad 3. Voor de morfologische
diagnose oligodendroglioom graad 3 is het voorkomen van microvasculaire proliferatie nodig, al of niet
vergezeld door gebieden met necrose. Morfologisch kunnen oligodendrogliomen graad 3 overlappen met
glioblastomen, die per definitie tot de astrocytaire tumoren behoren, echter de moleculaire eigenschappen
zijn leidend voor de diagnose.
 
Moleculaire veranderingen
Naast de diagnostische combinatie van IDH-mutatie en 1p/19q-codeletie zijn mutaties in de TERT-promotor
doorgaans aanwezig. De oligodendrogliale morfologie kan gezien worden bij andere tumoren zoals clearcell
ependymomen, neurocytomen, dysembryoplastische neuro-epitheliale tumoren, sommige metastasen, maar
deze tumoren missen de 1p/19q-codeletie. Anderzijds kan de oligodendrogliale genetische signatuur ook
gevonden worden in tumoren met overwegend astrocytaire morfologie, bijvoorbeeld tumoren met veel
gemistocytaire cellen, of in de randen van oligodendrogliomen, waar de morfologie van fibrillaire astrocyten
kan overheersen. De moleculaire signatuur is echter leidend voor de diagnose en prognose.
 
Glioblastomen, 
IDHwt, WHO graad 4
Gliomen
PDF aangemaakt op 
23-01-2025
90
/
971
Glioblastomen zijn diffuus infiltrerende astrocytomen van de hoogste maligniteitsgraad (WHO-graad 4),
gekenmerkt door kernatypie, mitosen, microvasculaire proliferatie en necrose waarin in wisselende mate nog
astrocytaire differentiatie wordt gezien.
 
Moleculaire veranderingen
Voor IDH-wildtype diffuse astrocytomen geldt dat de aanwezigheid van een 
TERT
 promotor (TERTp) mutatie,
en/of een 
EGFR
 gen amplificatie, en/of +7/-10 een graad 4 toekenning rechtvaardigt. De diagnose
glioblastoom, IDH-wildtype, WHO graad 4
 kan worden gesteld in IDH-wildtype gliomen met aanwezigheid
van necrose en/of microvasculaire proliferaties, en/of met aanwezigheid van één of meer van genoemde
moleculaire afwijkingen (Brat, 2018). Hoewel enige voorzichtigheid betracht dient te worden bij histologisch
graad 2 tumoren met enkel een TERTp mutatie (Berzero, 2021).
 
MGMT-promotormethylering
Patiënten met een WHO graad 4 glioom (IDHwt glioblastoom) met een gemethyleerde MGMT-promotor
hebben na behandeling met temozolomide mediaan een langere overleving dan patiënten zonder deze
methylering (Hegi, 2005; Wick, 2012). Echter ook bij patiënten zonder (aangetoonde) methylering van de
MGMT-promotor wordt de mediane overlevingsduur verlengd door behandeling met temozolomide, zij het
veel minder uitgesproken (Perry, 2017). Derhalve heeft de methyleringsstatus van MGMT zowel een
prognostische als predictieve waarde.
 
Diagnostische procedure
Histologische beoordeling (laesionaal, tumor of geen tumor, primair of metastatisch, diffuus of circumscript,
astro- of oligodifferentiatie, WHO-graad) dient altijd plaats te vinden op zo representatief mogelijk materiaal.
Het vaststellen van moleculaire kenmerken kan vervolgens op twee manieren gedaan worden. Middels een
next generation sequencing (NGS-)panel gericht op gliomen kunnen vrijwel alle voor gliomen relevante
moleculaire veranderingen worden opgespoord
. In geval van een histologisch niet diagnostisch biopt kan
moleculaire analyse soms toch een glioom op het spoor komen (Synhaeve, 2018). Een alternatieve en minder
kostbare manier om moleculaire veranderingen vast te stellen, is middels immuunhistochemie van
gemuteerde of overmatig tot expressie komende eiwitten. Mutatie van IDH1, EGFRvIII, TP53 en H3K27A leidt
tot expressie van een gemuteerd eiwit dat middels immuunhistochemie kan worden aangetoond. Ook ATRX-
mutatie kan immuunhistochemisch worden aangetoond door verlies van ATRX-expressie en sluit een
oligodendroglioom uit (Cancer Genome Atlas research Network, 2015).
 
 MGMT promotormethyleringsstatus wordt meestal in een aparte test bepaald.
De immunohistochemische test voor de expressie van het MGMT-eiwit correleert niet goed met gevoeligheid
voor alkylerende chemotherapie (Quillien, 2012).
 
Conclusie
De uiteindelijke diagnose is een geïntegreerde diagnose op basis van de morfologische en moleculaire
kenmerken. De gelaagde diagnose bestaat uit de histologische diagnose (tumorcategorie en WHO-graad),
gevolgd door (alle) resultaten uit het moleculair onderzoek.
Onderbouwing
1
1
Gliomen
PDF aangemaakt op 
23-01-2025
91
/
971
Achtergrond
In de richtlijn gliomen voor 2015 werd de diagnostiek van gliomen nog uitsluitend bepaald door microscopie,
eventueel met immunohistochemie. In 2018 werd de richtlijn gereviseerd aan de hand van de criteria zoals
neergelegd door de WHO in de gereviseerde vierde editie die in 2016 verscheen (Louis, 2016). In de laatste
jaren is de moleculaire karakterisering verder toegenomen en verbeterd. In 2021 is er een nieuwe, vijfde,
WHO-classificatie van centraal zenuwstelsel tumoren verschenen. Deze nieuwe classificatie is meegenomen in
de herziening van de richtlijn in 2022/2023.
Zoeken en selecteren
Om de uitgangsvraag te kunnen beantwoorden is geen systematische literatuuranalyse verricht maar is de
WHO-classificatie (Louis, 2016) gebruikt. Naast deze editie verschenen publicaties van auteurs van de WHO-
editie onder de titel cIMPACT-NOW (Consortium to Inform Molecular and Practical Approaches to CNS
Tumor Taxonomy – Not Official WHO) waarin additionele, bijgewerkte aanbevelingen worden gedaan. Ook
deze publicaties zijn meegenomen in deze modules. In ‘22/’23 is de module aangepast op basis van de vijfde
WHO-classificatie (2021).
Verantwoording
Laatst beoordeeld
 : 11-07-2023
Laatst geautoriseerd
 : 11-07-2023
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - van den Bent, M.J., Brandes, A.A., Taphoorn, M.J., et al. (2013). Adjuvant procarbazine, lomustine, and vincristine
chemotherapy in newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study
26951. J Clin Oncol; 31(3): 344-50.
2
 - Berzero G, Di Stefano AL, Ronchi S, Bielle F, Villa C, Guillerm E, Capelle L, Mathon B, Laurenge A, Giry M, Schmitt Y, Marie
Y, Idbaih A, Hoang-Xuan K, Delattre JY, Mokhtari K, Sanson M. IDH-wildtype lower-grade diffuse gliomas: the importance of
histological grade and molecular assessment for prognostic stratification. Neuro Oncol. 2021 Jun 1;23(6):955-966. doi:
10.1093/neuonc/noaa258. Erratum in: Neuro Oncol. 2023 Mar 21;: PMID: 33173941; PMCID: PMC8168809.
4
 - Brat, D.J., Aldape, K., Colman, H., Holland, E.C., Louis, D.N., Jenkins, R.B., Kleinschmidt-DeMasters, B.K., Perry, A.,
Reifenberger, G., Stupp, R., von Deimling, A., Weller, M. (2018). cIMPACT-NOW update 3: recommended diagnostic criteria
for "Diffuse astrocytic glioma, IDH-wild type, with molecular features of glioblastoma, WHO grade IV". Acta Neuropathol. 2018
Nov;136(5):805-810.
5
 - Cairncross, G., Wang, M., Shaw, E., et al. (2013). Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma:
long-term results of RTOG 9402. J Clin Oncol 31(3): 337-43.
6
 - Cancer Genome Atlas Research Network. (2015). Comprehensive, integrative genomic analysis of diffuse lower-grade
gliomas. New England Journal of Medicine, 372(26), 2481-2498.
7
 - Eckel-Passow, J.E., Lachance, D.H., Molinaro, A.M., et al. (2015). Glioma Groups Based on 1p/19q, IDH, and TERT Promoter
Mutations in Tumors. N Engl J Med 2015; 372(26): 2499-508.
8
 - Hegi, M., Diserens, A., Gorlia, T., et al. (2005). MGMT Gene Silencing and Benefit from Temozolomide in Glioblastoma. N
Engl J Med 2005; 352:997-1003.
9
 - Louis, D.N., Giannini, C., Capper, D., Paulus, W., Figarella-Branger, D., Lopes, M.B., Batchelor, T.T., Cairncross, J.G., van
den Bent, M., Wick, W., Wesseling P. (2018). cIMPACT-NOW update 2: diagnostic clarifications for diffuse midline glioma, H3
Gliomen
PDF aangemaakt op 
23-01-2025
92
/
971
K27M-mutant and diffuse astrocytoma/anaplastic astrocytoma, IDH-mutant. Acta Neuropathol. 2018 Apr;135(4):639-642.
1
0 - Louis, D.N., Perry, A., Reifenberger, G., et al. (2016). The 2016 World Health Organization Classification of Tumors of the
Central Nervous System: a summary. Acta Neuropathol 2016; 131(6): 803-20.
1
1 - Louis, D.N., Ohgaki, H., Wiestler, O.D., Cavenee, W.K., Ellison, D.W., Figarella-Branger, D., Perry A., Reifenberger G.,
Deimling von A. (2016). WHO classification of tumours of the Central Nervous System. 4 ed. Lyon: IARC.
1
2 - Louis, D.N., Wesseling, P., Paulus, W., Giannini, C., Batchelor, T.T., Cairncross, J.G., Capper, D., Figarella-Branger, D.,
Lopes, M.B., Wick, W., van den Bent, M. (2018). cIMPACT-NOW update 1: Not Otherwise Specified (NOS) and Not Elsewhere
Classified (NEC). Acta neuropathologica;135(3):481-484.
1
3 - Meyronet, D., Esteban-Mader, M., Bonnet, C., et al. (2017). Characteristics of H3 K27M-mutant gliomas in adults. Neuro
Oncol; 19(8): 1127-34.
1
4 - Perry, J.R., Laperriere, N., Mason, W.P. (2017). Radiation plus Temozolomide in Patients with Glioblastoma. N Engl J Med
2017;376:2197.
1
5 - Preusser, M., Charles Janzer, R., Felsberg, J., Reifenberger, G., Hamou, M.F., Diserens, A.C., Stupp, R., Gorlia, T., Marosi,
C., Heinzl, H., Hainfellner, J.A., Hegi, M. (2008). Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in
glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker.
Brain Pathol.;18(4):520-32.
1
6 - Quillien, V., Lavenu, A., Karayan?Tapon, L., Carpentier, C., Labussière, M., Lesimple, T., ... & Fina, F. (2012). Comparative
assessment of 5 methods (methylation?specific polymerase chain reaction, methylight, pyrosequencing, methylation?sensitive
high?resolution melting, and immunohistochemistry) to analyze O6?methylguanine?DNA?methyltranferase in a series of 100
glioblastoma patients. Cancer, 118(17), 4201-4211.
1
7 - Synhaeve, N.E., van den Bent, M.J., French, P.J., Dinjens, W.N.M., Atmodimedjo, P.N., Kros, J.M., Verdijk, R., Dirven,
C.M., Dubbink, H.J. (2018). Clinical evaluation of a dedicated next generation sequencing panel for routine glioma diagnostics.
Acta Neuropathol Commun. 23;6(1):126. doi: 10.1186/s40478-018-0633-y.
1
8 - Wick, W. et al. (2012). Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the
elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012; 13(7): 707-715.
1
9 - Wick, W., Hartmann, C., Engel, C., et al. (2009). NOA-04 randomized phase III trial of sequential radiochemotherapy of
anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide. J Clin Oncol; 27(35): 5874-80
Gliomen
PDF aangemaakt op 
23-01-2025
93
/
971
Behandeling Laaggradig glioom
Deze module is onderverdeeld in de volgende submodules en sub-submodules:
Klinisch prognostische factoren laaggradig glioom
Neurochirurgie
Resectie versus watchful waiting
Minimale mate van resectie bij laaggradig glioom
Radio-/Chemo-/systeemtherapie
Behandelingen bij laaggradig glioom
Recidief laaggradig glioom
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
Gliomen
PDF aangemaakt op 
23-01-2025
94
/
971
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
Gliomen
PDF aangemaakt op 
23-01-2025
95
/
971
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
Gliomen
PDF aangemaakt op 
23-01-2025
96
/
971
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
Gliomen
PDF aangemaakt op 
23-01-2025
97
/
971
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
Gliomen
PDF aangemaakt op 
23-01-2025
98
/
971
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Gliomen
PDF aangemaakt op 
23-01-2025
99
/
971
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Gliomen
PDF aangemaakt op 
23-01-2025
100
/
971
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
101
/
971
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Gliomen
PDF aangemaakt op 
23-01-2025
102
/
971
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
Gliomen
PDF aangemaakt op 
23-01-2025
103
/
971
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
Gliomen
PDF aangemaakt op 
23-01-2025
104
/
971
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
Gliomen
PDF aangemaakt op 
23-01-2025
105
/
971
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
Gliomen
PDF aangemaakt op 
23-01-2025
106
/
971
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
Gliomen
PDF aangemaakt op 
23-01-2025
107
/
971
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
Gliomen
PDF aangemaakt op 
23-01-2025
108
/
971
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
Gliomen
PDF aangemaakt op 
23-01-2025
109
/
971
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
Gliomen
PDF aangemaakt op 
23-01-2025
110
/
971
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
Gliomen
PDF aangemaakt op 
23-01-2025
111
/
971
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
112
/
971
Klinisch prognostische factoren laaggradig glioom
Uitgangsvraag
Wat zijn de klinisch prognostische factoren bij het laaggradig glioom?
Aanbeveling
De werkgroep is van mening dat onderstaande factoren nuttig zijn voor een onderbouwde inschatting van de
levensverwachting voor patiëntenvoorlichting en/of voor het identificeren van patiënten met een ongunstige
levensverwachting voor vroege behandeling bij het laaggradig glioom. Deze prognostische factoren zijn niet
gevalideerd voor toepassing als indicatiecriteria voor behandeling:
hogere leeftijd (afkapwaarde 40 jaar)
astrocytair subtype
grotere tumor (afkapwaarde 4 of 5 cm)
een tumor over de middenlijn
een slechtere conditie (KPS ≤80)
eloquente lokalisatie van de tumor
grotere diameter expansie
De werkgroep is van mening dat het bijhouden van een volume diametercurve prognostische informatie kan
geven over progressievrije overleving en levensverwachting en van pas kan komen bij timing van
behandeling.
Overwegingen
De prognostische factoren kunnen van pas komen om een onderbouwde inschatting van progressievrije
overleving en levensverwachting te kunnen geven in het kader van voorlichting. Belangrijk is hierbij te
realiseren dat de betrouwbaarheidsintervallen van deze schattingen groot zijn en dus de precisie van deze
schattingen van beperkte waarde.
Over het algemeen geldt dat bij aanwezigheid van een of meer ongunstige prognostische factoren vroege
behandeling en eventueel combinaties van behandelingen geadviseerd wordt. Daarbij is het belangrijk te
realiseren dat onbekend is of de effectiviteit van deze behandelingen verschilt tussen patiënten met een
hoger of lager risicoprofiel voor de levensverwachting. Deze prognostische factoren zijn daarom niet
gevalideerd voor toepassing als indicatiecriteria voor behandeling.
Het bijhouden van een volume diametercurve in de tijd gedurende de behandeling en follow-up geeft
additionele prognostische informatie over progressie en levensverwachting. Dit zou van meerwaarde kunnen
zijn voor de timing van vervolgbehandeling, maar dit is niet aangetoond.
Onderbouwing
Conclusies
Het is aannemelijk dat hogere leeftijd (afkapwaarde 40 jaar), astrocytair subtype, en grotere tumor
Gliomen
PDF aangemaakt op 
23-01-2025
113
/
971
(afkapwaarde 4 of 5 cm) ongunstige prognostische factoren zijn voor totale overleving en progressievrije
overleving. 
Pignatti 2002
, Gorlia 2013
, Chang 2008
, Youland 2013
Het is aannemelijk dat tumoruitbreiding over de middenlijn, een slechtere conditie, eloquente lokalisatie en
grotere diameterexpansie ongunstige prognostische factoren zijn.
Chang 2008
, Pallud 2009
Samenvatting literatuur
Pignatti [2002
] beschreef prognostische factoren voor totale overleving op basis van data van 322 patiënten
met een laaggradig glioom uit een klinische studie naar radiotherapie (constructieset) en valideerde de
prognostische factoren met data van 288 patiënten met een laaggradig glioom uit een andere klinische studie
(validatieset). De mediane follow-up was 6,6 jaar. In de multivariate analyse werden de volgende ongunstige
prognostische factoren vastgesteld: leeftijd ≥40 jaar, astrocytair subtype, grootste diameter ≥6 cm, tumor
over de middenlijn en aanwezigheid van neurologische functiestoornis. Een nieuwe analyse van dezelfde
constructieset werd beschreven door Gorlia [2013
] waarbij de aanwezigheid van neurologische
functiestoornis, een korte ziektegeschiedenis (<30 wk), astrocytair subtype, en tumordiameter >5 cm werden
vastgesteld als ongunstige prognostische factoren voor progressievrije overleving en totale overleving. De
factoren werden gevalideerd bij 450 patiënten van twee klinische studies. Drie risicogroepen (low,
intermediate en high) werden onderscheiden.
Chang beschreef prognostische factoren voor progressievrije overleving en totale overleving op basis van 281
patiënten met een laaggradig glioom uit een cohort van een centrum. De mediane follow-up was 5,8 jaar. In
de multivariate analyse werden deze ongunstige prognostische factoren vastgesteld: eloquente lokalisatie,
KPS ≤80, leeftijd>50 jaar en tumordiameter >4 cm [Chang 2008
].Chang valideerde deze prognostische
factoren bij data van 256 patiënten van drie andere ziekenhuizen. De som van deze prognostische factoren
met een weging van 1 per factor correspondeert met vier risicogroepen voor progressievrije overleving en
totale overleving.
De studie van Pallud beschrijft de volumetrische diameterexpansie (de diameter van het tumorvolume als
bolvorm; [2 x volume]^1/3, in de tijd) als prognostische factor voor maligne progressievrije overleving en
totale overleving op basis van 407 patiënten met een laaggradig glioom. De mediane follow-up was 7,2 jaar
[Pallud 2012
, Pallud 2013
]. Een expansie van ≥8 mm per jaar was een ongunstige prognostische factor
voor maligne progressievrije overleving (tijd tot maligne transformatie of overlijden) en totale overleving
onafhankelijk van leeftijd, tumorvolume, tumor over de middenlijn, contrastaankleuring en mate van resectie.
De studie van Youland beschrijft een groot cohort van 852 patiënten met een laaggradig glioom. De mediane
follow-up was 11,4 jaar. De volgende ongunstige prognostische factoren werden bevestigd in multivariate
analyse: leeftijd >40 jaar, astrocytaire subtype, tumordiameter ≥5 cm [Youland 2013
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
261
113
51
404
51
246
261
113
51
248
245
404
Gliomen
PDF aangemaakt op 
23-01-2025
114
/
971
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
Gliomen
PDF aangemaakt op 
23-01-2025
115
/
971
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
Gliomen
PDF aangemaakt op 
23-01-2025
116
/
971
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
Gliomen
PDF aangemaakt op 
23-01-2025
117
/
971
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
Gliomen
PDF aangemaakt op 
23-01-2025
118
/
971
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
Gliomen
PDF aangemaakt op 
23-01-2025
119
/
971
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
Gliomen
PDF aangemaakt op 
23-01-2025
120
/
971
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
Gliomen
PDF aangemaakt op 
23-01-2025
121
/
971
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
Gliomen
PDF aangemaakt op 
23-01-2025
122
/
971
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
Gliomen
PDF aangemaakt op 
23-01-2025
123
/
971
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
Gliomen
PDF aangemaakt op 
23-01-2025
124
/
971
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Gliomen
PDF aangemaakt op 
23-01-2025
125
/
971
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
Gliomen
PDF aangemaakt op 
23-01-2025
126
/
971
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
Gliomen
PDF aangemaakt op 
23-01-2025
127
/
971
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Gliomen
PDF aangemaakt op 
23-01-2025
128
/
971
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
Gliomen
PDF aangemaakt op 
23-01-2025
129
/
971
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
Gliomen
PDF aangemaakt op 
23-01-2025
130
/
971
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
Gliomen
PDF aangemaakt op 
23-01-2025
131
/
971
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
132
/
971
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
133
/
971
Neurochirurgie bij laaggradig glioom
Deze submodule is onderverdeeld in de volgende sub-submodules:
Resectie versus watchful waiting
Minimale mate van resectie bij laaggradig glioom
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
Gliomen
PDF aangemaakt op 
23-01-2025
134
/
971
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
135
/
971
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
Gliomen
PDF aangemaakt op 
23-01-2025
136
/
971
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
137
/
971
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
Gliomen
PDF aangemaakt op 
23-01-2025
138
/
971
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
Gliomen
PDF aangemaakt op 
23-01-2025
139
/
971
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
Gliomen
PDF aangemaakt op 
23-01-2025
140
/
971
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
Gliomen
PDF aangemaakt op 
23-01-2025
141
/
971
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
Gliomen
PDF aangemaakt op 
23-01-2025
142
/
971
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
Gliomen
PDF aangemaakt op 
23-01-2025
143
/
971
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
Gliomen
PDF aangemaakt op 
23-01-2025
144
/
971
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Gliomen
PDF aangemaakt op 
23-01-2025
145
/
971
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Gliomen
PDF aangemaakt op 
23-01-2025
146
/
971
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
147
/
971
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
Gliomen
PDF aangemaakt op 
23-01-2025
148
/
971
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
Gliomen
PDF aangemaakt op 
23-01-2025
149
/
971
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
Gliomen
PDF aangemaakt op 
23-01-2025
150
/
971
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
Gliomen
PDF aangemaakt op 
23-01-2025
151
/
971
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
152
/
971
Resectie versus watchful waiting bij laaggradig glioom
Uitgangsvraag
Wat is de beste behandelingsstrategie bij een patiënt met een vermoedelijk laaggradig glioom in termen van
kwaliteit van leven, symptoom vrije overleving, progressie vrije overleving, morbiditeit, mortaliteit en totale
overleving: resectie versus ‘watchfulwaiting'?
Aanbeveling
Voor een patiënt met een vermoedelijk laaggradig glioom dienen de risico's en de voordelen van de
verschillende behandelstrategieën, waaronder vroege resectie, biopt of watchful waiting, individueel
afgewogen te worden in een multidisciplinaire hersentumorwerkgroep.
De beslissing over de eerste behandelstappen bij een patiënt met een vermoedelijk laaggradig glioom dient
in multidisciplinair overleg genomen te worden waarbij tenminste aanwezig is: een neurochirurg met ervaring
met intraoperatieve stimulatiemapping van hersenfuncties, een neuroloog met oncologische expertise, een
neuroradioloog, een radiotherapeut, een oncoloog en optioneel een klinisch neuropsycholoog. Idealiter
wordt in de werkgroep een eerste behandelkeuze met de alternatieven geformuleerd.
De patiënt met een vermoedelijk laaggradig glioom dient daarna zo goed mogelijk geïnformeerd te worden
over het natuurlijk beloop en de verschillende behandelmogelijkheden op basis van de recente literatuur. De
onzekerheden van het effect van de behandelingen op overleving, kwaliteit van leven, progressievrije
overleving, morbiditeit en mortaliteit zijn onderdeel van de voorlichting.
Mogelijke argumenten voor een watchful waiting beleid kunnen bestaan uit:
twijfel aan de radiologische diagnose diffuus laaggradig glioom (ten opzichte van een benigne
aandoening)
het ontbreken van gerandomiseerd onderzoek naar het verschil in uitkomst tussen watchful waiting en
een resectie;
onzekerheid over het effect van een resectie op cognitie of kwaliteit van leven
het uitstellen van risico's op morbiditeit en mortaliteit van een vroege resectie
comorbiditeit die gepaard gaat met hogere morbiditeit en mortaliteit van een resectie.
Mogelijke argumenten voor een biopt kunnen bestaan uit:
twijfel aan de radiologische diagnose diffuus laaggradig glioom
het bepalen van moleculaire markers
de verwachting van een beperkte mate van resectie
uitgebreide infiltratie die past bij gliomatosis (zie module 
behandeling Gliomatosis cerebri
)
het vermijden van risico's op morbiditeit en mortaliteit (bijvoorbeeld door comorbiditeit) van een
resectie.
Gliomen
PDF aangemaakt op 
23-01-2025
153
/
971
Mogelijke argumenten voor een vroege resectie kunnen bestaan uit:
het verkrijgen van een representatieve histopathologische diagnose
het bepalen van moleculaire markers
het verminderen van neurologische en cognitieve symptomen
het verminderen van epileptische verschijnselen of nastreven van aanvalsvrijheid
het verlengen van tijd tot progressie
het verlengen van tijd tot hooggradige dedifferentiatie
het verlengen van levensverwachting
het verbeteren van respons op radiotherapie of chemotherapie
het voorkómen van een resectie van een grotere tumor op hogere leeftijd.
Over het algemeen zal bij een patiënt met één of meer risicofactoren (zie module 
Klinisch prognostische
factoren laaggradig glioom
) eerder een vroege resectie overwogen worden.
Onderbouwing
Conclusies
Voor de zoekvraag werd ‘watchful waiting' aanvankelijk gedefinieerd als een beleid zonder vroege
tumorbehandeling (operatie, bestraling of chemotherapie), zonder een weefseldiagnose bij een vermoedelijk
laaggradig glioom op basis van een MRI. Omdat voor deze vraag geen vergelijkende studies werden
gevonden, werd de zoekvraag uitgebreid en ‘watchful waiting' gedefinieerd als een beleid zonder vroege
tumorbehandeling met een weefseldiagnose door een hersenbiopt.
Kritische uitkomstmaten
Voor de overleving van patiënten met een diffuus laaggradig glioom is op basis van het beschikbare bewijs
geen directe vergelijking mogelijk tussen vroege resectie en watchful waiting 
zonder
 biopt, omdat geen
vergelijkende studies zijn gevonden.
Er is wetenschappelijk bewijs van lage kwaliteit dat de totale overleving van patiënten met een diffuus
laaggradig glioom na vroege resectie langer is dan na watchful waiting 
met 
een biopt. De invloed van
patiëntenselectie hierop is niet vastgesteld.
Pallud 2013
, Jakola 2012
, Jakola 2013
, De Mecado Bianco 2012, Sahgal 2013
, Schomas 2009
Enkel voor de subgroep van patiënten met een laaggradig astrocytoom in niet-eloquente gebieden is er
bewijs van lage kwaliteit dat de totale overleving significant beter is na resectie dan na biopsie, maar bij
gebrek aan risicocorrectie zijn deze resultaten onbetrouwbaar.
Bianco 2013
Er is geen wetenschappelijk bewijs beschikbaar over het effect van resectie versus biopsie / watchful waiting
van een laaggradig glioom op de kwaliteit van leven.
Belangrijke uitkomstmaten
247
149
150
288
302
17
Gliomen
PDF aangemaakt op 
23-01-2025
154
/
971
Voor patiënten met een diffuus laaggradig glioom is er bewijs van lage kwaliteit dat de progressievrije
overleving na resectie significant beter is dan na biopsie / watchful waiting.
Jakola 2012
, Jakola 2013
, Pallud 2013
Er is geen wetenschappelijk bewijs beschikbaar over het effect van resectie versus biopsie / watchful waiting
van een diffuus laaggradig glioom op de symptoomvrije overleving.
Voor patiënten met een diffuus laaggradig glioom is er bewijs van lage kwaliteit dat het aantal neurologische
en chirurgische complicaties en de operatieve mortaliteit na resectie niet significant hoger is dan na biopsie /
watchful waiting.
Jakola 2013
, Jakalo 2012
, Bianco 2013
Voor patiënten met een laaggradig glioom is er bewijs van lage kwaliteit dat het aantal maligne
transformaties na biopsie / watchful waiting significant hoger is dan na resectie. Bij gebrek aan risicocorrectie
zijn deze resultaten echter onbetrouwbaar.
Jakola 2012
Samenvatting literatuur
Voor de zoekvraag werd ‘watchful waiting' aanvankelijk gedefinieerd als een beleid zonder vroege
tumorbehandeling (operatie, bestraling of chemotherapie), zonder een weefseldiagnose bij een vermoedelijk
laaggradig glioom op basis van een MRI. Omdat voor deze vraag geen vergelijkende studies werden
gevonden, werd de zoekvraag uitgebreid en ‘watchful waiting' gedefinieerd als een beleid zonder vroege
tumorbehandeling met een weefseldiagnose door een hersenbiopt. Diffuus laaggradig glioom werd
gedefinieerd als WHO graad II glioom, zoals astrocytoom, oligodendroglioom of oligoastrocytoom (te
onderscheiden van WHO graad I gliomen, zoals pilocytair astrocytoom, ganglioglioom of dysembryoplastisch
neuro-epitheliale tumor). Publicaties werden geïncludeerd indien gepubliceerd na 2003 en met tenminste 30
patiënten. 
Met deze zoekvraag werden een Cochrane review [Veeravagu 2013
] en vier vergelijkende observationele
studies, beschreven in vijf publicaties [Jakola 2012
, Jakola 2013
, De MecadoBianco 2012, Sahgal
2013
, Schomas 2009
] geïdentificeerd. Na het uitwerken van de zoekvraag (23 oktober 2013) werd nog
een vijfde studie gepubliceerd die aan de criteria voldeed [Pallud 2013
].
Kwaliteit van het bewijs
De Cochrane review is van goede kwaliteit. Het risico op bias in de vijf vergelijkende observationele studies is
hoog. De vijf studies zijn retrospectief uitgevoerd. De vijf studies rapporteerden allen risicofactoren. Twee
studies corrigeerden voor risicofactoren in de analyse voor totale overleving [Jakola 2012
, Pallud
2013
].In geen enkele observationele studie werden de uitkomsten blind beoordeeld. In alle studies was
selectiebias aanwezig (selection on indication). Hierdoor zijn de gerapporteerde verschillen weinig
betrouwbaar.
Gewenste effecten
Effect op totale overleving (cruciale uitkomst)
In zes publicaties van vijf studies werd het effect op de totale overleving vergeleken tussen resectie en
149
150
245
150
149
17
149
364
149
150
288
301
245
149
245
Gliomen
PDF aangemaakt op 
23-01-2025
155
/
971
watchful waiting.
Een Cochrane review beoordeelde studies naar de klinische effectiviteit van een hersenbiopt vergeleken met
resectie bij nieuwe patiënten met een vermoedelijk laaggradig glioom [Veeravagu 2013
]. Veeravagu vond
geen gerandomiseerde gecontroleerde studies over deze vraag en beschrijft twintig studies die niet aan de
criteria voldeden in meer detail. De Cochrane review concludeert dat behandelaars vanwege het ontbreken
van gerandomiseerde studies voor elke patiënt de risico's en de voordelen van elke interventie individueel
moeten wegen totdat meer bewijs beschikbaar is. 
Jakola [2013
] beschrijft een populatiestudie met parallelle consecutieve cohorts bestaande uit 153
patiënten met een supratentorieel diffuus laaggradig glioom (WHO graad II) tussen 1998 en 2009 en een
mediane follow-up van 7 jaar: 66 patiënten uit een kliniek met een behandelvoorkeur voor watchful waiting
met biopt (47 ondergingen een biopt, 19 een vroege resectie) en 87 patiënten uit een kliniek met een
behandelvoorkeur voor vroege resectie (12 ondergingen een biopt, 75 een vroege resectie). De mediane
overleving in de kliniek met watchful waiting voorkeur was 5,9 jaar (95%CI 4,9 -7,3). De mediane overleving in
de kliniek met vroege resectie voorkeur werd in 10 jaar follow-up niet bereikt. De totale overlevig was
significant verschillend in het voordeel van de kliniek met vroege resectie voorkeur (log-rank p=0,01). De 5-
jaarsoverleving bedroeg 60% in de kliniek met watchful waiting voorkeur versus 74% in de kliniek met vroege
resectie voorkeur; de 7-jaarsoverleving bedroeg respectievelijk 44% en 68%. In de multivariate analyse met
correctie voor risicofactoren (leeftijd, preoperatieve tumor diameter, midlijn betrokkenheid, histologische
typering en neurologische symptomatologie) was de overleving ook significant verschillend in het voordeel
van de kliniek met vroege resectie voorkeur (HR 1,8; 95%CI 1,1-2,9; p=0,03).
Jakola beschrijft een subgroepanalyse gebaseerd op dezelfde studie [Jakola 2013
] van de 117 patiënten
met een laaggradig astrocytoom: 55 uit de kliniek met een behandelvoorkeur voor watchful waiting (43
ondergingen een biopt, 12 een vroege resectie), 62 uit de kliniek met een behandelvoorkeur voor vroege
resectie (11 ondergingen een biopt 51 een vroege resectie). De mediane overleving in de kliniek met
watchful waiting voorkeur was 5,6 jaar (95%CI 3,5-7,6). De mediane overleving in de kliniek met vroege
resectie voorkeur was 9,7 jaar (95%CI 7,5-11,9). De totale overleving was significant verschillend in het
voordeel van de vroege resectie kliniek (log-rank p=0,047). De 5-jaarsoverleving bedroeg 56% in de kliniek
met watchful waiting voorkeur versus 66% in de kliniek met vroege resectie voorkeur; de 7-jaarsoverleving
bedroeg 39% en 64%, respectievelijk. In multivariate analyse met correctie voor risicofactoren (leeftijd,
Karnofsky, preoperatieve tumor diameter, vroege radiotherapie) was de overleving ook significant
verschillend in het voordeel van vroege resectie voorkeur (HR 1,77; 95%CI1,02-3,05; p=0,041). 
De MacedoBianco beschrijft een cohort bestaande uit 82 patiënten met een hemisferisch laaggradig
astrocytoom tussen 1999 en 2008 met een mediane follow-up van 5 jaar [De MacedoBianco 2013]. Voor
tumoren in niet-eloquente gebieden werd een langere overleving gevonden bij 33 patiënten na vroege
resectie vergeleken met 9 patiënten na biopsie (4,7 versus 1,9 jaar, p=0,013). Voor tumoren in eloquente
gebieden werd geen verschil in overleving gevonden tussen 23 patiënten na vroege resectie en 17 patiënten
biopsie (4,5 versus 2,1 jaar; p=0,33). 
Sahgal beschrijft een cohort van verschillende universiteitsziekenhuizen, bestaande uit 182 patiënten met een
laaggradig astrocytoom tussen 1992 en 1996 en met een niet- beschreven follow-up duur [Sahgal 2013
].
De gemiddelde overleving was 5,5 jaar voor 84 patiënten na vroege resectie en 3,4 jaar voor 98 patiënten na
biopsie; statistische analyse werd niet gerapporteerd.
Schomas beschrijft een subgroepanalyse van een cohort van de Mayo Clinic, Rochester, VS, bestaande uit 32
patiënten ouder dan 55 jaar met een niet-pilocytair laaggradig glioom tussen 1960 en 1992 en een mediane
364
150
150
288
302
Gliomen
PDF aangemaakt op 
23-01-2025
156
/
971
follow-up van 17 jaar [Schomas 2009b
]. De mediane overleving van 16 patiënten na een vroege resectie
was 3,0 jaar en van 16 patiënten na een biopt was 2,2 jaar (p=0,57). 
Pallud beschrijft een cohort van verschillende universiteitsziekenhuizen bestaande uit 1509 patiënten met een
diffuus laaggradig glioom tussen 1992 en 2011 en een mediane follow-up van 7 jaar. Ten opzichte van 619
patiënten na biopt bestond geen verschil in overleving van 427 patiënten na partiële resectie (HR 0,95; 95%CI
0,76-1,19, p=0,663), een langere overleving van 313 patiënten na subtotale resectie (HR 0,62; 95%CI 0,47-
0,82, p=0,001, en een langere overleving van 150 patiënten na totale resectie (HR 0,32; 95%CI 0,20-0,53,
p<0,001). In de multivariate analyse met correctie voor risicofactoren (geslacht, leeftijd, epilepsie,
preoperatieve tumor diameter, midlijn betrokkenheid, tumor lokalisatie, pathologische typering,
radiotherapie en chemotherapie) bestond ten opzichte van de patiënten na biopt geen verschil in overleving
na partiële resectie (HR 1,10; 95%CI 0,87-1,40; p=0,409) of na subtotale resectie (HR 0,81; 95%CI 0,59-1,10;
p=0,169), wel na totale resectie (HR 0,51; 95%CI 0,30-0,88; p=0,016).
Kwaliteit van leven (cruciale uitkomst)
In geen van de gevonden studies werd het effect op kwaliteit van leven vergeleken tussen resectie en
watchful waiting.
Effect op progressievrije overleving (belangrijke uitkomst)
In drie publicaties van twee studies werd het effect op progressievrije overleving vergeleken tussen resectie
en watchful waiting [Jakola 2012
, Jakola 2013
, Pallud 2013
]. 
Jakola [Jakola 2012
] beschrijft voor patiënten met een diffuus laaggradig glioom een significant verschil in
progressie (nieuwe contrastaankleuring op MRI of WHO graad III/IV in nieuwe histopathologie) tussen biopt
en vroege resectie. Progressie werd geobserveerd in 56% van de 66 patiënten uit een kliniek met watchful
waiting voorkeur vergeleken met 37% van de 87 patiënten uit een kliniek met vroege resectie voorkeur
gedurende de follow-up (p=0,02). In de subgroep van patiënten met een laaggradig astrocytoom beschrijft
Jakola [Jakola 2013
] geen verschil in progressie tussen 56% van 66 patiënten uit een kliniek met watchful
waiting voorkeur vergeleken met 43% van de 62 patiënten uit een kliniek met vroege resectie voorkeur
gedurende de follow-up (p=0,163).
Pallud [Pallud 2013
] beschrijft voor patiënten met een diffuus laaggradig glioom een significant verschil in
progressie (nieuwe contrastaankleuring op MRI of WHO graad III/IV in nieuwe histopathologie) tussen biopt
en vroege resectie. Ten opzichte van 619 patiënten na biopt bestond een significant verschil in progressie
met 427 patiënten na partiële resectie (HR 0,83; 95%CI 0,71-0,97; p=0,019), met 313 patiënten na subtotale
resectie (HR 0,51; 95%CI 0,42-0,62; p<0,001) en met 150 patiënten na totale resectie (HR 0,29; 95%CI 0,21-
0,41; p<0,001). In de multivariate analyse met correctie voor risicofactoren bestond ten opzichte van de
patiënten na biopt ook een significant verschil in progressie na partiële resectie (HR 0,68; 95%CI 0,58-0,81;
p<0,001), na subtotale resectie (HR 0,43; 95%CI 0,35-0,53; P<0,001) en na totale resectie (HR 0,22; 95%CI
0,16-0,32; p<0,001).
Ongewenste effecten
Twee studies rapporteerden over neurologische complicaties na de ingreep [Jakola 2012
, Jakola 2013
,
Bianco 2013
]. Jakola vond geen significant verschil in nieuwe of toegenomen neurologische afwijkingen
binnen de 30 dagen na de ingreep (biopsie / watchful waiting 18% versus resectie 21%; p=0,70) [Jakola
2012a
]. Ook in de subgroep van 117 patiënten met een laaggradig astrocytoom vonden ze geen significant
302
149
150
245
149
150
245
149
150
17
149
150
Gliomen
PDF aangemaakt op 
23-01-2025
157
/
971
verschil (13% versus 21%; p=0.27) [Jakola 2013
]. Bianco rapporteerde een nieuwe blijvende neurologische
afwijking ten gevolge van de chirurgische ingreep bij 5% van de patiënten, maar zonder een vergelijking
tussen de twee behandelgroepen te rapporteren [Bianco 2013
].
Dezelfde twee studies rapporteerden ook over de perioperatieve mortaliteit. Jakola rapporteerde geen
significant verschil in 30-dagen mortaliteit tussen beide behandelgroepen (biopsie / watchful waiting 1%
versus resectie 0%; p=0.25) [Jakola 2012
]. Bianco vond geen operatieve mortaliteit voor de totale
populatie [Bianco 2013
].
Jakola vond geen significant verschil in chirurgische complicaties (biopsie / watchful waiting 9% versus
resectie 8%; p=0.82), zonder een goede definitie van deze complicaties te geven [Jakola 2012a
]. Bianco
rapporteerde een chirurgische infectie bij 2% van de patiënten, maar zonder een vergelijking tussen de twee
behandelgroepen te rapporteren [Bianco 2013
].
Tenslotte, Jakola rapporteerde significant meer maligne transformaties in de biopsiegroep (56% versus 37%,
p=0.02), maar zonder de cijfers te corrigeren voor risicofactoren [Jakola 2012a
].
Aanvullende consensus based samenvatting van de literatuur
Achtereenvolgens worden beschreven: andere (internationale) richtlijnen met aanbevelingen voor het beleid
bij diffuus laaggradig glioom, de literatuur van vóór 2004, observationele cohort studies van resectie of
watchful waiting, reviews over morbiditeit of mortaliteit van resectie of biopt en literatuur over een aantal
behandeldilemma's.
Twee recente richtlijnen zijn gepubliceerd over het beleid bij diffuus laaggradig glioom en doen
aanbevelingen voor de behandeling van het vermoedelijk laaggradig glioom op basis van een systematische
literatuursearch. 
De richtlijn van de European Association for Neuro-Oncology doet aanbevelingen op basis van level B bewijs
[Soffietti 2010
]. In deze richtlijn wordt resectie als eerste behandeloptie geadviseerd, met als doel aan de
ene kant maximaliseren van tumorverwijdering, en aan de andere kant minimaliseren van postoperatieve
morbiditeit. Een biopt (stereotactisch of open) zou kunnen plaatsvinden met als doel een histologische
diagnose, als een operatie niet haalbaar is (door de lokalisatie, uitgebreidheid of comorbiditeit).
De National Comprehensive Cancer Network beveelt, indien mogelijk, een maximale resectie aan met
vaststellen van de mate van resectie door een MRI binnen 72 uur na operatie [NCCN 2013
].
In de literatuur vóór 2004 werd een resectie vergeleken met watchful waiting met een biopt in zes niet-
gerandomiseerde vergelijkende observationele studies [Shaw 2002
, Jeremic 1998
, Van Veelen 1998
,
Rajan 1994
, Philippon 1993
, North 1990
]. In vijf van de zes studies werd een verschil beschreven in
totale overleving ten gunste van resectie, vergeleken met een biopt; in twee van de studies werd
gecorrigeerd voor risicofactoren. In één studie werd een verschil in progressievrije overleving vastgesteld ten
gunste van een uitgebreidere resectie.
Shaw includeerde 211 patiënten tussen 1986 en 1994 met een laaggradig glioom in een gerandomiseerde
studie naar lage en hoge dosis radiotherapie [Shaw 2002
]. Na vijf jaar was 71% van 103 patiënten na
biopsie in leven, vergeleken met 56% van 71 patiënten na een subtotale resectie en met 88% van 29
patiënten na een totale resectie (p=0,0151) na een mediane follow-up van 6,4 jaar. Tussen een totale resectie
en biopt (HR 0,38; p=0,07) en tussen subtotale resectie en biopt (HR 1,03; p=0,89) werd geen significant
verschil in overleving gevonden in multivariate analyse met correctie voor risicofactoren (leeftijd,
150
17
149
17
149
17
149
320
225
308
159
362
270
259
232
308
Gliomen
PDF aangemaakt op 
23-01-2025
158
/
971
preoperatieve tumor diameter, midlijn betrokkenheid, pathologische typering, radiotherapie en instituut).
Jeremic includeerde 37 patiënten tussen 1988 en 1993 met een supratentorieel laaggradig glioom [Jeremic
1998
]. Na vijf jaar was 58% van 19 patiënten na biopsie in leven, vergeleken met 94% van 14 patiënten na
een resectie (p=0,009) met een mediane follow-up van 6,2 jaar. 
Van Veelen includeerde 90 patiënten tussen 1975 en 1989 met een supratentorieel laaggradig glioom [Van
Veelen 1998
]. Na vijf jaar was 33% van 18 patiënten na biopsie in leven, vergeleken met 18% van 59
patiënten na een resectie <75% en met 62% van 13 patiënten na een resectie >75% (P<0,001). Na 5 jaar was
28% na biopsie progressievrij, vergeleken met 10% na een resectie <75% en 46% na een resectie >75%
(p<0,001).
Rajan includeerde 82 patiënten met een laaggradig glioom [Rajan 1994
]. De overleving na vijf jaar was 90%
bij 11 patiënten na een totale resectie, 52% bij 30 patiënten na subtotale resectie, 50% na partiële resectie en
42% na een biopt (p<0,05) met een mediane follow-up van 4,2 jaar. 
Philippon includeerde 174 patiënten tussen 1978 en 1987 met een supratentorieel laaggradig astrocytoom.
Na vijf jaar was 45% van 33 patiënten na een biopt in leven, 50% van 69 patiënten na een subtotale resectie
en 80% van 16 patiënten na totale resectie (p=0,00022). De operatieve behandeling was een significante
prognostische factor voor overleving (p<0,01) in multivariate analyse met correctie voor de risicofactoren
(leeftijd, lokalisatie, lateralisatie, contrast aankleuring, cyste, histologie en radiotherapie).
North includeerde 77 patiënten tussen 1975 en 1984 met een supratentorieel laaggradig glioom [North
1990
]. Na vijf jaar was 43% van 26 patiënten na biopsie in leven, vergeleken met 64% van 43 patiënten na
een subtotale resectie en met 85% van 8 patiënten na een totale resectie (p=0,002) met een mediane follow-
up van 5,8 jaar.
In de literatuur werden niet-vergelijkende observationele studies beschreven waarin de patiënten die een
biopt ondergingen werden ingedeeld bij patiënten met een beperkte resectie, of waarin de mate van resectie
als continue variabele werd geanalyseerd, of waarin patiënten na meer of minder uitgebreide resectie werden
beschreven [Capelle 2013
], Youland 2013
], Jung 2011
, Ahmadi 2009
, Smith 2008
, McGirt 2008
,
Schomas 2009
, Claus 2005
, Karim 1996
, Laws 1984
]. In negen van de tien niet-vergelijkende
observationele studies werd een verschil in totale overleving vastgesteld ten gunste van uitgebreidere
resectie, met in zeven studies correctie voor risicofactoren. In vier van de zes niet-vergelijkende
observationele studies werd een verschil in progressievrije overleving vastgesteld ten gunste van
uitgebreidere resectie, met in vier studies correctie voor risicofactoren.
Capelle includeerde 1097 patiënten tussen 1985 en 2007 met een laaggradig glioom [Capelle 2013
],
waarvan 272 patiënten na biopsie, 332 na een resectie met een tumorrest >10 ml, 262 na een resectie met
een tumorrest 0-10 ml en 80 na een totale resectie op basis van MRI. De totale overleving is in univariate
analyse sterk geassocieerd met het percentage tumorverwijdering (p<0,0001) met een mediane follow-up van
7,4 jaar. In de multivariate analyse is overleving eveneens geassocieerd met de mate van tumorverwijdering
(RR 0,569; 95%CI 0,382-0,847; p=0,0199) met correctie voor risicofactoren (leeftijd, Karnofsky, lokatie,
preoperatief tumorvolume, epilepsie).
Youland includeerde 852 patiënten tussen 1960 en 2011 met een laaggradig glioom [Youland 2013
],
waarvan 321 na biopsie, 211 na totale resectie op basis van MRI, 85 na resectie van 90-99%, en 235 na
resectie <90%. Na tien jaar was 60% van 296 patiënten na resectie >90% in leven en 33% van 556 patiënten
na resectie <90% (p<0.0001) met een mediane follow-up van 11,4 jaar. Na tien jaar was 34% van 296
patiënten na resectie >90% progressievrij en 16% van 556 patiënten na resectie <90% (p<0,0001).In de
159
362
270
232
43
404
160
2
319
214
301
62
163
197
43
404
Gliomen
PDF aangemaakt op 
23-01-2025
159
/
971
multivariate analyse is er een verschil in overleving (HR 0,51; 95%CI 0,40-0,65; p<0,0001) en in progressievrije
overleving (HR 0,44; 95%CI 0,36-0,54; p<0,0001) ten gunste van een resectie >90% in vergelijking met een
resectie <90% met correctie voor risicofactoren (leeftijd, hoofdpijn, epilepsie, taalstoornis, sensomotorische
stoornis, histologische subtypering, preoperatieve tumorgrootte, diepe ligging, contrastaankleuring,
radiotherapie en chemotherapie).
Jung includeerde 86 patiënten tussen 2000 en 2009 met een laaggradig glioom [Jung 2012], waarvan 40
patiënten na ‘totale' resectie, 22 na ‘subtotale' resectie en 24 na ‘partiële' resectie of biopt. Het type operatie
was geassocieerd met overleving (p<0,001) en met progressievrije overleving (p=0,001). De overleving is niet
geassocieerd met type operatie met correctie voor risicofactoren (leeftijd, Karnofsky, lokalisatie, histologische
subtypering, radiotherapie). In vergelijking met ‘partiële' resectie of biopt is de progressievrije overleving
gunstiger na ‘totale' resectie (HR 0,312; 95%CI 0,101-0,966; p=0,043) met correctie voor risicofactoren
(lokalisatie, diffuus groeipatroon, histologische subtypering, radiotherapie).
Ahmadi includeerde 130 patiënten tussen 1985 en 2003 met een laaggradig glioom [Ahmadi 2009
]. De
totale overleving bij 91 patiënten na totale resectie was gunstiger dan bij 39 patiënten na partiële resectie of
biopt (Logrankp=0,024) met een mediane follow-up van 7,8 jaar. De hazard ratio verschilde ten gunste van
totale resectie (HR 4,179; 95%CI 1,527-11,435) na correctie voor de risicofactoren (histologie, lokalisatie en
chemotherapie).
Smith includeerde 216 patiënten tussen 1989 en 2005 met een laaggradig glioom, waarbij biopten werden
geëxcludeerd [Smith 2008
]. Postoperatieve tumorrest (in mL) gemeten op MRI was geassocieerd met
overleving (HR 1,010; 95%CI 1,001-1,019, p=0,03) en met progressievrije overleving (HR 1,007; 95%CI 1,001-
1,014; p=0,035) in multivariate analyse met correctie voor risicofactoren (leeftijd, Karnofsky, lokalisatie,
histologische subtypering) met een mediane follow-up van 4,4 jaar. Het percentage tumorverwijdering was
geassocieerd met overleving (HR 0,972; 95%CI 0,960-0,983; p<0,001) in multivariate analyse met correctie
voor risicofactoren, en niet met progressievrije overleving (HR 0,992; 95%CI 0,984-1,001; p=0,088).
McGirt includeerde 170 patiënten tussen 1996 en 2007 met een laaggradig glioom [McGirt 2008
], waarvan
65 patiënten na totale resectie op basis van MRI, 39 na een bijna totale resectie met <3 mm resttumor en 66
na subtotale resectie met >3 mm resttumor. Na vijf jaar was 95% van 65 patiënten na totale resectie in leven,
80% van 39 na bijna totale resectie en 70% van 66 na subtotale resectie met een mediane follow-up van 4
jaar. Na tien jaar was dit 76%, 57% en 49%, respectievelijk. In vergelijking met patiënten na een subtotale
resectie was de overleving na een totale resectie gunstiger (HR 0,36; 95%CI 0,16-0,84, p=0,017) met correctie
voor risicofactoren (leeftijd, Karnofsky, histologische subtypering, preoperatieve, tumordiameter), maar niet
na een bijna totale resectie. De mediane progressievrije overleving na totale resectie was 7 jaar, na bijna
totale resectie 4 jaar en na subtotale resectie 3,5 jaar. In vergelijking met patiënten na een subtotale resectie
was de progressievrije overleving na een totale resectie gunstiger (HR 0,56; 95%CI 0,32-0,98, p=0,043) in
multivariate analyse met correctie voor risicofactoren (leeftijd, Karnofsky, histologische subtypering,
preoperatieve, tumordiameter), maar niet na een bijna totale resectie.
Schomas includeerde 134 patiënten tussen 1960 en 1992 met een laaggradig glioom, waarvan 41 patiënten
na ‘totale' resectie, 33 na ‘radicale subtotale' resectie, 130 na subtotale resectie en 110 na biopsie [Schomas
2009a
]. Na tien jaar was 30% van 240 patiënten na ‘subtotale' resectie of biopt in leven vergeleken met
57% van 74 patiënten na uitgebreidere resectie (p<0,001) met een mediane follow-up van 13,6 jaar. Een
uitgebreidere resectie was geassocieerd met totale overleving (RR 0,63; 95%CI 0,48-0,79; p=0,03) in
multivariate analyse met correctie voor risicofactoren (tumorgrootte, histologische subtypering,
symptomatologie, radiotherapie). Na tien jaar was 21% van 240 patiënten na ‘subtotale' resectie of biopt
2
319
214
301
Gliomen
PDF aangemaakt op 
23-01-2025
160
/
971
progressievrij vergeleken met 47% van 74 patiënten na uitgebreidere resectie (p<0,001). Een uitgebreidere
resectie was geassocieerd met progressievrije overleving (RR 0,74; 95%CI 0,55-0,96; p<0,001) met correctie
voor de risicofactor tumorgrootte. 
Claus includeerde 156 patiënten tussen 1997 en 2003 met een laaggradig glioom [Claus 2005
]. Geen
verschil werd gevonden tussen minder dan totale resectie en totale resectie in totale overleving (HR 4,9;
95%CI 0,61-40) of progressievrije overleving (HR 1,4; 95%CI 0,7-3.1) na correctie voor leeftijd met een
mediane follow-up van 3 jaar.
Karim includeerde 379 patiënten in een gerandomiseerde studie naar lage dosis versus hoge dosis
radiotherapie [Karim 1996
]. De mate van tumorverwijdering (156 patiënten na biopsie of <50% resectie,
103 patiënten na 50-89% resectie en patiënten na resectie >90%) was geassocieerd met overleving (p<0,01)
en met progressievrije overleving (p<0,001), ook in multivariate analyse met correctie voor risicofactoren
(leeftijd, conditie, en histologie) (p<0,05) met een mediane follow-up van 6,2 jaar.
Laws includeerde 461 patiënten tussen 1915 en 1975 met een supratentorieel laaggradig glioom. Na 5 jaar
was 32% van 356 patiënten na een biopt of ‘subtotale' resectie in leven, vergeleken met 44% van 48
patiënten na ‘radicale subtotale' resectie en met 61% van 57 patiënten na ‘totale' resectie (p<0.0001). 
In de literatuur werden twee niet-vergelijkende observationele studies beschreven met patiënten die watchful
waiting zonder biopt ondergingen [Reijneveld 2001
, Recht 1992
].
Reijneveld includeerde 24 patiënten tussen 1998 en 1999 met een vermoedelijk laaggradig glioom op basis
van beeldvorming en matchen deze cases met 24 controle patiënten met een laaggradig glioom na biopt of
resectie. Er werd geen verschil gevonden in Barthel Index, Neurologic Functional Status Scale, Karnofsky
Performance Scale en Cognitive Functioning Scale. In één van acht domeinen (vitaliteit, p<0,05) van de SF-38,
in twee van elf domeinen (motor dysfunctie, blaascontrole) van de BCM-20 en in een van vier domeinen
(psychomotor functioneren, p<0,005) van de Cognitive Performance Status werd een verschil gevonden ten
gunste van watchful waiting zonder biopt. Totale overleving of progressie-vrije overleving werd niet
geanalyseerd.
Recht includeerde 26 patiënten met een vermoedelijk laaggradig supratentoriaal glioom op basis van CT of
MRI die geen vroege behandeling ondergingen en 20 patiënten met een supratentorieel laaggradig glioom
die vroege behandeling ondergingen [Recht 1992
]. Bij 15 van 26 patiënten die aanvankelijk geobserveerd
werden, vond na uitstel van 4 tot 123 maanden alsnog een operatie plaats vanwege groei (4), epilepsie (4),
symptomatologie (3), en maligne transformatie (3). Bij 9 van 15 uitgestelde operaties werd een hooggradig
glioom vastgesteld (5 WHO graad III en 4 WHO graad IV). In 11 van 26 patiënten vond na 15 tot 98 maanden
observatie plaats. Er werd geen verschil in overleving gevonden(p=0,65) met een mediane follow-up van 3,8
jaar.
Een aantal reviews beschrijft argumenten die betrokken kunnen worden bij een behandeladvies voor
patiënten met een laaggradig glioom.
In een systematische review werd het therapeutisch effect van mate van resectie bij glioom beschreven, onder
andere voor laaggradig glioom [Sanai 2008
]. Sanai identificeerde drie studies met volumetrische data op
basis van MRI metingen na operatie voor laaggradig glioom, waarvan drie studies een gunstiger 5-
jaarsoverleving beschreven na uitgebreidere resecties.
In een meta-analyse werd de neurologische morbiditeit en mortaliteit van resectie bij glioom beschreven [De
Witt Hamer 2012
]. Op basis van 90 publicaties met 8091 patiënten werd een permanente nieuwe
62
163
277
274
274
291
76
Gliomen
PDF aangemaakt op 
23-01-2025
161
/
971
neurologische functiestoornis beschreven bij 7,1% (95%CI 5,3-9,0%), een permanent ernstige functiestoornis
bij 4,6% (95%CI 3,3-6,1%) en operatieve mortaliteit bij 0,26% (95%CI 0,01-0,50%). Resecties met
intraoperatieve stimulatie mapping van hersenfuncties gingen gepaard met minder permanent ernstige
neurologische functiestoornissen dan resecties zonder stimulatie mapping (OR 0,39; 95%CI 0,23-0,64).
In een review werden de effecten van resectie op de cognitie beschreven en werd geconcludeerd dat dit niet
systematisch onderzocht is, maar dat zowel verbetering als achteruitgang werd waargenomen [Klein 2012
].
Satoer includeerde 45 patiënten met een resectie van een glioom met eloquente lokalisatie, waarvan 27 met
een laaggradig glioom [Satoer 2014
]. In vergelijking met gezonde controles onderpresteerden patiënten
met een laaggradig glioom voor en na operatie in alle cognitieve domeinen. Drie maanden na operatie trad
cognitieve verbetering op voor geheugen (verbalrecall: t=-1,931; p=0,034) en cognitieve achteruitgang voor
taal (category fluency: t=2,517; p=0,030) ten opzichte van preoperatief. Tussen 3 maanden en 1 jaar na
operatie verbeterde de taal (naming: t=-2,781; p=0,026 en letter fluency: t=-1,975; p=0,047). Ernstige
cognitieve achteruitgang werd niet waargenomen (taal, geheugen, aandacht en executie). 
Een review over de morbiditeit en mortaliteit van een biopt bij glioom werd niet gevonden. In twee
publicaties na 2003 met meer dan 100 patiënten werd morbiditeit en mortaliteit van een biopt beschreven.
McGirt beschreef een permanente nieuwe neurologische functiestoornis bij 13 (5%) en postoperatieve
mortaliteit bij 3 (1%) van 270 patiënten na een hersenbiopt [McGirt 2005
]. Kongkham beschreef een
permanente neurologische functiestoornis bij 9 (1,5%) en postoperatieve mortaliteit bij 8 (1,3%) van 622
patiënten na een hersenbiopt [Kongkham 2008
].
De radiologische diagnose ‘vermoedelijk laaggradig glioom' op basis van MRI is niet accuraat volgens de
literatuur. Scott beschreef bij 21 (36%) van 58 patiënten met vermoedelijk laaggradig glioom op basis van
afwezigheid van contrastaankleuring een histologische gradering van WHO graad III [Scott 1992]. Meyer
beschreef bij 12 (46%) van 26 patiënten met vermoedelijk laaggradig glioom een histologische gradering van
WHO graad III [Meyer 2001
]. Pallud beschreef bij 143 (16%) van 927 patiënten met een WHO graad II
glioom contrastaankleuring [Pallud 2009
]. 
De histologische diagnose na een biopt komt niet overeen met de histologische diagnose na een resectie
volgens de literatuur: Jackson beschrijft bij 40 (49%) van 82 patiënten na een biopt voor een glioom een
andere histologische diagnose na resectie binnen 60 dagen na het biopt [Jackson 2001
]. Dit had
therapeutische consequenties bij 27 (33%) patiënten. Bij 13 (72%) van 18 patiënten met een histologische
diagnose WHO graad II na biopt was sprake van een WHO graad III of IV. Jackson reviewde 6 studies en
concludeerden dat de diagnostische precisie van een biopt 62-95% was in vergelijking met een histologische
diagnose op materiaal van een resectie.
Tot slot komt een aantal behandeldilemma's in de praktijk voor, dat gepaard gaat met meer onzekerheid
over de behandelstrategie op basis van de literatuur: ten eerste een vermoedelijk laaggradig glioom als
toevalsbevinding op beeldvorming, ten tweede een supratotale resectie voor een vermoedelijk laaggradig
glioom.
Beeldvorming bijvoorbeeld na een neurotrauma of de controlegroep in radiologisch onderzoek doet een
laaggradig glioom als toevalsbevinding, vermoeden bij 1 op 2000 MRI-onderzoeken [Morris 2009
]. Er
bestaat geen vergelijkend onderzoek tussen vroege en late behandeling bij patiënten met een laaggradig
glioom als toevalsbevinding. Voorstanders van een vroege resectie argumenteren dat de voordelen van
resectie van een laaggradig glioom in een zeer vroeg stadium groter kunnen zijn, omdat de tumor nog kleiner
is en completer operatief te verwijderen, terwijl de morbiditeit lager kan zijn [Kelly 2010
; Pallud 2010
;
177
298
216
180
217
246
147
222
168
247
85
263
Gliomen
PDF aangemaakt op 
23-01-2025
162
/
971
Duffau 2012
; Potts 2012
]. Voorstanders van een late behandeling argumenteren dat de nadelen van een
resectie veilig uitgesteld kunnen worden als MRI-follow-up plaatsvindt [Shah 2011
].
Er bestaat geen vergelijkend onderzoek voor een resectie met een ruime marge van niet-MRI-afwijkend
weefsel, een zogenaamde supratotale resectie. Voorstanders van een supratotale resectie argumenteren dat
een supratotale resectie waarschijnlijk een groter deel van de infiltrerende glioomcellen kan verwijderen mits
uitgevoerd met intraoperatieve stimulatie mapping voor hersenfuncties [Yordanova 2011
].
In de meerderheid van bovengenoemde studies wordt een betere overleving bij resectie gemeld dan bij de
‘watchful waiting' benadering. Dit behoeft enige nuancering. Alle genoemde artikelen zijn retrospectief van
aard of betreffen cohortstudies en kunnen dus geen uitsluitsel geven over welke benadering superieur is.
Prospectief gerandomiseerde studies zullen zeer waarschijnlijk niet snel uitgevoerd worden vanwege ethische
bezwaren. De belangrijkste problemen in de genoemde studies zijn de selectie bias en de eerder genoemde
sampling error bij biopsie en beeldvorming bij een vermoedelijk laaggradig glioom. Zeer waarschijnlijk spelen
de publicatiebias en conformation bias ook een rol, maar deze worden nu buiten beschouwing gelaten.
Hoewel een aantal studies corrigeert voor pathologische, klinische en radiologische karakteristieken in de
multivariate analyse, kan niet worden uitgesloten dat onbekende factoren een rol kunnen spelen bij de
selectie door de chirurg om te kiezen voor een radicalere benadering in plaats van watchful waiting. Een
voorbeeld is de delineatie van de tumor op MRI. Hier wordt in geen van de genoemde artikelen voor
gecorrigeerd. Een tumor met scherpe delineatie op MRI is over het algemeen makkelijker en ‘radicaler' te
opereren, maar heeft ook een betere prognose dan een infiltrerend laaggradig astrocytoom volgens
sommigen [Ius 2012
], terwijl andere auteurs dit weerspreken [Chang 2008
]. Hoe scherper de delineatie op
MRI, hoe eerder een chirurg zou kunnen beslissen om te opereren. De betere overleving kan zo gemakkelijk
gerelateerd worden aan chirurgie, terwijl patiënten met een dergelijke tumor in feite al op voorhand een
betere prognose hebben.
De keuze voor een behandeling kan afhankelijk zijn van veel factoren (zie aanbeveling). Belangrijk is om de
patiënt goed te informeren over de voor- en nadelen van de verschillende behandelopties. Vooralsnog blijkt
uit de literatuur niet dat een watchful waiting behandeling nadelig is voor geselecteerde patiënten met een
laaggradig glioom [Whittle 2010
]. De benadering van Whittle kan misschien dienen als voorbeeld, waarbij
het uitgangspunt is dat de patiënt zich comfortabel moet voelen met zijn of haar keuze voor een
behandelstrategie, en dat het behandelteam dit beter vanuit een zekere flexibiliteit kan benaderen dan vanuit
dogma.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
85
263
307
402
145
50
385
Gliomen
PDF aangemaakt op 
23-01-2025
163
/
971
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
Gliomen
PDF aangemaakt op 
23-01-2025
164
/
971
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
Gliomen
PDF aangemaakt op 
23-01-2025
165
/
971
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
Gliomen
PDF aangemaakt op 
23-01-2025
166
/
971
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
Gliomen
PDF aangemaakt op 
23-01-2025
167
/
971
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
Gliomen
PDF aangemaakt op 
23-01-2025
168
/
971
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
Gliomen
PDF aangemaakt op 
23-01-2025
169
/
971
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
Gliomen
PDF aangemaakt op 
23-01-2025
170
/
971
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
Gliomen
PDF aangemaakt op 
23-01-2025
171
/
971
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
Gliomen
PDF aangemaakt op 
23-01-2025
172
/
971
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
Gliomen
PDF aangemaakt op 
23-01-2025
173
/
971
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
174
/
971
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
Gliomen
PDF aangemaakt op 
23-01-2025
175
/
971
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
Gliomen
PDF aangemaakt op 
23-01-2025
176
/
971
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Gliomen
PDF aangemaakt op 
23-01-2025
177
/
971
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
Gliomen
PDF aangemaakt op 
23-01-2025
178
/
971
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
Gliomen
PDF aangemaakt op 
23-01-2025
179
/
971
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
Gliomen
PDF aangemaakt op 
23-01-2025
180
/
971
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
Gliomen
PDF aangemaakt op 
23-01-2025
181
/
971
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
182
/
971
Minimale mate van resectie bij laaggradig glioom
Uitgangsvraag
Wat is de minimale mate van resectie die zinvol is bij een patiënt met een laaggradig glioom?
Aanbeveling
Er is geen minimale mate van resectie aan te geven die zinvol is bij de indicatiestelling voor een operatie bij
een patiënt met een vermoedelijk laaggradig glioom. Er zijn aanwijzingen dat een grotere mate van resectie
zinvol kan zijn, maar er is geen minimaal zinvol percentage tumorverwijdering aan te geven en de
betrouwbaarheid van de preoperatieve inschatting van de mate van resectie door de neurochirurg is onzeker.
In het geval een resectie wordt uitgevoerd, is het meten van de mate van resttumor en de mate van
tumorverwijdering met behulp van pre- en postoperatieve MRI (flairopnames) te overwegen (zie module
Beeldvormende diagnostiek
).
Overwegingen
Omdat de mate van resectie alleen na een operatie vastgesteld kan worden en niet voorafgaand of tijdens
een operatie, is de uitgangsvraag ook in de toekomst niet te beantwoorden met een gerandomiseerde
studieopzet. Een grote of kleine mate van resectie kan niet tussen patiënten worden gerandomiseerd.
Bij de interpretatie van bovengenoemde studies is het evenwel een gegeven dat resultaten retrospectief zijn
en sterk beïnvloed kunnen zijn door selectiebias. Fittere patiënten ondergaan immers de meer uitgebreide
resecties, maar omdat gerandomiseerde data ontbreken kan geen uitspraak worden gedaan of de goede
performance vooraf óf de mate van resectie de belangrijkste parameter voor langere overleving is.
In de besproken literatuur werden verschillende methodes gebruikt om het resectiepercentage van de tumor
te meten. Tegenwoordig is volumemeting met flairopnames gebruikelijk, maar nog niet gestandaardiseerd.
Studies waarin gebruik gemaakt wordt van de impressie van de chirurg als mate van resectie via
operatieverslagen zijn onvoldoende betrouwbaar [Orringer 2012
].
De patiënten die in deze publicaties werden beschreven zijn geselecteerd op basis van de histopathologische
gradering die pas dagen na een operatie bekend is. Voor patiënten waarbij een inschatting gedaan wordt
over de minimale mate van resectie voorafgaand aan een operatie staat in de klinische praktijk (nog) niet vast
dat het daadwerkelijk een laaggradig glioom betreft. Wellicht verschilt de minimale mate van resectie bij een
anaplastisch glioom van een laaggradig glioom.
Het is niet bekend in hoeverre de preoperatieve schatting van mate van resectie correspondeert met de
behaalde mate van resectie voor deze patiënten. Zodoende is de waarde hiervan voor het selecteren van
patiënten voor een ‘zinvolle' resectie onduidelijk.
Onderbouwing
Conclusies
Er zijn aanwijzingen dat een grotere mate van resectie bij een laaggradig glioom gepaard gaat met een
241
Gliomen
PDF aangemaakt op 
23-01-2025
183
/
971
langere overleving en langere tijd tot progressie.
Pallud 2014
, Youland 2013
, Capelle 2013
, Ius 2012
, Schomas 2009
, McGirth 2008
, Smith
2008
Er zijn aanwijzingen dat bij een laaggradig glioom een langere overleving wordt behaald bij een minimaal
percentage tumorverwijdering van respectievelijk 40%, 50%, 70%, 90%, of 100%; of als alternatieve mate van
resectie uit een maximaal restvolume van nul mL, 10 mL, 15 mL, of 30 mL. Er is dus geen eenduidige
minimale mate van resectie die de overleving verlengt.
Smith 2008
, Capelle 2013
, Ius 2012
, Youland 2013
, Schomas 2009
, McGirth 2008
, Pallud
2014
Samenvatting literatuur
In de literatuur werd geen publicatie gevonden die deze uitgangsvraag als onderzoeksvraag direct
beantwoordt. In vergelijkend onderzoek in cohorten van patiënten die een operatie ondergingen voor een
laaggradig glioom werd de mate van resectie weergegeven als percentage verwijderd tumorvolume of als
restvolume. Deze parameters werden verschillend gecategoriseerd zonder dat duidelijk wordt op welke
gronden deze categorieën tot stand kwamen.
Hiernavolgend worden de publicaties besproken die (a) meer dan 100 patiënten na operatie voor laaggradig
glioom beschreven, (b) de mate van resectie baseerden op MRI-metingen, en (c) na 2000 werden
gepubliceerd.
In zeven retrospectieve chirurgische series werd een significante associatie vastgesteld tussen overleving en
uitgebreidere mate van resectie, waarbij de mate van resectie soms gekwantificeerd werd als percentage
tumorverwijdering, soms als rest tumorvolume in mL.
Pallud [Pallud 2014
] beschreef 1509 patiënten tussen 1992 en 2011, waarvan 890 een resectie ondergingen
en 619 een biopsie. Pre- en postoperatieve tumorvolumes werden gemeten op de flair- opnames van de MRI.
Partiële resectie werd gedefinieerd als een restvolume ≥ 10 mL (427 patiënten), subtotale resectie als een
restvolume < 10 mL maar > 0 mL (313 patiënten), en een totale resectie als afwezigheid van restvolume (150
patiënten) op de MRI. Ten opzichte van de subgroep met biopsie of partiële resectie was de overleving
langer bij totale resectie (HR: 0,51; 95%CI 0,30-0,88; p = 0,016) en bij subtotale resectie (HR: 0,81; 95%CI
0,59-1,10; P = 0,169). De tijd tot overlijden of maligne transformatie was langer na totale resectie (HR: 0,22;
95%CI 0,16-0,32; p <0,001) en na subtotale resectie (HR: 0,43; 95%CI 0,35-0,53; p <0,001) ten opzichte van
de subgroep na biopsie of partiële resectie.
Youland [Youland 2013
] beschreef 852 patiënten tussen 1960 en 2011, waarvan een subgroep van 517
patiënten werd behandeld tussen 1990 en 2011, waarbij 349 patiënten een resectie ondergingen en 222
patiënten een biopsie. De mate van resectie werd bepaald door pre- en postoperatieve beeldvorming te
vergelijken of, indien dit niet beschikbaar was, via de operatieverslagen. Totale resectie werd gedefinieerd als
afwezigheid van resttumor op MRI (176 patiënten), radicale subtotale resectie als een verwijderd volume van
> 90% (55 patiënten), en subtotale resectie als een verwijderd volume van < 90% (118 patiënten). Na totale of
radicale subtotale resectie leefden patiënten langer ten opzichte van de subgroep met biopsie of subtotale
244
404
43
145
301
214
319
319
43
145
404
301
214
244
244
404
Gliomen
PDF aangemaakt op 
23-01-2025
184
/
971
resectie (gecorrigeerde risico ratio: 0,61; 95%CI 0,43-0,86; p = 0,004). Na totale of radicale subtotale resectie
was de tijd tot progressie langer dan in de subgroep na biopsie of subtotale resectie (gecorrigeerde risico
ratio: 0,45; 95%CI 0,35-0,59; p < 0,001).
Capelle [Capelle 2013
] beschreef 1091 patiënten die behandeld werden tussen 1985 en 2007, waarvan 674
een resectie ondergingen, 619 een biopsie, en bij 165 behandeling werd uitgesteld. Pre- en postoperatieve
tumorvolumes werden gemeten op T1-, T2- en flairopnames. Er werd onderscheid gemaakt in het percentage
tumor dat verwijderd was. Bij 80 patiënten was de tumor voor 100% verwijderd, bij 418 patiënten was tussen
50 en 99% van de tumor verwijderd en bij 431 patiënten was minder dan 50% verwijderd. Complete resectie
werd gedefinieerd als geen restvolume op MRI (80 patiënten), subtotale resectie als een restvolume <10 mL
en > 0 mL (266 patiënten), een partiële resectie als een restvolume >10 mL (583 patiënten). Het percentage
tumorverwijdering als continue parameter was geassocieerd met een gunstiger overleving (gecorrigeerde
relatieve risico: 0,569; 95%CI 0,382-0,847; p = 0,0199). De overlevingscurves van complete, subtotale, en
partiële resectie lopen uiteen tot 14 jaar follow-up zonder dat hiervoor statistische significantie werd
berekend.
Ius [Ius 2012
] beschreef 190 patiënten die behandeld werden tussen 1998 en 2011, en die een resectie
ondergingen van een laaggradig glioom in een eloquente lokalisatie. De mate van resectie werd bepaald
door pre- en postoperatieve volumemetingen op T2-gewogen MRI-opnames. Dit werd gemeten als
percentage tumorverwijdering en als volume resttumor. Zo werd bij 30 patiënten minder dan 70% tumor
verwijderd, bij 69 werd tussen 70 en 89% en bij 91 werd meer dan 90%. Bij 11 patiënten bestond een tumor
restvolume van minder dan 10mL, bij 41 patiënten tussen 11 en 20 mL, bij 16 patiënten tussen 21 en 30 mL
en bij 22 patiënten meer dan 31mL. Patiënten met een percentage tumorverwijdering tussen 70 en 89%
leefden korter dan patiënten met meer dan 90% tumorverwijdering (HR: 4,85; 95%CI 1,79-13,1; p = 0,002).
Ook patiënten met minder dan 70% tumorverwijdering leefden korter dan patiënten met meer dan 90%
tumorverwijdering (HR: 19,7; 95%CI 7,01-54,8; p < 0,0001). Een hoger percentage tumorverwijdering als
continue parameter was significant geassocieerd met langere overleving (HR per procent: 0,933; 95%CI
0,915-0,952; p <0,0001). Bij patiënten met een rest tumorvolume van minder dan 10 mL was de overleving
langer dan bij een rest tumorvolume tussen 11 en 20 mL (HR: 3,28; 95%CI 1,34-8,04; p = 0,009), bij een rest
tumorvolume tussen 21 en 30 mL (HR: 6,50; 95%CI 2,43-17,4; P < 0,0001), en bij een rest tumorvolume meer
dan 30 mL (HR: 14,0; 95%CI 5,68-34,4; p <0,0001). Een kleiner rest tumorvolume als continue parameter was
geassocieerd met een langere overleving (HR per mL tumorrest: 1,02; 95%CI 1,01-1,03; P < 0,0001). Ten
opzichte van de patiënten met meer dan 90% tumorverwijdering hadden de patiënten met tussen 70 en 89%
tumorverwijdering kortere tijd tot maligne transformatie (HR: 2,55 (95%CI 1,35-4,84; p = 0,004), evenals de
patiënten met minder dan 70% tumorverwijdering (HR: 9,77; 95%CI 4,85-19,7; p< 0,0001). Meer
tumorverwijdering per procent was geassocieerd met kortere tijd tot maligne transformatie (HR: 0,944;
95%CI 0,928-0,960; p <0,0001). Ten opzichte van de patiënten met een rest tumorvolume van minder dan 10
mL was de tijd tot maligne transformatie korter voor patiënten met een rest tumorvolume tussen 11 en 20 mL
(HR: 1,54; 95%CI 0,80-2,97; p = 0,20), evenals voor patiënten met een rest tumorvolume tussen 21 en 30 mL
(HR: 2,98; 95%CI 1,37-6,50; p = 0,006), evenals voor patiënten met een rest tumorvolume van meer dan 31
mL (HR: 8,74; 95%CI 4,41-17,3; p <0,0001). Meer tumorrest per mL was geassocieerd met een kortere tijd tot
maligne transformatie (HR: 1,02; 95%CI 1,01-1,03; P < 0,0001).
43
145
301
Gliomen
PDF aangemaakt op 
23-01-2025
185
/
971
Schomas [Schomas 2009
] beschreef 314 patiënten tussen 1960 en 1992, waarvan 204 een resectie
ondergingen en 110 een biopsie. De mate van resectie werd bepaald door het operatieverslag, de impressie
van de chirurg en postoperatieve beeldvorming, indien aanwezig. Totale resectie werd gedefinieerd als
afwezigheid van resttumor (41 patiënten), radicale subtotale resectie als een verwijderd volume van meer dan
90% (33 patiënten), en subtotale resectie als een verwijderd volume van minder dan 90% (130 patiënten).
Patiënten leefden na biopsie of subtotale resectie korter dan patiënten na totale of radicale subtotale resectie
(gecorrigeerde relatieve risico: 0,74; 95%CI 0,55-0,96; P < 0,001).
McGirth [McGirth 2008
] beschreef 170 patiënten die tussen 1996 en 2007 een resectie ondergingen. De
mate van resectie werd door de radioloog bepaald op pre- en postoperatieve flairopnames van de MRI. Als
‘gross total resection' werd gedefinieerd de afwezigheid van resttumor (65 patiënten), als ‘near total
resection' een rest met een dikte minder dan 3 mm rond de resectieholte (39 patiënten), en als subtotale
resectie een nodulaire resttumor (66 patiënten). Ten opzichte van de patiënten met een subtotale resectie
leefden patiënten na een ‘gross total resection' langer (gecorrigeerde HR: 0,36; 95%CI 0,16-0,84; p = 0,017),
evenals na een ‘near total resection' (gecorrigeerde HR: 0,87; 95%CI 0,38-1,98; p = 0,63). Ten opzichte van de
patiënten na een subtotale resectie was de tijd tot progressie langer na ‘gross total resection' (gecorrigeerde
HR: 0,56; 95%CI 0,32-0,98; p = 0,043) evenals na ‘near total resection' (gecorrigeerde HR: 1,01; 95%CI 0,69-
1,99; p = 0,75).
Smith [Smith 2008
] beschreef 216 patiënten, behandeld tussen 1989 en 2005, die een resectie
ondergingen. Pre- en postoperatieve tumorvolumes werden gemeten op de flairopnames van de MRI. De
mate van resectie werd berekend als percentage tumorverwijdering op MRI. Bij 21 patiënten werd een
resectie met 0 tot 40% tumorverwijdering uitgevoerd, bij 94 patiënten met 41 tot 89%, bij 26 patiënten met
90 tot 99% en bij 75 patiënten met 100%. Daarnaast werd het tumor- restvolume berekend. Bij 75 patiënten
resteerde 0 mL tumor, bij 37 patiënten tussen 1 en 5 mL, en bij 38 patiënten tussen 5,1 en 15mL. Een hogere
mate van tumorverwijdering als percentage was geassocieerd met een langere overleving (gecorrigeerde HR
per procent: 0,972; 95%CI 0,960-0,983; p <0,001) en een langere tijd tot maligne transformatie
(gecorrigeerde HR per procent: 0,983; 95%CI 0,972-0,995; p = 0,005). Een kleinere mate van resttumor in mL
was eveneens geassocieerd met een langere overleving (gecorrigeerde HR per mL: 1,010; 95%CI 1,001-
1,019; p = 0,03) en een lange tijd tot maligne transformatie (HR: 1,005; 95%CI 0,996-1,014; p = 0,32).
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
301
214
319
Gliomen
PDF aangemaakt op 
23-01-2025
186
/
971
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
Gliomen
PDF aangemaakt op 
23-01-2025
187
/
971
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
Gliomen
PDF aangemaakt op 
23-01-2025
188
/
971
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
Gliomen
PDF aangemaakt op 
23-01-2025
189
/
971
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
Gliomen
PDF aangemaakt op 
23-01-2025
190
/
971
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
Gliomen
PDF aangemaakt op 
23-01-2025
191
/
971
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
Gliomen
PDF aangemaakt op 
23-01-2025
192
/
971
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
Gliomen
PDF aangemaakt op 
23-01-2025
193
/
971
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
Gliomen
PDF aangemaakt op 
23-01-2025
194
/
971
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
Gliomen
PDF aangemaakt op 
23-01-2025
195
/
971
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
Gliomen
PDF aangemaakt op 
23-01-2025
196
/
971
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
197
/
971
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
Gliomen
PDF aangemaakt op 
23-01-2025
198
/
971
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
Gliomen
PDF aangemaakt op 
23-01-2025
199
/
971
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Gliomen
PDF aangemaakt op 
23-01-2025
200
/
971
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
Gliomen
PDF aangemaakt op 
23-01-2025
201
/
971
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
Gliomen
PDF aangemaakt op 
23-01-2025
202
/
971
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
Gliomen
PDF aangemaakt op 
23-01-2025
203
/
971
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
Gliomen
PDF aangemaakt op 
23-01-2025
204
/
971
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
205
/
971
Radio-/chemotherapie bij laaggradig glioom
Deze submodule is onderverdeeld in de volgende sub-submodules:
Behandelingen bij laaggradig glioom
Recidief laaggradig glioom
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
Gliomen
PDF aangemaakt op 
23-01-2025
206
/
971
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
207
/
971
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
Gliomen
PDF aangemaakt op 
23-01-2025
208
/
971
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
209
/
971
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
Gliomen
PDF aangemaakt op 
23-01-2025
210
/
971
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
Gliomen
PDF aangemaakt op 
23-01-2025
211
/
971
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
Gliomen
PDF aangemaakt op 
23-01-2025
212
/
971
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
Gliomen
PDF aangemaakt op 
23-01-2025
213
/
971
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
Gliomen
PDF aangemaakt op 
23-01-2025
214
/
971
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
Gliomen
PDF aangemaakt op 
23-01-2025
215
/
971
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
Gliomen
PDF aangemaakt op 
23-01-2025
216
/
971
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Gliomen
PDF aangemaakt op 
23-01-2025
217
/
971
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Gliomen
PDF aangemaakt op 
23-01-2025
218
/
971
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
219
/
971
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
Gliomen
PDF aangemaakt op 
23-01-2025
220
/
971
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
Gliomen
PDF aangemaakt op 
23-01-2025
221
/
971
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
Gliomen
PDF aangemaakt op 
23-01-2025
222
/
971
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
Gliomen
PDF aangemaakt op 
23-01-2025
223
/
971
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
224
/
971
Behandeling bij nieuw gediagnosticeerd laaggradig glioom
Uitgangsvraag
Welke patiënten met een laaggradig glioom komen in aanmerking voor een vervolgbehandeling na operatie?
 
De zoekvraag omvat de volgende deelvragen:
Wat is het effect van chemotherapie bij patiënten met een laaggradig glioom?
Wat is het effect van radiotherapie bij patiënten met een laaggradig glioom?
Wat is het effect van chemotherapie en radiotherapie bij patiënten met een laaggradig glioom?
Aanbeveling
Bespreek een ‘wait and scan’ beleid met de patiënt indien er geen negatieve prognostische factoren
 zijn EN
er sprake is van een radicale resectie.
 
Geef radiotherapie gevolgd door chemotherapie bij:
minstens twee negatieve prognostische factoren
waarbij een grote rest tumor en/of farmacoresistente
epilepsie postoperatief ook als negatieve prognostische factoren gelden;
patiënten bij wie om andere redenen de indicatie voor nabehandeling gesteld is.
 
Geef radiotherapie 50,4 Gy bij patiënten met een laaggradig glioom zonder moleculaire hooggradige
kenmerken. Het is niet aangetoond dat meer dan 50,4 Gy de overleving verbetert.
 
Geef bij voorkeur bij tumoren met 1p/19q-codeletie zes kuren PCV-combinatietherapie en bij tumoren
zonder 1p/19q-codeletie bij voorkeur 12 kuren temozolomide monotherapie.
 
Beschouw tumoren met een IDHwt en met moleculaire kenmerken van een glioblastoom als een
glioblastoom.
 
Pas shared decision making toe waarbij de te verwachten effecten en voor- en nadelen van de verschillende
behandelopties met de patiënt besproken worden.
 
Bespreek dat sequentiele radio- en chemotherapie de gemiddelde overleving verlengt, maar dat een langere
overleving de kans op cognitieve verslechtering vergroot
 
Zie module ‘Klinisch prognostische factoren laaggradig glioom.
Overwegingen
In de nieuwste WHO-classificatie speelt moleculaire diagnostiek een grote rol, echter studies gepubliceerd
voor 2016 hielden daar geen rekening mee (Louis, 2016) (zie module Diagnostiek - neuropathologie -
typering/gradering diffuse gliomen). Bij een glioom die pathologisch gegradeerd wordt als een laaggradig
1
1 
1 
Gliomen
PDF aangemaakt op 
23-01-2025
225
/
971
glioom heeft de afwezigheid van een IDH-mutatie een slechte prognose. In combinatie met een EGFR-
amplificatie, +7/-10-mutatie en/of aanwezigheid van een TERT-promotormutatie kan de tumor worden
gekarakteriseerd als glioblastoom (zie module Diagnostiek - neuropathologie - typering/gradering diffuse
gliomen).
 
Alle gerandomiseerde studies geïncludeerd in de literatuursamenvatting zijn van toepassing op
supratentoriële laaggradige gliomen. Er kunnen dus geen uitspraken gedaan worden over infratentoriële of
ruggenmerggliomen.
 
Voorts ontbreekt een controlegroep zonder behandeling in de studies vanwege ethische overwegingen. Het
natuurlijk beloop van laaggradige gliomen kennen we daarom niet.
 
Als er geen negatieve prognostische factoren zijn (zie module Klinisch prognostische factoren laaggradig
glioom) EN er sprake is van een radicale resectie, dan kan er een afwachtend beleid volgen.
 
Chemotherapie
Vanwege de lage bewijskracht van de studie van Baumert (2016) kan geen harde uitspraak over het tijdstip
van inzetten van aanvullende behandeling gedaan worden, al wordt wel een periode van maximaal twaalf
weken tussen chirurgie en de aanvang van chemotherapie aanbevolen.
 
Radiotherapie
Alhoewel de EORTC-22854-studie kwaliteit van leven niet analyseerde, werd een significant lagere frequentie
van epilepsie na één jaar gezien in de groep patiënten die postoperatieve radiotherapie kreeg (25%) ten
opzichte van de groep met uitgestelde radiotherapie (41%) (p=0,0329), waardoor bij geselecteerde patiënten
met onbehandeld laaggradig glioom en moeilijk behandelbare epilepsie te overwegen valt om eerder te
bestralen (van den Bent, 2005).
 
Twee studies die niet in de literatuursamenvatting zijn meegenomen omdat deze de uitgangsvraag niet
beantwoordden, maar wel de effecten op cognitie na radiotherapie onderzochten, zijn Brown (2003) en Douw
(2009). Brown (2003) vond bij 203 volwassen patiënten, gerandomiseerd in twee groepen met lage of hoge
dosis radiotherapie, geen onderling verschil in MMSE-scores in 7,4 jaar follow-up. In beide groepen werd wel
een significante verbetering in cognitie gezien ten opzichte van de baselinemeting. Douw (2009) heeft in een
cohortstudie met een follow-up van twaalf jaar cognitie gemeten door middel van uitgebreide testen bij
patiënten met een laaggradig glioom behandeld met of zonder radiotherapie. Terwijl er zes jaar na diagnose
geen verschil in cognitie te zien was, bleek de concentratie beduidend verminderd te zijn twaalf jaar na
radiotherapie. Overigens zijn deze resultaten mogelijk gebiasd doordat patiënten met progressieve ziekte
werden geëxcludeerd. Daarom is het aan te raden om prognostische factoren (zie module Klinisch
prognostische factoren laaggradig glioom) door de behandelaar mee te laten wegen bij het al dan niet
vroegtijdig starten van radiotherapie (Pignatti, 2002; Douw, 2009; van den Bent, 2012; Shields, 2014).
 
Aanvullend is een Pubmed search op de termen “cognitive effects” en “neurocognition” in combinatie met
“low grade glioma” verricht. Hieruit kwamen 83 titels waarvan de meeste niet standaard therapie-effect op
neurocognitie onderzochten. Uiteindelijk werden 14 titels nader onderzocht op abstract waarbij opnieuw een
Gliomen
PDF aangemaakt op 
23-01-2025
226
/
971
aantal afvielen wegens pediatrische studie, enkel MMSE of niet gericht op effect van chemo- of
radiotherapie. Naast drie artikels uitgezocht op full tekst werd een artikel van Klein (2012) toegevoegd.
 
Correa (2007) onderzocht neurocognitief effect van radiotherapie en chemotherapie versus “wait-and-scan
beleid” bij 41 patiënten met een laaggradige glioom door middel van een uitgebreid gestandaardiseerd
neuropsychologische testpanel. Er mocht geen tumorprogressie tijdens follow-up zijn ontstaan bij een
mediane therapie interval van 3 jaar ten opzichte van testafname. Ondanks de kleine aantallen bleek de
behandelde groep significant lagere neurocognitieve scores te hebben ten opzichte van de onbehandelde
groep. Deze effecten bleken meer uitgesproken indien de behandeling langer geleden was dan 3 jaar.
 
Laack (2005) onderzocht neurocognitief effect van radiotherapie door middel van uitgebreide testbatterij
naast MMSE bij twintig patiënten met een laaggradig glioom. Metingen werden vooraf de bestraling en
vervolgens elke 18 maanden tot max 5 jaar na bestraling verricht. Er werd geen effect gezien in dosering van
bestraling tussen een groep met 50,4 Gy of 64,8 Gy. Hierbij dient bemerkt te worden dat dit om kleine
aantallen gaat.
 
Klein (2002) onderzocht neurocognitie in een veel grotere groep patiënten (n=195) met follow-up van 1 tot
22 jaar na bestraling van een laaggradig glioom. Ook in deze studie werden meerdere neuropsychologische
domeinen onderzocht middels testbatterijen. Ook hier werd leek bestraling een negatief effect op
neurocognitie te hebben echter het effect van de tumor zelf en het gebruik van anti-epileptica hadden een
groter effect op cognitie dan radiotherapie. In een vervolgstudie met langere follow-up van gemiddeld 12
jaar (n=65), echter, laat de helft van de bestraalde patiënten een achteruitgang zien van aandachtsfuncties in
vergelijking met 27% in de onbehandelde groep. Concluderend lijken er aanwijzingen te zijn dat
radiotherapie op lange termijn de cognitie (met name aandacht) negatief beïnvloedt.
 
Een bestralingsdosis van 50 tot 54 Gy in fracties van 1,8 Gy wordt wereldwijd het meest gebruikt en
geadviseerd bij de behandeling van patiënten met een laaggradig glioom. Indien de beslissing, in overleg
met de patiënt, genomen is om te bestralen, heeft het de voorkeur om sequentieel chemokuren toe te
dienen (op basis van CATNON- en NOA-04-studies), tenzij er specifieke contra-indicaties of wensen van de
patiënt zijn om dit niet te doen (Wick, 2009; van den Bent, 2017).
 
De radiotherapie en beeldvorming technieken hebben over de tijd een grote evolutie doorgemaakt,
waardoor het radiotherapie doelvolume nauwkeuriger kan worden bepaald en behandeld. De uitkomsten op
cognitie van de besproken studies zijn verkregen met radiotherapie technieken die niet representatief zijn
voor de huidige praktijk.
 
De definitie van het radiotherapie-doelvolume is gebaseerd op een recente MRI (Kwaliteitscriteria neuro-
oncologie 2017). Het te bestralen gebied omvat het hyper intense gebied op de T2- of FLAIR-sequenties met
een beperkte marge voor microscopische ziekte. Het gebruik van geavanceerde radiotherapietechnieken zijn
de norm (Werkafspraken volgens Landelijk Platform Neuro-oncologie van de NVRO).
 
Chemotherapie en radiotherapie
De studie van Buckner (2016) liet zien dat patiënten met IDHmut tumoren een langere progressievrije
Gliomen
PDF aangemaakt op 
23-01-2025
227
/
971
overleving hebben ten opzichte van IDHwt tumoren, ongeacht de behandelarm (echter was de subgroep met
IDHwt te klein voor een statistische analyse). Gunstige prognostische factoren zijn: behandeld met
chemotherapie gecombineerd met radiotherapie, oligodendroglioom als histologie en leeftijd jonger dan 40
jaar. De overall survival (OS) was superieur voor de gecombineerde therapie voor alle histologische groepen,
al was het verschil voor de astrocytoomgroep niet significant. De beperkte data die er zijn lieten geen afname
in kwaliteit van leven of cognitie zien door toevoeging van PCV-kuren aan radiotherapie (Prabhu, 2014;
Habets, 2014). Daarom wordt aangeraden dat de behandelaar altijd de gecombineerde behandeling in
overweging neemt.
 
Studies die temozolomide in plaats van PCV bij patiënten met laaggradige gliomen onderzoeken, ontbreken.
Bij de anaplastische gliomen werd echter in de gerandomiseerde fase III NOA-04-studie geen verschil
aangetoond in progressievrije overleving tussen PCV en temozolomide, maar de studie was hier ook niet voor
gepowered (Wick, 2009) (zie ook module Chemotherapie nieuw gediagnosticeerd anaplastisch glioom). De
CATNON-studie vergelijkt postoperatieve bestraling met en zonder temozolomide (van den Bent, 2017). De
interimresultaten van deze studie bij 745 patiënten met nieuw gediagnostiseerde anaplastische gliomen laat
zien dat de HR voor OS 0,65 (95%BI: 0,45-0,93) was. De OS na vijf jaar was 55,9% (95%BI: 47,2- tot 63,8)
vergeleken met 44,1% (36,3-51,6) bij respectievelijk met en zonder temozolomide. In analogie zou hierdoor
dus ook bij laaggradige gliomen de toevoeging van twaalf kuren temozolomide na bestraling overwogen
kunnen worden in plaats van zes PCV-kuren (Wick, 2009; van den Bent, 2017).
 
Shared decision making
In alle gevallen dient er sprake te zijn van shared decision making waarbij de te verwachten effecten en voor-
en nadelen van de verschillende behandelopties met de patiënt besproken worden.
Onderbouwing
Achtergrond
De behandeling van patiënten met een laaggradig glioom blijft een controversieel onderwerp. Door recente
ontwikkelingen in de moleculaire diagnostiek, de kennis over de diagnostische, prognostische en predictieve
waarde hiervan is er meer kennis over welke patiëntengroep welke behandeling (radiotherapie,
chemotherapie of beide) zou moeten krijgen. Het is van belang deze patiëntengroep te definiëren.
Conclusies
Chemotherapie
Laag
GRADE
Progressievrije overleving
 
Er is mogelijk een klinisch relevant verschil in progressievrije overleving tussen alleen
chemotherapie versus alleen radiotherapie in het voordeel van alleen radiotherapie bij
patiënten met een laaggradig glioom. Dit verschil is mogelijk meer uitgesproken bij
patiënten zonder gecombineerd verlies van 1p en 19q.
 
Bronnen: (Baumert, 2016)
 
Gliomen
PDF aangemaakt op 
23-01-2025
228
/
971
Laag
GRADE
Algehele overleving
 
Er zijn aanwijzingen dat er geen verschil in algehele overleving is tussen alleen
chemotherapie versus alleen radiotherapie bij patiënten met een glioom (al heeft de
huidige data geen power om dit te berekenen).
 
Bronnen: (Baumert, 2016)
 
Laag
GRADE
Kwaliteit van leven
 
Er zijn aanwijzingen dat er geen verschil in kwaliteit van leven is tussen chemotherapie en
radiotherapie bij patiënten met een laaggradig glioom.
 
Bronnen: (Reijneveld, 2016)
 
Laag
GRADE
Cognitie
 
Er zijn aanwijzingen dat er geen verschil in cognitie, gemeten met de MMSE-vragenlijst, is
tussen radiotherapie en chemotherapie na operatie in de eerste drie jaar na behandeling
bij patiënten met een laaggradig glioom.
 
Bronnen: (Reijneveld, 2016)
 
Radiotherapie
Laag
GRADE
Progressievrije overleving
 
Postoperatieve radiotherapie leidt mogelijk tot een toename in progressievrije overleving
vergeleken met radiotherapie die pas bij progressie van ziekte wordt gegeven bij
patiënten met een laaggradig glioom.
 
Bronnen: (Van den Bent, 2005)
 
Redelijk
GRADE
Progressievrije overleving
Er is waarschijnlijk geen verschil tussen hoge of lage dosis postoperatieve radiotherapie op
progressievrije-overleving bij patiënten met een laaggradig glioom.
 
Bronnen: (Shaw, 2002; Karim, 1996)
 
Gliomen
PDF aangemaakt op 
23-01-2025
229
/
971
Laag
GRADE
Algehele overleving
 
Er zijn aanwijzingen dat er geen statistisch significant verschil in algehele overleving tussen
lage of hoge dosis radiotherapie na operatie. Er zijn aanwijzingen dat er geen statistisch
significant verschil in algehele overleving is in de timing van radiotherapie direct na
operatie of bij ziekteprogressie bij patiënten met een laagdradig glioom.
 
Bronnen: (Van den Bent, 2005; Shaw, 2002; Karim, 1996)
 
Zeer laag
GRADE
Kwaliteit van leven
 
Er zijn voorzichtige aanwijzingen dat patiënt gerapporteerde vermoeidheid/malaise en
slapeloosheid direct na hoge dosis radiotherapie (59,4 Gy) significant erger zijn dan na
lagere dosis radiotherapie (45 Gy) bij patiënten met een laaggradig glioom. Op langere
termijn lijken patiënten na hogere dosis bestraling significant lager te scoren op
vrijetijdsbesteding en emotioneel functioneren.
 
Bronnen: (Kiebert, 1998)
 
Chemo- en radiotherapie
Laag
GRADE
Progressievrije overleving
 
Patiënten met een laaggradig glioom die zowel radiotherapie als chemotherapie (PCV)
krijgen na een operatie, hebben mogelijk een veel langere progressievrije overleving dan
patiënten die alleen radiotherapie krijgen.
 
Bronnen: (Buckner, 2016)
 
Laag
GRADE
Algehele overleving
 
Patiënten met een laaggradig glioom die zowel radiotherapie als chemotherapie (PCV)
krijgen, hebben mogelijk een veel langere algehele overleving dan patiënten die alleen
radiotherapie krijgen.
 
Bronnen: (Buckner, 2016)
 
Gliomen
PDF aangemaakt op 
23-01-2025
230
/
971
Laag
GRADE
Cognitie
 
Er is mogelijk geen verschil in cognitieve uitkomsten tussen chemo- en radiotherapie en
alleen radiotherapie, gemeten met de MMSE-vragenlijst, bij patiënten met een laaggradig
glioom.
 
Bronnen: (Buckner, 2016; Prabhu, 2014)
Samenvatting literatuur
Eén van de dertien geïncludeerde artikelen bleek een systematische review die het effect van chemotherapie
na operatie beschrijft bij patiënten met een laaggradig glioom (Ziu, 2015). Omdat deze review maar één RCT
(Shaw, 2012) includeerde die ook afzonderlijk is geïncludeerd, is ervoor gekozen deze RCT afzonderlijk te
beschrijven en de review van Ziu alsnog te excluderen. Er zijn dus 12 artikelen opgenomen in de
literatuuranalyse die beschreven wat het effect is van chemotherapie, radiotherapie, of chemo- en
radiotherapie na operatie bij volwassen patiënten met een laaggradig glioom op algehele overleving,
progressievrije overleving, kwaliteit van leven en/of cognitie. Het gaat om twee systematische
literatuurreviews en tien RCT’s. In enkele studies werden de resultaten uit eenzelfde trial gebruikt om
verschillende vragen te beantwoorden. De belangrijkste studiekarakteristieken en resultaten van de 12
artikelen zijn opgenomen in de evidencetabellen. De beoordeling van de individuele studieopzet (risk of bias)
is opgenomen in de risk of biastabellen.
 
Chemotherapie
Baumert (2016) en Reijneveld (2016) vergeleken het effect van chemotherapie (dose-dense temozolomide)
met radiotherapie voor de uitkomstmaten algehele overleving en progressievrije overleving (Baumert, 2016)
en kwaliteit van leven en cognitief functioneren (Reijneveld, 2016). Beiden beschreven de resultaten van de
EORTC-22033-26033-studie. In deze studie werden 477 volwassen patiënten met diffuus astrocytoom (WHO-
graad II), oligodendroglioom of gemengd oligoastrocytoom met een WHO-performancescore van 2 of lager,
gerandomiseerd in een groep die radiotherapie kreeg (n=237) en een groep die chemotherapie kreeg
(n=240).
 
Progressievrije overleving
De progressievrije overleving was voor dose-dense temozolomide 39 maanden (95%BI: 35 tot 44) (n=237) en
voor radiotherapie 46 maanden (95%BI: 40 tot 56) (n=240), hazard ratio (HR) 1,16 (95%BI: 0,9 tot 1,5,
p=0,22). Aanvullend bleek uit exploratieve analyse dat dit verschil in progressievrije overleving meer
uitgesproken was in de groep patiënten met gemuteerd IDH maar 
zonder
 verlies van 1p/19q (radiotherapie:
55 maanden (95% BI:47-66); chemotherapie 36 maanden (95%BI: 28-47) (n=165) HR 1,86 (95%BI: 1,21 tot
,87).
 
Algehele overleving
Hoewel Baumert (2016) algehele overleving als secundair eindpunt had gedefinieerd, werd bij de mediane
follow-up van 48 maanden de mediane algehele overleving niet bereikt in zowel de radiotherapiegroep als in
de chemotherapiegroep.
 
Gliomen
PDF aangemaakt op 
23-01-2025
231
/
971
Kwaliteit van leven
Reijneveld (2016) vergeleek de verschillen in aan gezondheid gerelateerde kwaliteit van leven (HRQoL) tussen
patiënten behandeld met radiotherapie en met chemotherapie. Het verschil in HRQoL tussen de twee
behandelgroepen was niet significant gedurende 36 maanden follow-up (gemiddeld over alle tijdstippen:
0,06, 95%BI: -4,64 tot 4,75, p=0,98). In beide groepen bleven de gemiddelde algehele gezondheid en de
kwaliteit van leven stabiel door de tijd.
 
Cognitie
Reijneveld (2016) vergeleek cognitie tussen patiënten behandeld met radiotherapie en patiënten behandeld
met chemotherapie gedurende een follow-up van drie jaar. Op baseline hadden 32 (13%) van de 239
patiënten die radiotherapie kregen en 32 (14%) van de 236 patiënten die temozolomide-chemotherapie
kregen een verminderde cognitieve functie volgens de Mini Mental State Examination-scores (MMSE). Na
randomisatie hadden 5 (8%) van de 63 patiënten die radiotherapie kregen en 3 (6%) van de 54 patiënten die
temozolomide-chemotherapie kregen, een verminderde cognitieve functie volgens MMSE-scores. Er werd
geen significant verschil gevonden tussen de twee behandelgroepen.
 
Radiotherapie
Er zijn zeven studies gevonden die effecten van radiotherapie na operatie bij patiënten met een laaggradig
glioom onderzochten, waaronder twee systematische reviews (Ryken, 2015; Sarmiento, 2015) en vijf RCT’s
(Karim, 1996; Kiebert, 1998; Karim, 2002; Shaw, 2002; van den Bent, 2005).
Systematische reviews
De systematische review van Ryken (2015) includeerde 142 studies waaronder zes RCT’s (Eyre, 1993 (past niet
binnen de uitgangsvraag); Karim, 1996; Kiebert, 1998; Karim, 2002; Shaw, 2002; van den Bent, 2005). Deze
RCT’s zijn allen apart geïncludeerd door de werkgroep en apart beschreven in deze module. De andere
studies geïncludeerd in Ryken zijn van mindere methodologische kwaliteit en daarom wordt Ryken hier niet
verder beschreven.
 
In de Cochrane review van Sarmiento (2015) werden de effecten van postoperatieve radiotherapie versus
radiotherapie uitgesteld tot tumorprogressie na biopsie of chirurgische resectie onderzocht. Sarmiento (2015)
includeerde slechts één studie: een multicenter RCT met patiënten met een laaggradig glioom (van den Bent,
2005; EORTC-22845). De patiënten werden gerandomiseerd in een postoperatieve radiotherapiegroep
(n=157) of in de groep met uitgestelde radiotherapie tot het optreden van progressie (n=157). Voor het
beschrijven van de studieresultaten wordt daarom gerefereerd aan van den Bent (2005).
 
RCT’s
Karim (2002) beschreef de eerste resultaten van bovengenoemde EORTC-studie (van den Bent, 2005).
Middels de RCT van Shaw (2002) werden de effecten van lage versus hoge dosis radiotherapie in 203
volwassenen met een supratentorieel laaggradig glioom onderzocht. Karim (1996) onderzocht eveneens de
effecten van lage versus hoge dosis radiotherapie in een RCT met 379 volwassenen met laaggradig glioom.
Kiebert (1998) onderzocht in dezelfde RCT als Karim (1996) de kwaliteit van leven, gerapporteerd door
patiënten zelf en door artsen, bij patiënten met laaggradig glioom welke een lage of een hoge dosis
radiotherapie kregen.
 
Gliomen
PDF aangemaakt op 
23-01-2025
232
/
971
Progressievrije overleving
Van den Bent (2005) liet zien dat postoperatieve radiotherapie geassocieerd is met een toename in tijd tot
progressie van de ziekte in vergelijking tot observatie/afwachtend beleid (en uitgestelde
radiotherapiebehandeling tot ziekteprogressie) voor mensen met een laaggradig glioom. De mediane
progressievrije overleving was 5,3 jaar in de postoperatieve radiotherapiegroep en 3,4 jaar in de uitgestelde
radiotherapiegroep (HR: 0,59, 95%BI: 0,45 tot 0,77; p<0,0001).
 
De studie van Shaw (2002) toonde geen significant verschil aan tussen een lage dosis (50,4 Gy, n=101)) en
hoge dosis radiotherapie (64,8 Gy, n=102) in de tijd tussen de start van behandeling en progressie van de
ziekte (TTP) (log rank P = 0,65). De gemiddelde TTP was 5,5 jaar.
 
Ook de studie van Karim (1996) vond geen significante verschillen in progressievrije overleving tussen lage
dosis (45 Gy, n=171) en hoge dosis radiotherapie (59,4 Gy, n=172). Het aantal overlevenden zonder
progressie van ziekte na 5 jaar is 47% bij lage dosis radiotherapie en 50% bij hoge dosis radiotherapie.
 
Algehele overleving
De mediane algehele overleving in de groep die postoperatieve radiotherapie kreeg, was 7,4 jaar, terwijl de
groep die late radiotherapie kreeg (bij ziekteprogressie) een mediane algehele overleving had van 7,2 jaar
(HR 0,97, 95%BI: 0,71-1,33; p= 0,872). Dit verschil was niet significant (van den Bent, 2005).
 
De studie van Shaw (2002) vond geen significant verschil tussen lage (50,4 Gy) en hoge (64,8 Gy) dosis
radiotherapie in algehele overleving (log rank P = 0,48). De 2- en 5-jaars overleving waren iets beter in de
lage dosis radiotherapie. De mediane overleving was 9,25 jaar.
 
De studie van Karim (1996) vond ook geen significante verschillen in algehele overleving tussen lage dosis (45
Gy) en hoge dosis (59,4 Gy) radiotherapie.
 
Kwaliteit van leven
De studie van Kiebert (1998) onderzocht de door patiënten zelf gerapporteerde kwaliteit van leven na lage
dosis radiotherapie (45 Gy) en na hoge dosis radiotherapie (59,4 Gy). Direct na bestraling rapporteerden de
patiënten in de hoge dosisgroep lagere niveaus in functioneren en meer klachten dan de patiënten in de lage
dosisgroep. Deze verschillen waren significant voor vermoeidheid/malaise (p=0,03) en slapeloosheid (p=0,05).
Na 7 tot 15 maanden na randomisatie scoorde de hoge dosisgroep significant slechter op vrijetijdsbesteding
(p=0,01) en emotioneel functioneren (p=0,01) dan de lage dosisgroep. Er waren geen verschillen in de
verschillende aspecten van kwaliteit van leven in beide groepen voor en na behandeling.
 
Cognitie
Er zijn geen studies geïncludeerd die voldoen aan de selectiecriteria en cognitie beschreven bij radiotherapie.
 
Chemo- en radiotherapie
Er zijn drie RCT’s die de effecten van chemo- en radiotherapie na operatie bij patiënten met een laaggradig
glioom onderzochten (Shaw, 2012; Prabhu, 2014; Buckner 2016). Shaw (2012) beschrijft de eerste resultaten
van de RTOG-9802 studie van Buckner (2016) en is daarom niet apart beschreven. Prabhu (2014) onderzocht
Gliomen
PDF aangemaakt op 
23-01-2025
233
/
971
het effect van additionele chemotherapie bij radiotherapie op cognitief functioneren (MMSE-scores) in
vergelijking tot alleen radiotherapie bij 251 patiënten met een laaggradig glioom. Hiervoor zijn resultaten van
de RTOG-9802-studie geanalyseerd. Buckner (2016) beschreef de lange termijneffecten van behandeling met
procarbazine, lomustine en vincristine na radiotherapie bij 251 patiënten met een astrocytoom,
oligoastrocytoom of oligodendroglioom, in vergelijking met enkel radiotherapie. Patiënten werden
geïncludeerd indien jonger dan 40 jaar met subtotale resectie of biopsie; of ouder dan 40 jaar met elke vorm
van resectie of biopsie.
 
Progressievrije overleving
Buckner (2016) vond een significant verschil in progressievrije overleving tussen 125 patiënten behandeld met
radiotherapie gevolgd door chemotherapie (PCV-kuren) (gemiddelde progressievrije overleving: 10,4 jaar,
95%BI: 6,1-niet behaald) en 126 patiënten met alleen radiotherapie als behandeling (gemiddelde
progressievrije overleving: 4,0 jaar, 95%BI: 3,1-5,5) (HR voor ziekteprogressie of sterfte: 0,50; p<0,001). Het
verschil in progressievrije overleving werd pas zichtbaar nadat 25% van de patiënten ziekteprogressie had en
het verschil nam toe gedurende de tijd.
 
Algehele overleving
Buckner (2016) beschreef bij patiënten met gecombineerde behandeling een langere mediane algehele
overleving dan bij patiënten met alleen radiotherapie (13,3 versus 7,8 jaar respectievelijk, HR voor overlijden:
0,59; p=0,003).
 
De algehele overleving na vijf jaar was 72% (95%BI: 64-80) in de groep die radiotherapie plus chemotherapie
kreeg versus 63% (95%BI: 55-72) in de groep die alleen radiotherapie kreeg. Deze percentages waren na 10
jaar 60% (95%BI: 51-69) en 40% (95%BI: 31-49) respectievelijk.
 
Kwaliteit van leven
De uitkomstmaat kwaliteit van leven is niet beschreven in de geïncludeerde studies die chemo- en
radiotherapie onderzochten.
 
Cognitie
In de RTOG-9802 studie heeft Prabhu (2014) gedurende vijf jaar een MMSE-score afgenomen. Het
toevoegen van chemotherapie (PCV) aan radiotherapie gaf geen significant grotere afname in MMSE-scores
dan alleen radiotherapie gedurende vijf jaar follow-up. Beide groepen ervaarden een statistisch significante
toename van de gemiddelde MMSE-score gedurende de tijd. Er was geen verschil tussen beide groepen
(P=0,57).
 
Bewijskracht van de literatuur
Volgens de GRADE-beoordeling starten RCT’s op een hoog niveau van bewijskracht.
 
Chemotherapie
De bewijskracht voor de uitkomstmaat progressievrije overleving is met twee niveaus verlaagd tot ‘laag’
gezien beperkingen in de onderzoeksopzet (risk of bias, gebrek aan blindering van de beoordelaars MRI) en
vanwege het overschrijden van de grens voor klinische relevantie (imprecisie). De bewijskracht voor algehele
Gliomen
PDF aangemaakt op 
23-01-2025
234
/
971
overleving is met twee niveaus verlaagd tot ‘laag’ gezien beperkingen in de onderzoeksopzet (risk of bias,
mediane overleving niet bereikt, twee niveaus afgetrokken). De bewijskracht voor de uitkomstmaten kwaliteit
van leven en cognitie is met twee niveaus verlaagd tot ‘laag’ gezien beperkingen in de onderzoeksopzet (risk
of bias, gebrek aan blindering) en het geringe aantal patiënten (imprecisie).
 
Radiotherapie
De bewijskracht voor de uitkomstmaat progressievrije overleving voor de vergelijking postoperatieve
radiotherapie versus radiotherapie bij progressie is met twee niveaus verlaagd tot ‘laag’ gezien beperkingen
in de onderzoeksopzet (risk of bias, vanwege gebrek aan blindering) en imprecisie (doorkruisen van de grens
voor klinische relevantie). De bewijskracht voor de uitkomstmaat progressievrije overleving voor de
vergelijking lage versus hoge dosis radiotherapie is met één niveau verlaagd tot ‘redelijk’ gezien beperkingen
in de onderzoeksopzet (risk of bias, vanwege gebrek aan blindering en onduidelijkheid in de manier van
randomiseren). De bewijskracht voor de uitkomstmaat algehele overleving is met twee niveaus verlaagd tot
‘laag’ gezien beperkingen in de onderzoeksopzet (geringe aantal patiënten en onduidelijkheid in de manier
van randomiseren). De bewijskracht voor de uitkomstmaat kwaliteit van leven is met drie niveaus verlaagd
gezien een aantal beperkingen in de onderzoeksopzet (risk of bias, waaronder gebrek aan blindering.
Daarnaast wordt veel zaken in het artikel niet nader toegelicht, zoals manier van randomiseren en hoeveel
patiënten er tijdens de studieduur zijn uitgevallen).
 
Chemo- en radiotherapie
De bewijskracht voor de uitkomstmaat progressievrije overleving en algehele overleving is met twee niveaus
verlaagd tot ‘laag’ gezien beperkingen in de onderzoeksopzet (risk of bias, gebrek aan blindering/het geringe
aantal patiënten). De bewijskracht voor de uitkomstmaat cognitie is met twee niveaus verlaagd gezien
beperkingen in de onderzoeksopzet (risk of bias, gebrek aan blindering, relatief hoge loss-to-follow-up) en
het geringe aantal patiënten (imprecisie).
Zoeken en selecteren
Om de uitgangsvraag te kunnen beantwoorden is er een systematische literatuuranalyse verricht naar de
volgende zoekvraag:
Wat is bij volwassen patiënten met een laaggradig glioom het effect van
chemotherapie/radiotherapie/chemo- en radiotherapie op progressievrije overleving, algehele overleving,
kwaliteit van leven en/of cognitie?
 
Relevante uitkomstmaten
De werkgroep achtte progressievrije overleving, algehele overleving, kwaliteit van leven en cognitie voor de
besluitvorming cruciale uitkomstmaten.
 
Zoeken en selecteren (Methode)
In de databases Medline (via OVID) en Embase (via Embase.com) is op 29 maart 2018 met relevante
zoektermen gezocht naar studies die bovengenoemde uitgangsvraag beantwoorden. De zoekverantwoording
is weergegeven onder het tabblad Verantwoording. De literatuurzoekactie leverde 514 artikelen op. Studies
werden geselecteerd op grond van de volgende selectiecriteria: systematische reviews of meta-analyses,
gerandomiseerde gecontroleerde studies of klinische studies, gepubliceerd na 1990 die voldeden aan de
Gliomen
PDF aangemaakt op 
23-01-2025
235
/
971
vooraf opgestelde PICO. Op basis van titel en abstract werden in eerste instantie 66 artikelen
voorgeselecteerd. Na raadpleging van de volledige tekst, werden vervolgens 53 artikelen geëxcludeerd (zie
exclusietabel onder het tabblad Verantwoording) en 13 artikelen definitief geselecteerd.
Verantwoording
Laatst beoordeeld
 : 03-12-2019
Laatst geautoriseerd
 : 03-12-2019
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Baumert, B.G., Hegi, M.E., van den Bent, M.J., von Deimling, A., Gorlia, T., Hoang-Xuan, K., et al. (2016). Temozolomide
chemotherapy versus radiotherapy in high-risk low-grade glioma (EORTC 22033-26033): a randomised, open-label, phase 3
intergroup study. The Lancet Oncology. 17(11):1521-32.
2
 - Van Den Bent, M.J., Afra, D., De Witte, O., Ben Hassel, M., Schraub, S., Hoang-Xuan, K., et al. (2005). Long-term efficacy of
early versus delayed radiotherapy for low-grade astrocytoma and oligodendroglioma in adults: The EORTC 22845 randomised
trial. Lancet. 366(9490):985-90.
3
 - Van den Bent, M.J., Snijders, T.J., Bromberg, J.E. (2012). Current treatment of low grade gliomas. Memo. 5(3):223-227.
4
 - Brown, P.D., Buckner, J.C., O'Fallon, J.R., Iturria, N.L., Brown, C.A., O'Neill, B.P. (2003). Effects of radiotherapy on
cognitive function in patients with low-grade glioma measured by the folstein mini-mental state examination. Journal of Clinical
Oncology. 21(13):2519-24.
5
 - Buckner, J.C., Shaw, E.G., Pugh, S.L., Chakravarti, A., Gilbert, M.R., Barger, G.R., et al. (2016). Radiation plus procarbazine,
CCNU, and vincristine in low-grade glioma. New England Journal of Medicine. 374(14):1344-55.
6
 - Correa, D. D., DeAngelis, L. M., Shi, W., Thaler, H. T., Lin, M., & Abrey, L. E. (2007). Cognitive functions in low-grade
gliomas: disease and treatment effects. Journal of neuro-oncology, 81(2), 175-184.
7
 - Douw, L., Klein, M., Fagel, S.S., van den Heuvel, J., Taphoorn, M.J., Aaronson, N.K., et al. (2009). Cognitive and radiological
effects of radiotherapy in patients with low-grade glioma: long-term follow-up. Lancet Neurology. 8(9):810-8.
8
 - Habets, E.J., Taphoorn, M.J., Nederend, S., Klein, M., Delgadillo, D., Hoang-Xuan, K., et al. (2014). Health-related quality of
life and cognitive functioning in long-term anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of Neuro-
oncology. 116(1):161-8.
9
 - Karim, A.B.M.F., Afra, D., Cornu, .P, Bleehan, N., Schraub, S., De Witte, O., et al. (2002). Randomized trial on the efficacy of
radiotherapy for cerebral low-grade glioma in the adult: European Organization for Research and Treatment of Cancer Study
22845 with the Medical Research Council study BRO4: An interim analysis. International Journal of Radiation Oncology Biology
Physics. 52(2):316-24.
1
0 - Karim, A.B.M.F., Maat, B., Hatlevoll, R., Menten, J., Rutten, E.H.J.M., Thomas, D.G.T., et al. (1996). A randomized trial on
dose-response in radiation therapy of low-grade cerebral glioma: European organization for research and treatment of cancer
(EORTC) study 22844. International Journal of Radiation Oncology Biology Physics. 36(3):549-56.
1
1 - Kiebert, G.M., Curran, D., Aaronson, N.K., Bolla, M., Menten, J., Rutten, E.H.J.M, et al. (1998). Quality of life after radiation
therapy of cerebral low-grade gliomas of the adult: Results of a randomized phase III trial on dose response (EORTC trial
22844). European Journal of Cancer. 34(12):1902-9.
1
2 - Klein, M. (2012). Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities.
Neuro-oncology, 14(suppl_4), iv17-iv24.
1
3 - Klein, M., Heimans, J.J. (2004). The measurement of cognitive functioning in low-grade glioma patients after radiotherapy.
Journal of Clinical Oncology. 22(5):966-7.
1
4 - Klein, M., Heimans, J. J., Aaronson, N. K., Van der Ploeg, H. M., Grit, J., Muller, M., ... & Ossenkoppele, G. J. (2002). Effect
of radiotherapy and other treatment-related factors on mid-term to long-term cognitive sequelae in low-grade gliomas: a
comparative study. The Lancet, 360(9343), 1361-1368.
Gliomen
PDF aangemaakt op 
23-01-2025
236
/
971
1
5 - Laack, N. N., Brown, P. D., Ivnik, R. J., Furth, A. F., Ballman, K. V., Hammack, J. E., ... & Buckner, J. C. (2005). Cognitive
function after radiotherapy for supratentorial low-grade glioma: a North Central Cancer Treatment Group prospective study.
International Journal of Radiation Oncology* Biology* Physics, 63(4), 1175-1183.
1
6 - Lois, D.N., Ohgaki, H., Wiestle, O.D., Cavenee, W.K. eds. (2016). WHO classification of tumours of the central nervous
system, revised 4th edn. Lyon: IARC.
1
7 - Pignatti, F., van den Bent, M., Curran, D., Debruyne, C., Sylvester, R., Therasse, P., et al. (2002). Prognostic Factors for
Survival in Adult Patients With Cerebral Low-Grade Glioma. Journal of Clinical Oncology 20:2076-2084.
1
8 - Prabhu, R.S., Won, M., Shaw, E.G., Hu, C., Brachman, D.G., Buckner, J.C., et al. (2014). Effect of the addition of
chemotherapy to radiotherapy on cognitive function in patients with low-grade glioma: Secondary analysis of RTOG 98-02.
Journal of Clinical Oncology. 32(6):535-41.
1
9 - Reijneveld, J.C., Taphoorn, M.J.B., Coens, C., Bromberg, J.E.C., Mason, W.P., Hoang-Xuan, K., et al. (2016). Health-
related quality of life in patients with high-risk low-grade glioma (EORTC 22033-26033): a andomized, open-label, phase 3
intergroup study. The Lancet Oncology. 17(11):1533-42.
2
0 - Ryken, T.C., Parney, I., Buatti, J., Kalkanis, S.N., Olson, J.J. (2015). The role of radiotherapy in the management of patients
with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. Journal of Neuro-Oncology.
125(3):551-83.
2
1 - Sarmiento, J.M., Venteicher, A.S., Patil, C.G. (2015). Early versus delayed postoperative radiotherapy for treatment of low-
grade gliomas. Cochrane Database of Systematic Reviews. 2015(6).
2
2 - Shaw, E., Arusell, R., Scheithauer, B., O’Fallon, J., O’Neill, B., Dinapoli, R., et al. (2002). Prospective randomized trial of
low-versus high-dose radiation therapy in adults with supratentorial low-grade glioma: Initial report of a North Central Cancer
Treatment Group/Radiation Therapy Oncology Group/Eastern Cooperative Oncology Group Study. Journal of Clinical
Oncology. 20(9):2267-76.
2
3 - Shaw, E.G., Wang, M., Coons, S.W., Brachman, D.G., Buckner, J.C., Stelzer, K.J., et al. (2012). Randomized trial of
radiation therapy plus procarbazine, lomustine, and vincristine chemotherapy for supratentorial adult low-grade glioma: Initial
results of RTOG 9802. Journal of Clinical Oncology. 30(25):3065-70.
2
4 - Shields, L.B., Choucair, A.K. (2014). Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World Neurosurgery. 82(1-2):e299-309.
2
5 - Wick, W., Hartmann, C., Engel, C., et al. (2009). NOA-04 randomized phase iii trial of sequential radiochemotherapy of
anaplastic glioma with pro- carbazine, lomustine, and vincristine or temozolomide. J Clin Oncol 2009;27:5874–80.
2
6 - Ziu, M., Kalkanis, S.N., Gilbert, M., Ryken, T.C., Olson, J.J. (2015). The role of initial chemotherapy for the treatment of
adults with diffuse low grade glioma: A systematic review and evidence-based clinical practice guideline. Journal of Neuro-
Oncology. 125(3):585-607.
 
Gliomen
PDF aangemaakt op 
23-01-2025
237
/
971
Recidief laaggradig glioom
Uitgangsvraag
Wat is de rol van chemotherapie bij een patiënt met een recidief bij een laaggradig glioom?
Aanbeveling
De voorkeur gaat uit naar behandeling in studieverband (TAVAREC NCT01164189 voor patiënten zonder co-
deletie van 1p en 19q). Indien geen studie beschikbaar, wordt geadviseerd behandeling met 12 kuren
temozolomide te overwegen; voor tumoren met een 1p-19q co-deletie is PCV een optie.
Verdere lijnsbehandeling, bijvoorbeeld PCV of lomustine monotherapie na temozolomide of temozolomide
na PCV kan in geselecteerde patiënten overwogen worden.
Overwegingen
Data over welk schema je moet kiezen ontbreken omdat er geen vergelijkende studies zijn in deze setting,
maar het ligt voor de hand om bij tumoren met een co-deletie van1p-19q te kiezen voor PCV, en de
patiënten met een tumor zonder 1p/19q co-deletie te behandelen met temozolomide.
Onderbouwing
Achtergrond
Deze module beschrijft de rol van chemotherapie bij een patiënt met een recidief bij een laaggradig glioom,
waarbij er sprake is van progressie op beeldvorming na resectie en aanvullende behandeling.
Conclusies
Er zijn aanwijzingen voor respons op temozolomide en PCV bij recidief laaggradige gliomen.
Pace 2003
, Van den Bent 2003
, Van den Bent 2006
, Van den Bent 2013
, Quinn 2003
, Levin
2006
Samenvatting literatuur
Er zijn verschillende studies die de meerwaarde van chemotherapie bij recidief laaggradige (astrocytaire en
oligodendrogliale) gliomen aantonen voor zowel PCV [Pace 2003
, Van den Bent 2003
, 2006
, 2013
]
als temozolomide [Quinn 2003
, Levin 2006
]. De huidige behandelopties geven een kans op respons van
ongeveer 50-75% afhankelijk van de morfologie, moleculaire opmaak en voorbehandeling. Voor verdere
lijnsbehandeling, bijvoorbeeld PCV of lomustine monotherapie na temozolomide of temozolomide na PCV, is
er slechts beperkte data uit ongecontroleerde patiëntenseries [Triebels 2004
]
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
243
358
352
351
269
201
243
358
352
351
269
201
344
Gliomen
PDF aangemaakt op 
23-01-2025
238
/
971
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
Gliomen
PDF aangemaakt op 
23-01-2025
239
/
971
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
Gliomen
PDF aangemaakt op 
23-01-2025
240
/
971
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
Gliomen
PDF aangemaakt op 
23-01-2025
241
/
971
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
Gliomen
PDF aangemaakt op 
23-01-2025
242
/
971
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
Gliomen
PDF aangemaakt op 
23-01-2025
243
/
971
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
Gliomen
PDF aangemaakt op 
23-01-2025
244
/
971
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
Gliomen
PDF aangemaakt op 
23-01-2025
245
/
971
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
Gliomen
PDF aangemaakt op 
23-01-2025
246
/
971
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
Gliomen
PDF aangemaakt op 
23-01-2025
247
/
971
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
Gliomen
PDF aangemaakt op 
23-01-2025
248
/
971
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Gliomen
PDF aangemaakt op 
23-01-2025
249
/
971
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
Gliomen
PDF aangemaakt op 
23-01-2025
250
/
971
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
Gliomen
PDF aangemaakt op 
23-01-2025
251
/
971
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Gliomen
PDF aangemaakt op 
23-01-2025
252
/
971
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
Gliomen
PDF aangemaakt op 
23-01-2025
253
/
971
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
Gliomen
PDF aangemaakt op 
23-01-2025
254
/
971
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
Gliomen
PDF aangemaakt op 
23-01-2025
255
/
971
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
256
/
971
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
257
/
971
Behandeling Hooggradig glioom
Deze module is onderverdeeld in de volgende submodules en sub-submodules:
Neurochirurgie
Chirurgische behandelingsstrategie hooggradig glioom
Minimale mate van resectie hooggradig glioom
Waarde en mate van re-resectie glioblastoom
Radiotherapie
Indicatie radiotherapie anaplastisch glioom
Indicatie radiotherapie glioblastoom
Radiotherapie bij progressie hooggradig glioom/recidief
Chemotherapie/systeemtherapie
Chemotherapie nieuw gediagnostiseerd anaplastisch glioom
Chemotherapie recidief anaplastisch glioom
Chemotherapie nieuw gediagnostiseerd glioblastoom
Chemotherapie recidief glioblastoom
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
Gliomen
PDF aangemaakt op 
23-01-2025
258
/
971
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
Gliomen
PDF aangemaakt op 
23-01-2025
259
/
971
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
Gliomen
PDF aangemaakt op 
23-01-2025
260
/
971
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
Gliomen
PDF aangemaakt op 
23-01-2025
261
/
971
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
Gliomen
PDF aangemaakt op 
23-01-2025
262
/
971
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
Gliomen
PDF aangemaakt op 
23-01-2025
263
/
971
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
Gliomen
PDF aangemaakt op 
23-01-2025
264
/
971
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
Gliomen
PDF aangemaakt op 
23-01-2025
265
/
971
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
Gliomen
PDF aangemaakt op 
23-01-2025
266
/
971
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
Gliomen
PDF aangemaakt op 
23-01-2025
267
/
971
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
Gliomen
PDF aangemaakt op 
23-01-2025
268
/
971
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
Gliomen
PDF aangemaakt op 
23-01-2025
269
/
971
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
Gliomen
PDF aangemaakt op 
23-01-2025
270
/
971
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
Gliomen
PDF aangemaakt op 
23-01-2025
271
/
971
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
Gliomen
PDF aangemaakt op 
23-01-2025
272
/
971
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
Gliomen
PDF aangemaakt op 
23-01-2025
273
/
971
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
Gliomen
PDF aangemaakt op 
23-01-2025
274
/
971
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
Gliomen
PDF aangemaakt op 
23-01-2025
275
/
971
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
276
/
971
Neurochirurgie bij hooggradig glioom
Deze submodule is onderverdeeld in de volgende sub-submodules:
Chirurgische behandelingsstrategie hooggradig glioom
Minimale mate van resectie hooggradig glioom
Waarde en mate van re-resectie glioblastoom
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
Gliomen
PDF aangemaakt op 
23-01-2025
277
/
971
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
Gliomen
PDF aangemaakt op 
23-01-2025
278
/
971
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
Gliomen
PDF aangemaakt op 
23-01-2025
279
/
971
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
Gliomen
PDF aangemaakt op 
23-01-2025
280
/
971
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
Gliomen
PDF aangemaakt op 
23-01-2025
281
/
971
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
Gliomen
PDF aangemaakt op 
23-01-2025
282
/
971
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
Gliomen
PDF aangemaakt op 
23-01-2025
283
/
971
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
Gliomen
PDF aangemaakt op 
23-01-2025
284
/
971
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
Gliomen
PDF aangemaakt op 
23-01-2025
285
/
971
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
Gliomen
PDF aangemaakt op 
23-01-2025
286
/
971
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
Gliomen
PDF aangemaakt op 
23-01-2025
287
/
971
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
Gliomen
PDF aangemaakt op 
23-01-2025
288
/
971
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
Gliomen
PDF aangemaakt op 
23-01-2025
289
/
971
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
Gliomen
PDF aangemaakt op 
23-01-2025
290
/
971
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
Gliomen
PDF aangemaakt op 
23-01-2025
291
/
971
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Gliomen
PDF aangemaakt op 
23-01-2025
292
/
971
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Gliomen
PDF aangemaakt op 
23-01-2025
293
/
971
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
Gliomen
PDF aangemaakt op 
23-01-2025
294
/
971
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
295
/
971
Chirurgische behandelingsstrategie hooggradig glioom
Uitgangsvraag
Wat is de beste neurochirurgische behandelingsstrategie bij een patiënt met een vermoedelijk hooggradig
glioom op beeldvorming?
Aanbeveling
Er wordt geadviseerd een resectie te verrichten zo maximaal als mogelijk is met behoud van kwaliteit van
leven. Zie module 
Minimale mate van resectie hooggradig glioom
.
Voor een patiënt met een vermoedelijk hooggradig glioom dienen de risico's en de voordelen van een zo
maximaal mogelijke resectie individueel afgewogen te worden in een multidisciplinaire
hersentumorwerkgroep, waaraan tenminste een neurochirurg, neuroloog, neuroradioloog, radiotherapeut,
een internist-oncoloog en optioneel een klinisch neuropsycholoog deelnemen. In de multidisciplinaire
werkgroep wordt een eerste behandelkeuze met alternatieven geformuleerd. 
Onder een zo goed mogelijke neurochirurgische behandeling wordt verstaan een zo maximaal mogelijke
resectie van tumorweefsel en necrotisch tumorweefsel waarbij kwaliteit van leven behouden wordt.
Verschillende operatietechnieken kunnen naar inzicht en ervaring van het neurochirurgisch team gebruikt
worden, zoals neuronavigatie, DTI, 5-ALA, intraoperatieve MRI of mapping met behulp van corticale en
subcorticale stimulatie. Er zijn geen argumenten in de literatuur dat het achterwege laten van een of meer van
deze technieken de patiënt benadeelt. De effectiviteit van carmustine wafers lijkt te klein in verhouding tot
de kostprijs om toe te passen.
Prognostisch ongunstige factoren, zoals hoge leeftijd, lage Karnofsky performance status, multifocaliteit en
bilaterale uitbreiding, dienen betrokken te worden in het advies voor de neurochirurgische
behandelstrategie. Over het algemeen zal een terughoudender strategie geadviseerd worden bij meer
prognostisch ongunstige factoren.
Overwegingen
Hiernavolgend zullen aanbevelingen uit andere richtlijnen en een aantal klinische dilemma's bij de
neurochirurgische behandelstrategie worden toegelicht.
De National Comprehensive Cancer Network (Verenigde Staten) beveelt multidisciplinaire indicatiestelling
voor een operatie aan in de vorm van, indien mogelijk, een maximale tumorverwijdering met minimale
morbiditeit en vaststellen van de mate van resectie door een MRI binnen 72 uur na operatie [NCCN2013].
Indien dit niet haalbaar is, wordt een biopt of een incomplete tumorverwijdering geadviseerd.
Een aantal dilemma's kan zich voordoen rondom behandelbeslissingen bij de verdenking op een hooggradig
glioom. Een selectie daarvan zal hier besproken worden aan de hand van de literatuur: de neurochirurgische
behandelstrategie voor anaplastisch glioom, voor multifocaal hooggradig glioom, voor bilateraal glioom en
voor de oudere patiënt.
In literatuur van de jaren 1980 en 1990 werden patiënten met een anaplastisch glioom (WHO graad III) veelal
samengenomen met patiënten met glioblastoom onder de noemer ‘hooggradig glioom'. In studies vanaf
Gliomen
PDF aangemaakt op 
23-01-2025
296
/
971
ongeveer het jaar 2000, naar het effect van een resectie bij patiënten met een anaplastisch glioom, wordt de
mate van resectie als onafhankelijke gunstige prognostische factor gevonden voor overleving en tijd tot
progressie [Keles 2006
], Puduvalli 2003
]. Op het moment dat een besluit over de neurochirurgische
behandelstrategie genomen moet worden is de histopathologische gradering nog niet bekend. Een deel van
de - achteraf - anaplastische gliomen toont geen of beperkte aankleuring met contrast waarbij een T2/FLAIR-
geleide resectie werd beoogd. Een ander deel bestaat echter voornamelijk uit contrastaankleuring, waarbij
een T1 met contrast gerichte resectie werd uitgevoerd. Er werd geen literatuur gevonden met vergelijkend
onderzoek tussen een T1 met contrast gerichte resectie of uitgebreidere T2/FLAIR-resectie bij deze
patiënten.
Aan patiënten met meerdere foci van een hooggradig glioom wordt over het algemeen geen resectie
geadviseerd. Uit de literatuur is niet duidelijk of een resectie minder effectief is bij multifocaliteit dan bij
unifocaliteit. Aan de ene kant is multifocaal glioblastoom geassocieerd met een kortere overleving in case-
control onderzoek van 47 patiënten, gematcht voor leeftijd, conditie en mate van resectie: 6 maanden (95%CI
4-10 maanden) bij multifocale lokalisatie, vergeleken met 11 maanden (95%CI 10-19 maanden) in geval van
unifocale lokalisatie (p = 0.02) [Patil 2012
]. Aan de andere kant wordt in een ander case-control onderzoek
van 20 patiënten met een multifocaal glioblastoom, gematcht voor leeftijd, conditie, eloquentie en mate van
resectie met een groep met een unifocale lokalisatie, een vergelijkbare overleving gevonden: 9,7 maanden
vergeleken met 10,5 maanden (p = 0.34) [Hassaneen 2011
].
Aan patiënten met een bilateraal hooggradig glioom (zogenaamd vlinderglioom of balkglioom) wordt over
het algemeen geen resectie geadviseerd. Uit de literatuur is echter niet duidelijk of een resectie bij deze
groep minder effectief is dan bij een unilaterale lokalisatie. In een beschrijving van 23 patiënten met een
bilateraal glioblastoom tussen 1990 en 2000 ondergingen 12 een biopt en 11 een resectie [Dziurzynski
2012
]. De groep na resectie had een mediane overleving van 8,8 maanden (95%CI 3-14.6 maanden).
Er bestaat discussie over de neurochirurgische behandeling bij patiënten met een hooggradig glioom op
hogere leeftijd (met als arbitraire grens 70 jaar of ouder). Aan de ene kant is hoge leeftijd een ongunstige
prognostische factor voor overleving en voor perioperatieve morbiditeit [Bauchet 2014
], aan de andere kant
is mate van resectie ook in deze subgroep een onafhankelijke gunstige prognostische factor voor overleving.
In een gerandomiseerde klinische studie bij patiënten met een glioblastoom ouder dan 65 jaar werd
vastgesteld, dat een resectie resulteerde in een significant langere overleving dan een biopt [Vuorinen
2003
]. 
Tanaka beschreef 105 patiënten met een glioblastoom ouder dan 65 jaar, die werden behandeld tussen 2003
en 2008, waarvan 52 patiënten een biopt ondergingen en 53 een resectie [Tanaka 2013
]. In multivariate
analyse was een resectie geassocieerd met een langere overleving (RR 0.54, 95%CI 0.31-0.94, p = 0.04) na
correctie voor leeftijd, unifocaliteit en adjuvante therapie. Adjuvante therapie lijkt hiervan de belangrijkste
factor. Patiënten die adjuvante therapie ondergingen na een resectie leefden langer (11,5 maanden) dan die
na een biopt (6,5 maanden). Postoperatieve complicaties werden beschreven bij 26 (25%) patiënten waarvan
16 na biopt. Postoperatieve mortaliteit ontstond bij 4 (4%) patiënten, allen na biopt. 
Scott beschreef 206 patiënten met een glioblastoom, ouder dan 70 jaar, behandeld tussen 1979 en 2007,
waarvan 113 een biopt ondergingen en 93 een resectie, waarvan 23 een radiologisch complete resectie
betrof [Scott 2011
]. In multivariate analyse hadden patiënten na een biopt een kortere overleving dan na
een resectie (HR: 3.09, 95%CI 2.09-4.56, p <0.001) na correctie voor conditie, bestraling en chemotherapie.
Na een biopt werd een mediane overleving van 2,8 maanden geobserveerd en na een resectie van 7,3
maanden (p <0.001). 
167
265
250
128
87
12
371
340
304
Gliomen
PDF aangemaakt op 
23-01-2025
297
/
971
Ewelt beschreef 103 patiënten met een glioblastoom, ouder dan 65 jaar, behandeld tussen 2002 en 2007
[Ewelt 2011
]. De mediane overleving was 2,2 maanden na biopt (95%CI 1,6-2,7 maanden, 43 patiënten), 7,0
maanden na partiële resectie (95%CI 6,3-7,7 maanden, 37 patiënten) en 13,9 maanden na radiologisch
complete resectie (95%CI 11,8-15,9 maanden, 23 patiënten) (p <0.05). In multivariate analyse, was een
uitgebreidere resectie geassocieerd met een langere overleving (HR 1.987, p <0.05) na correctie voor leeftijd
en conditie.
Onderbouwing
Conclusies
Er zijn aanwijzingen dat een resectie voor een hooggradig glioom de levensduur verlengt.
Hart 2011
, Tsitlakidis 2010
, Stummer 2008
, Lacroix 2001
, Chaichana 2014
, McGirt 2009
, Graus
2013, Bauchet 2010, Filippini 2008
Er zijn aanwijzingen dat na een resectie voor een hooggradig glioom de kwaliteit van leven en cognitie niet
verslechtert. Bij ongeveer de helft van de patiënten verbetert de conditie . Bij 5 tot 10% van de patiënten
leidt de resectie tot complicaties of verminderde conditieen bij minder dan 2% van de patiënten tot
postoperatieve mortaliteit.
Daigle 2013
, Brown 2005
, Yoshii 2008
, Talacchi 2011
, Satoer 2014
, Chang 2003
, De Witt Hamer
2012
,McGirt 2009
, Chaichana 2014
 
Hogere leeftijd, lagere Karnofsky performance status, multifocaliteit en bilaterale uitbreiding zijn
geassocieerd met een kortere levensverwachting.
Patil 2012
, Hassaneen 2011
, Dziurzynski 2012
, Bauchet 2014
, Vuorinen 2003
, Tanaka 2013
,
Scott 2011
Samenvatting literatuur
De literatuur voor de neurochirurgische behandeling van een vermoedelijk hooggradig glioom wordt
achtereenvolgens beschreven aan de hand van een Cochrane review, een systematische review en een meta-
analyse en publicaties over effectiviteit van een resectie in termen van overleving, progressievrije overleving,
verbetering van verschijnselen en kwaliteit van leven. Daarna wordt het risico van een resectie beschreven. Tot
slot de gerandomiseerde klinische studies die over operatietechnieken zijn gepubliceerd.
In een Cochrane review werd één klinische studie geïdentificeerd, waarin tussen biopsie en resectie werd
gerandomiseerd bij patiënten ouder dan 65 jaar in Finland tussen 1993 en 1996 [Hart 2011
]. De mediane
overleving was korter voor de 16 patiënten na biopsie (85 dagen, 95%CI 55-157) dan voor de 14 patiënten na
resectie (171 dagen, 95%CI 146-278; p = 0.0346). De hazard ratio, gecorrigeerd voor tumorgradering, was
2.621 (95%CI 1.035-6.641; p = 0.0422) en, gecorrigeerd voor radiotherapie, 2.729 (95%CI 1.035 7.195; p =
0.0423). Hoewel statistisch significante verschillen werden gevonden in overleving is deze studie
underpowered en zijn er methodologische beperkingen. 
In een meta-analyse naar het verschil tussen een biopt en resectie in termen van overleving, progressievrije
overleving en kwaliteit van leven, identificeerde Tsitlakidis dezelfde gerandomiseerde studie en vier
retrospectieve studies waarvan de gegevens van 1111 patiënten gepoold werden [Tsitlakidis 2010
]. Een
resectie was geassocieerd met een langere overleving dan een biopt (hazard ratio 0.61, 95%CI 0.52-0.71, p
93
124
346
328
190
48
215
95
67
35
403
339
298
52
76
215
48
250
128
87
13
371
340
304
124
346
Gliomen
PDF aangemaakt op 
23-01-2025
298
/
971
<0.0001). Statistische analyse was niet mogelijk voor progressievrije overleving en kwaliteit van leven,
vanwege het ontbreken van voldoende gegevens. 
In vier studies is de relatie tussen de mate van resectie en overleving onderzocht in tertiaire verwijscentra
voor hersentumoren, rekening houdend met bekende prognostische factoren als potentiële confounders.
Stummer verrichtte een posthoc analyse van prospectief verzamelde gegevens van 243 patiënten met een
glioblastoom in het kader van een gerandomiseerde multicenter studie in Duitsland naar conventionele wit
licht microscopie versus 5-ALA fluorescentie microscopie [Stummer 2008
]. De 122 patiënten waarbij na
resectie geen tumorrest aantoonbaar was op de MRI hadden een significant langere overleving (16,9
maanden) dan de 121 patiënten met een tumorrest (11,8 maanden) (p <0.0001). De hazard ratio voor
overleving na een complete versus incomplete resectie was 1.752 (95%: 1.258-2.438; p = 0.0004), na
correctie voor leeftijd, conditie, preoperatief tumorvolume, eloquentie, midline verplaatsing, oedeem en
ependymale infiltratie. 
Lacroix beschreef 416 patiënten met een glioblastoom die geopereerd werden tussen 1993 en 1999 [Lacroix
2001
]. Een uitgebreidere mate van resectie (>98%) was geassocieerd met een langere overleving (mediane
overleving 13 maanden, 95%CI 11,4-14,6 maanden), vergeleken met beperktere resecties (8,8 maanden,
95%CI 7.4-10.2 maanden; p <0.0001). In multivariate analyse was de hazard ratio 1.4 (95%CI 1.1-1.9) na
correctie voor leeftijd, conditie en radiologische necrose. Een langere overleving werd gevonden vanaf 89%
tumorresectie (rate ratio 1.3, 95%CI 1.1-1.6, p = 0.04).
Sanai beschreef 500 patiënten met een glioblastoom, die geopereerd werden tussen 1997 en 2009 [Sanai
2011
]. In multivariate analyse was de hazard ratio per procent resectie 0.99 (95%CI 0.98-0.99, p=0.004) na
correctie voor leeftijd, conditie en resttumor volume. Een langere overleving werd gevonden vanaf 78%
tumorresectie.
Chaichana beschreef 259 patiënten met een glioblastoom, die geopereerd werden tussen 2007 en 2011
[Chaichana 2014
]. In multivariate analyse was de hazard ratio per procent resectie 0.992 (95%CI 0.987-
0.997, p = 0.003) na correctie voor leeftijd, chemotherapie wafer, temozolomide, bestraling en preoperatief
tumorvolume.
McGirth beschreef 949 patiënten met een WHO-graad III of IV astrocytoom die geopereerd werden tussen
1996 en 2006 [McGirth 2009
]. In multivariate analyse was een uitgebreidere resectie geassocieerd met
langere overleving (radiologisch complete resectie vergeleken met een incomplete resectie HR: 0.449, p =
0.001; radiologisch bijna-complete resectie vergeleken met een incomplete resectie HR 0.614, p = 0.002) na
correctie voor leeftijd, conditie, chemotherapie wafer, temozolomide en vervolgbehandeling. 
In drie studies is de relatie tussen mate van resectie en overleving onderzocht in behandelpatronen van
ziekenhuizen zonder specifieke verwijsfunctie voor gliomen uitgevoerd in verschillende landen.
Vanuit Spanje werden door Graus 834 patiënten met een operatie voor glioblastoom tussen 2008 en 2010 in
19 ziekenhuizen beschreven [Graus 2013]. In multivariate analyse was de overleving van patiënt na een
resectie langer dan na een biopt (HR: 0.50; 95%CI, 0.41-0.60; p<0.001) na correctie voor leeftijd, conditie,
radiotherapie en chemotherapie.
Vanuit Frankrijk werden door Bauchet 952 patiënten met een operatie voor glioblastoom tussen 2004 en 2006
in 43 ziekenhuizen beschreven [Bauchet 2010]. In multivariate analyse was de overleving korter voor patiënten
na een biopt dan na een resectie (HR: 1.606, 95%CI 1.255-2.056, p=0.0002) na correctie voor leeftijd en
tumorlokalisatie.
Vanuit Italië werden door Filippini 676 patiënten met een operatie voor glioblastoom tussen 1997 en 2003
beschreven [Filippini 2008
]. In multivariate analyse was de overleving langer voor patiënten na resectie dan
328
190
292
48
215
95
Gliomen
PDF aangemaakt op 
23-01-2025
299
/
971
na biopt (HR 0.55, 95%CI 0.42 - 0.72, p<0.001) na correctie voor leeftijd, conditie, tumoruitbreiding,
chemotherapie en radiotherapie. 
Een aantal studies beschreef het effect van een resectie op de kwaliteit van leven. In een studie met 35
patiënten met een glioblastoom, geopereerd in 2010 en 2011, werd beschreven dat een uitgebreidere
resectie gepaard ging met een verbetering in functioneel welbevinden (r=0.616, p=0.005), een verbetering in
neurocognitief functioneren (r=0.51, p=0.026) en een verbetering in globale kwaliteit van leven (r=0.68,
p=0.001) drie maanden na operatie ten opzichte van voor operatie [Daigle 2013[157]]. In een andere studie
met 220 patiënten met een WHO-graad III of IV glioom geopereerd tussen 1999 en 2002 en verzameld in drie
klinische studies werd beschreven dat in multivariate analyse patiënten na een radiologisch complete resectie
minder risico op een slechte kwaliteit van leven hadden dan patiënten na een biopt (odds ratio: 0.14, 95%CI
0.04-0.57, p= 0.006) [Brown 2005
]. 
Andere studies beschreven de relatie tussen operatie voor hersentumoren, waarvan een deel hooggradig
glioom betrof, en cognitie. Yoshii beschreef 31 patiënten, waarvan 23 met een hooggradig glioom, die voor
en een maand na operatie neuropsychologisch onderzoek ondergingen [Yoshii 2008
]. De cognitie
verbeterde voor patiënten die een operatie ondergingen in de rechter hersenhelft, maar niet in de linker
hersenhelft. Talacchi beschreef 29 patiënten waarvan 17 met een hooggradig glioom, die voor en een week
na operatie neuropsychologisch onderzoek ondergingen [Talacchi 2011
]. Tenminste één cognitief domein
verbeterde bij 6 (21%) patiënten; tenminste één cognitief domein verslechterde bij 7 (24%) patiënten. Satoer
beschreef 45 patiënten waarvan 17 met een hooggradig glioom die voor en drie maanden en een jaar na
operatie neuropsychologisch onderzoek ondergingen [Satoer 2014
]. Drie maanden na operatie waren er
geen veranderingen in aandacht en executieve vaardigheden, een verbetering in geheugen (p=0.034) en een
kleine maar significante verslechtering in taalfunctie (p=0.030). Tussen drie maanden en een jaar na operatie
verbeterde de taalfunctie (p=0.026).
Het risico op permanente neurologische en neuropsychologische functiestoornissen na een resectie is 6,2%
(3.2-11.5%) in de subgroep van patiënten met een hooggradig glioom in een meta-analyse van 2104
patiënten in 18 studies [De Witt Hamer 2012
]. Het risico op postoperatieve mortaliteit is 0,26% (0.01-
0.50%).
Stummer beschreef bij 34 (14%) van 235 patiënten met een glioblastoom een functionele achteruitgang zes
weken na operatie en bij 95 (40%) een functionele vooruitgang in termen van NIH stroke score (National
Institutes of Health) [Stummer 2006
]. Postoperatieve mortaliteit deed zich voor bij 8 (3%) patiënten.
Chaichana beschreef bij 19 (7%) van 259 patiënten met een glioblastoom een permanente neurologische
functiestoornis [Chaichana 2014
]. 
McGirth beschreef bij 63 (7%) van 949 patiënten met een glioblastoom een nieuwe motorische
functiestoornis, bij 48 (5%) een nieuwe taalstoornis, bij 22 (2%) een infectieuze complicatie, bij 11 (1%) een
postoperatief hematoom, en bij 23 (2%) een longembolie [McGirth 2009
]. 
Chang beschreef bij 8,1% van 408 patiënten met een hooggradig glioom na een operatie een functionele
achteruitgang, en bij 53% een functionele verbetering [Chang 2003
]. Een regionale complicatie, zoals een
wondinfectie of liquorlekkage, ontstond bij 10%; een systemische complicatie, zoals een diepe veneuze
trombose of pneumonie, bij 9,2%. Postoperatieve mortaliteit deed zich voor bij 6 (1,5%) patiënten.
Verschillende operatietechnieken zijn geïntroduceerd en geëvalueerd in gerandomiseerde klinische studies:
chemotherapie wafer implantatie en beeldgeleide operatie met intraoperatieve MRI, 5-ALA fluorescentie en
functionele MRI en diffusion tensor imaging. Deze worden hier achtereenvolgens besproken.
In een Cochrane review [Hart 2011
] naar de effectiviteit van chemotherapie geïmpregneerde wafers in de
35
403
339
298
76
327
47
215
52
124
Gliomen
PDF aangemaakt op 
23-01-2025
300
/
971
resectieholte na operatie voor nieuw gediagnosticeerd hooggradig glioom, identificeerden de auteurs twee
gerandomiseerde studies met in totaal 272 patiënten, waarin radiotherapie alleen vergeleken werd met
radiotherapie plus carmustine wafers [Valtonen 1997
], Westphal 2003
]. Na wafer implantatie werd een
langere overleving waargenomen (HR: 0.65, 95%CI 0.48-0.86, p=0.003), zonder verschil in complicaties. De
mediane overleving was 13,9 maanden voor de carmustine wafer groep vergeleken met 11,6 maanden voor
de placebo groep, met een jaar overleving van 59,2% en 49,6%. Hoewel statistisch significant werd dit
verschil geïnterpreteerd als minimaal klinisch relevant. Carmustine wafers worden in Nederland niet vergoed
door zorgverzekeraars.
In een Cochrane review [Barone 2014
] naar verschillende beeldgeleide operatietechnieken voor
optimaliseren van de mate van resectie werden vier gerandomiseerde studies geïdentificeerd: een voor
intraoperatieve MRI [Senft 2011
], 5-ALA fluorescentie geleide resectie [Stummer 2006
], neuronavigatie
[Willems 2006
] en DTI-neuronavigatie [Wu 2007
]. De mate van resectie werd uitgebreider na
intraoperatieve MRI (risk ratio voor incomplete resectie: 0.13, 95%CI 0.02-0.96, lage kwaliteit bewijs), na 5-
ALA (RR 0.55, 95%CI 0.42-0.71) en DTI-neuronavigatie (RR 0.35, 95%CI 0.20-0.63, erg lage kwaliteit van
bewijs). De rapportage van complicaties was onvoldoende voor analyse, terwijl vroege neurologische
functiestoornis vaker voorkwamen na 5-ALA resectie. Een overlevingsvoordeel kon niet worden vastgesteld
voor 5-ALA (HR: 0.82, 95%CI 0.62-1.07) of DTI-neuronavigatie (HR 0.57, 95%CI 0.32-1.00) voor patiënten met
een hooggradig glioom. Progressie-vrije overleving werd niet gerapporteerd.
Senft verrichtte een prospectief gerandomiseerde studie (NCT01394692) naar het effect van intraoperatieve
MRI op radiologisch complete resectie bij contrast-aankleurend glioom [Senft 2011
]. Het primaire eindpunt
was de mate van tumorresectie op postoperatieve MRI. Secundaire eindpunten waren het resttumor volume
op postoperatieve MRI en progressievrije overleving na zes maanden. Er werden 58 patiënten geïncludeerd,
waarvan 8 geëxcludeerd werden na randomisatie vanwege de diagnose metastase en 1 op eigen verzoek. Na
randomisatie werden 24 patiënten geopereerd met intraoperatieve MRI en 25 zonder. In de intraoperatieve
MRI-groep werd een radiologisch complete resectie bij 24 patiënten (96%) vastgesteld en in de
controlegroep bij 17 patiënten (68%) (p=0.023). In de intraoperatieve MRI-groep werd minder resttumor
geobserveerd dan in de controlegroep (een mediaan resttumorvolume van 0 versus 0.03 mL, p=0.0015). Na
zes maanden bestond progressie bij 8 patiënten (33%) in de intraoperatieve MRI-groep en bij 16 patiënten
(64%) in de controlegroep (p=0.046).
Wu verrichtte een prospectief gerandomiseerde studie naar het effect van DTI-gebaseerde neuronavigatie
tijdens operatie voor gliomen nabij de pyramidebaan op motorische functiestoornissen, de mate van resectie
en overleving [Wu 2007
]. Eindpunten werden niet gedefinieerd. Na randomisatie van 238 patiënten
werden er 118 geopereerd met DTI-geleide neuronavigatie en 120 zonder. Een radiologisch complete
resectie werd vastgesteld bij 72% in de DTI-geleide neuronavigatie groep en bij 52% in de controlegroep
(p=0.002). Na operatie bestond een motorische functiestoornis bij 18 patiënten (15,3%) in de DTI-geleide
neuronavigatie groep en bij 39 patiënten (32,8%) in de controlegroep (p<0.001). De gemiddelde KPS bij zes
maanden was 86 in DTI-geleide neuronavigatie groep en 74 in de controlegroep (p<0.001). Survivalanalyse
werd alleen in de subgroep van 81 patiënten met hooggradig glioom verricht. De mediane overleving in de
DTI-geleide neuronavigatie groep met hooggradig glioom was 21,2 maanden en in de controle groep 14,0
maanden (p=0.048).
Stummer verrichtte een prospectief gerandomiseerde studie (NCT00241670) naar het gebruik van porphyrin
fluorescentie voor maligne glioom na toedienen van 5-aminolevulinezuur om de mate van resectie op
postoperatieve MRI te verbeteren en om de effecten van resectie op progressievrije overleving,
348
384
9
306
327
389
392
306
392
327
Gliomen
PDF aangemaakt op 
23-01-2025
301
/
971
neurologische morbiditeit en vervolgbehandeling te analyseren [Stummer 2006
]. De primaire eindpunten
waren het percentage patiënten zonder aankleurende resttumor op MRI en de progressievrije overleving na
zes maanden. Secundaire eindpunten waren het resttumorvolume op MRI, overleving, neurologisch
functiestoornissen en toxiciteit. Na interimanalyse bij 270 van 350 benodigde patiënten werd de studie
vroegtijdig beëindigd. Na randomisatie werden 139 patiënten geopereerd met 5-ALA fluorescentie licht door
de microscoop en 131 met conventioneel witlicht. Contrastaankleurende tumoren werden in de 5-ALA groep
bij 90 (65%) patiënten totaal verwijderd ten opzichte van bij 47 (36%) in de controle groep (p<0.0001). In de
5-ALA groep was 41,0% van patiënten progressievrij bij zes maanden vergeleken met 19,9% in de controle
groep (p=0.0003). De groepen verschilden niet in overleving of postoperatieve complicaties.
Willems verrichtte een prospectief gerandomiseerde studie naar het effect van neuronavigatie op de mate van
tumorverwijdering bij contrast-aankleurende hersentumoren [Willems 2006
]. Eindpunten werden niet
geformuleerd. Er werden 46 patiënten geïncludeerd (39 hooggradig gliomen, 6 metastasen en 1 later
geëxcludeerd meningeoom), waarvan na randomisatie 23 een resectie met neuronavigatie ondergingen en 22
zonder. De mate van tumorverwijdering en de resttumor verschilden niet. De mediane overleving was 5,6
maanden in de groep van resectie met neuronavigatie en 9 maanden in de controle groep (p=0.037).
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
327
389
Gliomen
PDF aangemaakt op 
23-01-2025
302
/
971
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
Gliomen
PDF aangemaakt op 
23-01-2025
303
/
971
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
Gliomen
PDF aangemaakt op 
23-01-2025
304
/
971
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
Gliomen
PDF aangemaakt op 
23-01-2025
305
/
971
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
Gliomen
PDF aangemaakt op 
23-01-2025
306
/
971
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Gliomen
PDF aangemaakt op 
23-01-2025
307
/
971
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
Gliomen
PDF aangemaakt op 
23-01-2025
308
/
971
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
Gliomen
PDF aangemaakt op 
23-01-2025
309
/
971
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
Gliomen
PDF aangemaakt op 
23-01-2025
310
/
971
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Gliomen
PDF aangemaakt op 
23-01-2025
311
/
971
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
Gliomen
PDF aangemaakt op 
23-01-2025
312
/
971
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
Gliomen
PDF aangemaakt op 
23-01-2025
313
/
971
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
Gliomen
PDF aangemaakt op 
23-01-2025
314
/
971
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
Gliomen
PDF aangemaakt op 
23-01-2025
315
/
971
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
Gliomen
PDF aangemaakt op 
23-01-2025
316
/
971
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
317
/
971
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
Gliomen
PDF aangemaakt op 
23-01-2025
318
/
971
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
Gliomen
PDF aangemaakt op 
23-01-2025
319
/
971
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
320
/
971
Minimale mate van resectie hooggradig glioom
Uitgangsvraag
Wat is de minimale mate van resectie die zinvol is bij een patiënt met een hooggradig glioom?
Aanbeveling
Er is geen minimale mate van resectie aan te geven die zinvol is bij de indicatiestelling voor een operatie bij
een patiënt met een vermoedelijk hooggradig glioom. Er zijn echter aanwijzingen dat bij een glioblastoom
een langere overleving wordt behaald bij een uitgebreidere resectie.
Zie voor de beste neurochirurgische behandelingsstrategie bij een patiënt met een vermoedelijk hooggradig
glioom, de module 
Chirurgische behandelingsstrategie hooggradig glioom
.
Het is onduidelijk of de te behalen mate van resectie preoperatief betrouwbaar is in te schatten. In het geval
een resectie wordt uitgevoerd, is het meten van de mate van resttumor en de mate van tumorverwijdering
met behulp van pre- en postoperatieve MRI aan te bevelen ter verslaglegging (zie module 
Beeldvormende
diagnostiek
).
Overwegingen
Het is maar zeer de vraag of een eenduidige afkapwaarde bestaat waarboven een resectie zinvol is en waar
beneden een resectie zinloos is. Deze argumenten zijn verwoord door Solheim [2014
]. Ten eerste is een
continuüm tussen verlengde overleving door verminderde tumorlast waarschijnlijker dan een exacte
afkapwaarde op basis van ‘biologica'. Ten tweede moeten klinische relevantie en statistische significantie
duidelijk onderscheiden worden: studies met grotere patiëntaantallen zullen kleinere verschillen in overleving
als statistisch significant kunnen aantonen, terwijl het natuurlijk gaat om de waarde van de mate van
levensverlenging. Ten derde is het onduidelijk of pre-operatief een goede inschatting te geven is van de te
verwachten mate van resectie.
Onderbouwing
Conclusies
Er zijn aanwijzingen dat een grotere mate van resectie en minder resttumor na operatie voor een
glioblastoom gepaard gaat met een langere overleving.
Chaichana 2014
, Sanai 2011
, Lacroix 2001
, Stummer 2008
Er zijn aanwijzingen dat bij een glioblastoom een langere overleving wordt behaald bij minimale resectie van
respectievelijk 70% -100%; of als alternatieve mate van resectie uit een maximaal restvolume van nul mL of 5
mL.
Chaichana 2014
, Sanai 2011
, Lacroix 2001
, Stummer 2008
Samenvatting literatuur
In de literatuur werden vier publicaties gevonden die deze uitgangsvraag als onderzoeksvraag direct
323
48
292
190
328
48
292
190
328
Gliomen
PDF aangemaakt op 
23-01-2025
321
/
971
proberen te beantwoorden voor glioblastoom.
Lacroix beschreef 416 patiënten, geopereerd voor glioblastoom tussen 1993 en 1999, waarvan 183 patiënten
eerdere tumorbehandeling in een ander centrum ondergingen [Lacroix 2001
]. De mate van resectie werd
op basis van MRI-volumetrie gemeten. In multivariate survivalanalyse werd een afkapwaarde van 98%
tumorresectie onderzocht, met correctie voor leeftijd, conditie en radiologische parameters (necrose en
aankleuring). Een tumorresectie van 98% of meer was significant geassocieerd (adjusted rate ratio 1.6, 95%CI
1.3-2, p < 0.0001) met een langere overleving: 13 maanden (95%CI 11,4-14,6 maanden) vergeleken met 8,8
maanden (95%CI7,4-10,2 maanden, p < 0.0001) voor patiënten met minder dan 98% tumorresectie. In
univariate analyse werden verschillende afkapwaarden voor mate van resectie geëxploreerd. Tot een
minimale afkapwaarde van 89% werd in deze groep een associatie met overleving gevonden.
Stummer beschreef 243 patiënten, geopereerd voor glioblastoom tussen 1999 en 2004, in het kader van een
multicenter klinische studie naar een operatietechniek (operatiemicroscopie met 5-ALA fluorescentie)
[Stummer 2008
]. De mate van resttumor werd op basis van MRI-volumetrie gemeten. In een multivariate
survivalanalyse werd afwezigheid van aankleurende resttumor onderzocht, met correctie voor leeftijd,
conditie, preoperatief tumorvolume, eloquentie, midlijn shift, mate van oedeem en ependymale
tumorinfitratie. Afwezigheid van resttumor was significant geassocieerd (adjusted hazard ratio 1.75, 95%CI
1.26-2.44, p < 0.001) met een langere overleving: 16,9 maanden vergeleken met 11,8 maanden voor
patiënten met resttumor. In kaplan meier survivalanalyse naar de afkapwaarde voor de mate van resttumor
bleken alle categorieën van resttumor (minder dan 0.7 mL, 0.7-1.5 mL,1.5-4.1 mL, en meer dan 4.1 mL)
significant te verschillen in overleving (p = 0.0006) van de patiënten met afwezigheid van resttumor.
Sanai beschreef 500 patiënten, geopereerd voor glioblastoom tussen 1997 en 2009. De mate van resttumor
werd op basis van MRI-volumetrie gemeten [Sanai 2011
]. In een multivariate survivalanalyse werden zowel
het volume resttumor als de mate van tumorresectie onderzocht, met correctie voor leeftijd en conditie. Een
uitgebreidere resectie (adjusted hazard ratio per procent tumorverwijdering 0.99, CI95%0.98-0.99, p = 0.004)
en minder resttumor (adjusted hazard ratio per mL 1.07, 95%CI 1.04-1.11, p<0.0001) waren significant
geassocieerd met langere overleving. In kaplan meier survivalanalyse werd een langere overleving
waargenomen tot een minimale afkapwaarde van 78%.
Chaichana beschreef 259 patiënten, geopereerd voor glioblastoom tussen 2007 en 2011 [Chaichana 2014
].
De mate van resttumor werd op basis van MRI-volumetrie gemeten. In een multivariate survivalanalyse werd
zowel de mate van tumorresectie als het volume resttumor onderzocht, met correctie voor leeftijd, conditie,
carmustinewafer implantatie en chemoradiatie. Een uitgebreidere resectie (adjusted hazard ratio per vijf
procent: 0.948,95%CI 0.918-0.978, p=0.0005) was significant geassocieerd met een langere overleving. De
minimale afkapwaarde voor de mate van tumorresectie die nog geassocieerd was met langere overleving is
70% (adjusted hazard ratio: 0.631, 95%CI 0.462-0.875, p=0.0006). De mediane overleving van patiënten met
meer dan 70% tumorverwijdering was 14,4 maanden, vergeleken met 10,5 maanden voor patiënten met
minder tumorverwijdering (p=0.0003). Een kleiner resttumorvolume (adjusted hazard ratio per 5 mL
resttumor: 1.147, 95%CI 1.053-1.261, p=0.001) was eveneens significant geassocieerd met langere
190
328
292
48
Gliomen
PDF aangemaakt op 
23-01-2025
322
/
971
overleving. De maximale afkapwaarde voor volume resttumor was 5 mL (adjusted hazard ratio: 0.725, 95%CI
0.534-0.991, p=0.01). De mediane overleving van patiënten met minder dan 5 mL resttumor was 14,4
maanden, vergeleken met 10,5 maanden voor patiënten met meer resttumor (p = 0.0003).
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
Gliomen
PDF aangemaakt op 
23-01-2025
323
/
971
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
Gliomen
PDF aangemaakt op 
23-01-2025
324
/
971
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
Gliomen
PDF aangemaakt op 
23-01-2025
325
/
971
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
Gliomen
PDF aangemaakt op 
23-01-2025
326
/
971
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
327
/
971
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
Gliomen
PDF aangemaakt op 
23-01-2025
328
/
971
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
Gliomen
PDF aangemaakt op 
23-01-2025
329
/
971
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
Gliomen
PDF aangemaakt op 
23-01-2025
330
/
971
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
Gliomen
PDF aangemaakt op 
23-01-2025
331
/
971
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
Gliomen
PDF aangemaakt op 
23-01-2025
332
/
971
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
Gliomen
PDF aangemaakt op 
23-01-2025
333
/
971
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
Gliomen
PDF aangemaakt op 
23-01-2025
334
/
971
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
Gliomen
PDF aangemaakt op 
23-01-2025
335
/
971
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
Gliomen
PDF aangemaakt op 
23-01-2025
336
/
971
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
Gliomen
PDF aangemaakt op 
23-01-2025
337
/
971
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
Gliomen
PDF aangemaakt op 
23-01-2025
338
/
971
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
Gliomen
PDF aangemaakt op 
23-01-2025
339
/
971
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Gliomen
PDF aangemaakt op 
23-01-2025
340
/
971
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
341
/
971
Waarde en mate van re-resectie glioblastoom
Uitgangsvraag
Wat is de waarde van een re-resectie bij progressie van een glioblastoom?
Hoe groot moet de resectie zijn bij een patiënt met progressie van een glioblastoom?
Aanbeveling
Patiënten met een recidief glioblastoom dienen in een multidisciplinair neuro-oncologisch overleg te worden
besproken. In de recidiefsetting dienen palliatieve behandelingen zoals chirurgie, radiotherapie en
chemotherapie telkens in overweging genomen te worden.
Er wordt geadviseerd een re-resectie bij recidief glioblastoom te overwegen bij een patiënt met gunstige
prognostische factoren (lagere leeftijd, betere conditie, localisatie tumor, lagere verwachte morbiditeit).
Voor de indicatiestelling van een re-resectie kan de NIH-schaal (National Institutes of Health) gebruikt
worden, waarbij meerdere prognostisch ongunstige factoren (tumor eloquent of nabij arteria cerebri media
gelegen, KPS <=80, tumorvolume >= 50 mL) geassocieerd zijn met een kortere levensverwachting en dus
een terughoudender beleid voor re-resectie.
Overwegingen
Verschillende oorzaken kunnen bijdragen aan bias in de genoemde publicaties. Ziekteprogressie is niet
eenduidig gedefinieerd waardoor patiënten met pseudoprogressie kunnen zijn geïncludeerd. Selectie van
patiënten speelt waarschijnlijk een rol, waardoor patiënten met een gunstiger prognose
oververtegenwoordigdzijn in de groep die een re-resectie onderging en dus de prognose en niet de re-
resectie oorzaak is van de langere overleving. 
De morbiditeit en mortaliteit varieert tussen de studies. Er worden percentages gemeld voor morbiditeit van
4,1% [Hoover 2013
] tot 45% [De Bonis 2013
]. De oorzaak van deze variatie is niet onderzocht. De
mortaliteit varieert van 0 % [Pinsker 2001
] tot 5% [Mandl 2008
].
Het lijkt te overwegen re-resectie te verrichten wanneer post-operatief zinvolle tumorremmende behandeling
mogelijk is, al dan niet in studieverband.
Onderbouwing
Conclusies
Er zijn aanwijzingen dat een re-resectie bij progressie van een glioblastoom gepaard gaat met een langere
overleving en progressievrije overleving. De mate van selectiebias is onduidelijk en is in de recidief setting
groter dan bij de novo tumoren. De resultaten van deze studies moeten daarom met grote voorzichtigheid
worden geïnterpreteerd.
Guyotat 2000
, Xu 2011
, De Bonis 2013
, Bloch 2012
, McGirt 2009
141
74
262
209
122
395
74
20
215
Gliomen
PDF aangemaakt op 
23-01-2025
342
/
971
Er zijn aanwijzingen dat een re-resectie gepaard gaat met morbiditeit en mortaliteit, vergelijkbaar met een
eerste resectie.
Dutzman 2012
Voor de indicatiestelling van een re-resectie kan de NIH schaal (National Institutes of Health) gebruikt
worden, waarbij meerdere prognostisch ongunstige factoren (tumor eloquent of nabij arteria cerebri media
gelegen, KPS <=80, tumorvolume >= 50 mL) geassocieerd zijn met een kortere levensverwachting en dus
een terughoudender beleid voor re-resectie.
Park 2010
Er is geen literatuur over de minimale mate van resectie bij progressie van een glioblastoom.
Samenvatting literatuur
In de literatuur worden artikelen gevonden die een resectie bij recidief hooggradig glioom hebben
onderzocht. Het betreft niet-vergelijkend cohortonderzoek. Vergelijkend gerandomiseerde studies die deze
vraag direct beantwoorden, werden niet gevonden. Alleen publicaties waarin specifiek gekeken is naar
overleving en/of progressievrije overleving, en/of morbiditeit en/of mortaliteit met betrekking tot resectie bij
recidief hooggradig glioom zijn geïncludeerd. Alleen publicaties na 2000 zijn geïncludeerd.
Guyotat vergeleek 2 groepen patiënten met progressief glioblastoom: 18 patiënten kregen een resectie en
36 patiënten kregen geen resectie [Guyotat 2000
]. De groepen werden gematcht voor leeftijd, conditie,
mate van resectie bij eerste operatie en het interval tot progressie. Beide groepen kregen de conventionele
nabehandeling (chemo-radiatie). De mediane overleving van patiënten na resectie was vijf maanden versus
twee maanden zonder resectie. Het verschil was statistisch significant in de univariate analyse. De mediane
overleving met een Karnofsky performance status (KPS) score >60, was voor patiënten na resectie vier
maanden, vergeleken met één maand voor patiënten zonder resectie.
Pinsker beschreef 38 patiënten met progressief glioblastoom die een resectie ondergingen tussen 1993 en
1998 (17% van 224 patiënten met een glioblastoom) [Pinsker 2001
]. De mediane overleving was 57 weken.
Een KPS van meer dan 90 was geassocieerd met een langere overleving. Functionele achteruitgang deed zich
niet voor. Er was geen perioperatieve mortaliteit.
Mandl onderzocht de effecten op overleving en complicaties van resectie bij progressief glioblastoom voor
32 (25%) van 126 glioblastoom patiënten tussen 1999 en 2005 [Mandl 2008
]. De mediane overleving na
progressie was 34 weken (95%CI 24,7-43,4) voor 11 patiënten die resectie gevolgd door nabehandeling
ondergingen, 13 weken (95%CI 1,3-24,7) voor 9 patiënten die resectie zonder nabehandeling ondergingen en
28 weken (95%CI 12,1-43,9) voor 12 patiënten die alleen chemotherapie of bestraling ondergingen
(p<0.0005).Chirurgische morbiditeit ontstond bij drie patiënten (15%); één (5%) patiënt overleed na operatie.
Xu beschreef 63 patiënten met progressie van een glioblastoom tussen 2006 en 2008, waarvan 21 patiënten
een resectie ondergingen en 42 niet [Xu 2011
]. De mediane overleving was voor de geopereerde
patiënten zeven maanden en voor de niet geopereerde patiënten vier maanden (p<0.001). De tijd tot
progressie van tumorgroei was voor de geopereerde patiënten vijf maanden en voor de niet geopereerde
86
249
122
262
209
393
Gliomen
PDF aangemaakt op 
23-01-2025
343
/
971
patiënten 2,5 maanden (p<0.001).
Clarke beschreef een posthocanalyse van gecombineerde data van fase II studies naar chemotherapie bij
progressie van een glioblastoom [Clarke 2011
]. Oudere studies (1998-2005) bevatten 105 patiënten van 511
die een operatie (biopt of resectie) ondergingen en nieuwere studies (2005-2008) bevatten 103 patiënten van
247 die een operatie (biopt of resectie) ondergingen. De overleving of progressievrije overleving van
patiënten die een operatie (biopt of resectie) ondergingen verschilde niet van patiënten die geen operatie
ondergingen.
Dutzman onderzocht het risico op ischemie en neurologische uitval bij re-resectie bij recidief groei van het
glioblastoom [Dutzman 2012
]. Van de 177 beschreven patiënten werden 130 patiënten (73,3%) één maal
geopereerd en 47 (26,5%) twee of meerdere malen geopereerd. Bekende prognostica waren evenredig
verdeeld over beide groepen. 46 patiënten (26%) hadden ischemie (DWI) op de postoperatieve MRI. Bij 18
patiënten (10,2%) was de ischemie groter dan 4 cm
. Elf van deze patiënten (6,2%) hadden ook neurologische
uitval. Er was echter geen verschil in ontstaan van ischemie (27.7 vs. 21.3%, p=0.77) en neurologische uitval
(10.0 vs. 10.6%, p=1.0) tussen de groepen die één maal of meer dan één maal werd geopereerd.
Tumorlocatie in de insula, operculum en temporaalkwab was wel geassocieerd met ontstaan van nieuwe
ischemische laesies. 
Moiyadi onderzocht in een cohort de postoperatieve complicaties bij patiënten met progressie van een
glioblastoom [Moiyadi 2012
]. Er werden 41 re-operaties in een database van 196 operaties voor gliomen
geëvalueerd. Neurologische achteruitgang werd beschreven bij 22,2% van de patiënten. Bij 44% van de
patiënten was er sprake van neurologische verbetering na de re-operatie. Bij 14,2% van de patiënten werden
regionale en bij 4,8 % werden systemische complicaties gemeld. De morbiditeit was 29,3% en de mortaliteit
was 2,4%.
De Bonis onderzocht de effectiviteit van resectie en adjuvante behandeling op overleving bij 76 patiënten
met progressie van een glioblastoom behandeld tussen 2002 en 2008 [De Bonis 2013
]. Zeventien patiënten
ondergingen alleen een resectie, 24 alleen adjuvantetherapie,16 resectie en adjuvante therapie, en19 geen
behandeling. Dit ging gepaard met een mediane overleving van 6, 8, 14 en 5 maanden (p=0.01). Patiënten
met een KPS <70 hadden een significant hoger risico om te overlijden (HR 2.8; p=0.001). Subgroepanalyse
toonde geen significante verschillen in overleving tussen een radiologisch complete of incomplete resectie.
Ook was er geen verschil in patiënten die verschillende adjuvante therapieën kregen. Postoperatieve
complicaties deden zich voor bij 16 (48%) van de 33 geopereerde patiënten.
Bloch onderzocht de relatie tussen de mate van resectie en de overleving bij 107 patiënten, die een tweede
resectie ondergingen bij progressie van een glioblastoom tussen 2005 en 2009 [Bloch 2012
]. De mediane
overleving vanaf de eerste diagnose was voor 31 patiënten met een radiologisch complete resectie bij zowel
eerste als tweede resectie 20,4 maanden. Voor 21 patiënten met een radiologisch complete resectie bij
eerste en een partiële resectie bij tweede operatie was deze18,4 maanden. Voor 26 patiënten met een
partiële resectie bij eerste en een radiologisch complete resectie bij tweede operatie was deze 19 maanden.
En voor 29 patiënten met zowel bij eerste als tweede operatie een partiële resectie was deze 15,9 maanden
(p = 0.004). De mediane overleving vanaf progressie verschilde eveneens: respectievelijk 11.5, 8.5, 16.7 en
60
86
3
221
74
20
Gliomen
PDF aangemaakt op 
23-01-2025
344
/
971
7.4 maanden (p = 0.001). In multivariate analyse was een uitgebreidere resectie geassocieerd met een
langere overleving (HR: 0.62, 95%CI 0.41-0.93, p = 0.03) na correctie voor leeftijd, conditie bij eerste resectie,
conditie bij tweede resectie en mate van eerste resectie.
Hong beschreef 42 patiënten met progressief gioblastoom die werden geopereerd tussen 2006 en 2010,
waarvan 34 patiënten een radiologisch complete re-resectie ondergingen en 10 patiënten met herhaalde re-
resecties [Hong 2013
]. De overleving na radiologisch complete re-resectie was 16 maanden en na
incomplete resectie 14 maanden (HR 1.86, 95%CI 0.86-3.92; p=0.112). 
Park beschreef 34 patiënten met een progressief glioblastoom op basis waarvan een prognostisch model voor
overleving na re-resectie werd opgesteld [Park 2010
]. Een kortere overleving na re-resectie was
geassocieerd met tumor in eloquente of kritische gebieden, een KPS <= 80, en een tumorvolume >= 50 mL.
Met deze drie factoren werden een totaalscore samengesteld van 0 tot 3 (voor aan-/afwezigheid van elk van
deze factoren). Een score van 0, 1-2 en 3 was respectievelijk geassocieerd met een postoperatieve overleving
van 10.8, 4.5 en 1.0 maanden (p <0.001). In een validatie cohort van 109 patiënten met een progressief
glioblastoom werd deze score geverifieerd, waarbij de prognostische waarde bevestigd werd met 9.2, 6.3 en
1.9 maanden, respectievelijk (HR 3.0, 95%CI 1.54-5.83, p<0.001).
McGirt beschreef 949 patiënten met een WHO-graad III of IV astrocytoom die geopereerd werden tussen
1996 en 2006, waarvan 400 een re-resectie ondergingen [McGirt 2009
]. Na een radiologisch complete re-
resectie was de mediane overleving elf maanden, na een bijna complete re-resectie negen maanden en na
een subtotale resectie vijf maanden. In multivariate analyse was een uitgebreidere re-resectie geassocieerd
met langere overleving (radiologisch complete resectie vergeleken met een subtotale resectie HR 0.566, p =
0.002; radiologisch bijna-complete resectie vergeleken met een subtotale resectie HR 0.630, p = 0.004) na
correctie voor leeftijd, conditie, motorische uitval, temozolomide en vervolgoperaties.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
140
249
215
Gliomen
PDF aangemaakt op 
23-01-2025
345
/
971
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
Gliomen
PDF aangemaakt op 
23-01-2025
346
/
971
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
Gliomen
PDF aangemaakt op 
23-01-2025
347
/
971
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
Gliomen
PDF aangemaakt op 
23-01-2025
348
/
971
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
Gliomen
PDF aangemaakt op 
23-01-2025
349
/
971
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Gliomen
PDF aangemaakt op 
23-01-2025
350
/
971
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
Gliomen
PDF aangemaakt op 
23-01-2025
351
/
971
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
Gliomen
PDF aangemaakt op 
23-01-2025
352
/
971
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
Gliomen
PDF aangemaakt op 
23-01-2025
353
/
971
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
Gliomen
PDF aangemaakt op 
23-01-2025
354
/
971
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
Gliomen
PDF aangemaakt op 
23-01-2025
355
/
971
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
Gliomen
PDF aangemaakt op 
23-01-2025
356
/
971
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
Gliomen
PDF aangemaakt op 
23-01-2025
357
/
971
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Gliomen
PDF aangemaakt op 
23-01-2025
358
/
971
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
Gliomen
PDF aangemaakt op 
23-01-2025
359
/
971
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
Gliomen
PDF aangemaakt op 
23-01-2025
360
/
971
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
Gliomen
PDF aangemaakt op 
23-01-2025
361
/
971
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
Gliomen
PDF aangemaakt op 
23-01-2025
362
/
971
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
363
/
971
Radiotherapie bij hooggradig glioom
Deze submodule is onderverdeeld in de volgende sub-submodules:
Indicatie radiotherapie anaplastisch glioom
Indicatie radiotherapie glioblastoom
Radiotherapie bij progressie hooggradig glioom/recidief
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
Gliomen
PDF aangemaakt op 
23-01-2025
364
/
971
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
Gliomen
PDF aangemaakt op 
23-01-2025
365
/
971
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
Gliomen
PDF aangemaakt op 
23-01-2025
366
/
971
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
Gliomen
PDF aangemaakt op 
23-01-2025
367
/
971
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
Gliomen
PDF aangemaakt op 
23-01-2025
368
/
971
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
Gliomen
PDF aangemaakt op 
23-01-2025
369
/
971
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
Gliomen
PDF aangemaakt op 
23-01-2025
370
/
971
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
Gliomen
PDF aangemaakt op 
23-01-2025
371
/
971
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
Gliomen
PDF aangemaakt op 
23-01-2025
372
/
971
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
Gliomen
PDF aangemaakt op 
23-01-2025
373
/
971
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
Gliomen
PDF aangemaakt op 
23-01-2025
374
/
971
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
Gliomen
PDF aangemaakt op 
23-01-2025
375
/
971
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
Gliomen
PDF aangemaakt op 
23-01-2025
376
/
971
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
Gliomen
PDF aangemaakt op 
23-01-2025
377
/
971
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
Gliomen
PDF aangemaakt op 
23-01-2025
378
/
971
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Gliomen
PDF aangemaakt op 
23-01-2025
379
/
971
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Gliomen
PDF aangemaakt op 
23-01-2025
380
/
971
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
Gliomen
PDF aangemaakt op 
23-01-2025
381
/
971
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
382
/
971
Indicatie radiotherapie anaplastisch glioom
Uitgangsvraag
Wat is de indicatie voor radiotherapie bij een patiënt met een anaplastisch glioom (WHO graad III) en hoe
dient dit uitgevoerd te worden?
Aanbeveling
Het meest gangbare fractioneringschema voor het anaplastisch glioom bedraagt 59.4 Gy in 33 fracties van 1.8
Gy gegeven in vijf fracties per week. De werkgroep is van mening dat dit tenminste met 3D conformal
radiation therapy (3DCRT-techniek) dient te worden gegeven.
Er wordt geadviseerd, in afwachting van de resultaten van de EORTC-26053-studie (CATNON), patiënten met
een anaplastisch glioom zonder gecombineerde 1p/19q-deletie te behandelen met postoperatieve
radiotherapie alleen.
Patiënten met een anaplastisch glioom met een 1p/19q-deletie dienen post-operatief behandeld te worden
met radiotherapie gevolgd door zes kuren PCV, volgens het EORTC-26951-protocol.
De werkgroep is van mening dat op indicatie, bijvoorbeeld bij groot bestralingsvolume en daardoor verhoogd
risico op toxiciteit van radiotherapie, overwogen kan worden patienten met een anaplastisch glioom te
behandelen met chemotherapie (PCV of temozolomide) in plaats van radiotherapie.
Overwegingen
Naar aanleiding van de resultaten van de NOA-4 studie, waarbij geen verschil tussen RT, PCV of
temozolomide werd gevonden in de mediane tijd tot progressieve ziekte bij postoperatieve nabehandeling
van anaplastische gliomen zonder 1p/19q-deletie, zou bij een zeer groot doelvolume en een hierbij te
verwachten grote kans op toxiciteit van radiotherapie, overwogen kunnen worden te kiezen voor
temozolomide als postoperatieve behandeling [Wick 2009
].
Moderne radiotherapie dient tenminste uitgevoerd te worden met 3D conformal radiation therapy. In veel
centra worden geavanceerde technieken als intensity modulated radiotherapy, volumetric arc therapy of
tomotherapie gebruikt, teneinde het hoge dosis gebied zo optimaal mogelijk te laten aansluiten bij het
doelgebied. Er bestaat echter geen bewijs dat geavanceerde planningstechnieken de prognose verbeteren of
het risico op complicaties verminderen. Vanwege vroege veranderingen in het operatiegebied en de
mogelijkheid van snelle progressie bij het hooggradig glioomis het aan te bevelen de MRI zo kort mogelijk
aan te laten sluiten bij het begin van de radiotherapie. In gevallen waarbij er een langer interval tussen de
operatie en start radiotherapie bestaat, dient de postoperatieve MRI dan ook herhaald te worden ten
behoeve van accurate vaststelling van doelgebieden. Het te bestralen gebied omvat de resectieholte, het
(resterende) aankleurende gebied op de T1-contrastsequentie van de (postoperatieve) MRI met 1,5-2 cm
marge voor microscopische ziekte, waarbij het hyperintense gebied op de T2/FLAIR-sequenties wordt
386
Gliomen
PDF aangemaakt op 
23-01-2025
383
/
971
geïncludeerd conform de recente en lopende EORTC studies (CATNON, CODEL). Tenslotte worden de
natuurlijke barrières in acht genomen. Wanneer er alleen een biopsie is verricht, volstaat de preoperatieve
MRI-scan.
Onderbouwing
Conclusies
Het is aannemelijk dat voor het anaplastisch glioom, een bestralingsdosis van 59.4 Gy in 33 fracties van 1.8 Gy
gegeven in 5 fracties per week, effectief is. Er zijn geen aanwijzingen dat een hogere bestralingsdosis
effectiever is.
Bleehen 1991
Toevoeging van PCV aan postoperatieve radiotherapie resulteert in een aanzienlijke verbetering van de
overleving bij anaplastische gliomen met een 1p/19q-deletie ten opzichte van postoperatieve radiotherapie
alleen.
Cairncross 2013
, Van den Bent 2013
Er is geen bewijs dat de toevoeging van PCV chemotherapie aan postoperatieve radiotherapie een
toegevoegde waarde heeft in de behandeling van het anaplastische glioom zonder een 1p/19q-deletie.
Cairncross 2013
, Van den Bent 2013
De gecombineerde behandeling met postoperatieve radiotherapie en PCV bleek geen verslechtering van
cognitie of kwaliteit van leven te veroorzaken op de lange termijn ten opzichte van radiotherapie alleen.
Van den Bent 2013
, Habets 2014
, Wang 2010
Samenvatting literatuur
Tot de anaplastische gliomen, ook geduid als WHO graad III tumoren, worden de verschillende subtypes
anaplastisch astrocytoom, anaplastisch oligodendroglioom en anaplastisch oligoastrocytoom gerekend [Louis
2007
].
Postoperatieve radiotherapie is van oudsher het standaard beleid bij anaplastisch glioom, hoewel de exacte
bewijsvoering hiervoor beperkt is. De hierover gerapporteerde studies bevatten een combinatie van
patiënten met hooggradige gliomen (HGG), waarbij het aantal geïncludeerde patiënten met een anaplastisch
glioom veelal te gering was voor subanalyses. Daarnaast waren de studies verschillend van opzet wat betreft
bestralingsdoses, definitie van doelgebieden en het al dan niet gecombineerd toedienen van bestraling en
chemotherapie [Walker 1978
, Kristiansen 1981
, Gannett 1994
, Laperierre 2002
, Mukherjee
2013]
.
De meest gangbare bestralingsdosis voor het anaplastisch glioom bedraagt 59.4 Gy in 33 fracties van 1.8 Gy
gegeven in 5 fracties per week, waarbij de kans op late neurotoxiciteit wordt verlaagd door het gebruik van
een lage dosis per fractie. Voor hooggradig glioom WHO graad III en IV, werd een dosis respons relatie
tussen 45 Gy en 60 Gy aangetoond in een oudere MRC studie; er bestaan geen gerandomiseerde data over
het nut van een hogere bestralingsdosis [Bleehen 1991
].
18
41
351
41
351
351
123
375
204
373
183
106
191
223
18
Gliomen
PDF aangemaakt op 
23-01-2025
384
/
971
In toenemende mate spelen moleculaire markers een rol in de diagnose en de behandeling van het
anaplastisch glioom, zoals bijvoorbeeld de MGMT-promotor methylatie, IDH-mutaties en het gecombineerde
verlies van 1p/19q [Roth 2013
, Gorlia 2013
], zie ook de module 
Moleculaire veranderingen diffuse
gliomen
. Het betrekken van de histologie, moleculaire markers met name het gecombineerde 1p/19q-verlies,
en andere individuele patiëntkarakteristieken geeft richting aan het bepalen van postoperatieve therapie
bestaande uit radiotherapie, een gecombineerde behandeling of chemotherapie alleen.
Het anaplastische astrocytoom is het meest voorkomende subtype van het anaplastisch glioom, waarbij
gecombineerd 1p/19q-verlies vrijwel niet wordt gezien (gemistocytair type 0%, fibrillair-type 7%) [Ohgaki
2005
]. De standaardbehandeling van anaplastische astrocytoom bestaat uit postoperatieve radiotherapie
zonder chemotherapie. Omdat door velen het anaplastische astrocytoom wordt gezien als een
voorloperstadium van het glioblastoom wordt internationaal veelvuldig volgens het EORTC ‘Stupp-schema'
behandeld met gelijktijdig en adjuvant temozolomide (TMZ), zonder dat hier bewijsvoering voor is. Om de
waarde van concomitante en adjuvante chemotherapie vast te stellen bij het anaplastische astrocytoom
dienen de resultaten van de lopende CATNON-studie (EORTC-26053)afgewacht te worden. In deze studie
worden patiënten met een anaplastische astrocytoom (en het anaplastisch oligodendroglioom en anaplastisch
oligoastrocytoom zonder 1p/19q-verlies) gerandomiseerd naar een van de vier armen (radiotherapie alleen,
radiotherapie met alleen concomitante TMZ, radiotherapie met alleen adjuvante TMZ, of radiotherapie met
concomitante en adjuvante TMZ).
Op het gebied van de anaplastisch oligodendroglioom en anaplastisch oligoastrocytoom-subtypes hebben
zich de laatste jaren veel ontwikkelingen voorgedaan. Gecombineerd verlies van 1p/19q komt, in
tegenstelling tot bij anaplastische astrocytoom, zeer frequent voor, bijvoorbeeld bij ongeveer 76% van het
anaplastisch oligodendroglioom en 24% bij het anaplastisch oligoastrocytoom in de hierna besproken RTOG-
studie [Cairncross 2013
]. De langetermijnresultaten van de EORTC-26951-studie en de RTOG-9402 studie,
waarbij werd gerandomiseerd werd tussen radiotherapie alleen of in combinatie met PCV (procarbazine,
lomustine, vincristine), lieten beiden een significant voordeel zien voor de gecombineerde behandeling bij
patiënten met 1p/19q-verlies (14,7 versus 7,3 jaar in de RTOG-studie - mediane overleving niet bereikt -
versus 112 maanden in de EORTC-studie) [Van den Bent 2013
, Cairncross 2013
]. In de groep patiënten
zonder 1p/19-verlies werd geen voordeel van de gecombineerde behandeling gevonden (2,6 versus 2,7 jaar).
Hoewel de gecombineerde behandeling met PCV meer vroege (hematologische) toxiciteit veroorzaakt, is
hiervan geen negatief effect op de cognitie of kwaliteit van leven aangetoond [Van den Bent 2013
, Habets
2014
, Wang 2010
]. Deze resultaten maken radiotherapie gecombineerd met PCV de huidige
standaardbehandeling voor patiënten metanaplastisch oligodendroglioom of anaplastisch oligoastrocytoom
met gecombineerd 1p/19q-verlies. Voor patiënten zonder deze gecombineerde deletie is, in afwachting van
de resultaten van de CATNON-studie, postoperatieve radiotherapie alleen de standaardbehandeling.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
283
113
235
41
351
41
354
123
375
Gliomen
PDF aangemaakt op 
23-01-2025
385
/
971
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
Gliomen
PDF aangemaakt op 
23-01-2025
386
/
971
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
Gliomen
PDF aangemaakt op 
23-01-2025
387
/
971
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
Gliomen
PDF aangemaakt op 
23-01-2025
388
/
971
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
Gliomen
PDF aangemaakt op 
23-01-2025
389
/
971
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
Gliomen
PDF aangemaakt op 
23-01-2025
390
/
971
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
Gliomen
PDF aangemaakt op 
23-01-2025
391
/
971
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
Gliomen
PDF aangemaakt op 
23-01-2025
392
/
971
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
Gliomen
PDF aangemaakt op 
23-01-2025
393
/
971
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
Gliomen
PDF aangemaakt op 
23-01-2025
394
/
971
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
Gliomen
PDF aangemaakt op 
23-01-2025
395
/
971
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
Gliomen
PDF aangemaakt op 
23-01-2025
396
/
971
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
Gliomen
PDF aangemaakt op 
23-01-2025
397
/
971
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
Gliomen
PDF aangemaakt op 
23-01-2025
398
/
971
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Gliomen
PDF aangemaakt op 
23-01-2025
399
/
971
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
Gliomen
PDF aangemaakt op 
23-01-2025
400
/
971
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
Gliomen
PDF aangemaakt op 
23-01-2025
401
/
971
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
Gliomen
PDF aangemaakt op 
23-01-2025
402
/
971
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
403
/
971
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
404
/
971
Indicatie radiotherapie glioblastoom
Uitgangsvraag
Wat is de indicatie voor radiotherapie bij een patiënt met een glioblastoom (WHO graad IV) en hoe dient dit
uitgevoerd te worden?
Aanbeveling
Bij patiënten met een glioblastoom in goede klinische conditie, jonger dan 61 jaar dient post-operatief een
radiotherapiedosis van 30 x 2 Gy gegeven te worden, gecombineerd met concomitant en adjuvant
temozolomide. Voor de behandeling van oudere patiënten met een glioblastoom wordt verwezen naar de
module 
Behandeling van ouderen
.
Er wordt geadviseerd geen hogere bestralingsdosis toe te dienen. De werkgroep adviseert hypofractionering
te overwegen bij patiënten die in een matige conditie zijn.
De werkgroep is van mening dat het doelgebied van de bestraling de resectieholte, het (resterende)
aankleurende gebied op de T1-sequentie met contrast van de postoperatieve MRI, met een marge van 1,5-2
cm voor microscopische ziekte, het doelgebied zou moeten zijn. Hierbij wordt rekening gehouden met het
hyperintense gebied op de T2- en FLAIR-sequenties en de anatomische barrières.
Overwegingen
De gecombineerde behandeling van hoge dosis radiotherapie en temozolomide toont de meeste winst in
overleving in de groep patiënten <50 jaar in een goede postoperatieve conditie. Bij patiënten met een KPS
<70 en een leeftijd ≥50 jaar is de winst van de gecombineerde behandeling beperkt.
Als er tijdens het behandelen klachten ontstaan die veroorzaakt worden door (radiotherapie-geïnduceerd)
oedeem, kan het starten met (een lage dosis) dexamethason geïndiceerd zijn.
De planning en uitvoering van de bestraling dient tenminste plaats te vinden met behulp van een 3DCRT-
techniek. Teneinde het hoge dosis gebied zoveel mogelijk te beperken tot het doelgebied, wordt het
gebruik van meer geavanceerde technieken zoals intensity modulated radiotherapy (IMRT), volumetric arc
therapy of tomotherapie, aangemoedigd. Er bestaat echter geen bewijs dat geavanceerde
planningstechnieken de prognose verbeteren of het risico op toxiciteit verminderen. Vanwege vroege
veranderingen in het operatiegebied en de mogelijkheid van snelle progressie bij het GBM is het aan te
bevelen de MRI zo kort mogelijk aan te laten sluiten bij het begin van de radiotherapie. In gevallen waarbij er
een langer interval tussen de operatie en start radiotherapie bestaat, dient de postoperatieve MRI dan ook
herhaald te worden ten behoeve van accurate vaststelling van doelgebieden.
Onderbouwing
Conclusies
Postoperatieve radiotherapie is standaardbeleid na resectie van een glioblastoom, indien de klinische situatie
van de patiënt dit toelaat. Een overlevingsvoordeel is aangetoond bij een dosis van 60 Gy ten opzichte van 45
Gliomen
PDF aangemaakt op 
23-01-2025
405
/
971
Gy, echter de mediane overleving lijkt niet te verbeteren bij verdere ophoging van de totale bestralingsdosis.
Walker 1979
, Bleehen 1981
, Nelson 1988
, Nakagaya 1998
, Chan 2002
Er zijn aanwijzingen dat postoperatieve hypofractionering een gelijkwaardige uitkomst geeft als
conventioneel gefractioneerde radiotherapie, maar dit is met name onderzocht bij patiënten met een
ongunstige prognose in een niet gerandomiseerde setting en bij oudere patiënten.
Slotman 1996
, Sayin 2007
, Hingorani 2012
Het is aangetoond dat een hogere lokale bestralingsdosis met behulp van een stereotactische radiochirurgie
of brachytherapieboost geen voordeel biedt ten opzichte van standaarddosis bestraling.
Souhami 2004
, Laperriere 1998
Het is aangetoond dat gecombineerd postoperatieve radiotherapie (60 Gy/30 fracties) met gelijktijdig en
adjuvant temozolomide een voordeel in overleving biedt ten opzichte van radiotherapie alleen.
Stupp 2005
, 2009
Samenvatting literatuur
Bij ongeveer 80% van de patiënten die zich presenteren met een hooggradig glioom is sprake van een
glioblastoom (WHO graad IV) [Omuro 2013
]. Zowel tumor- als patiëntgerelateerde factoren, zoals de mate
van resectie, de leeftijd en de klinische/neurologische conditie (Karnofsky performance score, KPS), hebben
een impact op de prognose en dienen meegenomen te worden bij het afstemmen van de postoperatieve
behandeling en het bestralingsschema. Gezien het palliatieve karakter van de behandeling moet
overlevingswinst worden afgewogen tegen de morbiditeit van de behandeling en het effect op de kwaliteit
van leven. De behandeling van het glioblastoom bij de oudere patiënt wordt afzonderlijk in de module
Behandeling van ouderen
 besproken.
De waarde van postoperatieve radiotherapie bij de behandeling van patiënten met een glioblastoom is in
meerdere gerandomiseerde studies aangetoond, waarbij er een winst in mediane overleving wordt gezien
van rond de 5 maanden ten opzichte van resectie alleen [Walker 1979
, Kristiansen 1981
].
Het bestralingsvolume omvat de resectieholte, het (resterende) aankleurende gebied op de T1- sequentie
met contrast van de postoperatieve MRI. Een marge van 1,5-2 cm voor microscopische ziekte (clinical target
volume, CTV) wordt aangehouden, waarbij het hyperintense gebied op de T2- en FLAIR-sequenties wordt
geïncludeerd. Het CTV kan worden aangepast op basis van anatomische barrières. Er zijn echter geen
aanwijzingen dat krappere marges het patroon van recidiveren van het glioblastoom beïnvloedt (80%
recidiveert binnen 2 cm van de oorspronkelijke tumor) [McDonald 2011
, Paulsson 2014
]. Wanneer er
alleen een biopsie is verricht volstaat de preoperatieve MRI-scan. 
In oudere gerandomiseerde studies is een overlevingsvoordeel aangetoond van een dosis van 60 Gy ten
opzichte van een dosis van 45 Gy [Walker 1979
, Bleehen 1981
]. De mediane overleving werd niet
verbeterd bij het verhogen van de dosis van 60 naar 70 Gy (9.3 versus 8.2 maanden) [Nelson 1988
,
Nakagaya 1998
, Chan 2002
]. In een gerandomiseerde studie werd geen voordeel gezien van de
toevoeging van stereotactische radiochirurgie (SRS) als boost aan conventionele radiotherapie [Souhami
2004
]. Evenmin kon een gerandomiseerde studie een verbetering van de overleving door de toevoeging
374
19
226
224
50
317
299
135
324
192
331
330
238
374
183
213
252
374
19
226
224
50
324
192
Gliomen
PDF aangemaakt op 
23-01-2025
406
/
971
van brachytherapie aan conventionele radiotherapie aantonen [Laperriere 1998
]. Gezien de beperkte
levensverwachting van patiënten met een glioblastoom heeft men in verschillende studies gekeken naar het
verkorten van de behandelduur met behulp van hypofractionering, vooral bij patiënten met een ongunstige
prognose [Slotman 1996
, Sayin 2007
]. Een overzichtsartikel over hypofractionering bij het glioblastoom
concludeert aan de hand van studies met verschillende bestralingsschema's, uiteenlopend van 30 Gy in 6
fracties tot 54 Gy in 18 fracties, dat hiermee een gelijkwaardige uitkomst wordt gezien als met conventionele
fractionering; dit ondanks een lagere totale bestralingsdosis. Er werd geen toename van toxiciteit gezien van
hypofractionering [Hingorani 2012
]. In de groep patiënten van 60 jaar of ouder met een glioblastoom is
behandeling met hypofractionering in een gerandomiseerde setting vergeleken met conventionele
fractionering, waarbij een vergelijkbare overleving werd gezien [Roa 2004
]. In de module 
Behandeling van
ouderen
 wordt verder ingegaan op de Nordic trial die bij patiënten van 60 jaar of ouder met een
glioblastoom gerandomiseerd heeft tussen behandeling met een gehypofractioneerd bestralingsschema,
conventionele fractionering en TMZ [Hingorani 2012
]. 
De toevoeging van chemotherapie in de vorm van temozolomide (TMZ) aan postoperatieve radiotherapie in
een dosis van 60 Gy in fracties van 2 Gy, is sinds de uitkomst van de EORTC- 26981/22981-NCIC CE3-studie
de standaardbehandeling na resectie van het glioblastoom [Stupp 2005
]. In een update van de resultaten
van de genoemde EORTC-studie werd het significante voordeel van de gecombineerde behandeling
bevestigd met een 5-jaars overleving van 10% voor de gecombineerde behandeling versus 2% met
radiotherapie alleen. Het overlevingsvoordeel van de gecombineerde behandeling was het grootst in de
groep patiënten jonger dan 50 jaar met een KPS van 90-100, waarbij de 2-jaars overleving toenam van 20%
naar 43% en de 5-jaars overleving 28% was [Mirimanoff 2006
, Stupp 2009
]. Bij patiënten, waarbij zowel
de KPS <70 was als de leeftijd ≥50 jaar,en bij patiënten met neurologische uitval, was de winst van de
gecombineerde behandeling beperkt: 10 maanden ten opzichte van 9 maanden voor radiotherapie alleen
[Mirimanoff 2006
, Stupp 2009
]. In enkele kleine prospectieve- en retrospectieve studies is
gehypofractioneerde radiotherapie gecombineerd met TMZ bestudeerd, vooral bij oudere patiënten
[Hingorani 2012
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
192
317
299
135
279
135
331
220
330
220
330
135
Gliomen
PDF aangemaakt op 
23-01-2025
407
/
971
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
Gliomen
PDF aangemaakt op 
23-01-2025
408
/
971
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
Gliomen
PDF aangemaakt op 
23-01-2025
409
/
971
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
Gliomen
PDF aangemaakt op 
23-01-2025
410
/
971
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
Gliomen
PDF aangemaakt op 
23-01-2025
411
/
971
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
Gliomen
PDF aangemaakt op 
23-01-2025
412
/
971
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
Gliomen
PDF aangemaakt op 
23-01-2025
413
/
971
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
Gliomen
PDF aangemaakt op 
23-01-2025
414
/
971
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
Gliomen
PDF aangemaakt op 
23-01-2025
415
/
971
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
Gliomen
PDF aangemaakt op 
23-01-2025
416
/
971
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Gliomen
PDF aangemaakt op 
23-01-2025
417
/
971
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
Gliomen
PDF aangemaakt op 
23-01-2025
418
/
971
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
Gliomen
PDF aangemaakt op 
23-01-2025
419
/
971
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
Gliomen
PDF aangemaakt op 
23-01-2025
420
/
971
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
Gliomen
PDF aangemaakt op 
23-01-2025
421
/
971
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
Gliomen
PDF aangemaakt op 
23-01-2025
422
/
971
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
Gliomen
PDF aangemaakt op 
23-01-2025
423
/
971
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
Gliomen
PDF aangemaakt op 
23-01-2025
424
/
971
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
425
/
971
Radiotherapie bij progressie hooggradig glioom/recidief
Uitgangsvraag
Wat is de indicatie voor radiotherapie bij een patiënt met een recidief of progressie van een hooggradig
glioom in een eerder bestraald gebied en hoe dient deze uitgevoerd te worden?
Aanbeveling
Patiënten met een recidief hooggradig glioom dienen in een multidisciplinair neuro-oncologisch overleg
besproken te worden. In de recidiefsetting dienen alle palliatieve behandelingen, waaronder radiotherapie en
chirurgie, telkens mede in overweging genomen te worden.
De werkgroep is van mening dat behandeling in studieverband de voorkeur verdient.
De werkgroep is van mening dat een minimaal interval van zes tot twaalf maanden aangehouden dient te
worden tussen de initiële bestraling en re-irradiatie. 
Bij de afweging of re-irradiatie een reële optie is, speelt de definitie van het doelgebied de belangrijkste rol.
De toepassing van kleinere marges dan in de primaire setting wordt geadviseerd.
Om het risico op radiatie-geïnduceerde complicaties zoveel mogelijk te beperken wordt geadviseerd re-
irradiatie te plannen met moderne bestralingstechnieken zoals stereotactische radiotherapie, intensity
modulated radiotherapy (IMRT) of volumetric modulated arc therapy (VMAT). 
De werkgroep is van mening dat er vanuit de literatuur geen optimaal fractioneringsschema vast te stellen is.
Voor zowel conventioneel gefractioneerde schema's, hypofractionering of een enkele fractie radiochirurgie
zijn series in de literatuur beschreven.
Overwegingen
Er bestaat geen standaardbehandeling voor een recidief hooggradig glioom (HGG), zodat de werkgroep van
mening is dat de eerste keuze voor patiënten in goede conditie een behandeling in studieverband is. 
Patiënten met een recidief HGG dienen in een neuro-oncologisch multidisciplinair overleg besproken te
worden, temeer daar er verschillende behandelopties, zoals reresectie, (tweedelijns)chemotherapie, gerichte
medische therapieën, re-irradiatie of combinaties bestaan.
Onderbouwing
Conclusies
Vanwege het ontbreken van gerandomiseerde studies die reresectie, re-irradiatie, (tweedelijns)
chemotherapie of gerichte medische therapieën met elkaar hebben vergeleken, bestaat er geen
standaardbehandeling voor patiënten met een recidief hooggradig glioom.
Amichetti 2011
5
Gliomen
PDF aangemaakt op 
23-01-2025
426
/
971
Er zijn aanwijzingen dat een minimaal interval van zes tot twaalf maanden moet worden aangehouden tussen
de initiële bestraling en re-irradiatie.
Niyazi 2011
Het is aannemelijk dat de definitie van het doelgebied de belangrijkste afweging is met betrekking tot de
mogelijkheid en verwachte toxiciteit van re-irradiatie [Nieder 2011[220]]. In de meeste series wordt het
doelgebied bepaald door de contrast-aankleurende gebieden op MRI met geringe marges van 0,5-1 cm.
Henke 2009
, Fokas 2009
, Combs 2005
, Vordermark 2005
Er zijn aanwijzingen dat moderne bestralingstechnieken zoals stereotactische radiotherapie,intensity
modulated radiotherapy (IMRT) of (volumetric modulated arc therapy) VMAT, het eerder bestraalde
hersenweefsel minder belasten, waardoor het risico op radiatie-geïnduceerde complicaties kleiner wordt.
Fogh 2010
Gezien de diversiteit van de studies is er geen goede aanbeveling voor het optimale fractioneringschema te
verkrijgen uit de literatuur. 
Hoewel niet gerandomiseerd onderzocht, lijkt de toevoeging van chemotherapie aan re-irradiatie de
overleving niet te verbeteren.
Amichetti 2011
Samenvatting literatuur
Hoewel er de laatste jaren vooruitgang is geboekt in de behandeling van geselecteerde patiënten met een
hooggradig glioom (HGG) met de combinatiebehandeling bestaande uit chirurgie, radiotherapie en
chemotherapie, ontstaat een recidief in ongeveer 90% van de patiënten binnen het eerdere
bestralingsgebied [Niyazi 2011
, Amichetti 2011
, Weller 2013
]. Het onderscheid tussen radiatie-
geïnduceerde veranderingen en tumorprogressie op grond van de beeldvorming kan lastig zijn en wordt
besproken in evidence based vraag 1. Bij blijvende twijfel is histologische verificatie noodzakelijk voor het
starten van tweedelijnsbehandeling, zeker ook indien re-irradiatie wordt overwogen.
Omdat bij een recidief HGG verschillende palliatieve behandelingsmogelijkheden voorhanden zijn zoals
reresectie, (tweedelijns)chemotherapie, re-irradiatie of combinaties hiervan, dient bespreking in een neuro-
oncologisch MDO plaats te vinden. Er bestaan geen gerandomiseerde studies in de recidief HGG setting die
de genoemde behandelingsmodaliteiten vergelijken. In module 2.1 en 2.2 wordt ingegaan op de rol van
reresectie en (tweedelijns)chemotherapie en gerichte medische therapieën bij een recidief HGG. De keuze
van behandeling wordt vooral bepaald door factoren als klinische conditie, interval tussen initiële behandeling
en diagnose van recidief, en de uitgebreidheid en lokatie van het recidief. Door het bovenstaande bestaat er
geen standaardbehandeling voor patiënten met een recidief HGG en is de eerste keuze voor patiënten in
goede conditie een behandeling in studieverband [Amichetti 2011
]. 
In tegenstelling tot de radiotherapie voor het primair HGG bestaat er geen consensus in de literatuur over
het optimale fractioneringsschema of de vaststelling van doelgebieden bij re-irradiatie van HGG. Wel wordt
in de meeste studies een minimaal interval van zes tot twaalf maanden aangehouden tussen de eerdere
bestraling en re-irradiatie [Niyazi 2011
]. De belangrijkste afweging met betrekking tot de mogelijkheid en
verwachte toxiciteit van re-irradiatie betreft niet zozeer de gebruikte bestralingsdosis, maar de definitie van
231
133
101
64
369
100
5
231
5
378
5
231
228
Gliomen
PDF aangemaakt op 
23-01-2025
427
/
971
het doelgebied [Nieder 2011
]. In de meeste gerapporteerde studies wordt het doelgebied bepaald door
de contrast-aankleurende gebieden op MRI met geringe marges van 0,5-1 cm, zonder de witte stof
afwijkingen op de T2 sequenties te includeren zoals gebruikelijk in de primaire behandeling [Henke 2009
,
Fokas 2009
, Combs 2005
, Vordermark 2005
]. Moderne bestralingstechnieken zoals stereotactische
radiotherapie, intensity modulated radiotherapy (IMRT) of volumetric modulated arc therapy (VMAT) maken
precisiebestraling mogelijk, waardoor de dosis van het eerder bestraalde hersenweefsel en daarmee het
risico op radiatie-geïnduceerde complicaties kleiner wordt. Een belangrijke ondersteunende studie voor het
belang van moderne technieken en beperkte doelgebieden is de studie van Fogh et al, waarbij re-irradiatie
van recidief HGG werd uitgevoerd in 147 patiënten met behulp van hypofractionering met stereotactische
precisie tot een mediane totale dosis van 35 Gy in fracties van 3,5 Gy. In deze studie werd uitsluitend het
aankleurende gebied op de T1-contrast MRI als doelgebied gebruikt. Niet alleen toonde deze relatief grote
studie een mediane overleving van tien tot elf maanden in zowel anaplastische gliomen als glioblastomen,
maar werd er eveneens vrijwel geen graad ≥3 toxiciteit gezien (slechts in 1 patiënt behandeld met een dosis
boven de 40 Gy) [Fogh 2010
]. Bij de afweging of re-irradiatie een reële optie is, speelt naast de
tumorlokatie ten opzichte van kritische normale organen, de definitie van de RTH doelgebieden, ook de
grootte van het contrast-aankleurende gebied op de MRI een rol, waarbij er in de literatuur geen consensus is
over de maximale grootte hiervan. In de praktijk blijkt men terughoudend te zijn bij re-irradiatie van een
aankleurend tumorrecidief dat groter is dan 5 cm.
Wat betreft het optimale fractioneringsschema is geen goede aanbeveling te verkrijgen uit de literatuur. Niet-
gerandomiseerde, veelal retrospectieve studies zijn gepubliceerd voor een enkele fractie radiochirurgie,
extreme of minder extreme hypofractionering, of conventioneel gefractioneerde (stereotactische) schema's
met uiteenlopende doses, en de resultaten hiervan zijn over het algemeen vergelijkbaar, evenals de toxiciteit.
Een vergelijkende studie tussen deze radiotherapie technieken ontbreekt echter, zodat het niet goed
mogelijk is een aanbeveling te doen. Een aantal studies rapporteren over de toepassing van brachytherapie
(meestal 
I of 
Ir), met eveneens wisselende resultaten en toxiciteit [Amichetti 2011
]. Het risico op
(symptomatische) radionecrose waarvoor reresectie noodzakelijk blijkt te zijn wordt zeer wisselend
gerapporteerd voor de verschillende behandelingen, maar kan oplopen tot 31% [Amichetti 2011
].
Herbestraling met ge(hypo)fractioneerde stereotactische radiotherapie werd in een aantal series
gecombineerd met chemotherapie, meestal temozolomide. Hoewel ook dit niet gerandomiseerd werd
vergeleken, verbeterde de toevoeging van chemotherapie de overleving niet ten opzichte van radiotherapie
alleen [Amichetti 2011
, Fogh 2010
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
228
133
101
64
369
100
125
192
5
5
5
100
Gliomen
PDF aangemaakt op 
23-01-2025
428
/
971
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
Gliomen
PDF aangemaakt op 
23-01-2025
429
/
971
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Gliomen
PDF aangemaakt op 
23-01-2025
430
/
971
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
Gliomen
PDF aangemaakt op 
23-01-2025
431
/
971
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
Gliomen
PDF aangemaakt op 
23-01-2025
432
/
971
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
Gliomen
PDF aangemaakt op 
23-01-2025
433
/
971
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
Gliomen
PDF aangemaakt op 
23-01-2025
434
/
971
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
Gliomen
PDF aangemaakt op 
23-01-2025
435
/
971
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
Gliomen
PDF aangemaakt op 
23-01-2025
436
/
971
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
Gliomen
PDF aangemaakt op 
23-01-2025
437
/
971
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
Gliomen
PDF aangemaakt op 
23-01-2025
438
/
971
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
Gliomen
PDF aangemaakt op 
23-01-2025
439
/
971
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
440
/
971
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
Gliomen
PDF aangemaakt op 
23-01-2025
441
/
971
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
Gliomen
PDF aangemaakt op 
23-01-2025
442
/
971
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
Gliomen
PDF aangemaakt op 
23-01-2025
443
/
971
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
Gliomen
PDF aangemaakt op 
23-01-2025
444
/
971
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
Gliomen
PDF aangemaakt op 
23-01-2025
445
/
971
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
Gliomen
PDF aangemaakt op 
23-01-2025
446
/
971
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
447
/
971
Chemotherapie/systeemtherapie bij hooggradig glioom
Deze submodule is onderverdeeld in de volgende sub-submodules:
Chemotherapie nieuw gediagnostiseerd anaplastisch glioom
Chemotherapie recidief anaplastisch glioom
Chemotherapie nieuw gediagnostiseerd glioblastoom
Chemotherapie recidief glioblastoom
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
Gliomen
PDF aangemaakt op 
23-01-2025
448
/
971
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
Gliomen
PDF aangemaakt op 
23-01-2025
449
/
971
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
Gliomen
PDF aangemaakt op 
23-01-2025
450
/
971
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
Gliomen
PDF aangemaakt op 
23-01-2025
451
/
971
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
Gliomen
PDF aangemaakt op 
23-01-2025
452
/
971
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
Gliomen
PDF aangemaakt op 
23-01-2025
453
/
971
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
Gliomen
PDF aangemaakt op 
23-01-2025
454
/
971
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
Gliomen
PDF aangemaakt op 
23-01-2025
455
/
971
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
Gliomen
PDF aangemaakt op 
23-01-2025
456
/
971
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
Gliomen
PDF aangemaakt op 
23-01-2025
457
/
971
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
Gliomen
PDF aangemaakt op 
23-01-2025
458
/
971
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
Gliomen
PDF aangemaakt op 
23-01-2025
459
/
971
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
Gliomen
PDF aangemaakt op 
23-01-2025
460
/
971
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
Gliomen
PDF aangemaakt op 
23-01-2025
461
/
971
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Gliomen
PDF aangemaakt op 
23-01-2025
462
/
971
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
Gliomen
PDF aangemaakt op 
23-01-2025
463
/
971
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
Gliomen
PDF aangemaakt op 
23-01-2025
464
/
971
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Gliomen
PDF aangemaakt op 
23-01-2025
465
/
971
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
466
/
971
Chemotherapie nieuw gediagnostiseerd anaplastisch glioom
Uitgangsvraag
Wat is de indicatie voor chemotherapie bij een patiënt met een nieuw gediagnostiseerd anaplastisch glioom?
Aanbeveling
Patiënten met een anaplastisch glioom met een 1p/19q-deletie dienen post-operatief behandeld te worden
met radiotherapie (zie module 
Indicatie radiotherapie anaplastisch glioom
) gevolgd door zes kuren PCV,
volgens het EORTC-26951-protocol.
Er wordt geadviseerd, in afwachting van de resultaten van de EORTC-26053-studie (CATNON), patiënten met
een anaplastisch glioom zonder gecombineerde 1p/19q-deletie te behandelen met postoperatieve
radiotherapie alleen.
Bij te verwachten grote neurotoxiciteit van radiotherapie door een zeer groot doelvolume zou overwogen
kunnen worden te kiezen voor temozolomide als postoperatieve behandeling bij anaplastische gliomen
zonder 1p/19q-deletie [Wick 2009
].
Overwegingen
Bij te verwachten grote neurotoxiciteit van radiotherapie door een zeer groot doelvolume zou overwogen
kunnen worden te kiezen voor temozolomide als postoperatieve behandeling bij anaplastische gliomen
zonder 1p/19q-deletie [Wick 2009
].
Onderbouwing
Conclusies
Bij anaplastische gliomen met een 1p/19q-deletie is een verlenging van de overleving aangetoond, door PCV
chemotherapie aan de radiotherapie toe te voegen. 
Van den Bent 2013
, Cairncross 2013
Er zijn aanwijzingen dat er geen verschil is in progressievrije overleving tussen nabehandeling met
monotherapie radiotherapie, PCV of TMZ.
Wick 2009
Samenvatting literatuur
Chemotherapie voorafgaand aan resectie (neoadjuvant)
Er zijn geen data die het toevoegen van chemotherapie voorafgaand aan een resectie, met als doel de tumor
kleiner te maken zodat een betere resectie kan worden verkregen, ondersteunen.
Adjuvante chemotherapie (= aanvullende chemotherapie direct na resectie) al dan niet in combinatie met
radiotherapie, zonder dat er op de scan sprake is van tumorprogressie.
Oligodendrogliale tumoren zijn gevoeliger voor chemotherapie dan tumoren die geen oligodendrogliale
386
386
351
41
386
Gliomen
PDF aangemaakt op 
23-01-2025
467
/
971
kenmerken hebben. De waarde van adjuvante chemotherapie voor patiënten met een 1p/19q-deletie werd
aangetoond in zowel de EORTC-26951 [van den Bent 2013
] als de RTOG-9402 [Cairncross 2013
] studie.
In de EORTC-26951 zijn 368 patiënten geïncludeerd met anaplastisch oligodendroglioom en gemengd
anaplastisch oligoastrocytoom (ten minste 25% oligodendrogliale-component) die werden gerandomiseerd
tussen radiotherapie (RT) en RT plus 6 kuren procarbazine, lomustine en vincristine (PCV). In 2006 werd na een
mediane follow-up van 5 jaar een verschil in progressievrije overleving (PFS) gevonden, echter geen statistisch
significant verschil in overleving [Van den Bent 2006
]. Na langere follow-up bleek echter dat de overleving
in de RT/PCV-arm significant langer was; 42.3 vs. 30.6 maanden in de RT-arm ([HR] 0,75; 95%CI 0,60-0,95).
Ook kwamen data beschikbaar over de 1p/19q-status van patiënten. Voor de patiënten met een 1p/19q-
deletie werd een mediane PFS van 157 vs. 50 maanden voor de gecombineerde behandeling ten opzichte
van RT alleen gevonden, en een trend naar verbeterde totale overleving (OS) (mediaan niet bereikt vs. 112
maanden (HR 0,56;95%CI 0,31-1,03)).
In de RTOG-9402 werden 291 patiënten met anaplastisch oligodendrocytoom en anaplastisch
oligoastrocytoom gerandomiseerd tussen vier cycli intensified PCV met een hogere dosering lomustine,
namelijk 130 mg/m2 i.p.v. 110 mg/m2 op dag 1 en zonder dosisbeperking per gift vincristine (de doses van
de verschillende middelen waren niet gelijk aan die van de EORTC-26951) gevolgd door RT vs. RT alleen.
Voor patiënten met een 1p/19q-deletie werd een overlevingswinst gevonden (mediaan 14,7 versus 7,3 jaar,
HR 0,59;95%CI 0,37-0,95) in de gecombineerde behandelingsarm. In de groep patiënten zonder 1p/19q-
verlies werd geen voordeel van gecombineerde behandeling gevonden (2,6 versus 2,7 jaar). Daarnaast lijkt er
op basis van deze studie een voordeel voor de patiënten waarbij de tumor geen 1p/19q-deletie bevat maar
wel een IDH1/2-mutatie voor PCV gevolgd door RT. Dit betreft echter een post-hoc analyse bij een relatief
kleine subgroep van 66 patiënten.
De NOA-4-studie is een gerandomiseerde fase III-studie bij patiënten met een anaplastisch glioom die als
postoperatieve behandeling 2:1:1 RT (arm A) ten opzichte PCV (arm B1) vs. temozolomide (TMZ) (arm B2)
heeft vergeleken [Wick 2009
]. Patiënten die in eerste instantie behandeld waren met postoperatieve
radiotherapie (arm A), werden bij onacceptabele toxiciteit of progressie opnieuw gerandomiseerd tussen
chemotherapie alleen met TMZ of PCV (arm B1 of B2). Andersom werden patiënten die direct
chemotherapeutisch behandeld waren, na progressieve ziekte behandeld middels RT (arm A). Er werden 274
patiënten geïncludeerd, waarbij geen verschil tussen de behandelarmen werd gevonden voor het primaire
eindpunt van de studie: gemiddelde (mediane) tijd tot progressieve ziekte. Voor geen van de subgroepen
anaplastisch astrocytoom, anaplastisch oligodendrocytoom of anaplastisch oligoastrocytoom was een van de
behandelarmen superieur. Er was geen verschil in progressievrije overleving tussen de patiënten die
behandeld werden met TMZ ten opzichte van PCV. Het is van belang om te vermelden dat deze patiënten
niet gerandomiseerd zijn op basis van 1p/19q-status van het anaplastische glioom. Ten tijde van rapportage
waren de resultaten voor overleving nog immatuur. In het licht van de nagekomen rapportages bij studies
EORTC 26951, RTOG 9402 en RTOG 8502 waarbij pas op lange follow-up algemene overleving significante
verschillen ten voordele van toevoeging PCV kuren liet zien, dienen we mogelijk bedacht te zijn op een
dergelijk nakomend bericht in deze studie.
Er is nog een retrospectieve studie met 109 patiënten [Brandes 2006a
] met een anaplastisch astrocytoom
beschikbaar die achteraf het verschil tussen PCV (49 patiënten) en TMZ (60 patiënten) heeft geanalyseerd.
Ook in deze analyse werd geen verschil in behandeluitkomst tussen de twee chemotherapieregimes
gevonden. 
351
41
352
386
29
Gliomen
PDF aangemaakt op 
23-01-2025
468
/
971
In 2014 loopteen grote gerandomiseerde fase III-trial voor anaplastische glioompatiënten zonder 1p/19q
deletie (CATNON, EORTC-26053). Dit is een 4-armige studie: RT alleen vs. RT plus concomitant
temozolomide vs. RT plus adjuvant temozolomide vs. RT plus concomitant en adjuvant temozolomide.
Aanvankelijk liep ook een gerandomiseerde fase III-trial voor patienten met 1p/19q-deletie (CO_DEL,
EORTC-26081). Dit was een 3-armige studie waarbij een van de armen radiotherapie alleen was. Na het
beschikbaar komen van de lange termijndata van zowel de EORTC-26951 als de RTOG-9402, werd RT alleen
echter als onderbehandeling gezien en is de studie gesloten.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
Gliomen
PDF aangemaakt op 
23-01-2025
469
/
971
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
Gliomen
PDF aangemaakt op 
23-01-2025
470
/
971
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Gliomen
PDF aangemaakt op 
23-01-2025
471
/
971
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
Gliomen
PDF aangemaakt op 
23-01-2025
472
/
971
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
Gliomen
PDF aangemaakt op 
23-01-2025
473
/
971
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
Gliomen
PDF aangemaakt op 
23-01-2025
474
/
971
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
Gliomen
PDF aangemaakt op 
23-01-2025
475
/
971
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
Gliomen
PDF aangemaakt op 
23-01-2025
476
/
971
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
Gliomen
PDF aangemaakt op 
23-01-2025
477
/
971
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
Gliomen
PDF aangemaakt op 
23-01-2025
478
/
971
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
Gliomen
PDF aangemaakt op 
23-01-2025
479
/
971
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
480
/
971
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
Gliomen
PDF aangemaakt op 
23-01-2025
481
/
971
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
Gliomen
PDF aangemaakt op 
23-01-2025
482
/
971
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
Gliomen
PDF aangemaakt op 
23-01-2025
483
/
971
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
Gliomen
PDF aangemaakt op 
23-01-2025
484
/
971
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
Gliomen
PDF aangemaakt op 
23-01-2025
485
/
971
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
Gliomen
PDF aangemaakt op 
23-01-2025
486
/
971
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
487
/
971
Chemotherapie recidief anaplastisch glioom
Uitgangsvraag
Wat is de indicatie voor chemotherapie bij een patiënt met een recidief anaplastisch glioom?
Aanbeveling
Patiënten met een recidief hooggradig glioom dienen in een multidisciplinair neuro-oncologisch overleg
besproken te worden. In de recidiefsetting dienen andere palliatieve behandelingen, zoals radiotherapie en
chirurgie, telkens mede in overweging genomen te worden.
De werkgroep is van mening dat patiënten met een recidief anaplastisch glioom bij voorkeur in studieverband
behandeld moeten worden.
Indien er geen studie beschikbaar is, wordt geadviseerd behandeling met twaalf kuren temozolomide te
overwegen. Vervolgbehandeling met PCV lijkt vooral voor tumoren met een 1p/19q-deletie voor de hand te
liggen.
Overwegingen
In de recidiefsetting dienen alle palliatieve behandelingen waaronder radiotherapie en chirurgie telkens mede
in overweging genomen te worden.
Onderbouwing
Conclusies
Er zijn aanwijzingen dat zowel PCV als temozolomide effectief kan zijn in zowel eerste als
tweedelijnsbehandeling van het recidief anaplastisch glioom.
Yung 1999
, Brandes 2006
, Van den Bent 2003
, Van den Bent 1998
, Brandes 2004
, Kouwenhoven
2006
Samenvatting literatuur
Er zijn meerdere studies die de waarde van chemotherapie bij het recidief anaplastisch glioom ondersteunen,
zowel in de eerste als in de tweede lijn. Deze data zijn er voor zowel temozolomide [Yung 1999
, Brandes
2006
, van den Bent 2003
] als PCV [van den Bent 1998
, Brandes 2004
, Kouwenhoven 2006
] in
verscheidende fase II-studies met patiënten aantallen variërend van 18-97. Prognose en respons op
chemotherapie is afhankelijk van de tijd tot recidief, histologie, moleculaire achtergrond en eerdere
behandeling. Bij ongeveer de helft van deze patiënten wordt een objectieve response rate gezien met een
progressievrije overleving na zes maanden van rond de 60% en na twaalf maanden van ongeveer 50%. In een
tweedelijnsbehandeling liggen deze getallen lager [Yung 1999
, van den Bent 2003
, van den Bent
2001
, Triebels 2004
, Chinot 2001
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
407
29
358
356
31
182
407
29
358
356
31
182
407
358
355
344
57
Gliomen
PDF aangemaakt op 
23-01-2025
488
/
971
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
Gliomen
PDF aangemaakt op 
23-01-2025
489
/
971
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
Gliomen
PDF aangemaakt op 
23-01-2025
490
/
971
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
Gliomen
PDF aangemaakt op 
23-01-2025
491
/
971
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
Gliomen
PDF aangemaakt op 
23-01-2025
492
/
971
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
Gliomen
PDF aangemaakt op 
23-01-2025
493
/
971
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
Gliomen
PDF aangemaakt op 
23-01-2025
494
/
971
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
Gliomen
PDF aangemaakt op 
23-01-2025
495
/
971
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
Gliomen
PDF aangemaakt op 
23-01-2025
496
/
971
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
Gliomen
PDF aangemaakt op 
23-01-2025
497
/
971
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
Gliomen
PDF aangemaakt op 
23-01-2025
498
/
971
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
Gliomen
PDF aangemaakt op 
23-01-2025
499
/
971
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
Gliomen
PDF aangemaakt op 
23-01-2025
500
/
971
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
Gliomen
PDF aangemaakt op 
23-01-2025
501
/
971
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Gliomen
PDF aangemaakt op 
23-01-2025
502
/
971
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
Gliomen
PDF aangemaakt op 
23-01-2025
503
/
971
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
Gliomen
PDF aangemaakt op 
23-01-2025
504
/
971
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
Gliomen
PDF aangemaakt op 
23-01-2025
505
/
971
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Gliomen
PDF aangemaakt op 
23-01-2025
506
/
971
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
507
/
971
Chemotherapie nieuw gediagnostiseerd glioblastoom
Uitgangsvraag
Wat is de indicatie voor chemotherapie bij een patiënt met een nieuw gediagnostiseerd glioblastoom?
Aanbeveling
Bij patiënten met een glioblastoom in goede conditie tot 60 jaar dient postoperatief radiotherapie gegeven
te worden, gecombineerd met concomitant en adjuvant temozolomide.
Voor de behandeling van patiënten met een glioblastoom ouder dan 60 jaar die niet fit genoeg zijn om deze
behandeling te ondergaan wordt verwezen naar de module 
Behandeling van ouderen
.
De chemotherapie dient gegeven te worden, door middel van temozolomide 75 mg/m2/d gedurende zes
weken, gecombineerd met radiotherapie tot een totale dosis van 60 Gy in 30 fracties, gevolgd door een
rustperiode van vier weken en daarna zes postradiatiekuren temozolomide 200 mg/m2/d dag 1-5 elke vier
weken. De eerste postradiatiekuur wordt gedoseerd op 150 mg/m
/d en opeenvolgende kuren worden
vervolgens op 200 mg/m
/d gedoseerd indien goed verdragen. Dose-dense schema's van temozolomide
hebben geen toegevoegde waarde voor het glioblastoom. Ook het toevoegen van bevacizumab aan het
Stupp-schema laat geen toename in overleving zien.
De werkgroep is van mening dat bij goede en voortgaande tumorrespons overwogen kan worden het aantal
postradiatie kuren uit te breiden van zes naar twaalf.
Overwegingen
Op farmacologische gronden kan getwijfeld worden aan de noodzaak tot reduceren van de dosis van de
eerste postradiatiekuur. Overwogen kan worden om de eerste postradiatiekuur ook op de dosis 200 mg/m
/d
toe te dienen. In uitzonderlijke gevallen (enkel bij goede tolerantie en voortdurende tumorrespons met in
achtneming dat het wetenschappelijk bewijs zeer beperkt is) kan de behandelaar overwegen het aantal
postradiatiekuren op te hogen tot maximaal twaalf. Er is een risico op pneumocystis jirovecii pneumonie
tijdens de chemoradiatie. Overweeg profylaxe [De Vos 2013
]. Bij 20-30% patiënten behandeld met
chemoradiatie wordt pseudoprogressie waargenomen [Wen 2010
].
Onderbouwing
Conclusies
Er is aangetoond dat bij patiënten met een nieuw gediagnostiseerd glioblastoom en in een goede conditie
chemoradiatie door middel van temozolomide resulteert in een langere overleving dan radiotherapie alleen. 
Stupp 2005
, Stupp 2009
De werkgroep is van mening dat het veilig is om het aantal postradiatiekuren bij zeer goede tumorrespons uit
te breiden. Door de opzet van de studies kan echter geen uitspraak worden gedaan over een mogelijk
overlevingsvoordeel. 
2
2
2
75
382
331
330
130
281
Gliomen
PDF aangemaakt op 
23-01-2025
508
/
971
Hau 2007
, Roldan 2012
Het is aangetoond dat toevoeging van bevacizumab aan het Stupp-schema niet leidt tot verlenging van de
totale overleving. 
Chinot 2014
, Gilbert 2014
Samenvatting literatuur
In 2005 werd een open gerandomiseerde fase III-onderzoek gepubliceerd verricht bij patiënten met een
nieuw-gediagnostiseerd glioblastoom waarmee de aanvullende waarde van temozolomide aan
(postoperatieve) radiotherapie werd aangetoond [Stupp 2005
]. In de studie werden 573 volwassen
patiënten tot 70 jaar (84% voorafgaande resectie, 16% alleen biopsie) gerandomiseerd tussen radiotherapie
alleen of een gecombineerde behandeling met tegelijkertijd radiotherapie en temozolomide gevolgd door
een behandeling met alleen temozolomide [Stupp 2005
]. Het primaire eindpunt was overleving en dit werd
geanalyseerd volgens het intention-to-treat-principe. De mediane overleving was 14,6 maanden in de
gecombineerde radio- en chemotherapiegroep en 12,1 maanden in de groep die alleen werd behandeld met
radiotherapie. Dit is een significant verschil, maar de grootte van het effect is gering. Na twee jaar waren
echter 30 (10,4%) patiënten in de radiotherapiegroep en 76 (26,5%) patiënten in de combinatiegroep in
leven, ook een significant verschil [Stupp 2005
]. Na vijf jaar waren respectievelijk 5(1,9%) en 28 (9,8%)
patiënten in de radiotherapie- en combinatiegroep nog in leven [Stupp 2009
]. Een post-hoc analyse van
206 patiënten suggereerde dat patiënten met een gemethyleerd DNA-herstelenzym O6-methylguanine-DNA
methyltransferase (MGMT) (aanwezig bij 45% van de onderzochte patiënten) een groter voordeel bij de
toevoeging van temozolomide aan radiotherapie hebben [Hegi 2005
]. De methyleringsstatus van MGMT
heeft zowel een prognostische als predictieve waarde (Hegi 2005; Wick 2012). Bij chemoradiatie bleek het
overlevingsvoordeel beduidend groter te zijn dan monotherapie radiotherapie bij patiënten met een
gemethyleerde MGMT promotor. Dit voordeel is veel kleiner bij patiënten met een ongemethyleerde MGMT
promotor. In geval dat de patiënt onvoldoende conditie heeft tot het verkrijgen van chemoradiatie, kan op
basis van deze methyleringsstatus geopteerd worden tussen een van beide monotherapiëen (dus ofwel
radiotherapie ofwel chemotherapie). Of het uitbreiden van het aantal postradiatiekuren zinvol is, is niet
bekend; het is vooral retrospectief beschreven. De enige prospectieve studie waarin een uitgebreid Stupp-
schema (meer dan zes postradiatiekuren temozolomide) wordt onderzocht, bevatte ook graad III gliomen
waardoor de mediane overleving van 58 maanden beïnvloed werd [Hau 2007
].
Retrospectief Canadees onderzoek bij 52 patiënten laat zien dat 29 patiënten die met meer dan zes
postradiatiekuren werden behandeld een mediane overleving van 24,6 maanden hadden versus 16,5
maanden bij een behandeling van zes postradiatiekuren. Doordat dit een retrospectieve studieopzet was, is
er dan ook sprake van enige patiëntenselectie-bias, aangezien zij met een betere respons op temozolomide
ook langer overleven [Roldan 2012
]. MGMT-status was geen doorslaggevende factor bij het besluit al dan
niet te continueren na zes postradiatiekuren. Er moet wel gewezen worden op de beperkingen van deze
studie: retrospectief, niet gekeken naar impact van type neurochirurgische ingreep of MGMT-status. 
Daarnaast is er onderzoek verricht naar de dosis temozolomide, waarbij de gedachte is dat een hogere dosis
leidt tot het teniet doen van de MGMT-gemedieerde resistentie. In een faseIII-studie werden 833 patiënten
gerandomiseerd in een arm met postradiatie temozolomide standaarddosering 200 mg/m2/d d1-5 versus
dose-dense schema 75 mg/m2/d d1-21 elke 4 weken in 6-12 cycli [Gilbert 2013
]. Deze studie liet geen
significante verbetering van totale overleving (OS) zien (16,6 versus 14,9 maanden), noch van mediane
130
281
58
109
331
331
331
330
132
130
281
110
Gliomen
PDF aangemaakt op 
23-01-2025
509
/
971
progressie vrije overleving (PFS) (5,5 versus 6,7 maanden). Echter, bij de MGMT-gemethyleerde groep werd
wel significant verbeterde OS en PFS gezien, ongeacht het regimen temozolomide (algemene overleving:
21,2 versus 14 maanden voor de standaarddosering temozolomidegroep versus dose-dense
temozolomidegroep, en progressievrije overleving: 8,7 versus 5,7 maanden voor de standaarddosering
temozolomidegroep versus dose-dense temozolomidegroep). Per behandelarm werd in de MGMT-
gemethyleerde groep geen significant verschil gevonden: OS 20,2 vs. 21,4 maanden en PFS van 6,5 vs. 10,1
maanden, respectievelijk in de standaard behandelarm en in de dose-dense behandelarm. Daarnaast werd
een forse toename aan graad 3 toxiciteit gezien met name lymfocytopenie en vermoeidheid in de dose-
dense arm ten opzichte van de standaardarm (53% versus 34%).
In een volgende studie werd gekeken naar de waarde van het postoperatief plaatsen van gliadel rasters (ook
carmustine implants genoemd) in de resectieholte [Bock 2010
]. Bij 44 patiënten met nieuw
gediagnostiseerd glioblastoom werden na het verwijderen van de tumor biologisch afbreekbare rasters
geïmpregneerd met carmustine in het tumorbed geïmplanteerd. Hierna volgde chemoradiatie met
temozolomide. Er werd geen beduidende overlevingswinst gezien met een mediane progressievrije
overleving van 7 maanden en een mediane overleving van 12,7 maanden en daarbij werd een toename in
toxiciteit gerapporteerd [Sabel 2008
].In een systematische review, die 19 studies met 795 patiënten
samenvat, is de eventuele toegevoegde waarde van carmustine implantsonderzocht. Hieruit bleek dat de
overlevingswinst marginaal was, terwijl er een hoog risico op postoperatieve complicaties van 42,7% werd
beschreven [Bregy 2013
]. Gerandomiseerd fase III-onderzoek over de toevoeging van carmustine implants
bij patiënten tijdens het Stupp-protocol ontbreekt.
Er is veel belangstelling voor de behandeling van glioblastomen met geneesmiddelen die de
signaaltransductie via VEGF remmen, zoals bevacizumab, een monoklonaal antilichaam tegen VEGF. In een
gerandomiseerde studie waarin de toevoeging van bevacizumab aan het Stupp-protocol werd onderzocht,
werd bij 921 patiënten een mediane PFS van 10,6 maanden in de bevacizumabgroep versus 6,2 maanden in
de placebogroep waargenomen. Deze significante verbetering vertaalde zich echter niet in overlevingswinst
(resp. 16,8 versus 16,7 maanden). Een kwaliteit van leven-analyse toonde voorts dat het langer duurde
voordat een toename in klachten optrad in de bevacizumabgroep (hazard ratio 0,64; 95%CI 0,56-0,74). Ook
bleek er een grotere groep patiënten die de deelname startten met corticosteroïden-gebruik deze tijdens
behandeling te kunnen staken indien ze behandeld werden met bevacizumab (66,3% versus 47,1%) [Chinot
2014[239]]. In een gelijkwaardige Amerikaanse studie met 978 patiënten, vertaalde een significant voordeel in
PFS voor patiënten die met bevacizumab behandeld werden (10,7 versus 7.3 maanden) zich eveneens niet in
algemeen overlevingsvoordeel (15,7 versus 16,1 maanden) [Gilbert 2014
]. Daarnaast liet deze studie een
snellere achteruitgang in neurocognitie zien in de bevacizumabgroep. De onderzoekers duiden dit als
vroegtijdige tumorprogressie dan wel bevacizumab-gerelateerde neurotoxiciteit. 
Blokkade van integrines 
α
v
β
3 en 
α
v
β
5 door cilengitide werd onderzocht bij patiënten met glioblastomen in
een fase III-onderzoek [Reardon 2008
], Stupp 2013
]. In deze gerandomiseerde studie werd de
toevoeging van cilengitide aan het Stupp-protocol onderzocht bij 272 patiënten met nieuw
gediagnostiseerde glioblastoom en gemethyleerde MGMT status. De mediane overleving was 26.3 maanden
in beide armen met hazard ratio 1,02 (95%CI; 0,81-1,29). Mediane PFS was niet significant verschillend (13,5
maanden in de cilengitidearm en 10,7 maanden in de controle-arm). Enkelarmige fase II-studies waarbij
nieuwe medicijnen aan het Stupp-protocol werden toegevoegd, melden een mediane overleving tussen 17 en
25 maanden, vergeleken met historische controles [Grossman 2009
], Butowski 2009
], Soffietti
21
287
32
109
273
333
117
39
321
Gliomen
PDF aangemaakt op 
23-01-2025
510
/
971
2014
].Hier kunnenechter, gezien het gebrek aan sluitend fase III-gerandomiseerd onderzoek, nog geen
conclusies aan verbonden worden. 
ICT-107 is een autologe dendritische cel vaccin met klasse I peptiden afkomstig van tumor-geassocieerde
antigenen met overexpressie op gliomen [Phuphanich 2013
]. Een placebo-gecontroleerde,
gerandomiseerde fase II- studie heeft het beoogde patiëntenaantal voor inclusie in 2013 bereikt.
Rindopepimut (CDX-110) induceert tumorspecifieke immuunrespons in tumoren met een epidermale
groeifactor receptor vIII (EGFRvIII) mutatie [Babu 2012
]. In 2013 is een gerandomiseerde fase III-studie (ACT-
IV/EORTC-26112) geopend met het streven 700 patiënten te includeren met een nieuwe gediagnostiseerde
glioblastoom met EGFRvIII mutatie. Tot slot, NovoTTF-100A is een op de behaarde hoofdhuid draagbaar
toedieningstoestel dat met afwisselende electrogebieden door middel van lage intensiteit tumorceldeling
onderbreekt [Davies 2013
]. Dit toestel is door de Food and Drug Administration (FDA) goedgekeurd. Deze
goedkeuring slaat op de veiligheidsaspecten in kader van de toepasbaarheid van het toestel en niet de
effectiviteit van de behandeling d.m.v. het toestel welke tot op heden niet is aangetoond bij het nieuw
gediagnostiseerde glioblastoom [Salzberg 2008
]. In 2013 is er een studie gestart (Effect of NovoTTF-100A
together with temozolomide in newly diagnosed glioblastoma multiforme (GBM). ClinicalTrials.gov Identifier
NTC00916409).
Verantwoording
Laatst beoordeeld
 : 07-08-2023
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
321
260
6
69
290
Gliomen
PDF aangemaakt op 
23-01-2025
511
/
971
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
512
/
971
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
Gliomen
PDF aangemaakt op 
23-01-2025
513
/
971
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
Gliomen
PDF aangemaakt op 
23-01-2025
514
/
971
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
Gliomen
PDF aangemaakt op 
23-01-2025
515
/
971
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
Gliomen
PDF aangemaakt op 
23-01-2025
516
/
971
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
Gliomen
PDF aangemaakt op 
23-01-2025
517
/
971
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
Gliomen
PDF aangemaakt op 
23-01-2025
518
/
971
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
Gliomen
PDF aangemaakt op 
23-01-2025
519
/
971
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
Gliomen
PDF aangemaakt op 
23-01-2025
520
/
971
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
Gliomen
PDF aangemaakt op 
23-01-2025
521
/
971
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
Gliomen
PDF aangemaakt op 
23-01-2025
522
/
971
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
Gliomen
PDF aangemaakt op 
23-01-2025
523
/
971
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Gliomen
PDF aangemaakt op 
23-01-2025
524
/
971
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
Gliomen
PDF aangemaakt op 
23-01-2025
525
/
971
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
Gliomen
PDF aangemaakt op 
23-01-2025
526
/
971
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Gliomen
PDF aangemaakt op 
23-01-2025
527
/
971
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
Gliomen
PDF aangemaakt op 
23-01-2025
528
/
971
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
529
/
971
Chemotherapie recidief glioblastoom
Uitgangsvraag
Wat is de rol van chemotherapie bij een patiënt met een recidief glioblastoom?
Aanbeveling
Bij een patiënt met een recidief glioblastoom in een goede conditie dient in eerste instantie een behandeling
in studieverband te worden overwogen. Bij het niet beschikbaar of geschikt zijn voor een studie, dient in
multidisciplinaire bespreking de verschillende behandelopties te worden besproken.
Als chemotherapeutische behandeling het advies is bij een aangetoond recidief glioblastoom zes maanden of
meer na beëindigen van het Stupp-schema, kan temozolomide 200 mg/m2/d op dagen 1-5 elke vier weken
overwogen worden.
Indien patiënten eerder behandeld zijn geweest met chemotherapie, wordt de eerste kuur gedoseerd op 150
mg/m2/d en worden opeenvolgende kuren vervolgens hoger gedoseerd, indien het goed wordt verdragen.
In het licht van de RESCUE studie kan dose dense temozolomide overwogen worden bij geselecteerde
patiënten met een vroeg recidief glioblastoom en weinig doorgemaakte toxiciteit tijdens Stupp-schema.
Indien het recidief al tijdens of binnen zes maanden na staken Stupp-schema wordt aangetoond, is afhankelijk
van de conditie van de patiënt PCV-kuren dan wel lomustine monotherapie een optie.
Behandeling met biologicals gebeurt in studieverband.
Overwegingen
Bij 20-30% van de patiënten behandeld met chemoradiatie wordt pseudoprogressie waargenomen [Wen
2010
]. Dit kan een rol spelen in de beoordeling van het effect van een vervolgbehandeling en benadrukt
de noodzaak van een ervaren neuro-radioloog binnen het multidisciplinaire team.
Nadat er een recidief is vastgesteld, is de eerste keuze voor patiënten met een recidief glioblastoom een
behandeling binnen studieverband. Er is geen gerandomiseerde studie die de verschillende
behandelingsmodaliteiten (her-operatie, her-bestraling of tweedelijnschemotherapie/andere systeemtherapie)
naast elkaar heeft bestudeerd en heeft vergeleken. Voor een adequate palliatieve behandeling buiten
studieverband voor patiënten met een recidief glioblastoom is het belangrijk verschillende individuele
patiëntgebonden factoren, zoals leeftijd, klinische conditie, mate van initiële resectie, respons op eerdere
therapie, tijd sinds diagnose, of het een lokaal of diffuus recidief betreft, in acht te nemen. Gezien de
beschikbaarheid van meerdere behandelingsmodaliteiten, dient bespreking in een neuro-oncologisch MDO
plaats te vinden.
Onderbouwing
Conclusies
382
Gliomen
PDF aangemaakt op 
23-01-2025
530
/
971
Het is aangetoond dat monotherapie temozolomide bij recidief glioblastoom effectief kan zijn, maar de kans
op en de duur van het effect zijn niet zo groot (ca. 20% progressievrij na zes maanden wanneer geen eerdere
behandeling met temozolomide is gegeven). 
Er zijn (beperkte) aanwijzingen dat, in geval van een recidief na eerstelijns behandeling met (radiotherapie en)
temozolomide, temozolomide opnieuw effectief kan zijn; de kans op effect lijkt groter wanneer het
behandelings-vrije interval groter is.
Brada 2010
, Wick 2009
, Perry 2008
, Perry 2010
Er zijn aanwijzingen dat op nitrosurea gebaseerde therapie als tweedelijnstherapie bij recidief glioblastoom in
geselecteerde patiëntengroepen een behandeloptie kan zijn. 
Kuhnhenn 2012
, Schmidt 2006
, Wick 2010
Er zijn aanwijzingen dat bevacizumab gecombineerd met lomustine bij recidief glioblastoom een aanvulling in
het behandelplan zou kunnen zijn. Bevestiging is nodig in een gerandomiseerde fase-III studie.
Taal 2014
Samenvatting literatuur
Cytostatica
Temozolomide
In een niet-geblindeerd, gerandomiseerd fase II onderzoek werd temozolomide vergeleken met procarbazine
bij 225 patiënten met een eerste recidief glioblastoom na operatie en radiotherapie [Yung 2000
]. De
progressievrije overleving na zes maanden was significant hoger met temozolomide dan procarbazine (21%
versus 8%). Een niet-geblindeerd, gerandomiseerd fase III-onderzoek waarbij temozolomide of PCV
(procarbazine-lomustine-vincristine) werd gegeven aan patiënten met recidief graad III en IV glioom (n=447),
die niet eerder met chemotherapie waren behandeld, liet geen verschil zien in mediane progressievrije
overleving en algemene overleving (respectievelijk, 3,6 versus 4,7 maanden en 6,7 versus 7,2 maanden)
[Brada 2010
].
Dose-dense schema's temozolomide
In een fase III-studie werden twee doseringen van temozolomide gebruikt: een geregistreerde dosering
temozolomide (200 mg/m
 dag 1-5 elke vier weken) of een off-label intensieve dosering (100 mg/m
 dag 1-21
elke 4 weken) [Brada 2010
]. Hierbij bleek er een duidelijk voordeel in kwaliteit van leven voor patiënten
behandeld met standaarddosering temozolomide ten opzichte van dose-dense therapie. Daarnaast werd er
ook minder toxiciteit in de vijfdaagse temozolomide behandelde groep vermeld. Echter, hierbij moet in acht
genomen worden dat de patiënten chemotherapie-naïef waren, omdat de studie plaatsvond voordat het
Stupp-protocol standaardbehandeling voor nieuw gediagnosticeerde glioblastomen werd. Retrospectieve
studies naar verscheidende rechallenge doseringsschema's met temozolomide bij recidief gliomen lieten een
bescheiden winst voor dose-dense schema's zien met een 6 maanden progressievrije overleving variërend van
28 - 57% [Wick 2009
, Perry 2008
]. De uitkomst van de rechallenge behandeling werd gunstig beïnvloed
naarmate de tijd tussen eerstelijnsbehandeling en vaststellen tumorprogressie groter werd.
Dit resulteerde in de Fase II RESCUE-studie waarbij recidief glioblastoom progressief na temozolomide
monotherapie behandeld werd met een continuschema [Perry 2010
].Dit leidde tot 24% 6-maanden PFS bij
26
386
258
255
185
300
388
335
406
26
2
2
26
386
258
255
Gliomen
PDF aangemaakt op 
23-01-2025
531
/
971
91 patiënten. Interessant is dat bij de groep met een vroegtijdig recidief (PD tijdens de eerste zes
postradiatiekuren) vergelijkbare overlevingsresultaten behaald werden ten opzichte van de groep met
laattijdig recidief (PD tijdens de zevende tot twaalfde postradiatiekuren) in vergelijking met de groep die
recidiveerde na meer dan twee maanden na staken postradiatiekuren. Er was verschil in 6-maanden PFS
(respectievelijk, 27,3 versus 7,4 versus 35,7%, p=0.0027) en in 1-jaars overleving (27,3 versus 14,8 versus
28,6%, niet significant). Hierbij werd rekening gehouden met de mogelijke invloed van pseudoprogressie,
door patiënten met PD binnen twaalf weken na beëindigen chemoradiatie te excluderen. De onderzoekers
konden geen verklaring vinden voor het verschil in overlevingsdata en vermoedden depletie van MGMT of
een antiangiogenetisch effect van het dose-dense toedieningsschema. In een gelijkwaardige studie werd een
6-maanden PFS van 19% met een totale overleving van 7 maanden bij 37 patiënten waargenomen. Eerdere
behandeling met bevacizumab leidde tot een lagere totale overleving (4 versus 13 maanden), maar dit kwam
doordat de bevacizumab voorbehandelde patiëntengroep meerdere behandellijnen voorafgaand aan de
behandeling met dose-dense temozolomide hadden gekregen. [Omuro 2013
]. Deze fase II-studie waarin
een dose-dense schema temozolomide bij recidief glioblastoma werd onderzocht in het bevacizumab-tijdperk
toonde aan dat de mediane overleving na recidief bij eerdere bevacizumab behandeling significant minder is
dan bij bevacizumab-naïeve patiënten (13 versus 4,3 maanden met hazard ratio 3,1). Hierbij werd een
objectiveerbare respons bijtwee patiënten gezien met een 6-PFS van 29%. Echter, een review over dose-dens
temozolomide schema's duidt op de verhoogde kans op lymfocytopenie gerelateerde Pneumocystis jirovecii
pneumonie in vergelijking met standaarddosering [Neyns 2010
].
Combinatiebehandelingen met temozolomide
Een review toonde aan dat combinaties van temozolomide met cisplatine, fotemustine, interferon, sorafenib,
celecoxib, irinotecan of PCV kuren geen verbetering in overleving gaf ten opzichte van standaard
temozolomide monotherapie [Weller 2013
]. De toevoeging van tamoxifen 80 mg/m2/d aan temozolomide
75-150 mg/m2op dagen 1-7 elke 2 weken werd in een fase II-studie bij 32 patiënten als tweedelijnstherapie
geëvalueerd [Di Cristofori 2013
]. De mediane totale overleving en progressie vrije overleving waren
respectievelijk 17,5 en 7 maanden. Aangetoond is dat mismatch mutaties of hypermethylatie van de
promotor regio van MSH6, een DNA-herstelmechanisme, frequent voorkomt bij recidief glioblastoom [Yip
2009
]. Hierdoor komen vaker DNA-fouten voor, die niet hersteld worden en hangt de overleving van de cel
meer af van het PARP-herstelmechanisme. Vandaar dat PARP-inhibitoren als nieuwe behandelstrategie
worden onderzocht om de efficiëntie van temozolomide te verhogen.
Nitrosurea (carmustine of lomustine)
Nitrosurea-gebaseerde kuren bij recidief glioblastoom na eerdere temozolomide behandeling toonde bij 69
patiënten een beperkte mediane progressie vrije overleving van 15 weken aan, met een partiële remissie bij 1
patiënt [Kuhnhenn 2012
]. Bij 86 patiënten met een recidief glioblastoom werden drie partiële remissies en
een mediane progressie vrije overleving gezien van 17,1 weken na PCV-kuren [Schmidt 2006
]. Lomustine
monotherapie bij 92 patiënten met een, met temozolomide behandeld, recidief glioblastoom, toonde in een
fase III-studie een 19% 6-PFS en een mediane totale overleving van 7 maanden [Wick 2010
].
Irinotecan
Irinotecan in recidiefsetting bij patiënten met een glioblastoom toonde geen respons bij alle 40 onderzochte
patiënten en is dus geen alternatieve behandeling bij een recidief [Chamberlain 2002
].
238
227
378
80
401
185
300
388
49
Gliomen
PDF aangemaakt op 
23-01-2025
532
/
971
Nieuwe middelen
Bevacizumab
Op grond van een gerandomiseerd fase II onderzoek bij 170 patiënten, waarin bevacizumab werd vergeleken
met de combinatie bevacizumab en irinotecan, is bevacizumab in de VS geregistreerd (conditional approval)
voor gebruik bij glioblastoom recidieven [Friedman 2009
]. De respons ratio was hoger dan verwacht: 53%
in de combinatie-arm, 43% in de bevacizumab-arm versus 10% bij historische controles. Echter,
overlevingsvoordeel was minder duidelijk met een mediane overleving van acht maanden, vergeleken met
zes maanden bij historische controles. Het ontbreken van een controlegroep zonder bevacizumab was voor
de European Medicines Agency reden om dezelfde registratieaanvraag af te wijzen. Een bijkomende
complicerende factor is dat bevacizumab pseudorespons in de hand werkt, door een effectieve therapie
tegen hersenoedeem te zijn en de bloedhersenbarriëre te sluiten waardoor aankleuring afneemt [Omuro
2007
]. In de gerandomiseerde Nederlandse fase II-studie BELOB [acroniem: 
Be
vacizumab vs. bevacizumab
plus 
lo
mustine vs. lomustine bij recidief G
B
M] werden drie behandelarmen met elkaar vergeleken:
bevacizumab, lomustine en lomustine in combinatie met bevacizumab bij 148 patiënten met recidief
glioblastoom [Taal 2014
]. In de combinatie-arm werd de dosering lomustine verlaagd van 110 naar 90
mg/m
 op dag 1 elke 6 weken, wegens beenmergsuppressie. Na 9 maanden was de OS 38% in de
bevacizumab-arm, 43% in de lomustine-arm, 59% in de combinatie-arm met lomustine 90 mg/m
 en 88% in
de combinatie-arm met lomustine 110 mg/m
. Op deze bevinding is de studie EORTC- 26101 aangepast naar
een fase IIItwee-arms-studie waarin lomustine monotherapie vergeleken wordt met de combinatie lomustine
en bevacizumab bij eerste recidief na Stupp-protocol.
Tot nu toe is er enkel retrospectief onderzocht of het zinvol is bevacizumab te continueren bij progressie
onder bevacizumab [Reardon 2012
]. Toevoeging van fotemustine, sorafenib, temsirolimus, combinatie
carboplatine-irinotecan, dose-dense schema temozolomide, interferon- en combinatie cetuximab-irinotecan
aan bevacizumab in de recidiefsetting gaf geen verbeterde overleving [Soffieti 2014
, Galanis 2013
,
Lassen 2013
, Desjardins 2012
, Groves 2009
, Hasselbach 2010
].
Enzastaurine en cediranib
In een gerandomiseerde fase III-studie werd lomustine monotherapie vergeleken met enzastaurine bij 266
patiënten met recidief glioblastoom na eerdere temozolomide behandeling [Wick 2010
]. Het onderzoek
werd voortijdig stopgezet bij een geprotocolleerde interim-analyse vanwege onvoldoende werkzaamheid. Op
dat moment was er geen significant verschil in het primaire eindpunt: het percentage patiënten dat
progressievrij was na zes maanden (11 versus 19%, respectievelijk enzastaurine en lomustine).Onderzoekers
verklaarden het niet aantonen van effectiviteit door een te vroeg opstarten van de fase III-studie zonder de
definitieve resultaten van de fase II-studie te hebben afgewacht. In een drie-arms fase III REGAL-studie werd
cediranib, een VEGF-receptor inhibitor, onderzocht ten opzichte van lomustine en de combinatie van beide
agentia [Batchelor 2013
].Bij 325 patiënten met een glioblastoom die vooraf met het Stupp-protocol
behandeld waren, werd geen significant verschil gezien in PFS tussen de drie behandelarmen, waarbij de
hazard ratio bij de combinatie-arm 0,76 met 95%CI 0,53-1,08 bedroeg. Mogelijk ligt nog onvoldoende kennis
van predictieve factoren aan de grondslag van het falen van deze studie.
Nieuwe toedieningswegen: NovoTTF-100A, CED en gliadel rasters
NovoTTF-100A werd in een gerandomiseerde fase III-studie onderzocht bij 237 patiënten in vergelijking met
103
240
335
2
2
2
272
321
104
193
78
118
129
388
11
Gliomen
PDF aangemaakt op 
23-01-2025
533
/
971
een behandeling naar keuze van de behandelaar. Na een mediaan van twee lijnen therapie voorbehandeling
werd een mediane overleving van 6.6 versus 6 maanden waargenomen [Butowski 2013
, Stupp 2012
].
Toevoeging van gliadel rasters in een recidiefsetting geeft geen noemenswaardige overlevingswinst [De
Bonis 2012
]. Een systematische review liet slechts bij een selecte groep patiënten in recidiefsetting, waarbij
een haast complete resectie van het recidief werd verkregen, enige overlevingswinst zien [Perry 2007
]. De
PRECISE-studie was een fase III-studie die convection-enhanced delivery (CED) van cintredekin besudotox
vergeleek met gliadel rasters [Kunwar 2010
]. Dit toeleveringssysteem omzeilt de bloed-hersenbarrière via
een druk-gedreven infusieflow, waarbij een recombinant eiwit bestaande uit interleukine-13 en een
gemuteerde vorm van Pseudomonas toxine werd toegediend. Ondanks het feit dat IL-13-receptoren
overvloedig in glioblastoom aanwezig zijn, werd geen significante overlevingswinst aangetoond. Of CED met
andere middelen effectief kan zijn, is onvoldoende bekend; het wordt in diverse studies onderzocht.
Noodzaak voor verder onderzoek
Het niet kunnen aantonen van effectiviteit bij verschillende fase III-studies bij recidief (en nieuw
gediagnostiseerd) glioblastoom heeft geleid tot hernieuwd preklinisch en translationeel onderzoek [Yin
2013
]. Het glioblastoom wordt onderverdeeld in verschillende histologische subklassen op basis van
genetisch profiel en moleculaire diagnostiek [Colman 2008
], Verhaak 2010
]. Epidermale groeifactor (EGF)
en de receptor EGFR, platelet-derived groeifactor (PDGF) A en B en de receptoren PDGFR 
α
 en ß, vasculair
endotheliale groeifactor (VEGF) en de receptor VEGFR, insuline-like groeifactor-1 (IGF-1) en de receptor
(IGFR), transforming groeifactor-
α
 (TFG-
α
), fibroblast groeifactor (FGF) en hepatocytair groeifactor (HGF)
spelen een grote rol binnen het tumorproces bij het glioblastoom. Stimulering van deze receptoren stuurt
drie grote cascadeprocessen aan: mitogen-activated proteïne kinase (MAPK); fosfoïnositide 3 kinase
(PI3K/Akt); en fosfolipase C
γ
 (PLC
γ
) en proteïne kinase C (PKC). Deze processen reguleren celdeling,
differentiatie en voorkomen apoptose. Hierop richt zich het klinisch onderzoek naar de ontwikkeling van
doelgerichte therapie. Dit heeft geleid tot een reeks fase II-studies waarin verschillende klassen ‘biologicals',
tyrosine kinase remmers en antilichamen zijn en worden onderzocht [Weller 2013
, Quant 2010
]. Het
falen van een fase III-studie waarin imatinib, een PDGFR inhibitor, gecombineerd met hydroxyurea, een
ribonucleotide reductase remmer, werd onderzocht in vergelijking met hydroxyurea alleen, werd door
onderzoekers verklaard vanwege een gebrek aan kennis van moleculaire en genetische karakteristieken
[Dreseman 2010
]. Hoewel beide agentia in monotherapie geen effect lieten zien, leek een eerdere fase II-
studie met combinatiebehandeling overlevingswinst aan te tonen [Reardon 2005
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
40
333
73
256
186
398
63
365
378
267
83
271
Gliomen
PDF aangemaakt op 
23-01-2025
534
/
971
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
Gliomen
PDF aangemaakt op 
23-01-2025
535
/
971
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Gliomen
PDF aangemaakt op 
23-01-2025
536
/
971
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
Gliomen
PDF aangemaakt op 
23-01-2025
537
/
971
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
Gliomen
PDF aangemaakt op 
23-01-2025
538
/
971
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
Gliomen
PDF aangemaakt op 
23-01-2025
539
/
971
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
Gliomen
PDF aangemaakt op 
23-01-2025
540
/
971
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
Gliomen
PDF aangemaakt op 
23-01-2025
541
/
971
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
Gliomen
PDF aangemaakt op 
23-01-2025
542
/
971
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
Gliomen
PDF aangemaakt op 
23-01-2025
543
/
971
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
Gliomen
PDF aangemaakt op 
23-01-2025
544
/
971
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
Gliomen
PDF aangemaakt op 
23-01-2025
545
/
971
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
546
/
971
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
Gliomen
PDF aangemaakt op 
23-01-2025
547
/
971
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
Gliomen
PDF aangemaakt op 
23-01-2025
548
/
971
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
Gliomen
PDF aangemaakt op 
23-01-2025
549
/
971
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
Gliomen
PDF aangemaakt op 
23-01-2025
550
/
971
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
Gliomen
PDF aangemaakt op 
23-01-2025
551
/
971
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
Gliomen
PDF aangemaakt op 
23-01-2025
552
/
971
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
553
/
971
Behandeling van ouderen bij glioblastoom
Uitgangsvraag
Wat is de beste behandeling voor oudere patiënten met een glioblastoom?
Aanbeveling
Bij oudere patiënten (> 60 jaar) in slechte conditie (KPS < 70;) en met cognitieve functiestoornissen (MMSE
<27/30) is de levensverwachting ≤ 4-5 maanden en lijkt de beperkte potentiële overlevingswinst van
behandeling niet op te wegen tegen de belasting van de behandeling. De werkgroep is van mening dat in
deze groep afzien van behandeling een realistische optie is.
Bij patiënten van 60-70 jaar, bij wie het behandelteam verwacht dat chemoradiatie volgens het Stupp-
protocol te zwaar uitvalt (bijvoorbeeld door comorbiditeit, minder goede conditie en/of afwijkende MMSE),is
de werkgroep van mening dat MGMT-promotoranalyse ingezet kan worden. Bij gemethyleerde promotor
wordt de patiënt dan monotherapie met temozolomide aangeraden, bij een niet gemethyleerde promotor
een kort schema radiotherapie. Er is een risico op een foutpositieve uitslag van de MGMT-
promotormethylering waardoor voor een individuele patiënt het weglaten van radiotherapie zou kunnen
betekenen dat hem/haar een effectieve behandeling wordt onthouden.
Bij patiënten ouder dan 70 jaar wordt geadviseerd MGMT-promotoranalyse in te zetten. Bij een
gemethyleerde promotor wordt de patiënt dan monotherapie met temozolomide aangeraden, bij een niet
gemethyleerde promotor een kort schema radiotherapie. Slechts in uitzonderlijke gevallen (zeer goede
conditie en MMSE én resectie ondergaan én geen comorbiditeit) kan het behandelteam overwegen om in
overleg met de patiënt alsnog chemoradiatie volgens het Stupp-protocol toe te dienen.
Overwegingen
In het algemeen leidt behandeling van het glioblastoom met radiotherapie en/of chemotherapie niet tot
verbetering van de klinische toestand, wel mogelijk tot verlenging van de overleving. De klinische conditie en
levenskwaliteit van de patiënt op het moment van aanvang van de behandeling bepalen daarom in sterke
mate of en op welke manier de patiënt behandeld dient te worden. Diverse geriatrische beoordelingsschalen
zijn onderzocht in de oncologie en kunnen wellicht aanvullende informatie geven betreffende prognose, maar
de toegevoegde waarde hiervan staat niet vast [Puts 2014
. Leeftijd is een belangrijke prognostische factor
en gemiddeld hebben oudere patiënten een slechtere prognose dan jongere patiënten, hoewel oudere
patiënten met overigens gunstige prognostische factoren ook baat kunnen hebben van intensieve
behandeling. Over de leeftijd waarop een patiënt oud of ouder is, bestaat geen consensus en ook in studies
worden verschillende leeftijden aangehouden. Doorgaans wordt met ‘ouder' een leeftijd bedoeld vanaf 60
tot 70 jaar.
Bij patiënten tot 70 jaar is de meerwaarde van gecombineerde bestraling en temozolomide chemotherapie
aangetoond. Bij oudere patiënten is alleen monotherapie bestraling vergeleken met monotherapie
temozolomide. Combinatiebehandeling bij ouderen, met een kort schema radiotherapie gecombineerd met
266
Gliomen
PDF aangemaakt op 
23-01-2025
554
/
971
temozolomide, is onderzocht in de EORTC/NCIC-ouderenstudie maar hiervan zijn de resultaten nog niet
bekend. Eventueel kan in afwachting van de resultaten van deze studie bij oudere patiënten met een
gemethyleerde MGMT promotor ook temozolomide met een kort schema radiotherapie worden overwogen.
Onderbouwing
Conclusies
Het is aangetoond dat bij oudere patiënten (> 60 jaar) in slechte conditie (KPS < 70;) en/of met cognitieve
functiestoornissen (MMSE <27/30) de levensverwachting kort is (≤ 4-5 maanden). 
Curran 1993
, Mirimanoff 2006
, Stupp 2009
Het is aannemelijk dat bij oudere patiënten (> 60 jaar)in slechte conditie (KPS < 70;) en/of met cognitieve
functiestoornissen (MMSE <27/30) de beperkte potentiële overlevingswinst van de behandeling niet opweegt
tegen de belasting van de behandeling.
Roa 2004
, Slotman 1996
, McAleese 2003
Het is aannemelijk dat voor patiënten van 60-70 jaar met gunstige prognostische factoren (goede
performance status, KPS>70 én MMSE ≥27/30 én resectie ondergaan) behandeling met standaard 60 Gy
radiotherapie met gelijktijdig en adjuvant temozolomide zinvol kan zijn. Voor deze groep geldt dat de
mediane overleving langer is dan 12 maanden en dat bij hen, evenals bij jongere patiënten, de kans op
levensverlenging met standaard 60Gy gecombineerde chemoradiotherapie groter is dan bij radiotherapie
alleen.
Stupp 2009
, Stupp 2005
, Yin 2013
Het is aangetoond dat de methyleringsstatus van de MGMT-promotor bij oudere patiënten (> 60-65 jaar)
predictieve waarde heeft ten aanzien van behandeling met temozolomide. 
Malmstrom 2012
, Yin 2014a/b
 
Het is aannemelijk dat een lang schema radiotherapie geen voordeel biedt boven een kort schema bij oudere
patiënten. 
Roa 2004
, Malmstrom 2012
Het is aannemelijk dat bij patiënten vanaf 60-65 jaar, in geval van een gemethyleerde promotor,
temozolomide chemotherapie tenminste gelijkwaardig is aan bestraling. 
Malmstrom 2012
, Wick 2012
, Yin 2014
Het is aannemelijk dat ook oudere patiënten in een suboptimale conditie temozolomide chemotherapie
kunnen verdragen.
Gallego Perez-Larraya 2011
Het is aangetoond dat de bepaling van de methyleringsstatus van de MGMT-promotor geen volmaakte
sensitiviteit en specificiteit heeft. Er is een risico op een foutpositieve uitslag van de MGMT-
65
220
330
279
317
212
330
331
398
208
397
400
279
208
208
387
397
105
Gliomen
PDF aangemaakt op 
23-01-2025
555
/
971
promotormethylering waardoor voor een individuele patiënt het weglaten van radiotherapie zou kunnen
betekenen dat hem/haar een effectieve behandeling wordt onthouden.
Quillien 2012
, Vlassenbroeck 2008
Samenvatting literatuur
De prognose voor oudere patiënten met een glioblastoom is slechter dan voor jonge patiënten, zeker
wanneer de algehele conditie of mentale status verminderd is. Het is de vraag of standaardbehandeling met
radiotherapie en gelijktijdig en adjuvant temozolomide haalbaar en zinvol is bij deze patiëntenpopulatie
[Curran 1993
, Mirimanoff 2006
, Stupp 2009
]. Bij aanwezigheid van de volgende prognostisch
ongunstige variabelen; leeftijd > 60 jaar, Karnofsky performance status (KPS) < 70, MMSE < 27/30, niet
hebben ondergaan van een resectie, wordt de prognose slechter en neemt de winst van aanvullende
behandelingen af [Mirimanoff 2006
, Stupp 2009
]. Subgroepanalyses van de gerandomiseerde fase III-
EORTC/NCIC-studie 26981, waarin behandeling met 60 Gy radiotherapie vergeleken werd met
gecombineerd 60 Gy radiotherapie en temozolomide, laten echter zien dat ook bij oudere patiënten (60-70
jaar) met gunstige prognostische factoren (ruime resectie, goede performance status en MMSE > 27/30) de
mediane overleving meer dan twaalf maanden is [Stupp 2009
, Stupp 2005
]. In een prospectieve serie van
42 opeenvolgende patiënten ouder dan 65 jaar (mediaan 71,3 jaar) bleek deze behandeling haalbaar bij 70%
van de patiënten, zonder behandelinggeïnduceerde toxiciteit, en was de prognose significant beter bij
patiënten met een KPS ≥ 80% [Fiorica 2010
]. Hoewel er geen andere gerandomiseerde studies beschikbaar
zijn, ondersteunt een recente meta-analyse van niet gerandomiseerde studies overlevingswinst met deze
behandeling ook voor patiënten ouder dan 65 jaar. In deze meta-analyse zijn ook patiënten boven de 80 jaar
geïncludeerd en, overeenkomstig de subgroepanalyse van de EORTC-26981-studie, was de winst van de
gecombineerde behandeling het grootste bij de patiënten met een goede performance status die een
resectie hadden ondergaan [Yin 2013
].Veel oudere patiënten zijn echter in een minder goede conditie of
hebben geen resectie ondergaan, waardoor de prognose beduidend slechter is [Curran 1993
, Chaichana
2011
].
Om deze patiënten een acceptabele maar minder belastende behandeling te kunnen aanbieden is een aantal
studies verricht. Behandeling met een kort schema radiotherapie is vergeleken met een lang schema
(standaard, 60 Gy) in een gerandomiseerde studie bij 100 patiënten van 60 jaar of ouder. Er werd geen
verschil gevonden in overleving na behandeling met 40 Gy in 15 fracties in vergelijking met 60 Gy in 30
fracties [Roa 2004
]. Enkele niet-gerandomiseerde studies toonden een vergelijkbaar resultaat met een
mediane overleving van 4-6 maanden [Roa 2004
, Slotman 1996
, McAleese 2003
]. Behandeling met
radiotherapie werd vergeleken met alleen ondersteunende therapie in een gerandomiseerde studie bij 85
patiënten van ≥ 70 jaar met een KPS van ≥ 70. Na alleen ondersteunende therapie werd een mediane
overleving gevonden van 16,9 weken en na 50 Gy gefractioneerde radiotherapie was de mediane overleving
29.3 weken [Keime-Guibert 2007
]. Oudere patiënten in een minder goede conditie (KPS < 70) zijn in deze
studies niet geïncludeerd; wel bleek uit een fase II-studie met 70 patiënten dat deze populatie behandeling
met temozolomide kan verdragen (13-14% neutro- en thrombopenie) en dat dit leidt tot een mediane
overleving van 25 weken (95%CI 19 tot 28 weken) [Gallego Perez-Larraya 2011
].
Of radiotherapie of temozolomide de voorkeur verdient bij oudere patiënten met een glioblastoom werd
onderzocht in twee gerandomiseerde fase III-studies. In de Nordic-studie werden 342 patiënten van 60 jaar of
268
367
65
220
330
220
330
330
331
99
398
65
47
279
280
317
212
166
105
Gliomen
PDF aangemaakt op 
23-01-2025
556
/
971
ouder gerandomiseerd voor behandeling met een kort schema radiotherapie (10 x 3.4 Gy), TMZ
chemotherapie (tot 6 kuren, 200 mg/d op dag 1-5/28) of een standaardschema radiotherapie (30 x 2 Gy)
[Malmstrom 2012
]. De overleving was langer voor patiënten die met temozolomide werden behandeld,
dan met een lang schema radiotherapie (8,5 vs. 6 mnd.; hazard ratio [HR] 0·70; 95%CI 0·52-0·93, p=0·01). Bij
patiënten boven de 70 jaar leidde bovendien een kort schema radiotherapie tot een langere overleving dan
een lang schema radiotherapie. Van de patiënten die werden behandeld met temozolomide hadden degenen
met een gemethyleerde MGMT- promotor een langere overleving dan die met een niet-gemethyleerde
MGMT-promotor (9,7 maanden [95%CI 8,0-11,4] vs.6,8 maanden [5,9-7,7]; HR 0,56 [95%CI 0,34-0,93],
p=0·02) [Malmstrom 2012
]. In de NOA 08-studie werden 373 patiënten van 65 jaar of ouder
gerandomiseerd tussen standaard radiotherapie (30 x 2 Gy) en dose-dense temozolomide (100 mg/m2/d op
dag1-7 en 15-21/28) [Wick 2012
]. Er was geen verschil in mediane overleving tussen de twee groepen,
getest volgens non-inferiority principe: 8,6 mnd. (95%CI 7,3-10,2) in de TMZ-groep versus 9,6 mnd. (95%CI
8,2-10,8) in de radiotherapiegroep (hazard ratio [HR] 1,09; 95%CI 0,84-1,42, p-non-inferiority=0,033). Hoewel
deze twee studies een verschillende dosering temozolomide gebruikten, is het niet waarschijnlijk dat dat de
resultaten heeft beïnvloed: een gerandomiseerde fase III-studie toonde geen verschil in effectiviteit aan
tussen adjuvant dose-dense temozolomide en adjuvante standaard dosering bij patiënten met een
glioblastoom [Gilbert 2013
].
In deze studies is de combinatie van een kort schema radiotherapie met chemotherapie niet onderzocht;
hiertoe is de EORTC/NCI-ouderenstudie (clinicaltrials.gov NCT00482677) opgezet, waarvan de inclusie
compleet is maar de resultaten nog niet bekend zijn.
In een meta-analyses van studies naar radiotherapie en temozolomide bij oudere glioblastoompatiënten blijkt
dat bij patiënten met gemethyleerde MGMT-promotor in hun tumor temozolomide effectiever was dan
radiotherapie voor verbetering van de overleving (temozolomide vs. radiotherapie: HR 0,66; 95%CI 0,47-0,93)
terwijl het tegenovergestelde gold voor patiënten met niet-gemethyleerde tumoren (HR 1,32; 95%CI 1.00-
1.76) [Yin AA 2014a/b
 
].
Hoewel in diverse studies MGMT-promotormethylering voorspellend was voor effectiviteit van temozolomide
is de praktijk van de bepaling niet eenvoudig. Diverse methodes voor het onderzoeken van de
methyleringsstatus zijn in gebruik en de uitslagen van de verschillende methodes voor individuele patiënten
zijn lang niet altijd in overeenstemming met elkaar [Quillien 2012
]. Bovendien bepaalt de keuze van het
afkappunt of de test een hogere sensitiviteit of specificiteit zal hebben [Vlassenbroeck 2008
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
208
208
387
110
397
400
268
367
Gliomen
PDF aangemaakt op 
23-01-2025
557
/
971
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
Gliomen
PDF aangemaakt op 
23-01-2025
558
/
971
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
Gliomen
PDF aangemaakt op 
23-01-2025
559
/
971
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Gliomen
PDF aangemaakt op 
23-01-2025
560
/
971
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
Gliomen
PDF aangemaakt op 
23-01-2025
561
/
971
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Gliomen
PDF aangemaakt op 
23-01-2025
562
/
971
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
Gliomen
PDF aangemaakt op 
23-01-2025
563
/
971
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
Gliomen
PDF aangemaakt op 
23-01-2025
564
/
971
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
Gliomen
PDF aangemaakt op 
23-01-2025
565
/
971
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Gliomen
PDF aangemaakt op 
23-01-2025
566
/
971
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
Gliomen
PDF aangemaakt op 
23-01-2025
567
/
971
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
Gliomen
PDF aangemaakt op 
23-01-2025
568
/
971
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
Gliomen
PDF aangemaakt op 
23-01-2025
569
/
971
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
Gliomen
PDF aangemaakt op 
23-01-2025
570
/
971
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
Gliomen
PDF aangemaakt op 
23-01-2025
571
/
971
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
Gliomen
PDF aangemaakt op 
23-01-2025
572
/
971
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
Gliomen
PDF aangemaakt op 
23-01-2025
573
/
971
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
Gliomen
PDF aangemaakt op 
23-01-2025
574
/
971
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
Gliomen
PDF aangemaakt op 
23-01-2025
575
/
971
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
576
/
971
Indicatie geriatrisch assessment
Uitgangsvraag
Bij welke patiënten met een middels pathologie bevestigd glioom en een indicatie voor behandeling is een
geriatrisch assessment geïndiceerd?
Aanbeveling
Verzamel zoveel mogelijk informatie die relevant is om de winst en risico’s van de verschillende
behandelmogelijkheden op korte en lange termijn zo goed mogelijk in te schatten evenals de
levensverwachting en kwaliteit van leven met en zonder behandeling. Betrek hierbij eventueel de huisarts.
Inventariseer aanvullend samen met de patiënt en/of naaste(n) de levensvisie, beleving en persoonlijke
behandeldoelen van de patiënt met een middels pathologie bewezen glioom.
 
Overweeg een geriater,  of verpleegkundig specialist geriatrie te betrekken indien er sprake is van één of
meerdere van onderstaande factoren:
- aanwijzingen voor kwetsbaarheid, aan de hand van een screeningsinstrument (bijvoorbeeld de ‘geriatric 8’
aangevuld met MMSE of 6CIT voor het in kaart brengen van cognitief functioneren),
- uitgebreide comorbiditeit met het risico op behandelcomplicaties (bijv. meer toxiciteit),
- polyfarmacie met risico van interacties met bijvoorbeeld chemotherapie,
- KPS tussen 60 en 70,
- twijfel bij behandelteam en/of patiënt/naasten over meest geschikte behandeling,
- twijfel over de wilsbekwaamheid van de patiënt.
 
Maak de definitieve behandelkeuze in samenspraak met patiënt en diens naaste(n).
Overwegingen
Het doel van deze uitgangsvraag was om te achterhalen of het uitvoeren van een geriatrisch assessment bij
oudere (kwetsbare) patiënten tot betere uitkomsten leidt, dan wanneer een geriatrisch assessment niet is
uitgevoerd. Hiervoor is geen literatuur gevonden. Daarom kunnen er op basis van systematisch gevonden
literatuur geen conclusies getrokken worden, en worden de aanbevelingen onderbouwd in de overwegingen.
 
Voor- en nadelen van de interventie en de kwaliteit van het bewijs
Het IDH wildtype glioblastoom, WHO graad 4, is de meest voorkomende primaire hersentumor bij
volwassenen, zeker bij ouderen. Hogere leeftijd is zowel een negatieve prognostische factor als ook een
risicofactor voor het optreden van bijwerkingen/toxiciteit van behandeling. Dit kan een nadelige invloed
hebben op de kwaliteit van leven. De groep oudere patiënten is meer heterogeen dan de jongere
patiëntengroep, waarbij rekening gehouden moet worden met comorbiditeit, fysiek en cognitief functioneren
en mate van zelfredzaamheid. Derhalve zijn de biologische leeftijd en fitheid belangrijker gebleken dan
kalenderleeftijd. (Balducci, 2005; Colloca, 2020) Indien de fitheid van de oudere patiënt niet correct wordt
ingeschat, bestaat het risico van onder- of overbehandeling, met als gevolg afname van kwaliteit van leven.
 
In diverse studies wordt gerefereerd aan Balducci (Balducci, 2005), die oudere oncologische patiënten indeelt
Gliomen
PDF aangemaakt op 
23-01-2025
577
/
971
in 3 categorieën: de zogenoemde Balducci 1 zijn de fitte ouderen die volledig zelfredzaam zijn zonder
comorbiditeit. Deze groep kan meestal dezelfde behandeling ondergaan als jongere patiënten. De tweede
categorie (Balducci 2) is de ‘kwetsbare oudere’, met 1-2 comorbiditeiten en/of beperkingen in ADL. Bij deze
groep patiënten zal de (standaard)behandeling moeten worden aangepast. De derde groep (Balducci 3) of
‘‘unfit elderly’’, betreft patiënten die 3 of meer comorbiditeiten hebben, ADL afhankelijk zijn, of een
progressief geriatrisch syndroom hebben. Bij deze groep lijkt de beperkte potentiële overlevingswinst van
behandeling niet op te wegen tegen de belasting van de behandeling.
 
Momenteel wordt fitheid – naast anamnese van patiënt en naaste(n) – vastgesteld met behulp van de
Karnofsky Performance Scale (KPS), European Organization for Research and Treatment of Cancer (EORTC)
classificatie van de WHO en Mini-Mental State Examination (MMSE). Dit zijn echter breed screenende
instrumenten die niet specifiek ontwikkeld zijn voor de neuro-oncologische patiënt.
 
Bij neuro-oncologische patiënten is het belangrijk de beoordeling van de cognitie mee te nemen in het
vaststellen van eventuele behandelopties. Cognitieve stoornissen hebben namelijk invloed op de
therapietrouw en de toxiciteit gerelateerd aan behandeling en daardoor op het vroegtijdig staken van
behandeling (Colloca, 2020). Cognitieve stoornissen kunnen derhalve als negatief prognostische factor
worden beschouwd. Cognitieve stoornissen kunnen ook van invloed zijn op de wilsbekwaamheid van een
patiënt (kan de patiënt zelf een adequate beslissing nemen ten aanzien van wel/geen behandeling en begrijpt
hij/zij de consequenties van zijn/haar keuze).
 
De gouden standaard om fitheid en kwetsbaarheid te beoordelen is een geriatrisch assessment, ook wel
‘Comprehensive Geriatric Assessment’ (CGA) genoemd. Het belangrijkste doel van zo’n CGA   is het
voorkomen of vertragen van functionele achteruitgang. In de Nederlandse richtlijn ‘Comprehensive Geriatric
Assessment 2021’ wordt aanbevolen om een risico-inschatting te maken op het risico op negatieve
uitkomsten als er behandeling wordt overwogen met een hoog risico op complicaties en/of functionele
achteruitgang, er potentieel beperkte opbrengst te verwachten is of wanneer er twijfel is over de
belastbaarheid van de patiënt. Omdat het uitvoeren van een CGA door een klinisch geriater arbeidsintensief
is, is het raadzaam om de patiënten te selecteren die baat kunnen hebben bij een CGA. Dit kan gebeuren aan
de hand van meetinstrumenten, waaronder de VMS-vragen (veiligheidsmanagementsysteem) of de G8
(‘Geriatric 8’) vragenlijst. Deze laatste vragenlijst is het meest gevalideerde screeningsinstrument binnen de
oncologische populatie. De G8 vragenlijst is speciaal ontwikkeld voor de oudere kankerpatiënt en heeft een
sensitiviteit van > 80% in 6 studies en een specificiteit van > 60% in 4 studies (Bruijnen, 2020). De vragenlijst
bestaat uit 8 vragen: afname van voedingsinname, gewichtsverlies, mobiliteit, neuropsychologische
problemen, BMI, polyfarmacie, inschatting eigen gezondheidstoestand en leeftijd (Bruijnen, 2020). De totale
score bedraagt 17 en de score is afwijkend indien deze ≤ 14 is. De afname duurt ongeveer 2 minuten. Een
beperking van de vragenlijst is de beperkte aandacht voor cognitieve problemen, welke – zoals hierboven
reeds vermeld – een belangrijk aspect zijn voor de prognose van de neuro-oncologische patiënt. Er wordt
derhalve geadviseerd om additioneel een MMSE of 6CIT af te nemen (richtlijn CGA).
 
Wanneer een patiënt vanuit de G8 mogelijk kwetsbaar is gebleken, kan worden overwogen een patiënt naar
de geriater of internist ouderengeneeskunde te verwijzen voor een uitgebreidere beoordeling. Deze
uitgebreidere beoordeling bestaat uit tenminste de volgende onderdelen : anamnese en hetero-anamnese
Gliomen
PDF aangemaakt op 
23-01-2025
578
/
971
ten aanzien van mate van zelfredzaamheid, voedingsstatus, vallen en mobiliteit, sociale omstandigheden,
steunsysteem, cognitieve dan wel stemmingsstoornissen en eerder doorgemaakt delier. Naast
voorgenoemde aspecten moet er aandacht zijn voor de wensen en verwachtingen van de patiënt zelf. Het
doel van de beoordeling wordt omschreven als: het formuleren van een conclusie met betrekking tot
geriatrische kwetsbaarheid en de invloed daarvan op beleid/behandeltraject.
 
Hamaker (2018) verrichtte een systematische review naar het effect van een geriatrisch evaluatie op de
oncologische en niet-oncologische behandeling van ouderen (> 70 jaar) met kanker en is dus niet specifiek
gericht op onze populatie. Daarbij werden 36 publicaties uit 35 studies geïncludeerd. Bij mediaan 28%
(spreiding 8 tot 45%) van de oudere patiënten met kanker werd op basis van de gegevens van de geriatrische
evaluatie het oncologische behandelplan aangepast. Daarnaast werd in mediaan 72% van de patiënten
(spreiding 26 tot 100%) één of meer niet-oncologische interventies ingezet gericht op het verbeteren van de
uitgangspositie van de patiënt. Het uiteindelijke effect op de behandeluitkomsten was wisselend, waarbij
vaker de ingestelde behandeling kon worden gegeven (positief effect in 75% van de studies) en er minder
behandelings-gerelateerde complicaties of toxiciteit optraden (positief effect in 55% van de studies).
 
Hoewel er geen vergelijkende studies zijn gevonden over de meerwaarde van geriatrische assessments bij
oudere patiënten met een glioblastoom zijn er in de afgelopen jaren wel diverse studies gedaan naar de
inzetbaarheid en het effect van screeningslijsten en assessments bij deze patiënten. Dit vanuit een behoefte
aan verbetering van de wijze waarop voor oudere patiënten de behandelkeuze wordt gemaakt. Het
geriatrische assessment (CGA) is in deze studies het meest onderzochte/gebruikte en (waarschijnlijk) het
meest aanbevolen instrument. Ook in neuro-oncologische centra waar geriatrische beoordeling wordt ingezet
bij glioblastoom patiënten bij wie er twijfel is over de optimale behandeling blijkt dat een geriatrisch
assessment kan bijdragen om tot een weloverwogen behandelkeuze te komen.
 
Waarden en voorkeuren van patiënten (en evt. hun naasten/ mantelzorgers)
Patiënten met een behandelwens hebben vaak tot doel om tijd van leven te verlengen met behoud van
kwaliteit van leven, zodat ze de dingen kunnen blijven doen die voor hen belangrijk zijn. Hiervoor is een zo
passend mogelijke behandelkeuze van belang. Een extra consult bij een geriater (assessment) kost tijd en
energie voor patiënt en naasten, maar kan wel helpend zijn in het behalen van het doel. Daarnaast kan dit
consult aandachtspunten naar voren halen die bij de neurologische beoordeling onderbelicht zijn gebleven.
Om te beoordelen of een patiënt gebaat kan zijn bij een dergelijke beoordeling kan gebruik gemaakt worden
van een screeningsinstrument zoals de G8. Bij een vitale oudere patiënt zonder risicofactoren voor functionele
achteruitgang heeft een uitgebreide geriatrische beoordeling geen meerwaarde, dit zal ook gelden voor een
terminale patiënt. 
Kosten (middelenbeslag)
Het inzetten van uitgebreide geriatrische assessments is arbeidsintensief en kost tijd. Hamaker et al (2018)
hebben in hun systematische review laten zien dat een geriatrisch assessment wel inzichten ten aanzien van
optimale behandelmogelijkheden kan opleveren, echter is er hierbij niet gekeken naar kosteneffectiviteit. De
werkgroep acht het mogelijk dat door het voorkomen van overbehandeling extra consulten en
ziekenhuisopnames beperkt worden.
 
Gliomen
PDF aangemaakt op 
23-01-2025
579
/
971
Aanvaardbaarheid, haalbaarheid en implementatie
Het inzetten van arbeidsintensieve uitgebreide geriatrische assessments vraagt om voldoende capaciteit bij
de afdeling geriatrie (geriater of verpleegkundig specialist) of de interne geneeskunde (met name internist
ouderengeneeskunde) en het is de vraag of dat dit haalbaar is gezien de sterke vergrijzing en de daarmee
toenemende incidentie van gliomen. Het is derhalve van groot belang de juiste groep patiënten te selecteren
waarbij deze interventie meerwaarde zal hebben. Gezien de bevindingen uit de systematische review van
Hamaker et al (2018) zal het bij vermoedelijk een kwart van de patiënten een verandering in behandelplan
teweegbrengen en zit de grootste winst in het verbeteren van de uitgangspositie van de patiënt door niet-
oncologische interventies.
Onderbouwing
Achtergrond
Vanwege toenemende vergrijzing zal de incidentie van gliomen de komende decennia verder stijgen, met
name in de hogere leeftijdsgroepen. Patiënten met een hogere leeftijd zijn vaak ondervertegenwoordigd in
wetenschappelijke studies en een optimale behandelstrategie ontbreekt derhalve in deze groep.
Kalenderleeftijd komt vaak niet overeen met de biologische leeftijd van patiënten, waarbij kwetsbaarheid een
belangrijke parameter is. Behoud van kwaliteit van leven en autonomie zijn belangrijk, vaak belangrijker dan
verlengen van levensduur. In het algemeen leidt behandeling van het glioblastoom met radiotherapie en/of
chemotherapie niet tot verbetering van de klinische toestand, wel mogelijk tot verlenging van de overleving.
Het is derhalve belangrijk met de individuele patiënt te bespreken wat de wensen of behandeldoelen zijn. De
klinische conditie en levenskwaliteit van de patiënt op het moment van aanvang van de behandeling bepalen
daarom in sterke mate of en op welke manier de patiënt behandeld dient te worden. Het is onduidelijk of het
zinvol is om een geriatrische evaluatie uit te voeren bij oudere patiënten die potentieel in aanmerking komen
voor behandeling. Sommige instituten doen het wel, andere niet. Ook de aanpak en bij wie deze evaluatie
wordt uitgevoerd verschilt.
 
Voor de tekst in deze module geldt dat waar ‘geriater’ geschreven staat, ook een verpleegkundig specialist
geriatrie of internist ouderengeneeskunde gelezen kan worden.
Conclusies
All outcomes
No GRADE
 
No evidence was found regarding the effect of geriatric assessment on any outcome when
compared with no geriatric assessment in elderly (frail) patients with glioma who are
potentially eligible for treatment.
 
Zoeken en selecteren
A systematic review of the literature was performed to answer the following question: Does a geriatric
assessment in elderly (frail) patients with glioma lead to different outcomes?
 
Patients:
 Elderly (frail) patients (over 60 years old) with pathology confirmed glioma who are potentially
Gliomen
PDF aangemaakt op 
23-01-2025
580
/
971
eligible for treatment
Intervention:
 Geriatric evaluation
Control:
 No geriatric evaluation
Outcomes:
 Treatment options, treatment related complications, complete treatment, survival, quality of life,
patient satisfaction
 
Relevant outcome measures
The guideline development group considered quality of life and overall survival as a critical outcome measure
for decision making; and treatment related complications, complete treatment, patient satisfaction, number
of treatment options as an important outcome measure for decision making.
 
Treatment options: eligible for systemic therapy, radiotherapy and/or resection.
 
For the other outcomes, the working group did not define the outcome measures listed above but used the
definitions used in the studies.
 
Per outcome, the working group defined the following differences as a minimal clinically (patient) important
differences:
Overall survival: Benefit > 12 weeks or hazard ratio < 0.7
Quality of life: The minimum important difference (MID) has been estimated to be a difference of 0.08 or
more points for the EQ-5D utility index, seven or more points for the EQ-5D VAS (Pickard, 2007), or ≥10
points on the Karnofsky Performance Score (KPS).
Cognitive functioning: MMSE ≥3 points, EORTC cognitive functioning subscale ≥10 points.
Adverse events: lethal < 5% (absolute difference), acute or severe < 25%.
Treatment options/treatment completement: RR ≤0.8 or ≥1.25
 
Search and select (Methods)
The databases Medline (via OVID) and Embase (via Embase.com) were searched with relevant search terms
until December 2
 2021. The detailed search strategy is depicted under the tab Methods. The systematic
literature search resulted in 52 hits. Studies were selected based on the following criteria:
Systematic reviews (searched in at least two databases, and detailed search strategy, risk of bias
assessment and results of individual studies available), randomized controlled trials, or observational
comparative studies;
Full-text English language publication;
Studies including ≥ 20 (ten in each study arm) patients; and
Studies according to the PICO
Five studies were initially selected based on title and abstract screening. After reading the full text, all studies
were excluded (see the table with reasons for exclusion under the tab Methods), and no studies were
included.
 
Results
No studies were included in the analysis of the literature.
nd
Gliomen
PDF aangemaakt op 
23-01-2025
581
/
971
 
Level of evidence of the literature
No studies were included in the analysis of the literature.
Verantwoording
Laatst beoordeeld
 : 11-07-2023
Laatst geautoriseerd
 : 11-07-2023
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Balducci L, Cohen HJ, Engstrom PF, Ettinger DS, Halter J, Gordon LI, Kiel K, Kneier A, Lim D, Petersdorf SH, Rosenthal R,
Silliman R, Vose JM, Walker MJ, Zachariah B; National Comprehensive Cancer Network. Senior adult oncology clinical practice
guidelines in oncology. J Natl Compr Canc Netw. 2005 Jul;3(4):572-90. doi: 10.6004/jnccn.2005.0032. PMID: 16038647.
2
 - Bruijnen CP, Heijmer A, van Harten-Krouwel DG, van den Bos F, de Bree R, Witteveen PO, Emmelot-Vonk MH. Validation of
the G8 screening tool in older patients with cancer considered for surgical treatment. J Geriatr Oncol. 2021 Jun;12(5):793-798.
doi: 10.1016/j.jgo.2020.10.017. Epub 2020 Nov 8. PMID: 33172806.
3
 - Colloca G, Tagliaferri L, Capua BD, Gambacorta MA, Lanzotti V, Bellieni A, Monfardini S, Balducci L, Bernabei R, Cho WC,
Valentini V. Management of The Elderly Cancer Patients Complexity: The Radiation Oncology Potential. Aging Dis. 2020 May
9;11(3):649-657. doi: 10.14336/AD.2019.0616. PMID: 32489709; PMCID: PMC7220284.
4
 - Hamaker ME, Te Molder M, Thielen N, van Munster BC, Schiphorst AH, van Huis LH. The effect of a geriatric evaluation on
treatment decisions and outcome for older cancer patients - A systematic review. J Geriatr Oncol. 2018 Sep;9(5):430-440. doi:
10.1016/j.jgo.2018.03.014. Epub 2018 Apr 7. PMID: 29631898.
5
 - Richtlijn Behandeling kwetsbare ouderen bij chirurgie 2017. 
www.richtlijnendatabase.nl
6
 - Richtlijn Colorectaal carcinoom, 2021. 
www.richtlijnendatabase.nl
7
 - Richtlijn Comprehensive geriatric assessment 2021. 
www.richtlijnendatabase.nl
Gliomen
PDF aangemaakt op 
23-01-2025
582
/
971
Behandeling ouderen/kwetsbaren
Uitgangsvraag
Met welke aandachtspunten dient rekening gehouden te worden specifiek in de behandeling van
ouderen/kwetsbare patiënten met een glioblastoom?
Aanbeveling
Zie bij patiënten af van behandeling indien er sprake is van een Karnofsky performance status (KPS) < 70 of
ernstige cognitieve functiestoornissen.
 
Bespreek de wensen en verwachtingen van de patiënt, de te verwachten therapeutische winst en de
mogelijke nadelen van de behandelingen. Raadpleeg bij twijfel een geriater/verpleegkundig specialist
geriatrie/internist ouderengeneeskunde conform de aanbevelingen in module '
Indicatie geriatrisch
assessment
’.
 
Bij patiënten met een behandelindicatie en wens tot behandeling:
Bied bij patiënten boven 60 jaar ook chemoradiatie volgens het Perry protocol als alternatief voor het
standaard Stupp protocol aan in afwezigheid van comorbiditeit/polyfarmacie met risico op
behandelcomplicaties.
Bied bij patiënten boven 60 jaar monotherapie op basis van MGMT-status aan (monotherapie
temozolomide bij gemethyleerde MGMT-tumor en radiotherapie bij ongemethyleerde tumor) indien ze
geen gecombineerde behandeling aankunnen door comorbiditeit of verhoogd risico op
behandelcomplicaties.
Overwegingen
Het doel van deze uitgangsvraag was om te achterhalen wat de waarde van oncologische behandeling is bij
oudere patiënten met een nieuw gediagnosticeerd glioblastoom is. Er is één Cochrane systematische review
met netwerk meta-analyse gevonden die oncologische behandeling vergeleek met ondersteunende
(palliatieve) zorg (Hanna, 2020). Naast enkele methodologische beperkingen waren de studiepopulaties
relatief klein. Bewijskracht voor de kritieke uitkomstmaten (progressievrije overleving, totaaloverleving en
kwaliteit van leven) was laag tot zeer laag. Dit betekent dat andere studies kunnen leiden tot nieuwe
inzichten. Er kunnen op basis van de literatuur alleen geen sterke aanbevelingen geformuleerd worden over
de toegevoegde waarde van oncologische behandeling voor oudere patiënten met nieuw gediagnosticeerde
glioblastoom.
 
Voor- en nadelen van de interventie en de kwaliteit van het bewijs
Op basis van de studies door Mirimanoff (2006) en Stupp (2009) concludeert de werkgroep dat de prognose
voor patiënten met een glioblastoom slechter is bij aanwezigheid van de volgende prognostisch ongunstige
variabelen: leeftijd > 60 jaar, Karnofsky performance status (KPS) < 70, MMSE < 27/30, niet hebben
Gliomen
PDF aangemaakt op 
23-01-2025
583
/
971
ondergaan van een resectie en afwezigheid van MGMT promotor hypermethylatie. Met aanwezigheid van
deze ongunstige variabelen  wordt de prognose slechter en neemt de winst van aanvullende behandelingen
af (Mirimanoff, 2006; Stupp, 2009).
 
In de beschreven meta-analyse van Hanna (2020) wordt een winst op overall survival (OS) beschreven bij het
toedienen van chemoradiatie bij ouderen van 70 jaar. Subgroepanalyse naar leeftijdsgroepen of MGMT
status was helaas niet mogelijk wegens onvoldoende beschikbare geaccumuleerde data (Hanna, 2020). In de
studies waar wel MGMT data beschikbaar was, ziet de werkgroep een overlevingsvoordeel (Minniti, 2012;
Perry, 2017). In de studie van Perry (2017) werden 562 patiënten gerandomiseerd tussen chemoradiatie of
radiotherapie, 281 per behandelarm. De mediane totale overleving was langer met chemoradiatie dan met
radiotherapie alleen (9,3 maanden vs. 7,6 maanden; hazard ratio (HR) voor overlijden, 0,67; 95%
betrouwbaarheidsinterval (CI), 0,56 tot 0,80; P<0,001), evenals de mediane progressievrije overleving (5,3
maanden versus 3,9 maanden; hazard ratio voor ziekteprogressie of overlijden, 0,50; 95% BI, 0,41 tot 0,60;
P<0.001). Bij 165 patiënten met MGMT gemethyleerde glioblastoom was de mediane totale overleving 13,5
maanden met chemoradiatie en 7,7 maanden met alleen radiotherapie (hazard ratio voor overlijden, 0,53;
95% BI: 0,38 tot 0,73; p-waarde <0,001). Kwaliteit van leven bleef onveranderd tussen beide groepen.
 
In de Nordic-studie werden 342 patiënten van 60 jaar of ouder gerandomiseerd voor behandeling met een
kort schema radiotherapie (10 x 3,4 Gy), temozolomide chemotherapie (tot 6 kuren, 200 mg/d op dag 1-5/28)
of een standaardschema radiotherapie (30 x 2 Gy) (Malmstrom, 2012). De overleving was langer voor
patiënten die met temozolomide werden behandeld, dan met een lang schema radiotherapie (8,5 vs. 6 mnd;
hazard ratio [HR] 0·70; 95%BI: 0,52 tot 0,93, p=0,01). Bij patiënten boven de 70 jaar leidde bovendien een
kort schema radiotherapie tot een langere overleving dan een lang schema radiotherapie. Van de patiënten
die werden behandeld met temozolomide hadden degenen met een gemethyleerde MGMT- promotor een
langere overleving dan die met een niet-gemethyleerde MGMT-promotor (9,7 maanden (95% BI:  8,0 tot
11,4) versus 6,8 maanden (5,9 tot 7,7); HR 0,56 (95%BI: 0,34 tot 0,93), p-waarde=0,02) (Malmstrom, 2012). In
de NOA 08-studie werden 373 patiënten van 65 jaar of ouder gerandomiseerd tussen standaard
radiotherapie (30 x 2 Gy) en dose-dense temozolomide (100 mg/m2/d op dag 1-7 en 15-21/28) (Wick, 2012).
Er was geen verschil in mediane overleving tussen de twee groepen, getest volgens non-inferiority principe:
8,6 mnd. (95% BI: 7,3 to 10,2) in de TMZ-groep versus 9,6 mnd. (95%BI: 8,2 tot 10,8) in de
radiotherapiegroep (HR 1,09; 95% BI: 0,84 tot 1,42, p-non-inferiority= 0,033). Zowel de NOA-08 als de
Nordic studie zijn opgenomen in de meta-analyse door Hanna (2020), echter niet individueel uitgelicht.
Hoewel deze twee studies een verschillende dosering temozolomide gebruikten, acht de werkgroep het niet
waarschijnlijk dat dit de resultaten heeft beïnvloed: een gerandomiseerde fase III-studie toonde geen verschil
in effectiviteit aan tussen adjuvant dose-dense temozolomide en adjuvante standaard dosering bij patiënten
met een glioblastoom (Gilbert, 2013). Hypogefractioneerde schema’s zijn niet inferieur aan standaard
bestralingsschema’s volgens deze review (de Melo, 2020). De verminderde belasting in tijd en verminderd
risico op bijwerkingen zijn argumenten ten voordele van hypofractionering.
 
In een meta-analyse van studies naar radiotherapie en temozolomide bij oudere glioblastoompatiënten blijkt
dat bij patiënten met gemethyleerde MGMT-promotor in hun tumor temozolomide effectiever was dan
radiotherapie voor verbetering van de overleving (temozolomide versus. radiotherapie: HR 0,66; 95%BI: 0,47
Gliomen
PDF aangemaakt op 
23-01-2025
584
/
971
tot 0,93) terwijl het tegenovergestelde gold voor patiënten met niet-gemethyleerde tumoren (HR 1,32; 95%BI
1,00 tot 1,76) (Yin, 2014).
 
Mits goede selectie op basis van patiënt- en tumorkarakteristieken acht de werkgroep dat therapievoordelen
(overleving en kwaliteit van leven) kunnen worden behaald zoals beschreven in meta-analyse (Nassiri, 2020).
 
Waarden en voorkeuren van patiënten (en evt. hun naasten/ mantelzorgers)
In de beslissing omtrent het te voeren beleid bij de oudere (>65 jaar), kwetsbare patiënt met een nieuw
gediagnosticeerd glioblastoom, zal te allen tijde de waarden en voorkeuren van de patiënt worden
meegenomen. Een belangrijk doel van een interventie is overlevingswinst met een acceptabele kwaliteit van
leven. Kwaliteit van leven zal voor de individuele patiënt verschillende waarden omvatten. Interventie kan er
echter ook voor zorgen dat de kwaliteit van leven achteruit gaat, bij de patiënt met een slechte initiële
uitgangssituatie, op basis van bijvoorbeeld de klinische conditie. Ook kan de keuze voor een interventie
zorgen voor frequente ziekenhuisbezoeken en dus extra belasting voor de patiënt opleveren. Dezen en
andere voor- en nadelen van een bepaalde interventie zullen door de behandelaar met de patiënt besproken
moeten worden waardoor er een weloverwogen afweging gemaakt kan worden of de belasting en impact
van een interventie voldoende meerwaarde voor hen heeft, afgewogen tegen de te verwachten
overlevingswinst en kwaliteit van leven (gedeelde besluitvorming).
 
Kosten (middelenbeslag)
Door patiënten beter te selecteren op behandelingen die haalbaar zijn op grond van objectieve parameters
kunnen best mogelijk behandeling leiden tot minder zorgbelasting (minder bezoeken aan het ziekenhuis,
minder bijwerkingen, kortere behandeltijd). Volgens de Dutch Brain Tumor Registry (DBTR) hebben 35% van
de glioblastoompatiënten ouder dan 70 jaar in de periode 2014 – 2017geen nabehandeling na operatie
gehad. 25% had enkel radiotherapie, 10% enkel temozolomide monotherapie en 30% een vorm van
gecombineerd schema. In dit rapport wordt geen gewag gemaakt over de overleving of levenskwaliteit per
behandeltype in deze categorie patiënten. Het is dus realistisch aan te nemen dat 65% van de oudere
patiënten na de diagnose een vorm van nabehandeling krijgt. Aangezien MGMT bepaling al standaard in het
diagnose pakket zit voor deze leeftijdscategorie, kan in het multidisciplinair overleg beter worden ingespeeld
op het type patiënt en tumor met een op maat gemaakte behandeling, leidend tot minder afgebroken
behandelingen door bijwerkingen of progressie. Uitgaande van 40% kans op aantreffen MGMT
gemethyleeerde tumor, verwacht de werkgroep dat het aandeel nabehandelde patiënten met chemotherapie
alleen zal stijgen naar 15 – 26%. Als we uitgaan dat de helft van de resterende patiënten chemoradiatie krijgt
en de andere helft radiotherapie, komen beide groepen rond 20 – 25% aandeel uit. Een kleinere groep zal de
gecombineerde behandeling krijgen, waarbij met een gehypofractioneerd schema men minder vaak naar het
ziekenhuis zal hoeven komen en men meer patiënten met dezelfde middelen kan behandelen. Minder
blootstelling aan zware behandelingschema’s leidt tot minder bijwerkingen en ziekenhuisopname. Kosten
zullen volgens de werkgroep enigszins gereduceerd worden, maar omdat deze behandelvormen naast
radiotherapie geen dure medicatie bevatten zal het qua besparing beperkt zijn.
 
Aanvaardbaarheid, haalbaarheid en implementatie
Gliomen
PDF aangemaakt op 
23-01-2025
585
/
971
De randvoorwaarde is om leeftijd niet als een beperking te beschouwen, maar als een gegeven naast de
overige prognostische factoren. Op basis van een volledig beeld gebaseerd op patiënt en
tumorkarakteristieken kan een arts het gesprek met de patiënt starten waarin de mogelijkheden en
uitdagingen liggen per behandeloptie in een proces van gedeelde besluitvoering. Gezien de soms beperkte
winst in prognose is het van belang om altijd de optie symptoomgericht in plaats van tumorgericht handelen
te bespreken. Bij twijfel kan de hulp van de huisarts voor context bepaling en van de geriater voor
ondersteunende maatregelen tijdens behandelen ingeroepen worden.
 
Rationale van de aanbeveling: weging van argumenten voor en tegen de interventies
Over de leeftijd waarop een patiënt oud of ouder is, bestaat geen consensus en ook in studies worden
verschillende leeftijden aangehouden. Doorgaans wordt in de internationale literatuur met ‘ouder' een
leeftijd bedoeld vanaf 60 of 70 jaar.
Aan oudere patiënten met goede Karnofsky performance status (KPS) ≥ 70, MMSE ≥ 27/30 (indien verricht bij
verdenking op cognitieve stoornissen), status na resectie en in aanwezigheid van MGMT-promotor
hypermethylatie kan volgens de werkgroep een chemoradiatie schema volgens de studie van Perry (2017)
worden aangeboden. Het betreft hypogefractioneerde bestraling van 15 sessies tot 40 Gy met gelijktijdig
temozolomide 75 mg/m2 gevolgd door zes postradiatiekuren temozolomide 200 mg/m2 dagen 1-5 elke 4
weken. Voor oudere patiënten met een of meer ongunstige prognostische factoren, maar die volgens de
eigen behandelaar wel nog in aanmerking voor aanvullende behandeling komen, kan op basis van MGMT-
status monotherapie hypogefractioneerde radiotherapie (ongemethyleerde tumoren) of monotherapie
temozolomide (gemethyleerde tumoren) met de patiënt en zijn naasten worden besproken. Naar analogie
met de NOA-08 studie zou een maximale behandelduur met TMZ van één jaar een overweging kunnen zijn.
Onderbouwing
Achtergrond
In de huidige situatie zijn er nog onvoldoende handvatten over welke overwegingen leiden tot de keuze van
het behandelbeleid bij de oudere (> 65 jaar oud) kwetsbare patiënt met een nieuw gediagnosticeerd
glioblastoom, welke in voldoende conditie verkeert om potentieel in aanmerking te komen voor een
behandeling. In verband met de vergrijzing van de bevolking zal deze vraag in de klinische praktijk steeds
vaker aan de orde zijn. De werkgroep heeft een advies geformuleerd over de overwegingen die een rol
kunnen spelen bij de keuze voor oncologische behandeling (bijvoorbeeld neurochirurgie, radiotherapie,
chemoradiotherapie, systemische therapie (inclusief chemotherapie)) dan wel best supportive care in deze
populatie.
Verdiepende informatie over de specifieke therapieën kunt u vinden in de betreffende modules, dat wil
zeggen de informatie over resectie, chemotherapie en radiotherapie wordt beschreven in de modules
behandeling hooggradig glioom, respectievelijk over neurochirurgie, radiotherapie en chemotherapie/
systeemtherapie.
Conclusies
1.1 Progression free survival (critical)
Gliomen
PDF aangemaakt op 
23-01-2025
586
/
971
Low
GRADE
The evidence suggests radiotherapy increases progression free survival when compared
with no treatment (supportive care) in elderly people with newly diagnosed glioblastoma.
 
Source: Hanna, 2020
 
1.2 Overall survival (critical)
Very low
GRADE
The evidence is very uncertain about the effect of RT40, RT60, CRT, RT40+BEV-CRT, BEV-
CRT, or TMZ on overall survival compared with no treatment (supportive care) in elderly
people with newly diagnosed glioblastoma.
 
Sources: Hanna, 2020
 
2. Quality of life, any length of follow-up (critical)
Very low
GRADE
The evidence is very uncertain about the effect of radiotherapy on quality of life,
compared with no treatment (supportive care) in elderly people with newly diagnosed
glioblastoma.
 
Sources: Hanna, 2020
 
3. Adverse events (critical); 4. Objective response (important)
No GRADE
No information was found regarding the effect of oncological treatment on adverse events
or objective response when compared with no treatment (best supportive care) in patients
with newly diagnosed glioblastoma.
 
Source: -
 
5. Cognitive functioning, any length of follow-up (important)
Very low
GRADE
The evidence is very uncertain about the effect of radiotherapy on cognitive functioning
compared with no treatment (supportive care) in elderly people with newly diagnosed
glioblastoma.
 
Sources: Hanna, 2020
 
Comparison with neurosurgery
No GRADE
No information was found regarding the effect of neurosurgery on any outcome when
compared with no treatment (best supportive care) in elderly patients with newly
diagnosed glioblastoma.
 
Source: -
Samenvatting literatuur
Gliomen
PDF aangemaakt op 
23-01-2025
587
/
971
Description of studies
The selection of Hanna (2020) was performed in April 2019. Twelve studies were included in the review.
Studies either included only elderly (65+ years) or performed separate analyses on an elderly subgroup of
patients. Participants had newly diagnosed glioblastoma, receiving interventions including best supportive
care, hypofractionated radiotherapy, standard radiotherapy, temozolomide, chemoradiotherapy, bevacizumab
with chemotherapy, and bevacizumab with radiotherapy. A network meta-analysis was performed for overall
survival, using six studies. Other outcomes (progression free survival, health related quality of life and
cognition) were reported for the comparison between radiotherapy (50 Gy) and supportive care, by Keime-
Guibert (2007).
 
Table 1. Study characteristics
Study ID
Intervention
(n)
RT EQD2
ab2/ab10
Control (n)
Age
Baseline KPS
 
Wirsching,
2018
RT 40.0 Gy (25)
48Gy/43Gy
BEV_RT 40.0
Gy (50)
Median 70 (range 65-87)
90-100: 41 (55%)
70-80: 27 (36%)
≥60: 7 (9%)
 
Saran, 2016
CRT (33)
60Gy/60Gy
BEV_CRT
(39)
NR for subgroup
NR for subgroup
 
Keime-
Guibert, 2007
RT 50 Gy with
supportive
care (39)
51Gy/53Gy
Supportive
care only
(42)
RT 50: median 73 (range
70-85)
Supp care: median 75
(range 70-84)
70: 43 (53%)
80: 29 (36%)
90: 7 (9%)
100: 2 (2%)
 
Malmstrom,
2012
TMZ (42)
60Gy/60Gy
RT 60.0 Gy
(41)
Approx. median age: 70
(range 60-88)
NR for subgroups
 
46Gy/38Gy
RT 34 Gy
(40)
 
Perry, 2017
RT 40.05 Gy
(281)
48Gy/43Gy
CRT (281)
Approx. median age: 73
(range 65 to 90)
NR
 
Roa, 2004
RT 60.0 Gy (47)
60Gy/60Gy
 
48Gy/43Gy
RT 40.0 Gy
(48)
RT 60: mean age 72.4 (SD:
5.4)
RT 40: mean age 71.0 (SD:
5.5)
median 70 (IQR: 60-
80)
 
Wick, 2012
RT 60.0 Gy
(178)
60Gy/60Gy
TMZ (195)
RT 60: median 72 (range
66-84)
TMZ: median 71 (range 66-
82)
Median 80 (range
60-100)
 
Abbreviations: ab2: alpha/beta ratio for central nervous system tissue; ab10: alpha/beta ratio for tumor;
BEV_(C)RT, bevacizumab (chemo)radiotherapy; CRT, Chemoradiotherapy; EQD2, equivalent dose in 2Gy
based on the Linear Quadratic Model; KPS, Karnofsky Performance Score; NR, Not Reported; RT,
Radiotherapy; TMZ, temozolomide IQR:
Gliomen
PDF aangemaakt op 
23-01-2025
588
/
971
 
Results
1. Survival (critical)
1.1 Progression free survival - radiotherapy 50 Gy versus supportive care
The outcome progression free survival was analyzed by Keime-Guibert (2007).  Median time to progression
was 14.9 weeks (95% CI 10.9 to 22.1) in participants receiving radiotherapy with supportive care, and 5.4
weeks (95% CI 4.4 to 7.6) in participants receiving supportive care only. The corresponding hazard ratio for
disease progression was 0.28 (95% CI 0.17 to 0.46). This difference was clinically relevant, favoring the group
receiving radiotherapy with supportive care.
 
1.2 Overall survival – network meta-analysis
The outcome overall survival was analyzed in a network using a total of seven RCTs (Wirsching, 2018; Saran,
2016, Keime-Guibert, 2007; Malmstrom, 2012; Perry, 2017; Roa, 2004; and Wick, 2012). Network estimates
for hazard ratios for overall survival are shown in table 2. The network is shown in figure 1.
 
Table 2. Network estimates for overall survival, reference supportive care only
Intervention (n)
Relative effect network meta-analysis, HR (95% CI)
Supportive care only (81)
1.0
RT 60.0 Gy (713)
0.47 (0.29 to 0.76)
BEV_RT (75)
0.48 (0.23 to 1.00)
RT 40.0 Gy (930)
0.44 (0.25 to 0.77)
TMZ (538)
0.42 (0.25 to 0.71)
CRT (635)
0.30 (0.17 to 0.53)
BEV_CRT (73)
0.25 (0.11 to 0.54)
Abbreviations: BEV_(C)RT, bevacizumab (chemo)radiotherapy; CRT, Chemoradiotherapy; RT, Radiotherapy;
TMZ, temozolomide
 
 
Figure 1. Network plot for overall survival
Gliomen
PDF aangemaakt op 
23-01-2025
589
/
971
 
2. Quality of life (critical) - radiotherapy 50 Gy versus supportive care
Health related quality of life was measured by Keime-Guibert (2007) at 30, 60, 90 and 135 days, using the
European Organization for Research and Treatment of Cancer Quality of life Questionnaire (EORTC QLQ-
C30) summary score (0-100), with higher scores indicating higher quality of life.
 
Quality of life (30 days)
At 30 days, mean quality of life in the group receiving radiotherapy with supportive care (n= 31) was 57.6 (SD
3.5). Mean quality of life in the group receiving supportive care (n= 28) was 61.8 (SD 4.7). This resulted in a
mean difference of -4.2 (95% CI -6.33 to -2.07). This difference was not clinically relevant.
 
Quality of life (60 days)
At 60 days, mean quality of life in the group receiving radiotherapy with supportive care (n= 23) was 56.6 (SD
3.9). Mean quality of life in the group receiving supportive care (n= 22) was 60.3 (SD 5). This resulted in a
mean difference of -4.7 (95% CI -7.33 to -2.07). This difference was not clinically relevant.
Gliomen
PDF aangemaakt op 
23-01-2025
590
/
971
 
Quality of life (90 days)
At 90 days, mean quality of life in the group receiving radiotherapy with supportive care (n= 22) was 49.1 (SD
4). Mean quality of life in the group receiving supportive care (n= 17) was 56.7 (SD 6.3). This resulted in a
mean difference of -7.6 (95% CI -11.03 to -4.17). This difference was not clinically relevant.
 
Quality of life (135 days)
At 135 days, mean quality of life in the group receiving radiotherapy with supportive care (n= 16) was 58.4
(SD 4.5). Mean quality of life in the group receiving supportive care (n= 10) was 48.1 (SD 6.7). This resulted in
a mean difference of 10.7 (95% CI 6.01 to 15.39). This difference was clinically relevant.
 
3. Adverse events (critical)
None of the RCTs assessed the effect of oncological treatment compared with no treatment (best supportive
care) in patients with newly diagnosed glioblastoma on adverse events.
 
4. Objective response (important)
None of the RCTs assessed the effect of oncological treatment compared with no treatment (best supportive
care) in patients with newly diagnosed glioblastoma on objective response.
 
5. Cognitive functioning (important) - radiotherapy 50 Gy versus supportive care
Cognition was measured by Keime-Guibert (2007) at 30, 60, 90 and 135 days, using the cognitive functioning
scale of the EORTC QLQ-C30 (0-100), with higher score indicating higher level of functioning. 
 
Cognitive functioning (30 days)
At 30 days, the mean score for cognitive functioning in the group receiving radiotherapy with supportive care
(n= 31) was 59.6 (SD 4.9). The mean score in the group receiving supportive care (n= 28) was 60 (SD 6.1). This
resulted in a mean difference of -0.4 (95% CI -3.24 to 2.44). This difference was not clinically relevant.
 
Cognitive functioning (60 days)
At 60 days, the mean score for cognitive functioning in the group receiving radiotherapy with supportive care
(n= 23) was 57.4 (SD 6.7). The mean score in the group receiving supportive care (n= 22) was 63 (SD 5.6). This
resulted in a mean difference of -5.6 (95% CI -9.2 to -2). This difference was not clinically relevant.
 
Cognitive functioning (90 days)
At 90 days, the mean score for cognitive functioning in the group receiving radiotherapy with supportive care
(n= 22) was 42.8 (SD 7.1). The mean score in the group receiving supportive care (n= 17) was 63.8 (SD 6.2).
This resulted in a mean difference of -21 (95% CI -25.18 to -16.82). This difference was clinically relevant.
 
Cognitive functioning (135 days)
At 135 days, the mean score for cognitive functioning in the group receiving radiotherapy with supportive
care (n= 16) was 43.8 (SD 6.7). The mean score in the group receiving supportive care (n= 10) was 56.8 (SD
7.8). This resulted in a mean difference of -13 (95% CI -18.84 to -7.16). This difference was clinically relevant.
 
Gliomen
PDF aangemaakt op 
23-01-2025
591
/
971
Level of evidence of the literature
1. Survival (critical)
1.1 Progression free survival
The level of evidence regarding the outcome measure progression free survival started as high because it was
based on an RCT and was downgraded by two levels to low because of 19/39 participants in the supportive
care only group underwent partial- or complete resection of the tumor (-1, bias due to indirectness) and a low
number of included patients (n= 81) (-1, imprecision). Because survival is an objective outcome and allocation
was centrally performed, the level of evidence was not downgraded for risk of bias.
 
1.2 Overall survival
RT40 & TMZ
: The level of evidence regarding the outcome overall survival started as high because it was
based on RCT’s and was downgraded by three levels to very low because the confidence interval crosses
both boundaries of clinical important difference (-3 imprecision).
RT60
: The level of evidence regarding the outcome overall survival was downgraded by three levels to very
low because the confidence interval crosses a boundary of clinical important difference (-1 imprecision),
heterogeneity (-1, inconsistency) and 19/39 participants in the supportive care only group underwent partial-
or complete resection of the tumor (-1, indirectness).
CRT, RT40+BEV-CRT, BEV-CRT
: The level of evidence regarding the outcome overall survival was
downgraded by three levels to very low because of study limitations (-1, risk of bias) and the confidence
interval crosses both boundaries of clinical important difference (-2, imprecision).
 
2. Quality of life (critical)
The level of evidence regarding the outcome measure quality of life started as high because it was based on
an RCT and was downgraded by three levels to very low because of lack of blinding and high attrition rates (-
2, risk of bias); and 19/39 participants in the supportive care only group underwent partial- or complete
resection of the tumor (-1, bias due to indirectness).
 
3. Adverse events (critical); 4. Objective response (important)
The level of evidence regarding the outcome measures adverse events and objective response was not
graded because of lack of data.
 
5. Cognitive functioning
The level of evidence regarding the outcome measure cognitive functioning started as high because it was
based on an RCT and was downgraded by three levels to very low because of lack of blinding and high
attrition rates (-2, risk of bias); and 19/39 participants in the supportive care only group underwent partial- or
complete resection of the tumor (-1, bias due to indirectness).
Zoeken en selecteren
The character of the clinical question was broad in order to meet the whole spectrum of potential treatment
paths a clinician considers when treating elderly (frail) patients. However, a more focused search question was
defined.
A systematic review of the literature was performed to answer the following question: What are the favorable
and unfavorable effects of oncologic treatment (i.e. neurosurgery, radiotherapy, systemic therapy (including
Gliomen
PDF aangemaakt op 
23-01-2025
592
/
971
chemotherapy) compared to no treatment in elderly (frail) patients with new diagnosed glioblastoma, who
qualify for treatment?
 
Patients
: Elderly (frail) patients (over 65 years old) with pathology confirmed glioblastoma who are potentially
eligible for treatment
Intervention
: Oncological treatment (including neurosurgery (resection/debulking), radiotherapy,
chemotherapy, chemoradiation, or systemic therapy)
Control
: No treatment after pathology confirmation (best supportive care)
Outcomes
: Objective Response, survival (progression-free, or overall), quality of life, cognitive functioning,
adverse events.
 
Relevant outcome measures
The guideline development group considered survival, quality of life and adverse events as a critical outcome
measure for decision making; and objective response and cognitive functioning as an important outcome
measure for decision making.
 
A priori, the working group did not define the outcome measures listed above but used the definitions used
in the studies.
 
Per outcome, the working group defined the following differences as a minimal clinically (patient) important
differences:
Survival (progression-free, or overall): hazard ratio < 0.7
Quality of life: The minimum important difference (MID) has been estimated to be a difference of 0.08 or
more points for the EQ-5D utility index, seven or more points for the EQ-5D VAS (Pickard, 2007), or ≥10
points on the Karnofsky Performance Score (KPS).
Cognitive functioning: EORTC cognitive functioning subscale ≥10 points.
Adverse events: lethal < 5% (absolute difference), acute or severe < 25%.
 
Search and select (Methods)
The databases Medline (via OVID) and Embase (via Embase.com) were searched with relevant search terms
until December 13
 2021. The detailed search strategy is depicted under the tab Methods. The systematic
literature search resulted in 109 hits. Studies were selected based on the following criteria:
Systematic reviews (searched in at least two databases, and detailed search strategy, risk of bias
assessment and results of individual studies available), randomized controlled trials;
Full-text English language publication;
Studies including ≥ 20 (ten in each study arm) patients; and
Studies according to the PICO
Nineteen studies were initially selected based on title and abstract screening. After reading full texts, one
systematic review with network meta-analysis was included (Hanna, 2020).
 
Results
One study was included in the analysis of the literature. Important study characteristics and results are
nd
Gliomen
PDF aangemaakt op 
23-01-2025
593
/
971
summarized in tables (see Table 1). The assessment of the risk of bias is summarized in the risk of bias tables.
Verantwoording
Laatst beoordeeld
 : 11-07-2023
Laatst geautoriseerd
 : 11-07-2023
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Gilbert MR, Wang M, Aldape KD, Stupp R, Hegi ME, Jaeckle KA, Armstrong TS, Wefel JS, Won M, Blumenthal DT, Mahajan
A, Schultz CJ, Erridge S, Baumert B, Hopkins KI, Tzuk-Shina T, Brown PD, Chakravarti A, Curran WJ Jr, Mehta MP. Dose-dense
temozolomide for newly diagnosed glioblastoma: a randomized phase III clinical trial. J Clin Oncol. 2013 Nov 10;31(32):4085-
91. doi: 10.1200/JCO.2013.49.6968. Epub 2013 Oct 7. PMID: 24101040; PMCID: PMC3816958.
2
 - Hanna C, Lawrie TA, Rogozi?ska E, Kernohan A, Jefferies S, Bulbeck H, Ali UM, Robinson T, Grant R. Treatment of newly
diagnosed glioblastoma in the elderly: a network meta-analysis. Cochrane Database Syst Rev. 2020 Mar 23;3(3):CD013261.
doi: 10.1002/14651858.CD013261.pub2. PMID: 32202316; PMCID: PMC7086476.
3
 - Keime-Guibert F, Chinot O, Taillandier L, Cartalat-Carel S, Frenay M, Kantor G, Guillamo JS, Jadaud E, Colin P, Bondiau
PY, Meneï P, Loiseau H, Bernier V, Honnorat J, Barrié M, Mokhtari K, Mazeron JJ, Bissery A, Delattre JY; Association of French-
Speaking Neuro-Oncologists. Radiotherapy for glioblastoma in the elderly. N Engl J Med. 2007 Apr 12;356(15):1527-35. doi:
10.1056/NEJMoa065901. PMID: 17429084.
4
 - Malmström A, Grønberg BH, Marosi C, Stupp R, Frappaz D, Schultz H, Abacioglu U, Tavelin B, Lhermitte B, Hegi ME, Rosell
J, Henriksson R; Nordic Clinical Brain Tumour Study Group (NCBTSG). Temozolomide versus standard 6-week radiotherapy
versus hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial.
Lancet Oncol. 2012 Sep;13(9):916-26. doi: 10.1016/S1470-2045(12)70265-6. Epub 2012 Aug 8. PMID: 22877848.
5
 - de Melo SM, Marta GN, Yan M, Cruz C, Moraes FY, Riera R. Management of elderly patients with glioblastoma: current
status with a focus on the post-operative radiation therapy. Ann Palliat Med. 2020 Sep;9(5):3553-3561. doi: 10.21037/apm-20-
768. Epub 2020 Aug 11. PMID: 32819127.
6
 - Minniti G, Lanzetta G, Scaringi C, Caporello P, Salvati M, Arcella A, De Sanctis V, Giangaspero F, Enrici RM. Phase II study of
short-course radiotherapy plus concomitant and adjuvant temozolomide in elderly patients with glioblastoma. Int J Radiat
Oncol Biol Phys. 2012 May 1;83(1):93-9. doi: 10.1016/j.ijrobp.2011.06.1992. Epub 2011 Nov 11. PMID: 22079725.
7
 - Mirimanoff RO, Gorlia T, Mason W, Van den Bent MJ, Kortmann RD, Fisher B, Reni M, Brandes AA, Curschmann J, Villa S,
Cairncross G, Allgeier A, Lacombe D, Stupp R. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. J Clin Oncol. 2006 Jun 1;24(16):2563-9.
doi: 10.1200/JCO.2005.04.5963. PMID: 16735709.
8
 - Nassiri F, Taslimi S, Wang JZ, Badhiwala JH, Dalcourt T, Ijad N, Pirouzmand N, Almenawer S, Stupp R, Zadeh G.
Determining the Optimal Adjuvant Therapy for Improving Survival in Elderly Patients with Glioblastoma: A Systematic Review
and Network Meta-analysis. Clin Cancer Res. 2020 Jun 1;26(11):2664-2672. doi: 10.1158/1078-0432.CCR-19-3359. Epub 2020
Jan 17. PMID: 31953312.
9
 - Perry JR, Laperriere N, O'Callaghan CJ, Brandes AA, Menten J, Phillips C, Fay M, Nishikawa R, Cairncross JG, Roa W,
Osoba D, Rossiter JP, Sahgal A, Hirte H, Laigle-Donadey F, Franceschi E, Chinot O, Golfinopoulos V, Fariselli L, Wick A,
Feuvret L, Back M, Tills M, Winch C, Baumert BG, Wick W, Ding K, Mason WP; Trial Investigators. Short-Course Radiation plus
Temozolomide in Elderly Patients with Glioblastoma. N Engl J Med. 2017 Mar 16;376(11):1027-1037. doi:
10.1056/NEJMoa1611977. PMID: 28296618.
1
0 - Roa W, Brasher PM, Bauman G, Anthes M, Bruera E, Chan A, Fisher B, Fulton D, Gulavita S, Hao C, Husain S, Murtha A,
Petruk K, Stewart D, Tai P, Urtasun R, Cairncross JG, Forsyth P. Abbreviated course of radiation therapy in older patients with
glioblastoma multiforme: a prospective randomized clinical trial. J Clin Oncol. 2004 May 1;22(9):1583-8. doi:
10.1200/JCO.2004.06.082. Epub 2004 Mar 29. PMID: 15051755.
Gliomen
PDF aangemaakt op 
23-01-2025
594
/
971
1
1 - Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R. Bevacizumab,
temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line
therapy. Neuro Oncol. 2016 Jul;18(7):991-1001. doi: 10.1093/neuonc/nov300. Epub 2016 Jan 24. PMID: 26809751; PMCID:
PMC4896538.
1
2 - Stupp R, Hegi ME, Mason WP, van den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K,
Hau P, Brandes AA, Gijtenbeek J, Marosi C, Vecht CJ, Mokhtari K, Wesseling P, Villa S, Eisenhauer E, Gorlia T, Weller M,
Lacombe D, Cairncross JG, Mirimanoff RO; European Organisation for Research and Treatment of Cancer Brain Tumour and
Radiation Oncology Groups; National Cancer Institute of Canada Clinical Trials Group. Effects of radiotherapy with
concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study:
5-year analysis of the EORTC-NCIC trial. Lancet Oncol. 2009 May;10(5):459-66. doi: 10.1016/S1470-2045(09)70025-7. Epub
2009 Mar 9. PMID: 19269895.
1
3 - Wick W, Platten M, Meisner C, Felsberg J, Tabatabai G, Simon M, Nikkhah G, Papsdorf K, Steinbach JP, Sabel M, Combs
SE, Vesper J, Braun C, Meixensberger J, Ketter R, Mayer-Steinacker R, Reifenberger G, Weller M; NOA-08 Study Group of
Neuro-oncology Working Group (NOA) of German Cancer Society. Temozolomide chemotherapy alone versus radiotherapy
alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol. 2012 Jul;13(7):707-15.
doi: 10.1016/S1470-2045(12)70164-X. Epub 2012 May 10. PMID: 22578793.
1
4 - Wirsching HG, Tabatabai G, Roelcke U, Hottinger AF, Jörger F, Schmid A, Plasswilm L, Schrimpf D, Mancao C, Capper D,
Conen K, Hundsberger T, Caparrotti F, von Moos R, Riklin C, Felsberg J, Roth P, Jones DTW, Pfister S, Rushing EJ, Abrey L,
Reifenberger G, Held L, von Deimling A, Ochsenbein A, Weller M. Bevacizumab plus hypofractionated radiotherapy versus
radiotherapy alone in elderly patients with glioblastoma: the randomized, open-label, phase II ARTE trial. Ann Oncol. 2018 Jun
1;29(6):1423-1430. doi: 10.1093/annonc/mdy120. PMID: 29648580.
1
5 - Yin AA, Zhang LH, Cheng JX, Dong Y, Liu BL, Han N, Zhang X. The predictive but not prognostic value of MGMT
promoter methylation status in elderly glioblastoma patients: a meta-analysis. PLoS One. 2014 Jan 13;9(1):e85102. doi:
10.1371/journal.pone.0085102. PMID: 24454798; PMCID: PMC3890309
Gliomen
PDF aangemaakt op 
23-01-2025
595
/
971
Behandeling Gliomatosis cerebri
Uitgangsvraag
Wat is het beleid bij gliomatosis cerebri?
Aanbeveling
Voor een patiënt met gliomatosis cerebri dienen de risico's en de voordelen van de verschillende
behandelstrategieën, waaronder chemotherapie en radiotherapie, afgewogen te worden in een
multidisciplinaire hersentumorwerkgroep. In de overweging voor de keuze van de primaire behandeling
moeten de volgende factoren meegenomen worden: grootte van het gebied van tumorinfiltratie,
histologische classificatie en gradering en moleculaire diagnostiek.
De werkgroep is van mening dat voor patiënten met gliomatosis cerebri:
chirurgische interventie niet geïndiceerd is, behoudens het verrichten van een biopt voor het stellen van
de pathologische diagnose. Daarnaast kan in uitzonderlijke gevallen een debulking worden overwogen
bij massawerking uitgaande van het tumorproces.
chemotherapie de eerste keus primaire behandeling is. Gekozen kan worden voor combinatie
procarbazine en lomustine of temozolomide.
radiotherapie kan worden overwogen als eerste en tweedelijnsbehandeling, maar bij de afweging dient
rekening te worden gehouden met het aanzienlijke risico op neurotoxiciteit.
Overwegingen
Gliomatosis cerebri is een zeldzame heterogene tumor. De heterogeniteit betreft zowel de histologische
classificatie als het klinisch beloop van de ziekte. Dit laatste kan variëren van snel progressief met
neurologische uitvalsverschijnselen tot een meer indolent beloop met weinig of geen klinische verschijnselen
behoudens epilepsie. Palliatieve therapeutische mogelijkheden zijn vooralsnog chemotherapie of
radiotherapie. Gezien de diffuse verspreiding van gliomatosis cerebri (over drie kwabben) zal bij radiotherapie
het bestralingsvolume groot zijn, waarbij de kans op vroege en late neurotoxiciteit aanzienlijk wordt geacht.
Mede hierdoor wordt bij patiënten met gliomatosis cerebri chemotherapie veelal als primaire behandeling
gekozen.
Onderbouwing
Conclusies
Er zijn aanwijzingen dat chemotherapie een effectieve behandeling is voor een deel van de patiënten met
gliomatosis cerebri.
Chen 2013
, Rudà 2014
, Glas 2011
Er zijn aanwijzingen dat temozolomide even effectief is als de combinatie chemotherapie procarbazine en
lomustine / CCNU (PC), maar alleen PC is in prospectieve setting onderzocht.
Glas 2011
, Mattox 2012
53
284
112
112
211
Gliomen
PDF aangemaakt op 
23-01-2025
596
/
971
De resultaten van radiotherapie uit verschillende retrospectieve studies laten onderling grote verschillen zien.
Samenvatting literatuur
Volgens de World Health Organization wordt gliomatosis cerebri gedefinieerd als een diffuus groeiend
glioom met uitbreiding in drie of meer hersenkwabben, meestal bilateraal voorkomend en met frequente
betrokkenheid van infratentoriële structuren. Gliomatosis cerebri wordt geclassificeerd als een WHO graad III
glioom, waarbij radiologische kenmerken worden gecombineerd met histologische kenmerken. De
histologische typering en gradering van gliomatosis cerebri door de patholoog is echter zeer variabel.
Ofschoon gliomatosis cerebri meestal bestaat uit astrocytaire cellen, kan er ook een oligodendrogliaal
fenotype zijn en is er in een minderheid van de gevallen sprake van glioblastoma multiforme. Er is geen
standaardbehandeling voor gliomatosis cerebri. Mede door de zeldzaamheid en de heterogeniteit van deze
tumorsoort zijn er geen vergelijkende studies verricht. Behandelkeuzes worden gemaakt aan de hand van één
fase II-studie, veelal kleine retrospectieve series, case reports en expert opinions. Zowel bestraling als
chemotherapie komen als behandelingsmodaliteit in aanmerking. Heel zelden is er een plaats voor
decompressiechirurgie.
In een retrospectieve analyse van 105 patiënten met de diagnose gliomatosis (die tussen 1955 en 1998
werden onderzocht in het MD Anderson Cancer Center), werden 30 patiënten geïdentificeerd van wie follow-
up data na bestraling beschikbaar waren [Perkins 2003
]. Binnen deze geselecteerde groep patiënten werd
geen verschil in totale overleving (OS) of progressie vrije overleving (PFS) gevonden tussen de groep die
alleen een biopt onderging en de groep die partiële resectie onderging. 21/30 patiënten kregen een vorm
van chemotherapie verdeeld over 9 regimes en ook hier werd geen verschil waargenomen tussen de wel of
niet met chemotherapie behandelde patiënten voor wat betreft PFS en OS. Alle patiënten kregen dus
radiotherapie, maar er werd geen verschil gevonden in PFS of OS tussen lokaal, versus whole brain RT (al dan
niet in combinatie met chemotherapie).
Chirurgie
Gezien de diffuse verspreiding van de ziekte komen patiënten met gliomatosis cerebri zelden in aanmerking
voor chirurgische interventie. Een biopt wordt verricht voor het stellen van de pathologische diagnose en in
geval van ernstige massawerking kan in uitzonderlijke gevallen debulking zinvol zijn. Er zijn geen data
beschikbaar die het effect van een operatie ondersteunen.
Radiotherapie
Er zijn alleen retrospectieve data over de effectiviteit van radiotherapie bij patiënten met gliomatosis cerebri
op PFS en OS. Bij al deze studies lijkt selectiebias een rol te spelen. De uitkomsten van de diverse studies
laten grote verschillen zien. Taillibert analyseerde retrospectief 296 patiënten met gliomatosis cerebri
gediagnostiseerd tussen 1993 en 2004, waarbij de OS van patiënten die radiotherapie ondergingen niet
verlengd werd in vergelijking met de groep die geen tumorremmende behandeling onderging [Taillibert
2006
]. Chen daarentegen beschreef een serie van 54 opeenvolgende patiënten waarbij radiotherapie (als
eerste behandeling) sterk geassocieerd was met een betere prognose (PFS 16,5 versus 4,5 mnd., p < 0,01;
OS 27,5 vs. 6,5 maanden, p< 0,01) [Chen 2013
]. De studie van Mattox pleit voor combinatie radiotherapie
en chemotherapie (temozolomide), gebaseerd op een casus en literatuuronderzoek [Mattox 2012
].
Chemotherapie
254
336
53
211
Gliomen
PDF aangemaakt op 
23-01-2025
597
/
971
Er is één prospectieve studie betreffende chemotherapie bij gliomatosis cerebri. Glas onderzocht in een fase
II-studie de effectiviteit van combinatie chemotherapie procarbazine en lomustine / CCNU (PC) bij 35
onbehandelde patiënten met gliomatosis cerebri [Glas 2011
]. Het percentage patiënten zonder
ziekteprogressie op 8 maanden betrof 50,3%. De mediane progressievrije overleving was 14 maanden (95%CI
6,4-21,6 maanden). De mediane overleving was 30 maanden (95%CI14,0-45,9 maanden). Sanson beschrijft
een retrospectieve serie van 63 patiënten met gliomatosis cerebri die initieel behandeld werden met
chemotherapie [Sanson 2004
]. Zeventien patiënten werden behandeld met combinatie chemotherapie
procarbazine, lomustine (CCNU) en vincristine (PCV) en 46 patiënten werden behandeld met monotherapie
temozolomide (TMZ). De PFS voor de gehele groep bedroeg 16 maanden en de OS bedroeg 28,8 maanden.
Er was geen significant verschil in PFS en OS tussen de met PCV behandelde groep en de met TMZ
behandelde groep. Oligodendrogliale tumoren hadden een betere PFS en OS dan astrocytaire en
oligoastrocytaire tumoren. In deze studie waren geen data over 1p/19q-status aanwezig. Levin beschreef een
serie van 11 patiënten die behandeld werd met TMZ waarbij 45% een objectieve respons optrad en een PFS
van 13 maanden werd gerapporteerd [Levin 2004
]. De PFS op 12 maanden was 55%.Louis beschreef in een
kleine groep patiënten een zeer goede response na TMZ bij gliomatosis cerebri van het oligodendrogliale
subtype [Louis 2003
].
Post-radiatie chemotherapie
Er is één studie die een aanwijzing vond voor voordeel van chemotherapie na radiotherapie [Kong 2010
].
Binnen deze retrospectieve analyse werd bij 19 patiënten alleen RT gegeven en bij 18 patiënten adjuvante
chemotherapie bestaande uit TMZ of lomustine. De mediane overleving voor de patiënten die niet met
adjuvante chemotherapie behandeld werden was 13,1 maanden versus 24 maanden voor de patiënten die
chemotherapie kregen.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
112
293
200
206
179
Gliomen
PDF aangemaakt op 
23-01-2025
598
/
971
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
Gliomen
PDF aangemaakt op 
23-01-2025
599
/
971
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
Gliomen
PDF aangemaakt op 
23-01-2025
600
/
971
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
Gliomen
PDF aangemaakt op 
23-01-2025
601
/
971
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Gliomen
PDF aangemaakt op 
23-01-2025
602
/
971
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
Gliomen
PDF aangemaakt op 
23-01-2025
603
/
971
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
Gliomen
PDF aangemaakt op 
23-01-2025
604
/
971
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
Gliomen
PDF aangemaakt op 
23-01-2025
605
/
971
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
Gliomen
PDF aangemaakt op 
23-01-2025
606
/
971
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
Gliomen
PDF aangemaakt op 
23-01-2025
607
/
971
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
Gliomen
PDF aangemaakt op 
23-01-2025
608
/
971
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
Gliomen
PDF aangemaakt op 
23-01-2025
609
/
971
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
Gliomen
PDF aangemaakt op 
23-01-2025
610
/
971
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
Gliomen
PDF aangemaakt op 
23-01-2025
611
/
971
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
Gliomen
PDF aangemaakt op 
23-01-2025
612
/
971
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
Gliomen
PDF aangemaakt op 
23-01-2025
613
/
971
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
Gliomen
PDF aangemaakt op 
23-01-2025
614
/
971
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
Gliomen
PDF aangemaakt op 
23-01-2025
615
/
971
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
616
/
971
Behandeling Recidief gliomen
De behandeling van recidief gliomen wordt beschreven in de volgende modules:
Systemische therapie
Chemotherapie recidief laaggradig glioom
Chemotherapie recidief anaplastisch glioom
Chemotherapie recidief glioblastoom
Neurochirurgie
Waarde en mate van re-resectie glioblastoom 
Radiotherapie
Radiotherapie bij progressie hooggradig glioom/recidief
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
Gliomen
PDF aangemaakt op 
23-01-2025
617
/
971
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
Gliomen
PDF aangemaakt op 
23-01-2025
618
/
971
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
Gliomen
PDF aangemaakt op 
23-01-2025
619
/
971
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
Gliomen
PDF aangemaakt op 
23-01-2025
620
/
971
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
Gliomen
PDF aangemaakt op 
23-01-2025
621
/
971
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
Gliomen
PDF aangemaakt op 
23-01-2025
622
/
971
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
Gliomen
PDF aangemaakt op 
23-01-2025
623
/
971
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
Gliomen
PDF aangemaakt op 
23-01-2025
624
/
971
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
625
/
971
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
Gliomen
PDF aangemaakt op 
23-01-2025
626
/
971
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
Gliomen
PDF aangemaakt op 
23-01-2025
627
/
971
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Gliomen
PDF aangemaakt op 
23-01-2025
628
/
971
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Gliomen
PDF aangemaakt op 
23-01-2025
629
/
971
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
Gliomen
PDF aangemaakt op 
23-01-2025
630
/
971
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
Gliomen
PDF aangemaakt op 
23-01-2025
631
/
971
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
Gliomen
PDF aangemaakt op 
23-01-2025
632
/
971
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
Gliomen
PDF aangemaakt op 
23-01-2025
633
/
971
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
Gliomen
PDF aangemaakt op 
23-01-2025
634
/
971
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
635
/
971
Medicamenteuze symptoombestrijding bij gliomen
Deze module is onderverdeeld in de volgende submodules en sub-submodules:
Corticosteroïden
Anti-epileptica
Rol van anti-epileptica bij de behandeling
Invloed van anti-epileptica op de behandeling
Medicatie in de terminale fase
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
Gliomen
PDF aangemaakt op 
23-01-2025
636
/
971
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
Gliomen
PDF aangemaakt op 
23-01-2025
637
/
971
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
Gliomen
PDF aangemaakt op 
23-01-2025
638
/
971
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
Gliomen
PDF aangemaakt op 
23-01-2025
639
/
971
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Gliomen
PDF aangemaakt op 
23-01-2025
640
/
971
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
Gliomen
PDF aangemaakt op 
23-01-2025
641
/
971
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
Gliomen
PDF aangemaakt op 
23-01-2025
642
/
971
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
Gliomen
PDF aangemaakt op 
23-01-2025
643
/
971
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Gliomen
PDF aangemaakt op 
23-01-2025
644
/
971
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Gliomen
PDF aangemaakt op 
23-01-2025
645
/
971
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
Gliomen
PDF aangemaakt op 
23-01-2025
646
/
971
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
Gliomen
PDF aangemaakt op 
23-01-2025
647
/
971
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
Gliomen
PDF aangemaakt op 
23-01-2025
648
/
971
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Gliomen
PDF aangemaakt op 
23-01-2025
649
/
971
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
Gliomen
PDF aangemaakt op 
23-01-2025
650
/
971
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
Gliomen
PDF aangemaakt op 
23-01-2025
651
/
971
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
Gliomen
PDF aangemaakt op 
23-01-2025
652
/
971
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
Gliomen
PDF aangemaakt op 
23-01-2025
653
/
971
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
654
/
971
Corticosteroïden bij gliomen
Uitgangsvraag
Wat is de rol van corticosteroïden bij de behandeling van patiënten met gliomen?
Aanbeveling
Corticosteroïden zijn effectief in het bestrijden van symptomen ten gevolge van vasogeen oedeem bij met
name hooggradige gliomen en vroege complicaties van radiotherapie. Gezien de mogelijke invloed op
tumorgroei, betrouwbaarheid van beeldvormend onderzoek, interacties met anti-epileptica en
chemotherapeutica en potentieel ernstige bijwerkingen op lange termijn, is de werkgroep van mening dat:
gestreefd moet worden naar een zo kort mogelijke toediening van corticosteroïden, in een zo laag
mogelijke dosering.
dexamethason als protocollaire medicatie rondom een operatie niet onderzocht is en wellicht
achterwege kan blijven, indien dexamethason nog niet gegeven werd.
dexamethason postoperatief zo snel als op klinische gronden mogelijk is, dient te worden afgebouwd.
de dosering van corticosteroïden bij klinische verslechtering tijdens radiotherapie tijdelijk verhoogd kan
worden; nadien moet opnieuw geprobeerd worden de medicatie af te bouwen.
gezien de verbeterende overleving, bij langdurig gebruik van corticosteroïden osteoporose-profylaxe
overwogen moet worden.
Overwegingen
Hoewel osteoporotische fracturen weinig voorkomen bij glioompatiënten, hebben ze een belangrijke invloed
op de kwaliteit van leven. Bij langdurig gebruik (>2,25 mg dexamethason en (verwachte) behandelduur van >
3 maanden) wordt geadviseerd osteoporose profylaxe toe te passen conform de CBO-richtlijn osteoporose.
Hoewel het perioperatief gebruik van corticosteroïden in veel klinieken gebruikelijk is voor reduceren van
postoperatief oedeem, ontbreekt hiervoor enige wetenschappelijke onderbouwing. In klinieken waar geen
corticosteroïden perioperatief worden gegeven per protocol, maar op indicatie voor symptoomreductie,
wordt geen toename van postoperatief oedeem waargenomen.
Onderbouwing
Conclusies
Corticosteroïden bestrijden tumor-geassocieerd vasogeen oedeem, met name bij hooggradige gliomen
[Dietrich 2011
]. Het gebruik van corticosteroïden kan gepaard gaan met vele ongewenste bijwerkingen. Er
zijn geen vergelijkende studies verricht naar optimale dosering of afbouwschema's.
Samenvatting literatuur
Corticosteroïden verminderen tumor-geassocieerd vasogeen oedeem, hetgeen leidt tot afname van
symptomen. Dexamethason is het middel van voorkeur gezien de lange halfwaardetijd en geringe
mineralocorticoïde werking [Dietrich 2011
, Ryan 2012
]. De halfwaardetijd rechtvaardigt een dosering van
eenmaal daags.
81
81
285
Gliomen
PDF aangemaakt op 
23-01-2025
655
/
971
Er zijn geen wetenschappelijk onderbouwde data met betrekking tot een gestandaardiseerde dosering of
afbouwschema's. Aanvangsdoses van 4-16 mg per dag zijn gebruikelijk [Ryan 2012
].
Bij (verdenking op) hooggradige gliomen wordt vaak snel gestart met corticosteroïden. Laaggradige gliomen
gaan gepaard met weinig oedeem, de rol van corticosteroïden is initieel meestal beperkt. Rondom een biopt
of resectie reduceren corticosteroïden het postoperatief oedeem gemeten met beeldvorming, maar klinische
uitkomstmaten, zoals postoperatieve complicaties, werden niet onderzocht [Dietrich 2011
, Kotsarini
2010
, Deutsch 2013
] 
Corticosteroïden zijn effectief bij de behandeling van vroege complicaties van radiotherapie. Een
prospectieve studie naar het gebruik van corticosteroïden tijdens radiotherapie voor hooggradige gliomen,
toont dat 87% van de patiënten tijdens radiotherapie behandeld wordt met corticosteroïden. Voor start van
radiotherapie was dit 70%. Bij 55% van de patiënten vond tijdens radiotherapie verhoging van de dosis
plaats, gemiddeld na 8 dagen. Drie maanden na bestraling was 29% van de patiënten zonder
corticosteroïden. Een initiële Karnofsky Performance Score van ≤80 was geassocieerd met een hogere
steroïdbehoefte tijdens en na radiotherapie. Een partiële resectie (vs. biopt) was geassocieerd met een lagere
steroïdbehoefte tijdens, maar niet na radiotherapie [Marantidou 2010
].
Er zijn - met name in vitro - aanwijzingen dat corticosteroïden de proliferatie van tumorcellen kunnen remmen
of juist stimuleren [Dietrich 2011
].
Corticosteroïden beïnvloeden de mate waarin contrastvloeistof de bloed-hersenbarrière passeert, hetgeen
radiologisch afname van aankleuring kan geven, zonder dat er daadwerkelijk sprake hoeft te zijn van
tumorrespons [Dietrich 2011
, Kotsarini 2010
].
Bij gelijktijdig gebruik van enzym-inducerende anti-epileptica, met name fenytoïne, kan er sprake zijn van
interactie: enerzijds kan het effect van dexamethason hierdoor afnemen, anderzijds kunnen de spiegels van
anti-epileptica sterker fluctueren. Tevens kan interactie met chemotherapeutica optreden. Er zijn aanwijzingen
dat dexamethason cellen kan beschermen tegen temozolomide geïnduceerde apoptose [Dietrich 2011
].
Bijwerkingen zijn onder andere hyperglycaemie, osteoporose, gewichtstoename, bijnierschors insufficiëntie,
myopathie, slapeloosheid, ontremming, psychotische ontregeling, tremor, visusklachten, een verhoogd risico
op opportunistische infecties en incidenteel cognitieve stoornissen [Dietrich 2011
, Ryan 2012
].
Een associatie tussen het gebruik van corticosteroïden en gastro-intestinale bloedingen kon bij retrospectieve
analyse van klinische studies niet worden aangetoond. Het standaard voorschrijven van een maagbeschermer
is dan ook niet geïndiceerd.
Vanwege het risico op bijwerkingen, dat samen lijkt te hangen met zowel de cumulatieve dosis als
behandelduur, moet herhaaldelijk getracht worden de corticosteroïden af te bouwen. Hiervoor bestaan geen
standaard schema's. Bij kort gebruik van corticosteroïden (korter dan 10 dagen) is een snelle afbouw
gerechtvaardigd, bij langer gebruik moet de dosis langzamer verlaagd worden, met name als fysiologische
doseringen bereikt worden om herstel van het adrenerge systeem te bevorderen en het risico op een steroïd
onhoudingssyndroom te verkleinen [Ryan 2012
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
285
81
181
79
210
81
81
181
81
81
285
285
Gliomen
PDF aangemaakt op 
23-01-2025
656
/
971
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
Gliomen
PDF aangemaakt op 
23-01-2025
657
/
971
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Gliomen
PDF aangemaakt op 
23-01-2025
658
/
971
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
Gliomen
PDF aangemaakt op 
23-01-2025
659
/
971
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
Gliomen
PDF aangemaakt op 
23-01-2025
660
/
971
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
Gliomen
PDF aangemaakt op 
23-01-2025
661
/
971
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
Gliomen
PDF aangemaakt op 
23-01-2025
662
/
971
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
Gliomen
PDF aangemaakt op 
23-01-2025
663
/
971
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
Gliomen
PDF aangemaakt op 
23-01-2025
664
/
971
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
Gliomen
PDF aangemaakt op 
23-01-2025
665
/
971
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
Gliomen
PDF aangemaakt op 
23-01-2025
666
/
971
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
Gliomen
PDF aangemaakt op 
23-01-2025
667
/
971
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
Gliomen
PDF aangemaakt op 
23-01-2025
668
/
971
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
Gliomen
PDF aangemaakt op 
23-01-2025
669
/
971
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
Gliomen
PDF aangemaakt op 
23-01-2025
670
/
971
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
Gliomen
PDF aangemaakt op 
23-01-2025
671
/
971
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
Gliomen
PDF aangemaakt op 
23-01-2025
672
/
971
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
Gliomen
PDF aangemaakt op 
23-01-2025
673
/
971
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
Gliomen
PDF aangemaakt op 
23-01-2025
674
/
971
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
675
/
971
Anti-epileptica bij gliomen
Deze submodule is onderverdeeld in de volgende sub-submodules:
Rol van anti-epileptica bij de behandeling
Invloed van anti-epileptica op de behandeling
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
Gliomen
PDF aangemaakt op 
23-01-2025
676
/
971
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
677
/
971
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
Gliomen
PDF aangemaakt op 
23-01-2025
678
/
971
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
679
/
971
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
Gliomen
PDF aangemaakt op 
23-01-2025
680
/
971
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
Gliomen
PDF aangemaakt op 
23-01-2025
681
/
971
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
Gliomen
PDF aangemaakt op 
23-01-2025
682
/
971
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
Gliomen
PDF aangemaakt op 
23-01-2025
683
/
971
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
Gliomen
PDF aangemaakt op 
23-01-2025
684
/
971
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
Gliomen
PDF aangemaakt op 
23-01-2025
685
/
971
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
Gliomen
PDF aangemaakt op 
23-01-2025
686
/
971
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Gliomen
PDF aangemaakt op 
23-01-2025
687
/
971
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Gliomen
PDF aangemaakt op 
23-01-2025
688
/
971
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
689
/
971
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
Gliomen
PDF aangemaakt op 
23-01-2025
690
/
971
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
Gliomen
PDF aangemaakt op 
23-01-2025
691
/
971
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
Gliomen
PDF aangemaakt op 
23-01-2025
692
/
971
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
Gliomen
PDF aangemaakt op 
23-01-2025
693
/
971
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
694
/
971
Rol van anti-epileptica bij de behandeling van gliomen
Uitgangsvraag
Wat is de (profylactische) rol van anti-epileptica bij de behandeling van patiënten met gliomen?
Aanbeveling
Bij patiënten met een glioom zonder epileptische aanvallen dienen geen profylactische anti-epileptica
voorgeschreven te worden.
De werkgroep is van mening dat perioperatief profylactisch gebruik van anti-epileptica bij patiënten met een
glioom niet gerechtvaardigd is.
De werkgroep is van mening dat bij patiënten met een glioom met epileptische aanvallen gekozen dient te
worden voor onderhoudsbehandeling met niet-enzym-inducerende anti-epileptica.
Overwegingen
Er zijn geen studies zijn die het gebruik van een specifiek anti-epilepticum ondersteunen. Het frequent
gebruik van comedicatie met potentiele interactie met anti-epileptica door patiënten met een glioom, is een
reden om bij voorkeur te kiezen voor niet- enzym-inducerende anti-epileptica.
Onderbouwing
Conclusies
Hoewel epileptische insulten frequent voorkomen bij patiënten met een glioom, zijn er geen
gerandomiseerde studies die de keuze voor een bepaald anti-epilepticum ondersteunen.
Het is aannemelijk dat profylactisch gebruik van fenytoïne bij patiënten die niet eerder een insult gehad
hebben, niet tot significante risico-reductie leidt, wel tot ongewenste bijwerkingen.
Tremont-Lukats 2008
Samenvatting literatuur
Het optreden van epileptische insulten bij patiënten met een glioom kan leiden tot toename van
uitvalsverschijnselen en ziekenhuisopname. De incidentie van insulten bij patiënten met een laaggradig
glioom varieert tussen 65-85% en bij patiënten met een hooggradig glioom tussen 30-62% in verschillende
series [Van Breemen 2007
]
Onderhoudstherapie wordt gestart bij klinisch manifeste insulten. Er zijn geen vergelijkende onderzoeken
naar effectiviteit en bijwerkingen van verschillende anti-epileptica bij gliomen [Kerrigan 2011
]. In kleine
studies naar met name het effect van de nieuwere anti-epileptica worden vaak zeer heterogene
patiëntengroepen beschreven. Bij de behandeling van epilepsie bij patiënten met een hersentumor hebben
anti-epileptica die het cytochroom P450-co-enzymsysteem induceren (carbamazepine, fenobarbital, fenytoïne,
oxcarbazepine en topiramaat) niet de voorkeur vanwege de interactie tussen anti-epileptica,
343
349
170
33
Gliomen
PDF aangemaakt op 
23-01-2025
695
/
971
chemotherapeutica en andere comedicatie, bijvoorbeeld dexamethason [Brodie 2013
]. Het ligt daarnaast
voor de hand te kiezen voor een eerste-keus middel bij de behandeling van partiële epilepsie [Vecht 2014
].
Voor een beschrijving van de beschikbare literatuur ten aanzien van individuele anti-epileptica bij neuro-
oncologische patiënten wordt verwezen naar de 
Richtlijn Epilepsie
.
De beschikbare literatuur geeft geen ondersteuning voor het profylactisch gebruik van anti-epileptica bij
gliomen, terwijl er wel een verhoogd risico bestaat op het optreden van bijwerkingen [Tremont-Lukats
2008
].
Een prospectieve gerandomiseerde trial naar het gebruik van perioperatieve profylaxe met fenytoïne toont
geen significante risico-reductie door het profylactisch gebruik van een adequate dosering fenytoïne in de
postoperatieve periode bij patiënten met een supratentorieel glioom of metastase [Wu 2013
]. De algehele
incidentie van insulten - ook in de controlegroep - was 8% in de eerste 30 dagen na operatie. De studie bleek
van onvoldoende power om een significant verschil tussen de groepen te kunnen aantonen.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
33
363
343
391
Gliomen
PDF aangemaakt op 
23-01-2025
696
/
971
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
Gliomen
PDF aangemaakt op 
23-01-2025
697
/
971
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
Gliomen
PDF aangemaakt op 
23-01-2025
698
/
971
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
Gliomen
PDF aangemaakt op 
23-01-2025
699
/
971
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
Gliomen
PDF aangemaakt op 
23-01-2025
700
/
971
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Gliomen
PDF aangemaakt op 
23-01-2025
701
/
971
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
Gliomen
PDF aangemaakt op 
23-01-2025
702
/
971
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
Gliomen
PDF aangemaakt op 
23-01-2025
703
/
971
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
Gliomen
PDF aangemaakt op 
23-01-2025
704
/
971
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Gliomen
PDF aangemaakt op 
23-01-2025
705
/
971
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
Gliomen
PDF aangemaakt op 
23-01-2025
706
/
971
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
Gliomen
PDF aangemaakt op 
23-01-2025
707
/
971
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
Gliomen
PDF aangemaakt op 
23-01-2025
708
/
971
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
Gliomen
PDF aangemaakt op 
23-01-2025
709
/
971
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
Gliomen
PDF aangemaakt op 
23-01-2025
710
/
971
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
711
/
971
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
Gliomen
PDF aangemaakt op 
23-01-2025
712
/
971
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
Gliomen
PDF aangemaakt op 
23-01-2025
713
/
971
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
714
/
971
Invloed van anti-epileptica op de behandeling van gliomen
Uitgangsvraag
Wat is de invloed van anti-epileptica op de (chemotherapeutische) behandeling?
Aanbeveling
De werkgroep is van mening dat het voorschrijven van enzym-inducerende anti-epileptica als fenytoïne,
carbamazepine, oxcarbazepine en topiramaat niet gewenst is bij patiënten die worden behandeld voor een
glioom.
De werkgroep is van mening dat er nog onvoldoende data zijn om een behandeladvies te baseren op de
aanwijzingen dat het gebruik van valproaat in combinatie met temozolomide de overleving positief zou
kunnen beïnvloeden.
Onderbouwing
Conclusies
Er zijn aanwijzingen dat valproaat de overleving van patiënten met een glioblastoom positief zou kunnen
beïnvloeden.
Weller 2011
, Simo 2013
, Tsai 2012
, Guthrie 2013
, Kerkhof 2013
Er zijn geen prospectieve gerandomiseerde onderzoeken die de invloed van specifieke anti-epileptica op de
chemotherapeutische behandeling beschrijven.
Samenvatting literatuur
Er zijn interacties beschreven tussen anti-epileptica en chemotherapeutica, gebaseerd op het gedeelde
cytochroom P450-metabolisme. Enzym-inducerende anti-epileptica als fenobarbital, fenytoïne en
carbamazepine geven verlaging van de spiegels van sommige chemotherapeutica en tevens een verhoogd
metabolisme van corticosteroïden en verdienen dus niet de voorkeur tijdens chemotherapeutische
behandeling [Brodie 2013
, Oberndorfer 2005
].
Valproaat heeft een complexe invloed op de tumorcelproliferatie, waarbij theoretisch zowel stopzetten van
de celcyclus als tumorproliferatie op kan treden. Preklinisch onderzoek toont een remmend effect van
valproaat aan op DNA-repair mechanismen. Hierdoor kan het cytotoxische effect van chemotherapie of
radiotherapie versterkt worden. Er worden in vitro geen aanwijzingen gevonden voor een remmend effect van
valproaat op het cytotoxisch effect van temozolomide [Chen 2012
, Ryu 2012
, Van Nifterik 2012
,
Berendsen 2012
].
In een retrospectieve analyse naar het gebruik van anti-epileptica bij patiënten met een glioblastoom die
tussen 2000 en 2002 deelnamen aan een studie waarin radiotherapie werd vergeleken met
chemoradiotherapie, hadden patiënten in de chemoradiatie-groep die werden behandeld met valproaat
monotherapie een significant betere mediane overleving (17 maanden, versus 14 maanden bij patiënten
zonder anti-epileptica of alleen enzym inducerende anti-epileptica) [Weller 2011
]. In de groep die alleen
behandeld werd met radiotherapie werd geen significant verschil gevonden in overleving. Wel trad bij het
380
313
345
121
169
33
233
55
286
361
15
380
Gliomen
PDF aangemaakt op 
23-01-2025
715
/
971
gebruik van valproaat in combinatie met temozolomide vaker trombocytopenie, neutropenie en leukopenie
op [Weller 2011
, Simo 2012
].
Ook in andere retrospectieve studies zijn er aanwijzingen dat valproaat de overleving positief zou kunnen
beïnvloeden. Er zijn echter geen gerandomiseerde trials die deze bevindingen bevestigen [Tsai 2012
,
Guthrie 2013
, Kerkhof 2013
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
380
313
345
121
169
Gliomen
PDF aangemaakt op 
23-01-2025
716
/
971
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
Gliomen
PDF aangemaakt op 
23-01-2025
717
/
971
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
Gliomen
PDF aangemaakt op 
23-01-2025
718
/
971
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
Gliomen
PDF aangemaakt op 
23-01-2025
719
/
971
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
Gliomen
PDF aangemaakt op 
23-01-2025
720
/
971
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
Gliomen
PDF aangemaakt op 
23-01-2025
721
/
971
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
Gliomen
PDF aangemaakt op 
23-01-2025
722
/
971
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
Gliomen
PDF aangemaakt op 
23-01-2025
723
/
971
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
Gliomen
PDF aangemaakt op 
23-01-2025
724
/
971
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
Gliomen
PDF aangemaakt op 
23-01-2025
725
/
971
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
Gliomen
PDF aangemaakt op 
23-01-2025
726
/
971
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
Gliomen
PDF aangemaakt op 
23-01-2025
727
/
971
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
Gliomen
PDF aangemaakt op 
23-01-2025
728
/
971
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
Gliomen
PDF aangemaakt op 
23-01-2025
729
/
971
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
Gliomen
PDF aangemaakt op 
23-01-2025
730
/
971
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
Gliomen
PDF aangemaakt op 
23-01-2025
731
/
971
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Gliomen
PDF aangemaakt op 
23-01-2025
732
/
971
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
Gliomen
PDF aangemaakt op 
23-01-2025
733
/
971
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
734
/
971
Medicatie in de terminale fase bij gliomen
Uitgangsvraag
Wat zijn effectieve medicamenteuze interventies om bij een patiënt met een glioom in de terminale fase (met
tekenen van intracraniële drukverhoging), de volgende klachten te verminderen:
hoofdpijnklachten
onrust
insulten
Aanbeveling
De werkgroep is van mening dat bij patiënten in de terminale fase:
hoofdpijnklachten behandeld kunnen worden met een combinatie van corticosteroïden (bij voorkeur
eenmaal daags gedoseerd) en opioïden. Als er sprake is van een gedaald bewustzijn kan overwogen
worden de toediening van corticosteroïden te staken.
onrust en agitatie bestreden kunnen worden met neuroleptica en sedativa.
de behandeling met anti-epileptica zo lang als mogelijk gecontinueerd dient te worden, zo nodig in
rectale, buccale, subcutane of intranasale toedieningsvorm. Clonazepam subcutaan (m.b.v. een pompje
of in bolussen) sublinguaal of buccaal in doseringen van 2-4 mg per dag lijkt een bruikbaar alternatief
als de reguliere anti-epileptica ten gevolge van slikstoornissen niet meer ingenomen kunnen worden.
het vroegtijdig starten van begeleiding en het geven van voorlichting over het palliatieve traject
raadzaam is om de beslissingen ten aanzien van het levenseinde te vergemakkelijken voor zowel patiënt
als naasten.
Onderbouwing
Conclusies
Er zijn geen prospectieve gerandomiseerde onderzoeken naar de beste behandeling van de frequent
voorkomende symptomen hoofdpijn, onrust en insulten in de terminale fase.
Het is aannemelijk dat corticosteroïden hoofdpijn en symptomen veroorzaakt door oedeem verminderen.
Ryan 2012
De werkgroep is van mening dat opioïden geschikte analgetica zijn in de terminale fase mede vanwege de
mogelijkheid tot subcutane toediening.
De werkgroep is van mening dat onrust en agitatie in de terminale fase bestreden kan worden met
neuroleptica of seditiva.
Er zijn aanwijzingen dat een aanzienlijk deel van de patiënten in de laatste week van het leven een epileptisch
insult doormaakt, daarom lijkt doorbehandelen met anti-epileptica ook bij dysfagie en bewustzijnsdaling
zinvol.
285
314
372
Gliomen
PDF aangemaakt op 
23-01-2025
735
/
971
Sizoo 2010
, Walbert 2014
Het is aannemelijk dat het vroegtijdig starten van begeleiding en het geven van voorlichting over het
palliatieve traject de beslissingen ten aanzien van het levenseinde kunnen vergemakkelijken en de kwaliteit
van leven kunnen vergroten.
Sizoo 2012
, Walbert 2014
Samenvatting literatuur
Uit enkele retrospectieve studies blijkt dat de meest voorkomende symptomen bij patiënten in de terminale
fase bewustzijnsdaling, dysfagie, toename van focale uitvalsverschijnselen, communicatieve problemen,
insulten, incontinentie, hoofdpijn, progressieve cognitieve stoornissen en onrust of verwardheid zijn.
Bewustzijnsdaling en dysfagie gaan vaak samen en treden met name in de laatste week voor overlijden op.
Hierdoor wordt de inname van medicatie bemoeilijkt [Sizoo 2010
, Walbert 2014
, Sizoo 2014
].
Corticosteroïden verminderen klachten van hoofdpijn en de symptomen veroorzaakt door oedeem [Ryan
2012
]. Er zijn geen onderbouwde richtlijnen ten aanzien van de dosering en de behandelduur in de
terminale fase. Als het ophogen van de dosis dexamethason niet binnen enkele dagen effectief is, dan is
continueren van een hogere dosis niet zinvol en wordt teruggegaan naar de eerdere dosering. Bij
slikstoornissen kan dexamethason in gelijke dosering subcutaan worden toegediend. Het continueren van
corticosteroïden wanneer inname niet meer mogelijk is door gedaald bewustzijn, lijkt niet zinvol. 
Er zijn geen prospectieve studies naar het gebruik van analgetica bij patiënten met een glioom in de
terminale fase. Opioïden worden in de terminale fase het meest frequent toegepast en kunnen subcutaan
worden toegediend. Terughoudendheid ten aanzien van het gelijktijdig gebruik van corticosteroïden en
NSAID's is op zijn plaats vanwege het risico op darmperforaties.
Onrust en agitatie in de terminale fase komen frequent voor bij patiënten met een glioom. Dit wordt
behandeld met neuroleptica of sedativa, er zijn geen prospectieve studies naar het effect van deze
behandelingen. 
Er zijn geen prospectieve studies naar het gebruik van anti-epileptica in de terminale fase. Omdat ruim een
derde van de glioompatiënten in de laatste week insulten doormaakt, lijkt het waardevol de behandeling met
anti-epileptica ook bij slikstoornissen of bewustzijnsdaling te continueren [Sizoo 2010
, Walbert 2014
]. In
de thuissituatie wordt bij voorkeur gekozen voor non-invasieve toediening. Rectale toediening van
carbamazepine, levetiracetam, natriumvalproaat en fenobarbital is mogelijk, maar preparaten moeten soms
door de apotheker speciaal bereid worden. Clonazepam buccaal of sublinguaal is een goed alternatief. Vaak
wordt gestart met een dosis van 1-2 mg en een onderhoudsdosering van 2-4 mg per dag. Insulten kunnen
gecoupeerd worden met diazepam rectioles, midazolam intranasaal of subcutaan of clonazepam buccaal.
In de terminale fase zijn patiënten door cognitieve stoornissen, fatische stoornissen of bewustzijnsstoornissen
vaak niet meer actief betrokken in de beslissingen rondom het levenseinde. Het is aannemelijk dat het
vroegtijdig starten van begeleiding en het geven van voorlichting over het palliatieve traject de beslissingen
ten aanzien van het levenseinde kunnen vergemakkelijken en de kwaliteit van leven kunnen vergroten [Sizoo
2012
, Walbert 2014
].
Verantwoording
314
372
315
372
314
372
316
285
314
372
315
372
Gliomen
PDF aangemaakt op 
23-01-2025
736
/
971
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Gliomen
PDF aangemaakt op 
23-01-2025
737
/
971
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
Gliomen
PDF aangemaakt op 
23-01-2025
738
/
971
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
Gliomen
PDF aangemaakt op 
23-01-2025
739
/
971
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
Gliomen
PDF aangemaakt op 
23-01-2025
740
/
971
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
Gliomen
PDF aangemaakt op 
23-01-2025
741
/
971
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
Gliomen
PDF aangemaakt op 
23-01-2025
742
/
971
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
Gliomen
PDF aangemaakt op 
23-01-2025
743
/
971
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
Gliomen
PDF aangemaakt op 
23-01-2025
744
/
971
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
Gliomen
PDF aangemaakt op 
23-01-2025
745
/
971
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
Gliomen
PDF aangemaakt op 
23-01-2025
746
/
971
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
Gliomen
PDF aangemaakt op 
23-01-2025
747
/
971
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
Gliomen
PDF aangemaakt op 
23-01-2025
748
/
971
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
Gliomen
PDF aangemaakt op 
23-01-2025
749
/
971
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Gliomen
PDF aangemaakt op 
23-01-2025
750
/
971
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
Gliomen
PDF aangemaakt op 
23-01-2025
751
/
971
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
Gliomen
PDF aangemaakt op 
23-01-2025
752
/
971
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
Gliomen
PDF aangemaakt op 
23-01-2025
753
/
971
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
Gliomen
PDF aangemaakt op 
23-01-2025
754
/
971
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
755
/
971
Cognitie, revalidatie en begeleiding bij gliomen
Deze module is onderverdeeld in de volgende submodules:
Revalidatie en begeleiding
Signalering en behandeling cognitieve en emotionele gevolgen
Voorlichting
Rol verpleegkundige/verpleegkundig specialist
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
Gliomen
PDF aangemaakt op 
23-01-2025
756
/
971
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
Gliomen
PDF aangemaakt op 
23-01-2025
757
/
971
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
Gliomen
PDF aangemaakt op 
23-01-2025
758
/
971
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
Gliomen
PDF aangemaakt op 
23-01-2025
759
/
971
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
Gliomen
PDF aangemaakt op 
23-01-2025
760
/
971
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
Gliomen
PDF aangemaakt op 
23-01-2025
761
/
971
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
Gliomen
PDF aangemaakt op 
23-01-2025
762
/
971
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
Gliomen
PDF aangemaakt op 
23-01-2025
763
/
971
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
Gliomen
PDF aangemaakt op 
23-01-2025
764
/
971
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
Gliomen
PDF aangemaakt op 
23-01-2025
765
/
971
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
Gliomen
PDF aangemaakt op 
23-01-2025
766
/
971
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
Gliomen
PDF aangemaakt op 
23-01-2025
767
/
971
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
Gliomen
PDF aangemaakt op 
23-01-2025
768
/
971
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
Gliomen
PDF aangemaakt op 
23-01-2025
769
/
971
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Gliomen
PDF aangemaakt op 
23-01-2025
770
/
971
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
Gliomen
PDF aangemaakt op 
23-01-2025
771
/
971
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
Gliomen
PDF aangemaakt op 
23-01-2025
772
/
971
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Gliomen
PDF aangemaakt op 
23-01-2025
773
/
971
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
774
/
971
Revalidatie en begeleiding bij gliomen
Uitgangsvraag
Welke vormen van revalidatie en begeleiding zijn effectief om cognitieve klachten, vermoeidheid en
stemmingsstoornissen te voorkomen/verminderen bij patiënten met een glioom?
Aanbeveling
Overweeg om patiënten met een laaggradig en anaplastisch glioom een revalidatieprogramma aan te
bieden, dat erop is gericht de cognitieve klachten en symptomen te verbeteren.
Onderbouwing
Conclusies
Voor patiënten met een laaggradig en anaplastisch glioom is er bewijs van lage kwaliteit dat direct na het
volgen van een revalidatieprogramma de cognitieve klachten verminderen.
Gehring 2009
Voor patiënten met een laaggradig en anaplastisch glioom is er bewijs van lage kwaliteit dat zes maanden na
het volgen van een revalidatieprogramma de aandacht, verbaal geheugen en vermoeidheid verbeteren.
Gehring 2009
Samenvatting literatuur
Ten aanzien van de beantwoording van bovenstaande uitgangsvraag zijn gerandomiseerde gecontroleerde
trials (RCT's) of gecontroleerde klinische trials schaars. Een Cochrane review [Khan 2013
] vond op grond
van 12 observationele studies 'very low level' evidentie voor de effectiviteit van een multidisciplinair
revalidatieprogramma op de verbetering van de functionele status en kwaliteit van leven van patiënten met
primaire hersentumoren. Hoewel recent de effectiviteit van cognitieve revalidatie bij een heterogene groep
patiënten (gliomen en meningeomen) met primaire hersentumoren binnen een RCT is aangetoond [Zucchella
2013
], evalueerde slechts één RCT de effecten van een revalidatieprogramma op het cognitief functioneren
van glioompatiënten [Gehring 2009
]. Binnen dit onderzoek werden 140 patiënten met een laaggradig of
anaplastisch glioom gerandomiseerd in een cognitief revalidatieprogramma of een wachtlijstgroep. De
interventie bestond uit een computertraining gericht op herstellen van cognitieve vaardigheden
gecombineerd met een face-to-face training gericht op compensatoire vaardigheden voor beperkingen in
aandachts-, geheugen- en executieve functies. De compensatietraining bestond uit zes sessies psycho-
educatie, met zowel didactische als praktische elementen. Deelnemers kregen een neuropsychologisch
onderzoek en vulden vragenlijsten in bij de start van de studie, na voltooiing van de interventie en na 6
maanden.
Direct na de interventie hadden de patiënten in de interventiegroep minder cognitieve klachten dan de
patiënten in de controlegroep (p = 0,001), maar werd er geen verschil gevonden in cognitieve prestaties. Zes
maanden na de interventie waren de aandachtsfuncties en het verbaal geheugen beter in de experimentele
groep dan in de controlegroep (respectievelijk p = 0,004, p = 0,009), maar er werd geen verschil meer
gevonden in cognitieve klachten. De interventie had geen significant effect op de kwaliteit van leven, wel
108
108
171
409
108
Gliomen
PDF aangemaakt op 
23-01-2025
775
/
971
rapporteerden patiënten in de experimentele groep na zes maanden minder vermoeidheidsklachten (p =
0,044).
Kwaliteit van het bewijs
Het risico op bias is hoog. Er is vooral een hoog risico op bias door de (onvermijdelijke) afwezigheid van
blindering van de patiënten, terwijl de uitkomsten van het vragenlijstonderzoek subjectief zijn. Er is ook geen
vermelding van allocation concealment. Hierdoor zijn de effecten van de zelf-gerapporteerde uitkomstmaten
weinig betrouwbaar.
Zoeken en selecteren
In de evidence tabellen vindt u de uitkomsten van het literatuuronderzoek voor de vraag: ‘Welke vormen van
revalidatie en begeleiding zijn effectief om cognitieve klachten, vermoeidheid en stemmingsstoornissen te
voorkomen/verminderen bij patiënten met een glioom?'
 
1. Welke diagnostische techniek (MRI, PET, CT perfusie, SPECT) is het beste in staat om bij patiënten met
gliomen tumorprogressie en therapie-effect (pseudoprogressie dan wel radionecrose) van elkaar te
onderscheiden ten einde een optimale behandelingsstrategie te kunnen kiezen?
 
P
: Patiënten met een glioom die zijn behandeld met radiotherapie waarbij sprake is van een groeiende
aankleurende laesie bij wie de differentiaal diagnose tumorprogressie dan wel therapie-effect
(radionecrose/pseudoprogressie) is
I
: MRI (aankleuring), MRI anatomie, MRI perfusie, MRI diffusie, MRI spectroscopie, PET (MET en FET tracers),
CT perfusie, SPECT
C
: bevestiging tumorprogressie danwel therapie-effect met PA of klinische follow-up diagnose
O
: tumorprogressie of therapie-effect (radionecrose/pseudoprogressie)
 
Search strategy
Searches were run on October 28, 2013 for systematic reviews and on November 19, 2013 for primary studies.
OVID Medline, Embase and the Cochrane Library were searched using a search strings provided in the
appendix.  The search limits were:
2004-2013 for systematic reviews and 2009-2013 for primary studies;
English and Dutch only;
At least 30 patients included.
 
Search results
Systematic reviews
After merging the search files into 1 file and removal of the duplicates, 262 hits were screened on title and
abstract. Of these, 245 were excluded. The most important reasons for exclusion were:
1
. 
Other population
: patients with other cancer types
2
. 
Other intervention
: interventions other than those specified
3
. 
Wrong study design
: narrative reviews, observational studies
Gliomen
PDF aangemaakt op 
23-01-2025
776
/
971
4
. 
Wrong language
: N=32
Of the remaining 17 papers, the full-text was retrieved. Based on the full-text, an additional 12 studies were
excluded. Exclusion Table 1 provides an overview of these excluded studies.
 
Exclusion Table 1. overview of excluded reviews based on full-text evaluation.
Gliomen
PDF aangemaakt op 
23-01-2025
777
/
971
Author
Reference
Title
Reason
 
Health Technology
Assessment Database
2008 3):
PET for glioma and sarcoma (Project record)
No full-text, not
published yet
Alexiou GA
J Neurooncol 2009
95(1):1-11
Glioma recurrence versus radiation necrosis:
accuracy of current imaging modalities
Narrative review
Brandsma D
Curr Opin Neurol 2009
22(6):633-8
Pseudoprogression and pseudoresponse in the
treatment of gliomas
Narrative review
Caroline I
J Clin Neurosci 2012
19(5):633-7
Imaging modalities in high-grade gliomas:
pseudoprogression, recurrence, or necrosis?
No quality
assessment
Chen W
Semin Nucl Med 2008
38(4):240-50
Advances in evaluation of primary brain tumors
Narrative review
IqwiG
Health Technology
Assessment Database
2010 3):
Positron emission tomography (PET) in high-
grade malignant glioma (grades III and IV)
(Structured abstract)
German
Javier CJ
Health Technology
Assessment Database
2008 3):
Perfusion MR Imaging in differentiating brain
gliomas. Meta-analysis and economic
assessment (Structured abstract)
Only executive
summary
Mertens K
Eur J Nucl Med Mol
Imaging 2010
37(11):2188-93
PET with (18)F-labelled choline-based tracers
for tumour imaging: a review of the literature
Narrative review
Shah AH
Neurosurg 2011
31(6):E12
The management of incidental low-grade
gliomas using magnetic resonance imaging:
systematic review and optimal treatment
paradigm
On management of
glioma
Shah AH
J Neurooncol 2013
112(2):141-52
Discriminating radiation necrosis from tumor
progression in gliomas: a systematic review
what is the best imaging modality?
No quality
assessment
Treglia G
Ann Nucl Med 2012
26(6):451-61
The role of positron emission tomography
using carbon-11 and fluorine-18 choline in
tumors other than prostate cancer: a
systematic review
No quality
assessment
van den Bent
MJ
Lancet Oncol 2011
12(6):583-93
Response assessment in neuro-oncology (a
report of the RANO group): assessment of
outcome in trials of diffuse low-grade gliomas
Narrative review
 
Primary studies
After merging the search files into 1 file and removal of the duplicates, 2502 hits were screened on title and
abstract. Of these, 2479 were excluded. The most important reasons for exclusion were:
Gliomen
PDF aangemaakt op 
23-01-2025
778
/
971
1
. 
Other population
: patients with other cancer types
2
. 
Other intervention
: interventions other than those specified
3
. 
Wrong study design
: case reports, reviews, less than 30 patients
4
. 
Wrong language
: N=72
Of the remaining 23 papers, the full-text was retrieved. Based on the full-text, an additional 6 studies were
excluded. Exclusion Table 2 provides an overview of these excluded studies.
 
Exclusion Table 2. overview of excluded primary studies based on full-text evaluation.
Author
Reference
Title
Reason
Agarwal A
J. Neuro-Oncol. 2013
112(3):413-420
Morphologic MRI features, diffusion tensor
imaging and radiation dosimetric analysis to
differentiate pseudo-progression from early
tumor progression
Only MRI used as
reference standard
Constantin A
Artif. Intell. Med. 2012
55(1):61-70
Identifying malignant transformations in
recurrent low grade gliomas using high
resolution magic angle spinning spectroscopy
Not on
distinguishing
progression from
necrosis
Hu X
J. Magn. Reson.
Imaging 2011 33(2):296-
305
Support vector machine multiparametric MRI
identification of pseudoprogression from
tumor recurrence in patients with resected
glioblastoma
Only MRI used as
reference standard
Matsunaga S
Int. J. Radiat. Oncol.
Biol. Phys. 2013
85(1):47-52
Semiquantitative analysis using thallium-201
SPECT for differential diagnosis between
tumor recurrence and radiation necrosis after
gamma knife surgery for malignant brain
tumors
27 patients with
glioma and 48
patients with brain
metastases
Narang J
Neuro-Oncology 2011
13(9):1037-1046
Differentiating treatment-induced necrosis
from recurrent/progressive brain tumor using
nonmodel-based semiquantitative indices
derived from dynamic contrast-enhanced T1-
weighted MR perfusion
29 patients with
treated gliomas and
8 patients with
treatment-naïve
gliomas
Xu JL
Chin. J. Med. Imaging
Technol. 2010
26(4):639-642
Differentiation of postoperative recurrent
glioma and radiation injury with two-
dimensional proton MR spectroscopy
Chinese
 
2. Wat is de beste behandelingsmethode bij een patiënt met een laaggradig glioom op beeldvorming in
termen van kwaliteit van leven, symptom free survival, progression free survival, morbiditeit, mortaliteit en
overal survival: resectie versus watchful waiting?
 
P
: patiënten met een laaggradig glioom op beeldvorming
I
: resectie
Gliomen
PDF aangemaakt op 
23-01-2025
779
/
971
C
: watchful waiting
O
: kwaliteit van leven, symptom free survival, progression free survival, morbiditeit, mortaliteit, overal survival
 
Search strategy
Searches were run on October 23, 2013.
OVID Medline, Embase and the Cochrane Library were searched using a search strings provided in the
appendix.  The search limits were:
2004-2013;
English and Dutch only;
At least 30 patients included.
 
Search results
After merging the search files into 1 file and removal of the duplicates, 1515 hits were screened on title and
abstract. Of these, 245 were excluded. The most important reasons for exclusion were:
1
. 
Other population
: patients with other cancer types
2
. 
Other intervention
: interventions other than those specified
3
. 
Wrong study design
: narrative reviews, editorial, etc
4
. 
Wrong language or publication date
: N=101
Of the remaining 38 papers, the full-text was retrieved. Based on the full-text, an additional 31 studies were
excluded. Exclusion Table 3 provides an overview of these excluded studies.
 
Exclusion table 3. overview of excluded papers based on full-text evaluation.
Author
Reference
Title
Reason
Abeloos L
Neurochirurgie 2007
53(4):277-283
Management of low-grade glioma: a
retrospective study concerning 201 patients
No full-text
Creach KM
J Neurooncol 2012
106(2):377-82
Oligodendrogliomas in children
Biopsy not
separately analysed
El-Hateer H
J Neurosurg 2009
111(2):265-71
Low-grade oligodendroglioma: an indolent
but incurable disease? Clinical article
Biopsy not
separately analysed
Fisher PG
Pediatr Blood Cancer
2008 51(2):245-50
Outcome analysis of childhood low-grade
astrocytomas
Biopsy not
separately analysed
Horowitz PM
Neurosurgery 2013
72(2):N19
Adult low-grade gliomas: surgery vs biopsy?
Editorial
Klimo P, Jr.
J Neurosurg Pediatrics
2013 Pediatrics..
11(3):274-81
Management and outcome of focal low-grade
brainstem tumors in pediatric patients: the St.
Jude experience
Children with
brainstem tumors
Li F
Chin. J. Clin. Oncol. 2009
36(1):5-8
Predictive factors for postoperative survival of
glioma patients: A report of 56 cases
Chinese
Gliomen
PDF aangemaakt op 
23-01-2025
780
/
971
Markert JM
JAMA 2012
308(18):1918-9
The role of early resection vs biopsy in the
management of low-grade gliomas
Editorial
Martino J
Neurocirugia 2012
23(3):104-111
WHO grade II gliomas: Review of the current
management
Spanish
Park K-J
J Neurooncol 2011
103(3):523-32
Early or delayed radiosurgery for WHO grade
II astrocytomas
Radiosurgery
Perkins SM
Int. J. Radiat. Oncol. Biol.
Phys. 2011 80(4):1117-
1121
Glioblastoma in children: A single-institution
experience
Glioblastoma
Peters O
Pediatr. Blood Cancer
2004 43(3):250-256
Impact of location on outcome in children with
low-grade oligodendroglioma
Biopsy not
separately analysed
Potts MB
J Neurosurg 2012
116(2):365-72
Natural history and surgical management of
incidentally discovered low-grade gliomas
Biopsy not
separately analysed
Pouratian N
Nat. Clin. Pract. Neurol.
2007 3(11):628-639
Surgery Insight: The role of surgery in the
management of low-grade gliomas
No quality appraisal
of included studies
Rogne SG
Acta Neurol Scand 2009
120(5):288-94
Intracranial tumor surgery in patients >70
years of age: is clinical practice worthwhile or
futile?.[Erratum appears in Acta Neurol Scand.
2009 Dec;120(6):453]
82/87 had grade IV
astrocytoma
Schomas DA
Neuro-oncol 2009
11(4):437-45
Intracranial low-grade gliomas in adults: 30-
year experience with long-term follow-up at
Mayo Clinic
Biopsy not
separately analysed
Smith SF
J. Clin. Neurosci. 2005
12(8):915-920
What progress has been made in surgical
management of patients with astrocytoma and
oligodendroglioma in Australia over the last
two decades?
No quantified results
about comparison
Stummer W
Curr. Opin. Neurol. 2009
22(6):645-649
The importance of surgical resection in
malignant glioma
Narrative review
Taylor M
Curr. Oncol. 2004
11(2):53-62
Evidence-based review of the role of surgery
for malignant glioma
Malignant glioma
Tsitlakidis A
J Neurosurg 2010
112(5):1020-32
Biopsy versus resection in the management of
malignant gliomas: a systematic review and
meta-analysis
High-grade glioma
Ushio Y
Neurol Med Chir (Tokyo)
2005 45(9):454-60;
discussion 460-1
Effect of surgical removal on survival and
quality of life in patients with supratentorial
glioblastoma
Glioblastoma
Author
Reference
Title
Reason
Gliomen
PDF aangemaakt op 
23-01-2025
781
/
971
Uzuka T
Neurol. Med.-Chir. 2012
52(8):570-576
Effectiveness of maximal safe resection for
glioblastoma including elderly and low
Karnofsky performance status patients:
Retrospective review at a single institute
Glioblastoma
Youland RS
Am. J. Clin. Oncol.
Cancer Clin. Trials 2012
Adult low-grade glioma: 19-year experience
at a single institution
Biopsy not
separately analysed
Compton JJ
J. Neurosurg. 2012
117(5):825-830
Long-term outcomes for low-grade
intracranial ganglioglioma: 30-Year
experience from the Mayo Clinic
Biopsy not
separately analysed
Lebrun C
Neurology 2004
62(10):1783-7
Long-term outcome of oligodendrogliomas
No quantified results
about comparison
Martinez R
Zentralbl. Neurochir.
2007 68(4):176-181
Gross-total resection of malignant gliomas in
elderly patients: Implications in survival
Malignant glioma
Pontes LDB
J. Geriatr. Oncol. 2013
4(4):388-393
Patterns of care and outcomes in elderly
patients with glioblastoma in Sao Paulo, Brazil:
A retrospective study
Glioblastoma
Robinson CG
Int J Radiat Oncol Biol
Phys 2005 63(1):91-100
Long-term survival and functional status of
patients with low-grade astrocytoma of spinal
cord
Some pts in WW
group received
radiotherapy
Tait MJ
Br. J. Neurosurg. 2007
21(5):496-500
Survival of patients with glioblastoma
multiforme has not improved between 1993
and 2004: Analysis of 625 cases
Glioblastoma
Walker DA
Neuro-oncol 2013
15(4):462-8
A multi-disciplinary consensus statement
concerning surgical approaches to low-grade,
high-grade astrocytomas and diffuse intrinsic
pontine gliomas in childhood (CPN Paris 2011)
using the Delphi method
No methodological
information
Yamini B
Expert Rev. Neurother.
2005 5(6 SUPPL.):S13-
S19
Surgery for low-grade gliomas: Current
evidence and controversies
Narrative review
Author
Reference
Title
Reason
 
3. Welke vormen van revalidatie en begeleiding zijn effectief om cognitieve klachten, vermoeidheid en
stemmingsstoornissen te voorkomen/verminderen bij patiënten met een glioom?
 
P
: patiënten met een glioom die zijn/worden behandeld, met neurochirurgie, radiotherapie e/o
chemotherapie
I
:  revalidatie, (neuro)psychologische begeleiding, zijnde (inspanningstherapie, progressieve spierkracht
training, cognitieve gedragstherapie, problem solving therapie, cognitieve revalidatie) 
C
: geen revalidatie en (neuro)psychologische begeleiding
Gliomen
PDF aangemaakt op 
23-01-2025
782
/
971
O
: kwaliteit van leven, (neuro)psychologisch functioneren (cognitief, emotioneel (angst-depressie),
vermoeidheid)
 
Search strategy
PubMed, Embase, PsychInfo en CINAHL were searched. The search strategies can be found in the appendix.
Articles published before 2009 and not written in English or Dutch were excluded.
 
Search results
The PubMed search yielded 209 hits (9-1’14), the Embase search 143 hits (24-1’14), the PsychInfo search
yielded 57 hits (23-1’14) and the CINAHL search yielded 18 hits (27-1’14).
 
Studies were selected if a comparison was made between a control group and an intervention group receiving
care to reduce cognitive and emotional functioning and fatigue.
Studies were not selected in case a pharmacological intervention was investigated.
 
After merging all search files into 1 file (410) and removal of the duplicates, 387 hits were screened on title
and abstract. Of these, 375 were excluded. The most important reasons for exclusion were:
Studies were not on patient with gliomas
Studies did not make a comparison between interventions
Of the remaining 12 studies the full-text was retrieved. Based on the full-text, an additional 11 studies were
excluded. EclusionTable 4 provides an overview the reason of exclusion of studies.
 
Exclusion Table 4. overview of excluded studies based on full-text evaluation.
Gliomen
PDF aangemaakt op 
23-01-2025
783
/
971
Referentie
Reden exclusie
Ford, E., Catt, S., Chalmers, A., & Fallowfield, L. (2012). Systematic review of
supportive care needs in patients with primary malignant brain tumors. 
Neuro-
Oncology, 14
(4), 392-404.
No comparison between
intervention
Gehring, K., Aaronson, N. K., Gundy, C. M., Taphoorn, M. J. B., & Sitskoorn,
M. M. (Mar 2011). Predictors of neuropsychological improvement following
cognitive rehabilitation in patients with gliomas. 
Journal of the International
Neuropsychological Society, 17
(2), 256-266.
No comparison between
intervention
Gehrke, A. K., Baisley, M. C., Sonck, A. L. B., Wronski, S. L., & Feuerstein, M.
(2013). Neurocognitive deficits following primary brain tumor treatment:
Systematic review of a decade of comparative studies. 
Journal of Neuro-
Oncology, 115
(2), 135-142.
No comparison between
intervention
Henriksson, R., Asklund, T., & Poulsen, H. S. (2011). Impact of therapy on
quality of life, neurocognitive function and their correlates in glioblastoma
multiforme: A review. 
Journal of Neuro-Oncology, 104
(3), 639-646.
No comparison between
intervention
Keilani, M., Krall, C., Marosi, C., Flechl, B., Dieckmann, K., Widhalm, G., et al.
(2012). Strength of skeletal muscle and self-reported physical performance in
austrian glioblastoma-patients. 
Wiener Klinische Wochenschrift, 124
(11-12),
377-383.
No comparison between
intervention
Physical function and fatigue outcomes in patients with high-grade glioma
undergoing concurrent chemo-radiation and outpatient physical therapy: A
pilot study.(2012). 
Rehabilitation Oncology, 30
(1), 25-25.
No comparison between
intervention
Boele, F. W., Hoeben, W., Hilverda, K., Lenting, J., Calis, A. -., Sizoo, E. M., et
al. (2013). Enhancing quality of life and mastery of informal caregivers of high-
grade glioma patients: A randomized controlled trial.
 Journal of Neuro-
Oncology, 111
(3), 303-311.
Effect on informal caregivers
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
Gliomen
PDF aangemaakt op 
23-01-2025
784
/
971
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
Gliomen
PDF aangemaakt op 
23-01-2025
785
/
971
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
Gliomen
PDF aangemaakt op 
23-01-2025
786
/
971
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
Gliomen
PDF aangemaakt op 
23-01-2025
787
/
971
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
Gliomen
PDF aangemaakt op 
23-01-2025
788
/
971
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
Gliomen
PDF aangemaakt op 
23-01-2025
789
/
971
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
Gliomen
PDF aangemaakt op 
23-01-2025
790
/
971
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
Gliomen
PDF aangemaakt op 
23-01-2025
791
/
971
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
Gliomen
PDF aangemaakt op 
23-01-2025
792
/
971
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
Gliomen
PDF aangemaakt op 
23-01-2025
793
/
971
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
Gliomen
PDF aangemaakt op 
23-01-2025
794
/
971
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
795
/
971
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
Gliomen
PDF aangemaakt op 
23-01-2025
796
/
971
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
Gliomen
PDF aangemaakt op 
23-01-2025
797
/
971
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Gliomen
PDF aangemaakt op 
23-01-2025
798
/
971
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
Gliomen
PDF aangemaakt op 
23-01-2025
799
/
971
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
Gliomen
PDF aangemaakt op 
23-01-2025
800
/
971
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
Gliomen
PDF aangemaakt op 
23-01-2025
801
/
971
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
Gliomen
PDF aangemaakt op 
23-01-2025
802
/
971
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
803
/
971
Signalering en behandeling cognitieve en emotionele gevolgen na glioom
Uitgangsvraag
Op welke wijze dienen de cognitieve en emotionele gevolgen van de tumor en/of behandeling te worden
gesignaleerd en behandeld?
Aanbeveling
Alle glioompatiënten en directe naasten dienen standaard en structureel gescreend te worden op
lichamelijke, cognitieve, emotionele en gedragsmatige beperkingen.
Alle glioompatiënten en directe naasten dienen standaard en structureel gescreend te worden op de
behoefte aan psychosociale zorg en zo nodig worden doorverwezen.
De werkgroep adviseert om bij het in kaart brengen van de gevolgen van de tumor en/of behandeling
gebruik te maken van de 
Signaleringslijst Volwassenen met Niet-Aangeboren Hersenletsel
 en de
Richtlijn Detecteren behoefte psychosociale zorg
.
De werkgroep adviseert om voor het maken van een eerste inschatting van de belasting van de
mantelzorger de screeningsvragenlijst ‘Ervaren druk door informele zorg' (EDIZ) te gebruiken die is
opgenomen in de 
richtlijn mantelzorg
 op 
http://www.oncoline.nl/
. De werkgroep is van mening dat
verwijzen naar een revalidatiearts, psycholoog of klinisch neuropsycholoog zinvol is voor
glioompatiënten die hinder ervaren van fysieke en/of cognitieve en emotionele veranderingen
waardoor zij beperkt worden in hun dagelijks leven of bij hun maatschappelijke participatie. Voor de
behandeling wordt verwezen naar de volgende richtlijnen:
Richtlijn Neuropsychiatrische gevolgen van niet-aangeboren hersenletsel
Richtlijn Niet-aangeboren Hersenletsel en arbeidsparticipatie
Er wordt geadviseerd bij de behandeling van vermoeidheidsklachten non-farmacologische interventies
toe te passen, zoals deze onder meer beschreven staan in de 
Richtlijn Vermoeidheid bij kanker
.
Er wordt geadviseerd om bij de behandeling van angststoornissen en depressie gebruik te maken van
de 
multidisciplinaire evidence-based GGZ-richtlijnen voor de diagnostiek en behandeling van patiënten
met psychische stoornissen
.
Er wordt geadviseerd bij overbelasting van de informele zorgverleners van hooggradig
glioompatiënten, psychologische interventies toe te passen die het mentaal functioneren en gevoelens
van controle van informele zorgverleners stabiliseert of verbetert.
Onderbouwing
Conclusies
Cognitieve beperkingen
Cognitieve revalidatieprogramma's ontwikkeld voor patiënten met niet-aangeboren hersenletsel, lijken
ook bruikbaar voor glioompatiënten [Cicerone 2011].
De werkgroep is van mening dat instrumenten ontwikkeld om veranderingen in emotie, cognitie en
gedrag in kaart te brengen bij patiënten met niet aangeboren hersenletsel, mogelijk ook bruikbaar zijn
bij glioompatiënten.
De werkgroep is van mening dat de verschillende digitaal beschikbare evidence-based
Gliomen
PDF aangemaakt op 
23-01-2025
804
/
971
behandelprotocollen voor cognitieve stoornissen bij patiënten met niet-aangeboren hersenletsel, zinvol
kunnen zijn voor glioompatiënten.
Cognitieve klachten
Er is vaak een beperkte samenhang tussen cognitieve klachten en cognitieve beperkingen zoals deze
gevonden worden in het neuropsychologisch onderzoek [Aaronson 2011, Boele 2014, Klein 2011].
Klachten over vermoeidheid en klachten van depressieve aard kunnen cognitieve klachten versterken
[Cull 1996].
De werkgroep is van mening dat instrumenten ontwikkeld om bovengenoemde klachten in kaart te
brengen bij patiënten met niet aangeboren hersenletsel bruikbaar zijn bij glioompatiënten.
Vermoeidheid
Vermoeidheid is één van de meest voorkomende en meest ingrijpende symptomen bij glioompatiënten
[Lovely 1999].
Farmacologische behandeling van vermoeidheid met modafinil is niet effectiever dan een placebo
[Boele 2013
].
Stemmingsstoornissen
Van alle oncologische patiënten hebben patiënten met een glioom de grootste kans op psychiatrische
symptomen [Rooney 2011
].
Er is vaak sprake van een multifactorieel beeld, waarbij bij één patiënt sprake is van zowel depressie als
van vermoeidheid en cognitieve beperkingen [Taphoorn 2004
].
De werkgroep is van mening dat verschillende digitaal beschikbare evidence-based
behandelprotocollen voor patiënten met psychische stoornissen zinvol kunnen zijn voor
glioompatiënten.
Partners
De begeleiding van en zorg voor glioompatiënten heeft, in vergelijking met de begeleiding van en zorg
voor andere kankerpatiënten, door de veranderingen van gedrag en cognitie een grotere invloed op
het welbevinden van een informele zorgverlener [Boele 2013
, Schubart 2008
].
Er zijn aanwijzingen dat psychologische interventies het mentaal functioneren en de gevoelens van
controle van informele zorgverleners van patiënten met hooggradig gliomen stabiliseren of verbeteren
[Boele 2013
].
Samenvatting literatuur
Cognitieve beperkingen
Glioompatiënten worden geconfronteerd met serieuze bedreigingen voor hun kwaliteit van leven [Liu
2009
]. De draaglast is hoog en het gevoel van onvermogen is aanzienlijk, vooral bij patiënten met
hooggradige gliomen of bij een recidief van de tumor. 
Ongeveer 80% van de glioompatiënten heeft cognitieve beperkingen [Giordana 2006
]. Deze beperkingen
kunnen veroorzaakt worden door de tumor zelf of samenhangen met de medische behandeling, waaronder
23
282
341
23
303
23
203
111
341
Gliomen
PDF aangemaakt op 
23-01-2025
805
/
971
radiotherapie, chirurgie, en anti-epileptica [Taphoorn 2004
]. De cognitieve beperkingen kunnen
veroorzaakt worden door corticale laesies, maar kunnen door de vele corticaal-subcorticale verbindingen ook
de oorzaak zijn van subcorticale schade of schade aan cerebellaire structuren. Patiënten met een tumor in de
dominante (linker) hemisfeer, hebben vaak meer in het oog springende cognitieve stoornissen dan patiënten
met een tumor in de niet-dominante hemisfeer.
Beperkingen komen voor in verschillende cognitieve domeinen, maar voornamelijk in de aandachts- en
concentratiefuncties, het geheugen en de executieve functies [Taphoorn 2004
]. Hoewel deze beperkingen
relatief mild kunnen zijn, kunnen cognitieve beperkingen wel interfereren met het dagelijks leven, zoals werk,
sociale- en gezinssituaties.
Relevant voor de screening van glioompatiënten is de 
Signaleringslijst Volwassenen met Niet-Aangeboren
Hersenletsel
. Aan de hand van deze vragenlijst, die is ontwikkeld voor patiënten met cerebrale schade die
niet veroorzaakt is door hersentumoren, kunnen veranderingen in emotie, cognitie en gedrag in kaart worden
gebracht. Deze signaleringslijst kan ook gebruikt worden ter signalering van dergelijke veranderingen bij
glioompatiënten. Een geschikt moment voor afname ligt in de subacute fase binnen drie maanden na de
diagnose en/of behandeling. Een aanvullend neuropsychologisch onderzoek is zinvol, indien sprake is van een
onduidelijk beeld of om onderscheid te maken tussen een depressie en cognitieve problematiek. 
Voor wat betreft cognitieve revalidatiemogelijkheden, lijken programma's, die overwegend zijn ontwikkeld
voor patiënten met traumatisch hersenletsel en cerebrovasculaire schade, ook bruikbaar te zijn voor neuro-
oncologische patiënten [Formica 2011
]. Ten aanzien van de mogelijkheden om cognitieve beperkingen te
behandelen is het onderzoek van het door 
ZonMw
 gefinancierde consortium Cognitieve Revalidatie relevant.
Dit consortium heeft in een aantal onderzoeksprojecten behandelingen van cognitieve stoornissen op
effectiviteit geëvalueerd en dit heeft geresulteerd in de 
Richtlijn Cognitieve revalidatie bij Niet-Aangeboren
Hersenletsel
. De richtlijnen, ontwikkeld voor verschillende cognitieve stoornissen en gebaseerd zijn op de
resultaten van onderzoek van dit consortium, zijn vooral toepasbaar in de settings die hebben deelgenomen
aan de effectevaluaties (dit zijn revalidatieafdelingen, zowel binnen de revalidatiecentra als binnen het
verpleeghuis en het ziekenhuis). Echter, ook andere settings waar patiënten met niet-aangeboren
hersenletsel behandeld worden, kunnen baat hebben bij deze richtlijnen. Verschillende 
evidence-based
behandelprotocollen
 zijn digitaal beschikbaar en kunnen worden gedownload. Hierbij is het nadrukkelijk van
belang dat de deskundigheid van de zorgverlener van dien aard moet zijn, dat toepassing van de richtlijnen
en gebruik van de protocollen verantwoord kan gebeuren.
Cognitieve klachten
De cognitieve klachten die patiënten rapporteren komen vaak niet overeen met de resultaten van het
neuropsychologische onderzoek [Janda 2007
]. Patiënten met een depressieve stemming kunnen hun
cognitieve mogelijkheden onderschatten en de cognitieve klachten die zij uiten zijn vaak een weergave van
angstige of depressieve gevoelens of worden veroorzaakt door vermoeidheidsklachten in plaats van
cognitieve beperkingen [Hermelink 2010
,Taphooorn 2004
]. Het hebben van vermoeidheidsklachten
en/of een depressie kunnen cognitieve klachten dus versterken.
Om te kunnen beoordelen of verwijzing naar een revalidatiearts, psycholoog of klinisch neuropsycholoog
zinvol is voor een individuele patiënt, is het van belang dat de gevolgen van het glioom en/of de behandeling
goed in kaart worden gebracht. 
In aanvulling op de 
Signaleringslijst Volwassenen met Niet-Aangeboren Hersenletsel
 dienen volgens de
Kwaliteitscriteria neuro-oncologie
, patiënten standaard gescreend te worden op de behoefte aan
341
341
102
153
134
341
Gliomen
PDF aangemaakt op 
23-01-2025
806
/
971
psychosociale zorg en zo nodig te worden doorverwezen. Screening vindt op meerdere ziekte- of
behandelingsrelevante momenten in het zorgproces bij voorkeur plaats met de 
Lastmeter
. De patiënt wordt
geïnformeerd over de mogelijkheid voor psychosociale ondersteuning in het ziekenhuis of in de eigen
omgeving van de patiënt en deze wordt op indicatie en in overleg doorverwezen naar gespecialiseerde
aanbieders van psychosociale zorg. De follow-up frequentie wordt bepaald in overleg en op indicatie en is
bekend bij patiënt en naasten. De werkwijze en frequentie van de follow-up staan beschreven in het dossier.
Bij het inschatten van de aard van de eventuele doorverwijzing kunnen onderstaande richtlijnen met
betrekking tot neuropsychiatrische symptomen en gevolgen van hersenletsel voor de arbeidsparticipatie, die
verschenen zijn voor patiënten met hersenletsel, ook voor glioompatiënten bruikbaar zijn. 
Richtlijn Neuropsychiatrische gevolgen van niet-aangeboren hersenletsel, CBO en Nederlandse Vereniging
voor Revalidatieartsen, 2007.
Richtlijn Niet-aangeboren Hersenletsel en arbeidsparticipatie, CBO 2012.
Vermoeidheid
Vermoeidheid is één van de meest voorkomende en meest ingrijpende symptomen bij glioompatiënten
[Lovely 1999]. Het is het symptoom met de grootste invloed op de kwaliteit van leven en het dagelijks
functioneren van patiënten en hun naasten [Wefel 2008]. Uit resultaten van een kleine studie bleek dat van
alle geteste variabelen vermoeidheid de sterkste relatie had met kwaliteit van leven bij patiënten met een
laaggradig glioom [Gustafsson 2006
].De meest gerapporteerde klachten zijn overmatige slaperigheid,
lethargie, concentratieproblemen en onhandigheid [Pelletier 2002
]. Bij 80% van de glioompatiënten die
behandeld worden met radiotherapie is er sprake van vermoeidheid. Vermoeidheid blijkt echter ook na
behandeling, waarbij geen radiotherapie is gebruikt, te blijven bestaan, naar schatting bij 40% van de
glioompatiënten [Struik 2008].
De behandeling van vermoeidheid bij gliomen is moeilijk, omdat er nog weinig bekend is over de
pathofysiologie en er vaak meerdere factoren tegelijkertijd een rol spelen. De enige dubbelblinde RCT
waarbinnen onderzocht werd of een farmacologische behandeling met modafinil beter was dan placebo in de
behandeling van vermoeidheid, cognitief functioneren en kwaliteit van leven liet zien dat modafinil niet
effectiever was dan placebo [Boele 2013
]. Een wegens moeizame inclusie voortijdig beëindigde open-label
RCT [Gehring 2012
] vond naast inconsistente effecten van methylfenidaat en modafinil op cognitie enige
gunstige effecten op zelf-gerapporteerde vermoeidheid, stemming en kwaliteit van leven. Voor wat betreft de
zelf-gerapporteerde uitkomsten waren er geen verschillen in de tijd tussen de condities.
Gezien het ontbreken van consistente effecten en de beperkte bereidheid van patiënten om medicatie te
gebruiken voor vermoeidheidsklachten dienen non-farmacologische interventies overwogen te worden.
Binnen de oncologische zorg is de 
Richtlijn Vermoeidheid bij kanker
 verschenen. Hierin wordt ook aandacht
besteed aan non-farmacologische interventies gericht op onder meer het helpen vinden van een balans
tussen inspanning en rust, het aanbieden van fysieke trainingsprogramma's, ontspanningstherapie en
psychosociale ondersteuning.
Stemmingsstoornissen
Neuropsychiatrische problemen kunnen ontstaan door het ziekteproces zelf en door de behandeling van
neurologische symptomen; zo kan het gebruik van hoge doses corticosteroïden resulteren in
restverschijnselen zoals een labiel affect of gedragsveranderingen [Pelletier 2002
]. De primaire symptomen
120
253
22
107
253
Gliomen
PDF aangemaakt op 
23-01-2025
807
/
971
van een depressie zijn bij glioompatiënten moeilijk te onderscheiden van de gevolgen van de tumor of de
medische behandeling [Rooney 2011
]. Daadwerkelijke klinische depressie komt echter regelmatig voor
wanneer de gezondheidstoestand vermindert. Van alle kankerpatiënten hebben patiënten met een glioom de
grootste kans op psychiatrische symptomen, waarbij de prevalentie van depressie bij glioompatiënten wordt
geschat op 6-28% [Rooney 2011
]. De negatieve gemoedstoestand is geassocieerd met de neurologische
uitval en wordt versterkt door comorbide psychosociale problemen zoals reactieve depressie, verlies van
werk, financiële problemen en echtelijke conflicten [Pelletier 2002
].
Cognitieve beperkingen en vermoeidheidsklachten kunnen het beroepsmatig- en sociaal functioneren verder
beperken en leiden tot gevoelens van frustratie en controleverlies, die een voedingsbodem zijn voor
depressieve klachten [Sohlberg 2001]. Een groot deel van de patiënten spreekt hierover niet met zijn of haar
behandelend arts, omdat ze deze te druk of onvoldoende toegerust achten om hierin begeleiding te bieden
[Wefel 2011
]. 
Het cognitief functioneren is gecorreleerd met toenemende vermoeidheid en depressie [Liu 2009
]. Er is dan
ook vaak sprake van een multifactorieel beeld, waarbij bij één patiënt sprake is van zowel depressie als van
vermoeidheid en cognitieve beperkingen. Bij onderzoek naar specifieke symptoomclusters bij
glioompatiënten vormen depressie, vermoeidheid, verstoring van de slaap en cognitieve beperkingen een
cluster dat 29% van de variantie van kwaliteit van leven verklaart. Daarnaast vormen depressie, vermoeidheid,
verstoring van slaap, cognitieve beperkingen en pijn een cluster dat 62% van de functionele status van de
patiënt verklaart [Liu 2009
]. 
Bij de behandeling van angststoornissen en depressie kan gebruik worden gemaakt van de 
multidisciplinaire
evidence-based richtlijnen voor de diagnostiek en behandeling van patiënten met psychische stoornissen
.
Deze richtlijnen zijn ontwikkeld onder auspiciën van de Landelijke Stuurgroep Multidisciplinaire
Richtlijnontwikkeling in de GGZ en/of het Trimbos-instituut.
Partners
Net als bij andere ziektes heeft de diagnose van een glioom grote impact op het leven van de patiënt [Gupta
2011
]. Aangezien glioompatiënten naast fysieke symptomen ook worden geconfronteerd met
veranderingen in cognitie, stemming en persoonlijkheid hebben zij meer ondersteuning nodig van hun
omgeving dan patiënten met een tumor waarbij de hersenen niet zijn betrokken. Inherent aan de
problematiek van glioompatiënten is de mogelijkheid dat door de ernst van de cognitieve stoornissen niet de
patiënt degene is die de hulpvraag uit, maar zijn omgeving. In de meeste gevallen is de partner de primaire
informele zorgverlener [Boele 2013
]. Het verzorgen van een glioompatiënt heeft, in vergelijking met de
verzorging van andere kankerpatiënten, door de veranderingen van gedrag en cognitie een grotere invloed
op het welbevinden van een informele zorgverlener [Boele 2013
, Schubart 2008
].
Patiënten en hun zorgverleners worden geconfronteerd met de taak de diagnose en behandeling te
begrijpen en veranderingen bij de patiënt te identificeren en hiermee om te leren gaan [Gupta 2011
].
Sommige patiënten zullen na behandeling al snel compleet hersteld zijn; er is echter een groot deel van de
patiënten dat steun en zorg nodig heeft in de jaren die daarop volgen [Janda 2007
. Deze zorg wordt over
het algemeen gegeven door partners en naaste familie. De stress die met de verzorging gepaard gaat, is
aanzienlijk en heeft een significant negatieve invloed op het welzijn van de informele zorgverlener zelf [Janda
2007
]. Bij 10% van de informele zorgverleners is sprake van een depressieve stemming [Janda 2006
] en
met name informele zorgverleners van hooggradig glioompatiënten lijken in de acute fase van de ziekte het
meeste risico te lopen [Boele 2013
]. Daarnaast is er sowieso sprake van toenemende symptomen van angst,
282
282
253
376
203
203
119
23
23
303
119
153
153
152
23
Gliomen
PDF aangemaakt op 
23-01-2025
808
/
971
psychosomatische problemen, beperkingen van activiteiten, huwelijksproblemen en slechtere fysieke
gezondheid bij informele zorgverleners van kankerpatiënten [Weitzner 1999
.Een recente RCT [Boele
2013
] laat zien dat psychologische interventies het mentaal functioneren en gevoelens van controle van
informele zorgverleners van patiënten met hooggradig gliomen kan stabiliseren of verbeteren. Voor het
maken van een eerste inschatting van de belasting van de mantelzorger is de screeningsvragenlijst ‘Ervaren
druk door informele zorg' (EDIZ) ontwikkeld die is opgenomen in de 
richtlijn mantelzorg
 op 
www.oncoline.nl/
.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
377
23
Gliomen
PDF aangemaakt op 
23-01-2025
809
/
971
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
810
/
971
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
Gliomen
PDF aangemaakt op 
23-01-2025
811
/
971
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
812
/
971
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
Gliomen
PDF aangemaakt op 
23-01-2025
813
/
971
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
Gliomen
PDF aangemaakt op 
23-01-2025
814
/
971
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
Gliomen
PDF aangemaakt op 
23-01-2025
815
/
971
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
Gliomen
PDF aangemaakt op 
23-01-2025
816
/
971
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
Gliomen
PDF aangemaakt op 
23-01-2025
817
/
971
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
Gliomen
PDF aangemaakt op 
23-01-2025
818
/
971
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
Gliomen
PDF aangemaakt op 
23-01-2025
819
/
971
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Gliomen
PDF aangemaakt op 
23-01-2025
820
/
971
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Gliomen
PDF aangemaakt op 
23-01-2025
821
/
971
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
Gliomen
PDF aangemaakt op 
23-01-2025
822
/
971
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
Gliomen
PDF aangemaakt op 
23-01-2025
823
/
971
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
Gliomen
PDF aangemaakt op 
23-01-2025
824
/
971
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
Gliomen
PDF aangemaakt op 
23-01-2025
825
/
971
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
Gliomen
PDF aangemaakt op 
23-01-2025
826
/
971
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
827
/
971
Voorlichting bij gliomen
Uitgangsvraag
Welke voorlichting dienen de patiënt met gliomen en zijn naasten/omgeving (inclusief huisarts) te ontvangen?
Aanbeveling
De werkgroep is van mening dat de 
Kwaliteitscriteria neuro-oncologie
 gevolgd dienen te worden:
De patiënt ontvangt de PA-diagnose van de hoofdbehandelaar volgens de richtlijn
slechtnieuwsgesprek.
Door de hoofdbehandelaar en/of verpleegkundige/verpleegkundig specialist neuro-oncologie wordt
uitleg gegeven over: de ziekte/behandeling, de mogelijke gevolgen hiervan op cognitief, lichamelijk en
sociaal gebied en de laatste levensfase.
In de dialoog tussen hulpverlener en patiënt moeten alle facetten van de mogelijke behandelingsopties,
zoals de te verwachten uitkomsten en lasten voor de patiënt, aan de orde komen. Daarnaast is het
raadzaam dat de hulpverlener zich op de hoogte stelt van de angsten, visie en prioriteiten van de
patiënt.
De huisarts is op de hoogte van de diagnose en het behandelplan.
De hoofdbehandelaar draagt zorg voor een schriftelijk overdracht naar de huisarts in alle fasen van het
behandelproces. Indien er geen behandeling (meer) aan de patiënt gegeven kan worden en de zorg
overgaat op het bestrijden van symptomen in de laatste levensfase, draagt de hoofdbehandelaar de
zorg over aan de huisarts.
Met patiënten worden eventuele alternatieve therapieën besproken. Zorgverleners dienen hier
specifiek naar te vragen.
Mondelinge voorlichting wordt ondersteund door schriftelijk of online voorlichtingsmateriaal
(bijvoorbeeld van 
http://hersentumor.nl/
).
Overwegingen
Er is geen literatuur beschikbaar van waaruit een uitspraak gedaan kan worden over specifieke behoeften van
patiënten met een kwaadaardige hersentumor ten aanzien van communicatie, informatie en begeleiding. De
literatuur die voorhanden is niet van recente data. De studies zijn vooral in de Verenigde Staten en Engeland
verricht. De laatste tien jaar is er in de Nederlandse ziekenhuizen veel veranderd aan de zorg voor patiënten
met hersentumoren. Vrijwel alle academische ziekenhuis en de grote perifere ziekenhuizen in Nederland waar
neuro-oncologie een aandachtsgebied is, hebben een gespecialiseerd verpleegkundige/verpleegkundig
specialist binnen de keten, die op basis van specifieke deskundigheid betrokken is bij de zorg voor deze
complexe patiëntengroep. Daarnaast vervult de verpleegkundige de functie van casemanager en is zij mede
verantwoordelijk voor de juiste logistiek in het gehele ziekteproces van de patiënt.
Onderbouwing
Conclusies
Er zijn aanwijzingen dat patiënten vooral behoefte hebben aan gesprekken met arts en gespecialiseerd
verpleegkundige waarin aandacht is voor de individuele patiënt en van diens naasten.
Gliomen
PDF aangemaakt op 
23-01-2025
828
/
971
Davies 2002
, Madsen 2011
Er zijn aanwijzingen dat patiënten behoefte hebben aan zorg op maat, aangepast aan zijn of haar copingstijl.
Davies 1997
Er zijn aanwijzingen dat naasten van patiënten de zorg voor hun zieke partner met een hersentumor als
bijzonder zwaar ervaren. De gedragsverandering die met de ziekte gepaard gaat is hierbij van grote invloed.
Salander 1996
Er zijn aanwijzingen dat patiënten en naastenbehoefte hebben aan begeleiding in het ziekenhuis van artsen
en verpleegkundigen. Tevens zoeken ze steun bij lotgenoten.
Horowitz 1996
Samenvatting literatuur
Het doel van het geven van voorlichting is het informeren van de patiënt en zijn naasten over de diagnose en
de gevolgen die dit heeft op het dagelijks leven van zowel de patiënt als zijn omgeving. Deze voorlichting
moet opzettelijk en doelbewust gegeven worden. De kennis kan de patiënt en naasten helpen om zelfstandig
en bewust, zoveel mogelijk overeenkomstig zijn eigen belang en welzijn, beslissingen te nemen [Van den Ban
1985
]. Er is beperkte literatuur beschikbaar waaruit een uitspraak gedaan kan worden over specifieke
behoeften van patiënten met een kwaadaardige hersentumor ten aanzien van communicatie, informatie en
begeleiding. De beschikbare data zijn verkregen uit observationele studies met kleine aantallen patiënten
met een hersentumor. Veelal zijn het ook patiënten met de meest maligne hersentumoren. Deze vooral
kwalitatieve studies dateren van (ver) voor 2000 en zijn veelal uitgevoerd in de Verenigde Staten of Engeland.
Een systematische review uit 2003 [Davies
] en uit 2011 [Madsen
] bevat aanwijzingen dat patiënten vooral
behoefte hebben aan gesprekken met een arts en een gespecialiseerd verpleegkundige waarin aandacht is
voor de individuele patiënt en van diens naasten. De zorgverleners moeten de tijd nemen voor een
zorgvuldig voorbereid gesprek. Patiënten vragen om informatie op maat, aangepast aan de eigen copingstijl
[Davies 1997
]. Ten aanzien van de diagnose benoemen patiënten dat de hoop ze niet ontnomen mag
worden. Patiënten zijn zich ervan bewust dat de prognose somber is maar dat dit niet steeds benadrukt hoeft
te worden. Patiënten zijn kritisch of het ziekenhuis deze ondersteuning wel kan bieden [Davies 1997
].
Patiënten, maar vooral ook naasten, zoeken contact binnen lotgenotengroepen om ervaringen te delen en
om te leren omgaan met de ziektelast en met veranderingen binnen het gezin [Leavitt 1996]. Vooral naasten
ervaren de zorglast als erg zwaar. De mantelzorgers worden extra belast als de patiënt te maken krijgt met
persoonlijkheidsveranderingen. Er ontstaat afstand tussen partners en het verdriet neemt toe [Salander
1996
]. In de lotgenotengroepen wordt door de naasten openlijk gesproken over het omgaan met
gedragsveranderingen zonder dat de patiënt hierbij aanwezig is. Ze vinden hierbij duidelijk steun van de
lotgenoten [Horowitz 1996
]. 
Een inventarisatie onder patiënten in Nederland beschrijft dat, indien de diagnose hersentumor wordt
gesteld, de behandelend arts met de patiënt het behandelplan bespreekt en de vervolgstappen in de
behandeling en begeleiding. ‘Shared decision making' is hierbij het uitgangspunt [Kwaliteitscriteria cerebraal
2011
]. In het gehele zorgtraject geven patiënten aan dat ze niet zozeer behoefte hebben aan standaard
71
207
72
289
142
7
71
207
72
72
289
142
189
Gliomen
PDF aangemaakt op 
23-01-2025
829
/
971
routinecontroles, maar dat de behoefte groter is aan meer individueel gefocuste zorg. Qua medische
behandeling heeft een groot deel van de patiënten voldoende aan advies van het multidisciplinaire
behandelteam; maar een deel van de patiënten zoekt naar alternatieve genezingen [Verhoef 1999
]. Niet
altijd wordt dit met de behandelend arts in het ziekenhuis besproken. Het is niet aangetoond welke wijze van
informatie het meest ondersteunend is voor patiënten maar het is aannemelijk dat de spanning van, en
tijdens een slechtnieuwsgesprek ertoe bijdraagt dat niet alle informatie wordt opgenomen(zie 
Richtlijn
Handreiking slecht-nieuws gesprek
). Het is daarom belangrijk dat de mondelinge informatie ondersteund
wordt met schriftelijk informatie. Patiëntenfolders zijn hierbij belangrijk, maar uiteraard ook informatie op het
internet, zoals op 
www.hersentumor.nl
. Er is tevens uitgebreide informatie beschikbaar van de diverse
ziekenhuizen, maar ook van patiëntenverenigingen. Hiermee kunnen patiënten worden geïnformeerd over de
operatie, de bestraling of de behandeling met chemotherapie. Voor lotgenotencontact, informatie en
belangenbehartiging kunnen patiënten terecht bij een patiëntenvereniging. Voor patiënten met
hersentumoren is dat Vereniging Cerebraal, een patiëntenvereniging voor mensen die getroffen zijn door
hersenletsel.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
366
Gliomen
PDF aangemaakt op 
23-01-2025
830
/
971
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
Gliomen
PDF aangemaakt op 
23-01-2025
831
/
971
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
Gliomen
PDF aangemaakt op 
23-01-2025
832
/
971
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
Gliomen
PDF aangemaakt op 
23-01-2025
833
/
971
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
Gliomen
PDF aangemaakt op 
23-01-2025
834
/
971
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
Gliomen
PDF aangemaakt op 
23-01-2025
835
/
971
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
Gliomen
PDF aangemaakt op 
23-01-2025
836
/
971
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
Gliomen
PDF aangemaakt op 
23-01-2025
837
/
971
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
Gliomen
PDF aangemaakt op 
23-01-2025
838
/
971
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
Gliomen
PDF aangemaakt op 
23-01-2025
839
/
971
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
Gliomen
PDF aangemaakt op 
23-01-2025
840
/
971
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Gliomen
PDF aangemaakt op 
23-01-2025
841
/
971
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Gliomen
PDF aangemaakt op 
23-01-2025
842
/
971
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
Gliomen
PDF aangemaakt op 
23-01-2025
843
/
971
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
Gliomen
PDF aangemaakt op 
23-01-2025
844
/
971
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
Gliomen
PDF aangemaakt op 
23-01-2025
845
/
971
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
Gliomen
PDF aangemaakt op 
23-01-2025
846
/
971
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
Gliomen
PDF aangemaakt op 
23-01-2025
847
/
971
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
848
/
971
Rol verpleegkundige/verpleegkundig specialist bij gliomen
Uitgangsvraag
Wat is de rol van de verpleegkundige/verpleegkundig specialist bij de behandeling van patiënten met
gliomen?
Aanbeveling
De werkgroep is van mening dat de 
kwaliteitscriteria neuro-oncologie
 gevolgd dienen te worden:
Patiënten met een glioom weten wie de inhoudelijk eindverantwoordelijke (hoofdbehandelaar) is, wie
het aanspreekpunt en wie de zorgcoördinator is, tijdens alle fasen van de ziekte (diagnose-,
behandeltraject, follow-up en palliatieve/ terminale fase).
Binnen het behandelteam is er een gespecialiseerd verpleegkundige/verpleegkundig specialist neuro-
oncologie.
De verpleegkundige/verpleegkundig specialist neuro-oncologie of de hoofdbehandelaar is het
aanspreekpunt voor patiënten en zijn/haar naasten in alle fasen van de ziekte.
De verpleegkundige/verpleegkundig specialist neuro-oncologie kan vragen van de patiënt over
behandeling/ ziekte/problemen adequaat beantwoorden, hetzij op basis van eigen kennis, hetzij door
de benodigde informatie bij anderen na te vragen.
Patiënten ontvangen schriftelijk gegevens over bereikbaarheid van de verpleegkundige/verpleegkundig
specialist neuro-oncologie.
Patiënten weten bij wie ze terecht kunnen met (acute) problemen, binnen en buiten kantooruren.
De verpleegkundige/verpleegkundig specialist neuro-oncologie heeft structureel een eigen spreekuur
op de polikliniek, waar patiënten/naasten terecht kunnen voor advies/informatie aangaande hun ziekte.
Follow-up frequentie indien medische behandeling afgesloten is, wordt bepaald in overleg met patiënt
en naasten.
Overwegingen
In 2012 is het Beroepsprofiel voor de verpleegkundig specialist vastgesteld [Beroepsprofiel verpleegkundig
specialist V&V 2020, 2012
]. Hierin staat nauwkeurig beschreven wat de functie inhoudt en waar de taken uit
kunnen bestaan. De inhoud sluit goed aan bij de wensen van patiënten en hun naasten ten aanzien van de
zorg en begeleiding in het zorg- en behandelproces. Kernprincipes zijn:
De verpleegkundig specialist gaat eigen behandelrelaties aan binnen het aandachtsgebied waarin zij
deskundig is.
Vanuit de zorgvraag van de patiënt integreert de verpleegkundig specialist ‘cure en care' met als doel
de bevordering van de continuïteit en kwaliteit van de verpleegkundige zorg en de medische
behandeling, het vermogen tot zelfmanagement van de patiënt en de kwaliteit van leven
Vrijwel alle academische ziekenhuizen en de grote perifere ziekenhuizen in Nederland waar neuro-oncologie
een aandachtsgebied is, hebben een gespecialiseerd verpleegkundige/ verpleegkundig specialist binnen de
keten die op basis van specifieke deskundigheid betrokken is bij de zorg voor deze complexe patiënten
16
Gliomen
PDF aangemaakt op 
23-01-2025
849
/
971
groep. Daarnaast vervult de verpleegkundige de functie van casemanager en is zij mede verantwoordelijk
voor de juiste logistiek in het gehele ziekteproces van de patiënt.
Onderbouwing
Conclusies
Er zijn aanwijzingen dat de gespecialiseerde verpleegkundige zorg een belangrijke rol heeft in de neuro-
oncologische keten. De gespecialiseerde verpleegkundige richt zich in de zorg en begeleiding op de patiënt
met een hersentumor maar ook op de naasten.
Laurant 2009
, James 1994
, Leavitt 1996
, Sardell 2001
, Davies 1996
, Spetz 2005
, Clarke 2003
Samenvatting literatuur
Voorlichting en begeleiding over de gevolgen van de ziekte en behandeling is bij uitstek het terrein van een
gespecialiseerd verpleegkundige of verpleegkundig specialist met neuro-oncologie als aandachtsgebied.
Voor patiënten is het niet noodzakelijk dat alleen de arts de rol van voorlichter op zich neemt. Mits duidelijk is
wie welke rol vervuld is hier een grote ruimte voor een gespecialiseerd verpleegkundige [Laurant 2009
].
Binnen de neuro-oncologie wordt de rol van een gespecialiseerd verpleegkundige aanbevolen [James
1994
, Leavitt 1996
]. Een telefonisch spreekuur heeft zijn dienst al bewezen [Sardell 2001
].
Mantelzorgers maken ruim twee keer zoveel gebruik van telefonische zorg als patiënten zelf. De vragen
betreffen vooral het opnieuw informatie verstrekken, vragen over symptomen van de ziekte, en emotionele
ondersteuning [Curren 2001
]. De beste de zorg lijkt echter een combinatie van medisch en
(gespecialiseerde) verpleegkundige zorg [Davies 1996
]. Patiënten en naasten beschrijven de rol van de
verpleegkundige als een actief kameraadschap door het gehele ziekteproces. Belangrijke pijlers zijn
bereikbaarheid, een proactieve rol, flexibele ondersteuning en professionaliteit en tevens een persoonlijke
benadering [Spetz 2005
, Clarke 2003
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
194
151
198
297
70
325
61
194
151
198
297
66
70
325
61
Gliomen
PDF aangemaakt op 
23-01-2025
850
/
971
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
Gliomen
PDF aangemaakt op 
23-01-2025
851
/
971
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
Gliomen
PDF aangemaakt op 
23-01-2025
852
/
971
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
Gliomen
PDF aangemaakt op 
23-01-2025
853
/
971
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
Gliomen
PDF aangemaakt op 
23-01-2025
854
/
971
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
Gliomen
PDF aangemaakt op 
23-01-2025
855
/
971
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
Gliomen
PDF aangemaakt op 
23-01-2025
856
/
971
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
Gliomen
PDF aangemaakt op 
23-01-2025
857
/
971
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
Gliomen
PDF aangemaakt op 
23-01-2025
858
/
971
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
Gliomen
PDF aangemaakt op 
23-01-2025
859
/
971
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
Gliomen
PDF aangemaakt op 
23-01-2025
860
/
971
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
Gliomen
PDF aangemaakt op 
23-01-2025
861
/
971
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
Gliomen
PDF aangemaakt op 
23-01-2025
862
/
971
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
Gliomen
PDF aangemaakt op 
23-01-2025
863
/
971
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
Gliomen
PDF aangemaakt op 
23-01-2025
864
/
971
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
Gliomen
PDF aangemaakt op 
23-01-2025
865
/
971
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
Gliomen
PDF aangemaakt op 
23-01-2025
866
/
971
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
Gliomen
PDF aangemaakt op 
23-01-2025
867
/
971
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
868
/
971
Follow-up na gliomen
Deze module is onderverdeeld in de volgende submodules:
Onderscheiden tumorprogressie en therapie-effect
Radiologische follow-up tijdens behandeling
Postoperatieve scan
Radiologische follow-up na afronden behandeling
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
Gliomen
PDF aangemaakt op 
23-01-2025
869
/
971
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
Gliomen
PDF aangemaakt op 
23-01-2025
870
/
971
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
Gliomen
PDF aangemaakt op 
23-01-2025
871
/
971
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
Gliomen
PDF aangemaakt op 
23-01-2025
872
/
971
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
Gliomen
PDF aangemaakt op 
23-01-2025
873
/
971
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
Gliomen
PDF aangemaakt op 
23-01-2025
874
/
971
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
Gliomen
PDF aangemaakt op 
23-01-2025
875
/
971
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
Gliomen
PDF aangemaakt op 
23-01-2025
876
/
971
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
Gliomen
PDF aangemaakt op 
23-01-2025
877
/
971
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
Gliomen
PDF aangemaakt op 
23-01-2025
878
/
971
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
Gliomen
PDF aangemaakt op 
23-01-2025
879
/
971
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
Gliomen
PDF aangemaakt op 
23-01-2025
880
/
971
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
Gliomen
PDF aangemaakt op 
23-01-2025
881
/
971
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
Gliomen
PDF aangemaakt op 
23-01-2025
882
/
971
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Gliomen
PDF aangemaakt op 
23-01-2025
883
/
971
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
Gliomen
PDF aangemaakt op 
23-01-2025
884
/
971
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
Gliomen
PDF aangemaakt op 
23-01-2025
885
/
971
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Gliomen
PDF aangemaakt op 
23-01-2025
886
/
971
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
887
/
971
Onderscheiden tumorprogressie en therapie-effect bij gliomen
Uitgangsvraag
Welke diagnostische techniek (MRI, PET, CT perfusie, SPECT) is het beste in staat om bij patiënten met
gliomen tumorprogressie en therapie-effect (pseudoprogressie danwel radionecrose) van elkaar te
onderscheiden teneinde een optimale behandelingsstrategie te kunnen kiezen?
Aanbeveling
De werkgroep is van mening dat patiënten vervolgd dienen te worden met T1 MRI zonder en met contrast in
drie richtingen, aangevuld met T2/FLAIR beeldvorming. Indien hiermee in de follow-up twijfel ontstaat over
tumorprogressie of therapie-effect (pseudoprogressie dan wel radionecrose), kan worden overwogen de
specificiteit voor het aantonen van tumorprogressie te verhogen middels aanvullende MRI-series (zoals
perfusie-MRI-wegingen of spectroscopie), Tc-MIBI-, Thallium-, of GBA-SPECT en of C-MET-, F-DOPA-, of
FET-PET. Het beloop in de tijd, beoordeeld middels normale follow-up of eventueel met een vervroegde
controle-MRI-scan, kan ook waardevolle informatie verschaffen. Gezien het beperkt beschikbare bewijs, is
zowel het vervolgen als de aanvullende diagnostiek een keuze die per patiënt gemaakt kan worden. Bij
blijvende twijfel met name bij een symptomatische patiënt valt reoperatie te overwegen voor diagnostiek en
eventueel symptoombestrijding.
Overwegingen
Bij een aanzienlijk deel (30-50%) van de patiënten die met radiotherapie, eventueel gecombineerd met
chemotherapie, behandeld wordt voor een primaire hersentumor, zal vroeg of laat in het follow-up traject, op
beeldvorming onzekerheid optreden of er sprake is van tumorprogressie of therapie-effect (pseudoprogressie
dan wel radionecrose) [Taal 2008
, Brandes 2008
, Fink 2011
]. In de literatuur wordt de term
pseudoprogressie meestal gereserveerd voor de initiële post-behandeling scans; de term radionecrose wordt
vaak later in de follow-up gebruikt. Meestal zal deze twijfel ontstaan door toename in volume van de laesie,
nieuwe en/of toegenomen aankleuring zichtbaar na toediening van contrast op de follow-up-MRI binnen het
volume van de hersenen dat tot hoge dosis bestraald is. Het huidige literatuuronderzoek laat zien dat een
eerste post-behandeling-MRI vaak niet conclusieve beelden laat zien met aankleuring die meer oorzaken kan
hebben (sensitiviteit hoog, specificiteit laag). In de praktijk wordt de eerste MRI na behandeling dan ook
gebruikt als een uitgangsscan, en wordt een al dan niet versnelde opvolgende MRI scan gebruikt om meer
duidelijkheid te verkrijgen. Bij blijvende twijfel staat een scala aan aanvullende technieken, zoals aanvullende
MRI-technieken (perfusie, spectroscopie), PET (C-MET-PET, F-DOPA-PET, FET-PET) en SPECT (Tc-MIBI,
Tl,GBA-SPECT) ter beschikking. Gezien echter de matige kwaliteit van de beschikbare literatuur en de overlap
in specificiteit van de verschillende methodes kan geen voorkeur uitgesproken worden voor een daarvan. Een
belangrijke overweging in de keuze voor aanvullende beeldvorming is de ervaring met een van deze
specifieke onderzoeken binnen het centrum. Ook bij deze aanvullende onderzoeken zal echter enige
onzekerheid blijven bestaan over de aard van de progressieve afwijkingen. Men moet zich realiseren dat de
kans op pseudoprogressie het grootste is in de eerste drie maanden na de bestraling en afname in de tijd
nadien, past derhalve bij pseudoprogressie. Indien twijfel blijft bestaan kan, met name in geval van klinische
verschijnselen van de aankleurende laesie, besloten worden tot reoperatie voor een definitieve diagnose en
334
28
97
Gliomen
PDF aangemaakt op 
23-01-2025
888
/
971
tevens symptoombestrijding. De a-priori kans op pseudoprogressie/radionecrose, die het grootste is in de
eerste drie maanden na de bestraling of chemoradiatie en na hogere bestralingsdoses (>50 Gy), dient te
worden meegenomen in deze overweging.
Onderbouwing
Conclusies
Het is aannemelijk dat contrast-enhanced-MR een sensitiviteit van 71-97% en een specificiteit van 24-90%
heeft voor de detectie van tumorprogressie (versus radionecrose/pseudoprogressie).
Niveau 2
: B Karunanithi 2013
, Khangembam 2013
, Santra 2011b
, Santra 2012
, Ozsunar 2010
,
Barajas 2009
, Chung 2013
, Fink 2012
, Xu 2010
, Xu 2011
 
Het is aannemelijk dat perfusie-MR een sensitiviteit van 88% en een specificiteit van 85% heeft.
Niveau 2
: B Deng 2013
Het is aannemelijk dat MR-spectroscopie een sensitiviteit van 64-89% en een specificiteit van 82-89% heeft.
Niveau 2
: : B Hollingworth 2006
Er zijn aanwijzingen dat perfusie-CT een sensitiviteit van 82% en een specificiteit van 82-90% heeft.
Niveau 3
: B Jain 2011
Het is aannemelijk dat Tc-MIBI-SPECT een sensitiviteit van 90% en een specificiteit van 92% heeft.
Niveau 2
: B Cheng 2011
Het is aannemelijk dat 
TI-SPECT een sensitiviteit van 40-100% en een specificiteit van 25-100% heeft.
Niveau 2
: B Vos 2007
Er zijn aanwijzingen dat SPECT/CT een sensitiviteit van 86% en een specificiteit van 63% heeft.
Niveau 3
: B Karunanithi 2013a
Het is aannemelijk dat GHA-SPECT een sensitiviteit van 85-86% en een specificiteit van 97% heeft.
Niveau 2
: B Santra 2011a/b
 
Het is aannemelijk dat C-MET-PET een sensitiviteit van 55-87% en een specificiteit van 70-100% heeft.
Niveau 2
: : B Deng 2013
, Nihashi 2013
Het is aannemelijk dat FDG-PET een sensitiviteit van 77% en een specificiteit van 78% heeft op basis van een
meta-analyse [Nihashi] en een sensitiviteit van 81% en een specificiteit van 90% op basis van een bijkomende
oorspronkelijke studie [Ozsunar].
Niveau 2
: B Nihashi 2013
, Ozsunar 2010
Er zijn aanwijzingen dat FLT/FET-PET een sensitiviteit van 82-91% en een specificiteit van 88-100% heeft.
Niveau 3
: B Jeong 2010
164
172
295
296
242
8
59
97
394
395
77
139
148
56
201
370
164
294
295
77
229
229
242
158
Gliomen
PDF aangemaakt op 
23-01-2025
889
/
971
Het is aannemelijk dat F-DOPA-PET/CT een sensitiviteit van 100% en een specificiteit va 88-89% heeft.
Niveau 2
: B Kanunanithi 2013a/b
 
Er zijn aanwijzingen dat N-ammonia-PET/CT een sensitiviteit van 83% en een specificiteit van 86%
heeft.
Niveau 3
: B Khangembam 2013
Er zijn aanwijzingen dat C-MET PET/CT een sensitiviteit van 96% en een specificiteit van 88% heeft.
Niveau 3
: B Li 2012
Het is aannemelijk dat FDG-PET/CT een sensitiviteit van 40-70% en een specificiteit van 97-100% heeft.
Niveau 2
: B Li 2012
, Santra 2011a
, Santra 2012
Bovenstaande conclusies zijn in onderstaande tabel 1 schematisch weergegeven.
Tabel 1. Differentiëren tussen tumorprogressie en therapie-effect
164
165
172
202
202
294
296
Gliomen
PDF aangemaakt op 
23-01-2025
890
/
971
Voor de diagnose van
recurrence
Test
Sens (%)
Spec (%)
Studies
Het is aannemelijk dat de
sensitiviteit en de
specificiteit....
(
Niveau 2)
Tc-MIBI-SPECT
90
92
Cheng 2011
201TI-SPECT
40-100
25-100
Vos 2007
GHA-SPECT
85-86
97
Santra 2011a/b
 
C-MET PET/CT
55-96
70-100
Deng 2013
, Nihashi 2013
, Li
2012
FDG PET/CT
40-81
78-100
Nihashi 2013
, Ozsunar
2010
, Li 2012
, Santra
2011a
, Santra 2012
F-DOPA PET/CT
100
88-89
Kanunanithi 2013a/b
 
Contrast-enhanced
MR
71-97
24-90
Karunanithi 2013
,
Khangembam 2013
, Santra
2011b
, Santra 2012
,
Ozsunar 2010
, Barajas 2009
,
Chung 2013
, Fink 2012
, Xu
2010/2011
 
Perfusie MR
88
85
Deng 2013
MR spectroscopie
64-89
82-89
Hollingworth 2006
Er zijn aanwijzingen dat dat
de sensitiviteit en de
specificiteit....... 
(
Niveau 3)
SPECT/CT
86
63
Karunanithi 2013a
FLT/FET PET
82-91
88-100
Jeong 2010
N-ammonia PET/CT
83
86
Khangembam 2013
Perfusie CT
82
82-90
Jain 2011
Samenvatting literatuur
We selecteerden vijf systematische reviews, welke in totaal 62 studies includeerden. Bijkomend werden 17
artikelen (16 studies) geselecteerd. Van deze 16 studies is er nog mogelijke overlap tussen de twee studies
van Karunanithi en tussen de drie studies van Santra. Het is om die reden onmogelijk het totaal aantal
patiënten correct te berekenen, maar uitgaande van de gerapporteerde patiëntenaantallen werden in de
oorspronkelijke studies maximaal 831 patiënten ingesloten (mediaan 40, minimum 30, maximum 93). In de
volgende studies werden ook patiënten met graad I-gliomen opgenomen: [Karunanithi 2013a
] (3,7% van
de populatie), [Karunanithi 2013b
] (6%), [Khangembam 2013
] (1,9%), [Santra 2011a
] (9%), [Santra
2011b
] (4,8%), [Santra 2012
] (10%).
De studies die in de systematische reviews werden geïncludeerd en de bijkomende oorspronkelijke studies
die door ons werden geïdentificeerd hadden allemaal belangrijke methodologische tekortkomingen. Slechts
een studie kreeg een A2-niveau van evidence [Chung 2013
], alle andere studies kregen een B. De
belangrijkste redenen voor dit lage niveau van evidence zijn de kleine patiëntenpopulaties en het gebruik van
56
370
294
295
77
229
202
229
242
202
294
296
164
165
164
172
295
296
242
8
59
97
394
395
77
139
164
158
172
148
164
165
172
294
295
296
59
Gliomen
PDF aangemaakt op 
23-01-2025
891
/
971
meerdere referentiestandaarden waarbij in vele gevallen ook de indextest werd gebruikt als
referentiestandaard tijdens follow-up (incorporation bias). 
MRI (Magnetic Resonance Imaging)
De sensitiviteit van contrast-enhanced-MRI was 92,3-96,7% en de specificiteit 24,1-48,3% in vier studies
[Karunanithi 2013b
, Khangembam 2013
, Santra 2011b
 en Santra 2012
]. In de studies van
Khangembam en Santra werd de accuratesse ook berekend voor subgroepen naar glioomtype. Er werden
geen duidelijke verschillen teruggevonden op basis van de 95%-betrouwbaarheidsintervallen. Arterial spin-
labeled beelden hadden een sensitiviteit van 88% en een specificiteit van 89%, en dynamic susceptibility
contrast-enhanced cerebral bloodvolume beelden een sensitiviteit van 86% en specificiteit van 70% [Ozsunar
2010
]. Daarnaast kunnen Dynamic Contrast-Enhanced Magnetic Resonance (DCE MR) (T1) perfusie
opnames worden gebruikt [Chung 2013
].
Vijf studies evalueerden de accuratesse van verschillende afkappunten voor MRI-beelden [Barajas 2009
,
Chung 2013
, Fink 2012
, Ozsunar 2010
, Xu 2010
/2011
]. De afwezigheid van 95%-
betrouwbaarheidsintervallen of statistische toetsing maakt dat we geen duidelijke uitspraken kunnen doen
over eventuele verschillen; de sensitiviteit varieert van 71%-95,7% en de specificiteit van 40%-90,0%.
Een bepaald MRI-patroon suggestief voor recurrence (solid enhancement with distinct margins or focally
enhancing nodules) had een sensitiviteit van 85% en een specificiteit van 33% [Reddy 2013
]. Tenslotte
kwam in een studie alleen subependymale aankleuring naar voren als significant teken van progressie,
sensitiviteit was 38,1% en de specificiteit 93,3% [Young 2011
].
De systematische review van Deng includeerde zeven studies voor perfusie-MRI en vond een sensitiviteit van
88% en een specificiteit van 85%. 
Hollingworth includeerde vier studies voor MRI-spectroscopie en rapporteerde een sensitiviteit tussen 64-
89% en een specificiteit tussen 82-89%. 
CT (Computed Tomography)
Er was een studie beschikbaar naar de accuratesse van perfusie-CT, met een sensitiviteit van 81,5% en een
specificiteit van 81,8-90% voor twee verschillende parameters (rCBV 1,5 en PS 2,5) [Jain 2011
].
SPECT (Single-Photon Emission Computed Tomography)
De diagnostische accuratesse van SPECT werd gerapporteerd in twee systematische reviews [Cheng 2011
,
Vos 2007
] en in drie oorspronkelijke studies [Karunanithi 2013a
, Santra 2011a
, Santra 2011b
].
De sensitiviteit en specificiteit van Tc-MIBI-SPECT (Technetium Methoxyisobutylisonitrile SPECT) was
respectievelijk 89,8% en 91,9% op basis van een meta-analyse van zes studies [Cheng 2011
].
De systematische review van Vos voerde geen meta-analyse uit omwille van de belangrijke heterogeniteit, en
rapporteerde voor 
TI (Thallium)-SPECT een sensitiviteit tussen 43-100% en een specificiteit tussen 25-
100%. 
Een primaire prospectieve studie vond voor SPECT-CT een sensitiviteit van 86,4% en een specificiteit van
62,5% [Karunanithi 2013a
]. Het hanteren van verschillende afkapwaarden resulteerde in lagere sensitiviteit
en hogere specificiteit: T/S (tumour/striatum) ratio van 0,83 sensitiviteit 75%, specificiteit 86%; T/NP
(tumour/nasopharynx) ratio 0,2 sensitiviteit 50%, specificiteit 95%. 
Tenslotte werd GHA (glucoheptonate)-SPECT geëvalueerd in twee studies met een sterk vermoeden van
gedeeltelijke overlap in de patiëntenpopulatie [Santra 2011a
, Santra 2011b
]. In deze studies werd een
165
172
295
296
242
59
8
59
97
242
394
395
275
405
148
56
370
164
294
295
56
201
164
294
295
Gliomen
PDF aangemaakt op 
23-01-2025
892
/
971
sensitiviteit van 84,7%-86,5% en specificiteit van 96,8-96,5% gerapporteerd. 
PET (Positron Emission Tomography)
Er waren twee systematische reviews met resultaten over PET [Deng 2013
, Nihashi 2013
]. Deng vond
voor C-MET (Methionine)-PET een gepoolde sensitiviteit en specificiteit van 87% en 81,3% op basis van elf
studies, Nihashi heeft voor C-MET-PET geen meta-analyse uitgevoerd en vond een sensitiviteit van 55-80% en
een specificiteit van 70-100% op basis van zeven studies. Voor enkel hooggradige gliomen leek de sensitiviteit
iets hoger (70%). 
Nihashi vond voor FDG-PET een gepoolde sensitiviteit van 77% en een gepoolde specificiteit van 78%, met
vergelijkbare accuratesse bij enkel hooggradige gliomen. Bijkomend werd voor FDG-PET een sensitiviteit van
81% en een specificiteit van 90% gevonden in een primaire diagnostische studie [Ozsunar 2010
]. 
FLT/FET-PET werd gerapporteerd in een oorspronkelijke studie [Jeong 2010
] voor verschillende
afkapwaarden, variërend met een sensitiviteit van 81,8-91,3% en een specificiteit van 87,5-100%. 
PET/CT
Twee studies evalueerden F-DOPA (Fluorodopa) PET/CT [Karunanithi 2013a
, Karunanithi 2013b
], waarbij
er mogelijke een overlap is tussen deze studies. De sensitiviteit was 100% in beide studies, de specificiteit
87,5% en 88,9% respectievelijk. In de eerste studie werden ook nog verschillende afkappunten geanalyseerd,
resulterend in een onveranderde sensitiviteit (87,5%) en een specificiteit variërend tussen 95,4-100%. 
N-ammonia-PET/CT had in een studie een sensitiviteit van 82,6% en een specificiteit van 86,2%; verschillende
afkapwaarden resulteerden in een sensitiviteit variërend tussen 65,2-73,9% en een specificiteit tussen 82,8-
89,7% [Khangembam 2013
]. 
Er was een oorspronkelijke studie voor C-MET-PET/CT welke een sensitiviteit van 96,4% en een specificiteit
van 87,5% rapporteerde [Li 2012
]. 
Voor FDG (Fludeoxyglucose)-PET/CT waren drie studies beschikbaar [Li 2012
, Santra 2011a
, Santra
2012
], maar deze twee rapporteren identieke resultaten en zijn vermoedelijk gebaseerd op dezelfde
patiënten [Santra 2011a, Santra 2012]. Hierdoor zijn er slechts twee in plaats vandrie sets van resultaten
beschikbaar: de sensitiviteit is46,4% en 69,5%, de specificiteit is 100% en 96,8%.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
77
229
242
158
164
165
172
202
202
294
296
Gliomen
PDF aangemaakt op 
23-01-2025
893
/
971
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
Gliomen
PDF aangemaakt op 
23-01-2025
894
/
971
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
Gliomen
PDF aangemaakt op 
23-01-2025
895
/
971
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
Gliomen
PDF aangemaakt op 
23-01-2025
896
/
971
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
Gliomen
PDF aangemaakt op 
23-01-2025
897
/
971
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
Gliomen
PDF aangemaakt op 
23-01-2025
898
/
971
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
Gliomen
PDF aangemaakt op 
23-01-2025
899
/
971
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
Gliomen
PDF aangemaakt op 
23-01-2025
900
/
971
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
Gliomen
PDF aangemaakt op 
23-01-2025
901
/
971
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
Gliomen
PDF aangemaakt op 
23-01-2025
902
/
971
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
Gliomen
PDF aangemaakt op 
23-01-2025
903
/
971
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
Gliomen
PDF aangemaakt op 
23-01-2025
904
/
971
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
Gliomen
PDF aangemaakt op 
23-01-2025
905
/
971
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
Gliomen
PDF aangemaakt op 
23-01-2025
906
/
971
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
Gliomen
PDF aangemaakt op 
23-01-2025
907
/
971
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
Gliomen
PDF aangemaakt op 
23-01-2025
908
/
971
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
Gliomen
PDF aangemaakt op 
23-01-2025
909
/
971
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
Gliomen
PDF aangemaakt op 
23-01-2025
910
/
971
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
911
/
971
Radiologische follow-up tijdens behandeling bij het glioblastoom
Uitgangsvraag
Met welke frequentie dient radiologische follow-up plaats te vinden tijdens behandeling bij het glioblastoom?
Aanbeveling
De werkgroep is van mening dat, zeker indien een (experimentele) vervolgbehandeling tot de mogelijkheden
behoort, MRI-beeldvorming op gezette tijden de meest voor de hand liggende strategie is. In overleg met de
patiënt kan hier van worden afgezien en op klinische indicatie beeldvorming worden verricht.
Overwegingen
Omdat MRI-beeldvorming tijdens chemoradiotherapie behandeling verwarrende uitkomsten kan opleveren,
zal voorafgaand aan het verrichten van deze beeldvorming het doel en de consequentie hiervan bij de
behandelaren alsmede de patiënt en diens naasten duidelijk moeten zijn. Een MRI-scan met moeilijk te
interpreteren beelden kan onrust veroorzaken bij patiënt en familie. Echter, wanneer de eerste scan pas na
de zesde adjuvante kuur gemaakt wordt, worden patiënten potentieel langer dan nodig blootgesteld aan
ineffectieve chemotherapie.
Steeds zal de onrust, veroorzaakt door een potentieel moeilijk interpreteerbare MRI kort na de bestraling,
moeten worden afgewogen tegen het voordeel van op een vroeger tijdstip vaststellen van een recidief met
potentieel een betere uitgangssituatie voor (experimentele) vervolgbehandeling evenals het tijdig staken van
ineffectieve chemotherapie.
Onderbouwing
Conclusies
De werkgroep is van mening dat er geen bewijs is voor een specifieke strategie ten aanzien van het maken
van vervolgscans tijdens gecombineerde chemoradiatiebehandeling, maar dat de enige onderzochte
strategie MRI-beeldvorming is vier weken na (chemo-)radiotherapie en na de derde en zesde adjuvante kuur.
Stupp 2005
Samenvatting literatuur
De direct postoperatieve MRI wordt in de module 
Postoperatieve scan
 besproken. In deze module zal alleen
worden ingegaan op de MRI-beeldvorming tijdens chemo-radiotherapie behandeling. Er zijn geen publicaties
gevonden waarin de invloed van het moment en de frequentie van MRI-beeldvorming tijdens de behandeling
op het ziektebeloop of de prognose wordt onderzocht.
In de oorspronkelijke studie waarin de toegevoegde waarde van gelijktijdig en adjuvant temozolomide
chemotherapie bij het glioblastoom werd aangetoond, EORTC-studie-26981, werd MRI-beeldvorming
verricht vier weken na de radiotherapie, evenals na de derde en na de zesde adjuvante kuur [Stupp 2005
].
Een MRI met name in de eerste drie maanden na de (chemo)radiotherapie levert vaak moeilijk
interpreteerbare beelden op met 20-30% pseudoprogressie als gevolg van de behandeling [Wen 2010
, Van
den Bent 2011
, Vogelbaum 2012
]. Zie ook de evidence based module 
Onderscheiden tumorprogressie
332
331
382
359
368
Gliomen
PDF aangemaakt op 
23-01-2025
912
/
971
en therapie-effect
. Deze pseudoprogressie is zichtbaar als aankleuring op een T1-gewogen opname na
contrast en is moeilijk met zekerheid te onderscheiden van werkelijke tumorprogressie. Alleen wanneer er
binnen de eerste drie maanden na bestraling een nieuwe aankleurende laesie is 
buiten
 het bestralingsveld
kan met zekerheid gesteld worden dat er sprake is van progressie. Het doel van de MRI vier weken na de
radiotherapie is dan ook voornamelijk om een uitgangswaarde te hebben waarmee vervolgscans kunnen
worden vergeleken. Een andere mogelijkheid is om de eerste MRI na de chemoradiotherapie behandeling
pas laat te maken bijvoorbeeld na drie adjuvante kuren of zelfs na beëindiging van de gehele behandeling.
Het risico van deze strategie is dat een recidief pas wordt vastgesteld wanneer klinische achteruitgang is
opgetreden met verslechtering van de conditie en daarmee een slechtere uitgangssituatie voor
(experimentele) vervolgbehandeling. Net als bij het nieuw gediagnostiseerd glioom is ook bij patiënten met
een recidief glioom een slechtere performancestatus bij aanvang van de recidiefbehandeling een
prognostisch ongunstige factor [Wong 1999
, Park 2010
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
390
249
Gliomen
PDF aangemaakt op 
23-01-2025
913
/
971
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
Gliomen
PDF aangemaakt op 
23-01-2025
914
/
971
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
Gliomen
PDF aangemaakt op 
23-01-2025
915
/
971
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
Gliomen
PDF aangemaakt op 
23-01-2025
916
/
971
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
Gliomen
PDF aangemaakt op 
23-01-2025
917
/
971
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
Gliomen
PDF aangemaakt op 
23-01-2025
918
/
971
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
Gliomen
PDF aangemaakt op 
23-01-2025
919
/
971
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
Gliomen
PDF aangemaakt op 
23-01-2025
920
/
971
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
Gliomen
PDF aangemaakt op 
23-01-2025
921
/
971
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Gliomen
PDF aangemaakt op 
23-01-2025
922
/
971
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
Gliomen
PDF aangemaakt op 
23-01-2025
923
/
971
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
Gliomen
PDF aangemaakt op 
23-01-2025
924
/
971
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
Gliomen
PDF aangemaakt op 
23-01-2025
925
/
971
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
Gliomen
PDF aangemaakt op 
23-01-2025
926
/
971
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
Gliomen
PDF aangemaakt op 
23-01-2025
927
/
971
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
Gliomen
PDF aangemaakt op 
23-01-2025
928
/
971
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
Gliomen
PDF aangemaakt op 
23-01-2025
929
/
971
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
Gliomen
PDF aangemaakt op 
23-01-2025
930
/
971
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
931
/
971
Postoperatieve scan bij gliomen
Uitgangsvraag
Wat is het moment waarop de eerste postoperatieve scan moet worden gemaakt bij patiënten met een
laaggradig/anaplastisch/glioblastoom?
Aanbeveling
De werkgroep is van mening dat een vroege postoperatieve MRI (<72uur) voor zowel laag- als hooggradige
tumoren zinvol kan zijn. Er is echter geen bewijs dat het weglaten van deze vroege postoperatieve MRI
nadelige prognostische consequenties heeft. Daarom is het wel of niet maken van een direct postoperatieve
MRI een keuze die in samenspraak tussen de verschillende behandelaars gemaakt dient te worden.
Onderbouwing
Conclusies
Het is aannemelijk dat op een vroege postoperatieve MRI-scan de mate van tumorresectie kan worden
vastgesteld bij aankleurende gliomen.
Van den Bent 2013
, Cairncross 2013
, Zaidi 2014
, Smets 2013
, Albert 1994
, Ekinci 2003
Het is aannemelijk dat een vroege postoperatieve MRI-scan als uitgangsscan kan dienen voor verdere follow-
up MRI's bij aankleurende gliomen.
Van den Bent 2013
, Cairncross 2013
, Zaidi 2014
, Smets 2013
, Albert 1994
, Ekinci 2003
Er zijn aanwijzingen dat een vroege postoperatieve MRI het meest betrouwbaar is zo vroeg mogelijk na de
operatie en in ieder geval binnen 72 uur.
Zaidi 2014
, Smets 2013
, Albert 1994
, Ekinci 2003
Het is niet bekend of het wel of niet maken van een direct postoperatieve MRI tot verschillen leidt in
behandeling en/of overleving.
Zaidi 2014
, Smets 2013
, Albert 1994
, Ekinci 2003 
Samenvatting literatuur
In de RANO-richtlijnen [Wen 2010
, Van den Bent 2011
, Vogelbaum 2012
] wordt aangeraden de eerste
postoperatieve scan bij laag- en hooggradige gliomen zo vroeg mogelijk en in ieder geval binnen 72 uur na
de operatie te maken om resttumor en operatie-effecten zoals ischemie (zichtbaar als diffusierestrictie) en
contusie vast te kunnen stellen. Als de MRI-scan later wordt gemaakt kunnen postoperatieve effecten zorgen
voor aankleuring op T1-gewogen MRI-opnames na contrast die niet te onderscheiden is van rest- of
recidieftumor [Cairncross 2013
, Zaidi 2014
]. Voor glioblastoom en anaplastisch glioom (met aankleuring)
kan deze MRI tevens dienen als uitgangs-MRI voor de mate van resttumor. Bij laaggradige tumoren en
anaplastisch glioom zonder aankleuring is het volgens de RANO-richtlijn raadzaam de uitgangs-MRI voor T2-
gewogen beelden later dan twaalf weken na de operatie plaats te laten vinden [Wen 2010
, Van den Bent
2011
, Vogelbaum 2012
]. Bij een eerdere MRI-scan kan er nog postoperatief oedeem aanwezig zijn die
354
41
408
318
4
90
354
41
408
318
4
90
408
318
4
90
408
318
4
90
382
359
368
41
408
382
359
368
Gliomen
PDF aangemaakt op 
23-01-2025
932
/
971
niet te onderscheiden is van resttumor. Echter ook voor laaggradige tumoren kan worden overwogen om een
vroege MRI te maken korter dan 72 uur na de operatie. Het eventuele effect van een vroege postoperatieve
MRI op behandelkeuzes en patiënten-uitkomstmaten is niet bekend. Voor de interpretatie van veranderingen
op MRI bij verdere follow-up met MRI-beeldvorming is de uitgangs-MRI-scan wel van belang.
Gezien de rol van de (rest)aankleuring bij de afweging om een MRI-scan vroeg (<48-72uur) of laat (>12
weken) na de operatie te maken zal bij hooggradige gliomen het moment van de MRI-scan afhangen van de
wel/niet aanwezige aankleuring. Als er aankleuring aanwezig is, lijkt het het meest logisch om ook bij deze
hooggradige gliomen de postoperatieve MRI binnen 48-72uur na de operatie te maken [Van den Bent
2013
, Cairncross 2013
].Er is discussie over de waarde van deze direct postoperatieve MRI omdat er ook
al vroeg aankleuring aanwezig kan zijn, bijvoorbeeld door operatieve manipulatie en bloed-hersenbarrière
verstoring [Zaidi 2014
]. Wel is de aanwezigheid van aankleuring op een vroege postoperatieve scan een
prognostische factor [Smets 2013
, Albert 1994
, Ekinci 2003
]. Er zijn geen vergelijkende studies gedaan
waarbij de prognostische waarde is vergeleken tussen de vaak gehanteerde <48uur of <72uur postoperatieve
MRI's [Albert 1994
, Ekinci 2003
].
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
354
41
408
318
4
90
4
90
Gliomen
PDF aangemaakt op 
23-01-2025
933
/
971
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
Gliomen
PDF aangemaakt op 
23-01-2025
934
/
971
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
Gliomen
PDF aangemaakt op 
23-01-2025
935
/
971
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
Gliomen
PDF aangemaakt op 
23-01-2025
936
/
971
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
Gliomen
PDF aangemaakt op 
23-01-2025
937
/
971
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Gliomen
PDF aangemaakt op 
23-01-2025
938
/
971
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
Gliomen
PDF aangemaakt op 
23-01-2025
939
/
971
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
Gliomen
PDF aangemaakt op 
23-01-2025
940
/
971
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
Gliomen
PDF aangemaakt op 
23-01-2025
941
/
971
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Gliomen
PDF aangemaakt op 
23-01-2025
942
/
971
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
Gliomen
PDF aangemaakt op 
23-01-2025
943
/
971
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
Gliomen
PDF aangemaakt op 
23-01-2025
944
/
971
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
Gliomen
PDF aangemaakt op 
23-01-2025
945
/
971
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
Gliomen
PDF aangemaakt op 
23-01-2025
946
/
971
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
Gliomen
PDF aangemaakt op 
23-01-2025
947
/
971
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
Gliomen
PDF aangemaakt op 
23-01-2025
948
/
971
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
Gliomen
PDF aangemaakt op 
23-01-2025
949
/
971
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
Gliomen
PDF aangemaakt op 
23-01-2025
950
/
971
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
951
/
971
Radiologische follow-up na afronden behandeling bij glioblastoom
Uitgangsvraag
Met welke frequentie dient radiologische follow-up plaats te vinden na afronden van de behandeling bij het
laaggradig/anaplastisch/glioblastoom?
Aanbeveling
De werkgroep is van mening dat radiologische follow-up bij patiënten met een glioom alleen moet worden
verricht wanneer er klinische en/of therapeutische consequenties zijn. 
Het doel van radiologische follow-up is het in een vroeg stadium opsporen van tumorgroei en daarmee de
mogelijkheid voor en de slagingskans van vervolgbehandeling al dan niet in studieverband te optimaliseren.
De werkgroep is van mening dat de volgende radiologische follow-up frequentie gehanteerd kan worden:
patiënten met een glioblastoom (WHO graad IV): drie tot zes maanden
patiënten met een anaplastisch glioom (WHO graad III): drie tot zes maanden
patiënten met een laaggradig glioom (WHO graad II): zes tot twaalf maanden
De werkgroep is van mening dat mede gezien het ontbreken van wetenschappelijk bewijs, tumorfactoren en
patiëntgerelateerde factoren een rol spelen in het komen tot een optimale follow-up frequentie voor de
individuele patiënt binnen de hierboven genoemde grenzen.
Overwegingen
De optimale radiologische follow-up frequentie bij patiënten met een laag- of hooggradig glioom zal van
verschillende factoren afhankelijk zijn. Bij het ontbreken van vergelijkende studies of series in de literatuur
zullen klinische en/of patiëntgerelateerde argumenten een grote rol spelen. Zo kan grootte en lokatie van
(rest)tumor belangrijk zijn en kan ook de wens van de patiënt meegewogen worden. Daarnaast kan
kosteneffectiviteit een argument zijn in de besluitvorming over follow-up frequentie.
Geplande follow-up zal in het algemeen alleen plaatsvinden als er behandelmogelijkheden of klinische
consequenties bestaan bij aantonen van recidief tumor, tumorgroei of radiologische kenmerken van
dedifferentiatie naar hogere gradering. Het doel van de follow-up is om voorgenoemde events in een vroeg
stadium op te sporen, vóór de patiënt (ernstige) neurologische uitvalsverschijnselen vertoont. De
mogelijkheid voor en de slagingskans van een vervolgbehandeling of behandeling in studieverband is
namelijk sterk afhankelijk van de performance status van de patiënt.
In hoeverre de hoge follow-up frequentie in de studies van Stupp en Van den Bent daadwerkelijk heeft
bijgedragen aan de overlevingswinst van respectievelijk patiënten met een glioblastoom en een AO is niet
duidelijk. Het vroeg opsporen van recidieftumor of tumorgroei heeft mogelijk wel geleid tot het eerder of
vaker starten van een vervolgbehandeling.
Onderbouwing
Conclusies
Gliomen
PDF aangemaakt op 
23-01-2025
952
/
971
De werkgroep is van mening dat op basis van de literatuur geen uitspraak kan worden gedaan over de
optimale frequentie van radiologische follow-up voor patiënten met hoog- en laaggradige gliomen. In een
aantal klinische trials is de methode en frequentie van follow-up duidelijk beschreven [Stupp 2005
, Van den
Bent 2013
]. In de overige trials is de frequentie van follow-up variabel óf niet beschreven.
Samenvatting literatuur
Er zijn voor zowel laag- als hooggradige gliomen geen studies waarin verschillende frequenties van
radiologische follow-up worden vergeleken. 
In de studie van Stupp [Stupp 2005
],die de standaardbehandeling van het glioblastoom herdefinieerde,
werd een follow-up frequentie van drie maanden aangehouden. Twee trials bij anaplastische
oligodendrogliomen [Van den Bent 2013
, Cairncross 2013
] hanteerden verschillende follow-up
frequenties. In de studie van Van den Bent werd elke drie maanden een MRI of CT verricht. In de studie van
Cairncross wordt geen precieze follow-up frequentie genoemd, maar beschreven als variabel en oplopend
qua interval, naarmate de overleving langer werd. Na vijf jaar werd een MRI of CT jaarlijks gemaakt of alleen
‘wanneer nodig'. Bij deze twee studies waren de progressie vrije overleving (PFS) en de totale overleving (OS)
vergelijkbaar. Wick onderzocht bij patiënten met een anaplastische astrocytoom de volgorde van
behandeling (radiotherapie gevolgd door chemotherapie en andersom) daarbij werd de frequentie en
methode van follow-up niet beschreven [Wick 2009
, Wick 2012
]. Bij laaggradige tumoren is in studies en
beschreven series de gehanteerde follow-up frequentie variabel (zes tot twaalf maanden) óf niet
gerapporteerd.
Verantwoording
Laatst beoordeeld
 : 15-04-2015
Laatst geautoriseerd
 : 15-04-2015
Voor de volledige verantwoording, evidence tabellen en eventuele aanverwante producten raadpleegt u de
Richtlijnendatabase.
Referenties
1
 - Agarwal S, Sharma MC, Jha P, et al. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA
sequencing. Neuro-oncology 2013;15(6):718-26.
2
 - Ahmadi R, Dictus C, Hartmann C, et al. Long-term outcome and survival of surgically treated supratentorial low-grade
glioma in adult patients. Acta neurochirurgica 2009;151(11):1359-65.
3
 - Ahmadi R, Stockhammer F, Becker N, et al. No prognostic value of IDH1 mutations in a series of 100 WHO grade II
astrocytomas. Journal of neuro-oncology 2012;109(1):15-22.
4
 - Albert FK, Forsting M, Sartor K et al. Early postoperative magnetic resonance imaging after resection of malignant glioma:
objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery. 1994 Jan;34(1):45-60;
discussion 60-1.
5
 - Amichetti M, Amelio D. A Review of the Role of Re-Irradiation in Recurrent High-Grade Glioma (HGG). Cancers
2011;3(4):4061-89.
6
 - Babu R, Adamson DC. Rindopepimut: an evidence-based review of its therapeutic potential in the treatment of EGFRvIII-
positive glioblastoma. Core evidence 2012;7:93-103.
7
 - Ban, A.W. van de. Voorlichting en voorlichtingskunde 1985
8
 - Barajas, R.F., Jr. et al., Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam
radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology, 2009. 253(2): p.
331
354
331
351
41
386
387
Gliomen
PDF aangemaakt op 
23-01-2025
953
/
971
486-96.
9
 - Barone DG, Lawrie TA, Hart MG. Image guided surgery for the resection of brain tumours. The Cochrane database of
systematic reviews 2014;1:CD009685.
1
0 - Barratt A, Trevena L, Davey HM, et al. Use of decision aids to support informed choices about screening. Bmj
2004;329(7464):507-10.
1
1 - Batchelor TT, Mulholland P, Neyns B, et al. Phase III randomized trial comparing the efficacy of cediranib as monotherapy,
and in combination with lomustine, versus lomustine alone in patients with recurrent glioblastoma. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2013;31(26):3212-8.
1
2 - Bauchet L, Mathieu-Daude H, Fabbro-Peray P, et al. Oncological patterns of care and outcome for 952 patients with newly
diagnosed glioblastoma in 2004. Neuro-oncology 2010;12(7):725-35.
1
3 - Bauchet L, Zouaoui S, Darlix A, et al. Assessment and treatment relevance in elderly glioblastoma patients. Neuro-
oncology 2014;16(11):1459-68.
1
4 - Baumert BG MW, Ryan G et al. Temozolomide chemotherapy versus radiotherapy in molecularly characterized (1p loss)
low-grade glioma: A randomized phase III intergroup study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-
26033). Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(Abstract 2007).
1
5 - Berendsen S, Broekman M, Seute T et al.(2012). Valproic acid for the treatment of malignant gliomas: review of the
preclinical rationale and published clinical results. Expert Opin Investig Drugs, 21(9):1391-415
1
6 - Beroepsprofiel verpleegkundig specialist V&V 2020, 2012
1
7 - Bianco Ade M, Miura FK, Clara C, et al. Low-grade astrocytoma: surgical outcomes in eloquent versus non-eloquent brain
areas. Arquivos de neuro-psiquiatria 2013;71(1):31-4.
1
8 - Bleehen NM, Stenning SP. A Medical Research Council trial of two radiotherapy doses in the treatment of grades 3 and 4
astrocytoma. The Medical Research Council Brain Tumour Working Party. British journal of cancer 1991;64(4):769-74.
1
9 - Bleehen NM, Wiltshire CR, Plowman PN, et al. A randomized study of misonidazole and radiotherapy for grade 3 and 4
cerebral astrocytoma. British journal of cancer 1981;43(4):436-42.
2
0 - Bloch O, Han SJ, Cha S, et al. Impact of extent of resection for recurrent glioblastoma on overall survival: clinical article.
Journal of neurosurgery 2012;117(6):1032-8.
2
1 - Bock HC, Puchner MJ, Lohmann F, et al. First-line treatment of malignant glioma with carmustine implants followed by
concomitant radiochemotherapy: a multicenter experience. Neurosurgical review 2010;33(4):441-9.
2
2 - Boele FW, Hoeben W, Hilverda K, et al. Enhancing quality of life and mastery of informal caregivers of high-grade glioma
patients: a randomized controlled trial. Journal of neuro-oncology 2013;111(3):303-11.
2
3 - Boele, F. W., Douw, L., de Groot, M., van Thuijl, H. F., Cleijne, W., Heimans, J. J., et al. (2013). The effect of modafinil on
fatigue, cognitivefunctioning, andmood in primarybrain tumor patients: a multicenter randomizedcontrolled trial. Neuro Oncol,
15(10), 1420-1428.
2
4 - Boele, F. W., Heimans, J. J., Aaronson, N. K., Taphoorn, M. J., Postma, T. J., Reijneveld, J. C., et al. (2013). Health-
relatedquality of life of significant others of patientswithmalignant CNS versus non-CNS tumors: a comparativestudy. J
Neurooncol, 115(1), 87-94.
2
5 - Boots-Sprenger SH, Sijben A, Rijntjes J, et al. Significance of complete 1p/19q co-deletion, IDH1 mutation and MGMT
promoter methylation in gliomas: use with caution. Modern pathology : an official journal of the United States and Canadian
Academy of Pathology, Inc 2013;26(7):922-9.
2
6 - Brada M, Stenning S, Gabe R, et al. Temozolomide versus procarbazine, lomustine, and vincristine in recurrent high-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(30):4601-8.
2
7 - Brada M, Viviers L, Abson C, et al. Phase II study of primary temozolomide chemotherapy in patients with WHO grade II
gliomas. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2003;14(12):1715-21.
2
8 - Brandes AA, Franceschi E, Tosoni A et al. MGMT promoter methylation status can predict the incidence and outcome of
pseudoprogression after concomitant radiochemotherapy in newly diagnosed glioblastoma patients. J Clin Oncol
2008;26(13):2192-2197.
2
9 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
Gliomen
PDF aangemaakt op 
23-01-2025
954
/
971
3
0 - Brandes AA, Tosoni A, Cavallo G, et al. Correlations between O6-methylguanine DNA methyltransferase promoter
methylation status, 1p and 19q deletions, and response to temozolomide in anaplastic and recurrent oligodendroglioma: a
prospective GICNO study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2006;24(29):4746-53.
3
1 - Brandes AA, Tosoni A, Vastola F, et al. Efficacy and feasibility of standard procarbazine, lomustine, and vincristine
chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer
2004;101(9):2079-85.
3
2 - Bregy A, Shah AH, Diaz MV, et al. The role of Gliadel wafers in the treatment of high-grade gliomas. Expert review of
anticancer therapy 2013;13(12):1453-61.
3
3 - Brodie MJ, Mintzer S, Pack AM et al. (2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
4 - Brodie MJ, Mintzer S, Pack AM et al.(2013) Enzyme induction with antiepileptic drugs: Cause for concern? Epilepsia
54(1):11-27
3
5 - Brown PD, Maurer MJ, Rummans TA, et al. A prospective study of quality of life in adults with newly diagnosed high-grade
gliomas: the impact of the extent of resection on quality of life and survival. Neurosurgery 2005;57(3):495-504; discussion 495-
504.
3
6 - Buckner JC PS, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and vincristine
(PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. . Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(5s).
3
7 - Buckner JC, Gesme D, O'Fallon JR et al. Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for
patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. J
Clin Oncol 2003;21(2):251-255
3
8 - Buckner JC, Pugh SL, Shaw EG. Phase III study of radiation therapy (RT) with or without procarbazine, CCNU, and
vincristine (PCV) in low-grade glioma: RTOG 9802 with Alliance, ECOG, and SWOG. J Clin Oncol 32:5s, 2014 (suppl; abstr
2000)
3
9 - Butowski N, Chang SM, Junck L, et al. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly
diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). Journal of neuro-oncology
2009;91(2):175-82.
4
0 - Butowski N, Wong ET, Mehta MP, et al. A roundtable discussion on the clinical challenges and options for the treatment
of glioblastoma: introducing a novel modality, TTFields. Seminars in oncology 2013;40(6):S2-4.
4
1 - Cairncross G, Wang M, Shaw E, et al. Phase III trial of chemoradiotherapy for anaplastic oligodendroglioma: long-term
results of RTOG 9402. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2013;31(3):337-43.
4
2 - Cairncross JG, Wang M, Jenkins RB, et al. Benefit from procarbazine, lomustine, and vincristine in oligodendroglial tumors
is associated with mutation of IDH. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2014;32(8):783-90.
4
3 - Capelle L, Fontaine D, Mandonnet E, et al. Spontaneous and therapeutic prognostic factors in adult hemispheric World
Health Organization Grade II gliomas: a series of 1097 cases: clinical article. Journal of neurosurgery 2013;118(6):1157-68.
4
4 - Capper D, Zentgraf H, Balss J, et al. Monoclonal antibody specific for IDH1 R132H mutation. Acta neuropathologica
2009;118(5):599-601.
4
5 - Central Brain Tumor Registry of the United States. Statistical Report: Primary Brain Tumors in the United States, 1998-
2002. 2005 [cited 2006].
4
6 - Chaichana KL, Chaichana KK, Olivi A et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. J Neurosurg 2011;114(3):587-594.
4
7 - Chaichana KL, Chaichana KK, Olivi A, et al. Surgical outcomes for older patients with glioblastoma multiforme:
preoperative factors associated with decreased survival. Clinical article. Journal of neurosurgery 2011;114(3):587-94.
4
8 - Chaichana KL, Jusue-Torres I, Navarro-Ramirez R, et al. Establishing percent resection and residual volume thresholds
affecting survival and recurrence for patients with newly diagnosed intracranial glioblastoma. Neuro-oncology 2014;16(1):113-
22.
4
9 - Chamberlain MC. Salvage chemotherapy with CPT-11 for recurrent glioblastoma multiforme. Journal of neuro-oncology
Gliomen
PDF aangemaakt op 
23-01-2025
955
/
971
2002;56(2):183-8.
5
0 - Chan JL, Lee SW, Fraass BA, et al. Survival and failure patterns of high-grade gliomas after three-dimensional conformal
radiotherapy. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(6):1635-42.
5
1 - Chang EF, Smith JS, Chang SM, et al. Preoperative prognostic classification system for hemispheric low-grade gliomas in
adults. Journal of neurosurgery 2008;109(5):817-24.
5
2 - Chang SM, Parney IF, McDermott M, et al. Perioperative complications and neurological outcomes of first and second
craniotomies among patients enrolled in the Glioma Outcome Project. Journal of neurosurgery 2003;98(6):1175-81.
5
3 - Chen S, Tanaka S, Giannini Cet al. Gliomatosis cerebri: clinical characteristics, management, and outcomes. J Neurooncol.
2013 Apr;112(2):267-75. doi: 10.1007/s11060-013-1058-x. Epub 2013 Jan 23. PubMed PMID: 23341100; PubMed Central
PMCID: PMC3907195.
5
4 - Chen Y, Hu F, Zhou Y, et al. MGMT promoter methylation and glioblastoma prognosis: a systematic review and meta-
analysis. Archives of medical research 2013;44(4):281-90.
5
5 - Chen Y, Tsai YH, Tseng SH (2012) Valproic acid affected the survival and invasiveness of human glioma cells through
diverse mechanisms. J Neurooncol 109:23-33
5
6 - Cheng, X. et al., A meta-analysis of 99mTc-MIBI SPECT for detection of recurrent glioma after radiation therapy. J Clin
Neurosci, 2011. 18(3): p. 307-12.
5
7 - Chinot OL, Honore S, Dufour H, et al. Safety and efficacy of temozolomide in patients with recurrent anaplastic
oligodendrogliomas after standard radiotherapy and chemotherapy. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2001;19(9):2449-55.
5
8 - Chinot OL, Wick W, Mason W, et al. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma.
The New England journal of medicine 2014;370(8):709-22.
5
9 - Chung, W.J. et al., Recurrent glioblastoma: Optimum area under the curve method derived from dynamic contrast-
enhanced T1-weighted perfusion MR imaging. Radiology, 2013. 269(2): p. 561-568.
6
0 - Clarke JL, Ennis MM, Yung WK, et al. Is surgery at progression a prognostic marker for improved 6-month progression-
free survival or overall survival for patients with recurrent glioblastoma? Neuro-oncology 2011;13(10):1118-24.
6
1 - Clarke. A. (2003) A rol of the neuro-oncology nurse specialist in managing glioma patients. Cancer Nursing Practice
2003;2,21-25
6
2 - Claus EB, Horlacher A, Hsu L, et al. Survival rates in patients with low-grade glioma after intraoperative magnetic
resonance image guidance. Cancer 2005;103(6):1227-33.
6
3 - Colman H, Aldape K. Molecular predictors in glioblastoma: toward personalized therapy. Archives of neurology
2008;65(7):877-83.
6
4 - Combs SE, Gutwein S, Thilmann C, et al. Stereotactically guided fractionated re-irradiation in recurrent glioblastoma
multiforme. Journal of neuro-oncology 2005;74(2):167-71.
6
5 - Curran Jr Wj, Scott CB, Horton J et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy
Oncology Group malignant glioma trials. J Natl Cancer Inst 1993; 85:704-710.
6
6 - Curren, JR., (2001) Support needs of brain tumour patients and their carers: the place of a telephone service. Int. J. Palliat
Nurs, 7, 589-598
6
7 - Daigle K, Fortin D, Mathieu D, et al. Effects of surgical resection on the evolution of quality of life in newly diagnosed
patients with glioblastoma: a report on 19 patients surviving to follow-up. Current medical research and opinion
2013;29(10):1307-13.
6
8 - Dandois V, Rommel D, Renard L, et al. Substitution of 11C-methionine PET by perfusion MRI during the follow-up of
treated high-grade gliomas: preliminary results in clinical practice. Journal of neuroradiology Journal de neuroradiologie
2010;37(2):89-97.
6
9 - Davies AM, Weinberg U, Palti Y. Tumor treating fields: a new frontier in cancer therapy. Annals of the New York Academy
of Sciences 2013;1291:86-95.
7
0 - Davies, E., Clarke, C., Hopkins, A., (1996). Malignant cerebral glioma ll. Perspective of patients and relatives on the value
of radiotherapy. BMJ 313, 1512-1516
7
1 - Davies, E., Higginson, I. Communication, information and support for adults with malignant cerebral glioma: a systematic
literature review.Support Care Cancer (2003) 11:21–29 DOI 10.1007/s00520-002-0392-x.
7
2 - Davies, E., Hopkins, A., (1997). Good practice in the management of adults with malignant cerebral glioma: clinical
Gliomen
PDF aangemaakt op 
23-01-2025
956
/
971
guidelines. Br. J Neurosurg 11,318-330
7
3 - De Bonis P, Anile C, Pompucci A, et al. Safety and efficacy of Gliadel wafers for newly diagnosed and recurrent
glioblastoma. Acta neurochirurgica 2012;154(8):1371-8.
7
4 - De Bonis P, Fiorentino A, Anile C, et al. The impact of repeated surgery and adjuvant therapy on survival for patients with
recurrent glioblastoma. Clinical neurology and neurosurgery 2013;115(7):883-6.
7
5 - De Vos FY, Gijtenbeek JM, Bleeker-Rovers CP, et al. Pneumocystis jirovecii pneumonia prophylaxis during temozolomide
treatment for high-grade gliomas. Critical reviews in oncology/hematology 2013;85(3):373-82.
7
6 - De Witt Hamer PC, Robles SG, Zwinderman AH, et al. Impact of intraoperative stimulation brain mapping on glioma
surgery outcome: a meta-analysis. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2012;30(20):2559-65.
7
7 - Deng, S.M. et al., Detection of glioma recurrence by 11C-methionine positron emission tomography and dynamic
susceptibility contrast-enhanced magnetic resonance imaging: a meta-analysis. Nucl Med Commun, 2013. 34(8): p. 758-66.
7
8 - Desjardins A, Reardon DA, Coan A, et al. Bevacizumab and daily temozolomide for recurrent glioblastoma. Cancer
2012;118(5):1302-12.
7
9 - Deutsch MB, Panageas KS, Lassman AB et al. (2013) Steroid management in newly diagnosed glioblastoma. J Neurooncol
113:111-116
8
0 - DI Cristofori A, Carrabba G, Lanfranchi G, et al. Continuous tamoxifen and dose-dense temozolomide in recurrent
glioblastoma. Anticancer research 2013;33(8):3383-9.
8
1 - Dietrich J, RAo K, Pastorino S et al (2011) Corticosteroids in brain cancer patients: benefits and pitfalls. Expert Rev Clin
Pharmacol 4(2):233-242
8
2 - Douw L, Klein M, Fagel SS, et al. Cognitive and radiological effects of radiotherapy in patients with low-grade glioma:
long-term follow-up. The Lancet Neurology 2009;8(9):810-8.
8
3 - Dresemann G, Weller M, Rosenthal MA, et al. Imatinib in combination with hydroxyurea versus hydroxyurea alone as oral
therapy in patients with progressive pretreated glioblastoma resistant to standard dose temozolomide. Journal of neuro-
oncology 2010;96(3):393-402.
8
4 - Dubbink HJ, Taal W, van Marion R, et al. IDH1 mutations in low-grade astrocytomas predict survival but not response to
temozolomide. Neurology 2009;73(21):1792-5.
8
5 - Duffau H. Awake surgery for incidental WHO grade II gliomas involving eloquent areas. Acta neurochirurgica
2012;154(4):575-84; discussion 84.
8
6 - Dutzmann S, Gessler F, Bink A, et al. Risk of ischemia in glioma surgery: comparison of first and repeat procedures. Journal
of neuro-oncology 2012;107(3):599-607.
8
7 - Dziurzynski K, Blas-Boria D, Suki D, et al. Butterfly glioblastomas: a retrospective review and qualitative assessment of
outcomes. Journal of neuro-oncology 2012;109(3):555-63.
8
8 - Easaw J.C. et al. Canadian recommendations for treatment of recurrent or progressive glioblastoma multiforme. Current
Oncology-2011 Jun;18(3):e126-136.
8
9 - Effect of NovoTTF-100A together with temozolomide in newly diagnosed glioblastoma multiforme (GBM).
ClinicalTrials.gov Identifier NTC00916409.
9
0 - Ekinci G1, Akpinar IN, Baltacio?lu F et al. Early-postoperative magnetic resonance imaging in glial tumors: prediction of
tumor regrowth and recurrence.Eur J Radiol. 2003 Feb;45(2):99-107.
9
1 - Ellingson BM, Kim HJ, Woodworth DC, et al. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-
weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology
2014;271(1):200-10.
9
2 - Erdem-Eraslan L, Gravendeel LA, de Rooi J, et al. Intrinsic molecular subtypes of glioma are prognostic and predict benefit
from adjuvant procarbazine, lomustine, and vincristine chemotherapy in combination with other prognostic factors in
anaplastic oligodendroglial brain tumors: a report from EORTC study 26951. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2013;31(3):328-36.
9
3 - Ewelt C, Goeppert M, Rapp M, et al. Glioblastoma multiforme of the elderly: the prognostic effect of resection on survival.
Journal of neuro-oncology 2011;103(3):611-8.
9
4 - Eyre HJ, Crowley JJ, Townsend JJ, et al. A randomized trial of radiotherapy versus radiotherapy plus CCNU for
incompletely resected low-grade gliomas: a Southwest Oncology Group study. Journal of neurosurgery 1993;78(6):909-14.
Gliomen
PDF aangemaakt op 
23-01-2025
957
/
971
9
5 - Filippini G, Falcone C, Boiardi A, et al. Prognostic factors for survival in 676 consecutive patients with newly diagnosed
primary glioblastoma. Neuro-oncology 2008;10(1):79-87.
9
6 - Fink J, Born D et al, Pseudoprogression: relevance with respect to treatment of high-grade glioma, Curr Treat Opt Oncol
(2011)
9
7 - Fink, J.R. et al., Comparison of 3 Tesla proton MR spectroscopy, MR perfusion and MR diffusion for distinguishing glioma
recurrence from posttreatment effects. J. Magn. Reson. Imaging, 2012. 35(1): p. 56-63.
9
8 - Fiorentino A, Caivano R, Pedicini P, et al. Clinical target volume definition for glioblastoma radiotherapy planning:
magnetic resonance imaging and computed tomography. Clinical & translational oncology : official publication of the
Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2013;15(9):754-8.
9
9 - Fiorica F, Berretta M, Colosimo C et al. Glioblastoma in elderly patients: safety and efficacy of adjuvant radiotherapy with
concomitant temozolomide. Arch Gerontol Geriatr 2010;51(1):31-35.
1
00 - Fogh SE, Andrews DW, Glass J, et al. Hypofractionated stereotactic radiation therapy: an effective therapy for recurrent
high-grade gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(18):3048-53.
1
01 - Fokas E, Wacker U, Gross MW, et al. Hypofractionated stereotactic reirradiation of recurrent glioblastomas : a beneficial
treatment option after high-dose radiotherapy? Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft
[et al] 2009;185(4):235-40.
1
02 - Formica, V., Del Monte, G., Giacchetti, I., Grenga, I., Giaquinto, S., Fini, M., et al. (2011). Rehabilitation in neuro-
oncology: a meta-analysis of published data and a mono-institutionalexperience. Integr Cancer Ther, 10(2), 119-126.
1
03 - Friedman HS, Prados MD, Wen PY, et al. Bevacizumab alone and in combination with irinotecan in recurrent
glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(28):4733-40.
1
04 - Galanis E, Anderson SK, Lafky JM, et al. Phase II study of bevacizumab in combination with sorafenib in recurrent
glioblastoma (N0776): a north central cancer treatment group trial. Clinical cancer research : an official journal of the American
Association for Cancer Research 2013;19(17):4816-23.
1
05 - Gallego Perez-Larraya J, Ducray F, Chinot O et al. Temozolomide in elderly patients with newly diagnosed glioblastoma
and poor performance status: an ANOCEF phase II trial. J Clin Oncol 2011;29(22):3050-3055.
1
06 - Gannett DE, Wisbeck WM, Silbergeld DL, et al. The role of postoperative irradiation in the treatment of
oligodendroglioma. International journal of radiation oncology, biology, physics 1994;30(3):567-73.
1
07 - Gehring, K., Patwardhan, S. Y., Collins, R., Groves, M. D., Etzel, C. J., Meyers, C. A., et al. (2012). A randomized trial on
the efficacy of methylphenidate and modafinil for improving cognitive functioning and symptoms in patients with a primary
brain tumor. J Neurooncol, 107(1), 165-174.
1
08 - Gehring, K., Sitskoorn, M. M., Gundy et al. (2009). Cognitive rehabilitation in patients with gliomas: a randomized,
controlled trial. J ClinOncol, 27(22), 3712-3722.
1
09 - Gilbert MR, Dignam JJ, Armstrong TS, et al. A randomized trial of bevacizumab for newly diagnosed glioblastoma. The
New England journal of medicine 2014;370(8):699-708.
1
10 - Gilbert MR, Wang M, Aldape KD et al. Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized
Phase III Clinical Trial. J Clin Oncol 2013;31(32):4085-4091.
1
11 - Giordana, M. T., & Clara, E. (2006). Functional rehabilitation and braintumour patients. A review of outcome. NeurolSci,
27(4), 240-244.
1
12 - Glas M, Bähr O, Felsberg Jet al.; Neuro-Oncology Group of the German Cancer Society. NOA-05 phase 2 trial of
procarbazine and lomustine therapy in gliomatosiscerebri. Ann Neurol. 2011 Sep;70(3):445-53. doi: 10.1002/ana.22478. Epub
2011 Jun 27. PubMed PMID: 21710625.
1
13 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
1
14 - Gorlia T, Delattre JY, Brandes AA, et al. New clinical, pathological and molecular prognostic models and calculators in
patients with locally diagnosed anaplastic oligodendroglioma or oligoastrocytoma. A prognostic factor analysis of European
Organisation for Research and Treatment of Cancer Brain Tumour Group Study 26951. European journal of cancer
2013;49(16):3477-85.
Gliomen
PDF aangemaakt op 
23-01-2025
958
/
971
1
15 - Graus F, Bruna J, Pardo J, et al. Patterns of care and outcome for patients with glioblastoma diagnosed during 2008-
2010 in Spain. Neuro-oncology 2013;15(6):797-805.
1
16 - Griffin CA, Burger P, Morsberger L, et al. Identification of der(1;19)(q10;p10) in five oligodendrogliomas suggests
mechanism of concurrent 1p and 19q loss. Journal of neuropathology and experimental neurology 2006;65(10):988-94.
1
17 - Grossman SA, Ye X, Chamberlain M, et al. Talampanel with standard radiation and temozolomide in patients with newly
diagnosed glioblastoma: a multicenter phase II trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2009;27(25):4155-61.
1
18 - Groves MD, Puduvalli VK, Gilbert MR, et al. Two phase II trials of temozolomide with interferon-alpha2b (pegylated and
non-pegylated) in patients with recurrent glioblastoma multiforme. British journal of cancer 2009;101(4):615-20.
1
19 - Gupta, S. R. G. (2011). Role of support groups and caregivers in neuro-oncology. In S. M. Chang, A. Guha, H. B. Newton
& M. A. Vogelbaum (Eds.), Principles and practice of neuron-oncology: A multidisciplinary approach (pp. 316-319). New York:
Demos Medical Publishing.
1
20 - Gustafsson, M., Edvardsson, T., & Ahlstrom, G. (2006). The relationship between function, quality of life and coping in
patientswith low-grade gliomas. Support Care Cancer, 14(12), 1205-1212.
1
21 - Guthrie GD, Eljamel S (2013) Impact of particular antiepileptic drugs on the survival of patients with glioblastoma
multiforme. J Neurosurg 118:859-865
1
22 - Guyotat J, Signorelli F, Frappaz D, et al. Is reoperation for recurrence of glioblastoma justified? Oncology reports
2000;7(4):899-904.
1
23 - Habets EJ, Taphoorn MJ, Nederend S, et al. Health-related quality of life and cognitive functioning in long-term
anaplastic oligodendroglioma and oligoastrocytoma survivors. Journal of neuro-oncology 2014;116(1):161-8.
1
24 - Hart MG, Grant R, Garside R, et al. Chemotherapy wafers for high grade glioma. The Cochrane database of systematic
reviews 2011(3):CD007294.
1
25 - Hartmann C, Hentschel B, Tatagiba M, et al. Molecular markers in low-grade gliomas: predictive or prognostic? Clinical
cancer research : an official journal of the American Association for Cancer Research 2011;17(13):4588-99.
1
26 - Hartmann C, Hentschel B, Wick W, et al. Patients with IDH1 wild type anaplastic astrocytomas exhibit worse prognosis
than IDH1-mutated glioblastomas, and IDH1 mutation status accounts for the unfavorable prognostic effect of higher age:
implications for classification of gliomas. Acta neuropathologica 2010;120(6):707-18.
1
27 - Hartmann C, Meyer J, Balss J, et al. Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and
oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas. Acta neuropathologica 2009;118(4):469-74.
1
28 - Hassaneen W, Levine NB, Suki D, et al. Multiple craniotomies in the management of multifocal and multicentric
glioblastoma. Clinical article. Journal of neurosurgery 2011;114(3):576-84.
1
29 - Hasselbalch B, Lassen U, Hansen S, et al. Cetuximab, bevacizumab, and irinotecan for patients with primary glioblastoma
and progression after radiation therapy and temozolomide: a phase II trial. Neuro-oncology 2010;12(5):508-16.
1
30 - Hau P, Koch D, Hundsberger T, et al. Safety and feasibility of long-term temozolomide treatment in patients with high-
grade glioma. Neurology 2007;68(9):688-90.
1
31 - Haywood K, Marshall S, Fitzpatrick R. Patient participation in the consultation process: a structured review of intervention
strategies. Patient education and counseling 2006;63(1-2):12-23.
1
32 - Hegi ME, Diserens AC, Gorlia T, et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. The New
England journal of medicine 2005;352(10):997-1003.
1
33 - Henke G, Paulsen F, Steinbach JP, et al. Hypofractionated reirradiation for recurrent malignant glioma. Strahlentherapie
und Onkologie : Organ der Deutschen Rontgengesellschaft [et al] 2009;185(2):113-9.
1
34 - Hermelink, K., Kuchenhoff, H., Untch, M., Bauerfeind, I., Lux, M. P., Buhner, M., et al. (2010). Two different sides of
'chemobrain': determinants andnondeterminants of self-perceivedcognitivedysfunction in a prospective, randomized,
multicenter study. Psychooncology, 19(12), 1321-1328.
1
35 - Hingorani M, Colley WP, Dixit S, et al. Hypofractionated radiotherapy for glioblastoma: strategy for poor-risk patients or
hope for the future? The British journal of radiology 2012;85(1017):e770-81.
1
36 - Ho VK, Reijneveld JC, Enting RH, et al. Changing incidence and improved survival of gliomas. European journal of cancer
2014;50(13):2309-18.
1
37 - Ho VKY, Gijtenbeek JMM. (2014). Gliomen. In: Siesling S, Sonke G, De Raaf A, Jansen M. Kankerzorg in beeld. Utrecht:
IKNL.
Gliomen
PDF aangemaakt op 
23-01-2025
959
/
971
1
38 - Hoang-Xuan K, Capelle L, Kujas M et al. Temozolomide as initial treatment for adults with low-grade oligodendrogliomas
or oligoastrocytomas and correlation with chromosome 1p deletions. J Clin Oncol 2004;22(15):3133-3138.
1
39 - Hollingworth, W. et al., A systematic literature review of magnetic resonance spectroscopy for the characterization of
brain tumors. AJNR Am J Neuroradiol, 2006. 27(7): p. 1404-11.
1
40 - Hong B, Wiese B, Bremer M, et al. Multiple microsurgical resections for repeated recurrence of glioblastoma multiforme.
American journal of clinical oncology 2013;36(3):261-8.
1
41 - Hoover JM, Nwojo M, Puffer R, et al. Surgical outcomes in recurrent glioma: clinical article. Journal of neurosurgery
2013;118(6):1224-31.
1
42 - Horowitz, S., Passik, SD., Malkin, MG. (1996). 'In sickness and in Health': a group intervention for spouses caring for
patients with braintumors. J Psychosoc Oncol 2014, 43-56
1
43 - Houben MP, Aben KK, Teepen JL, et al. Stable incidence of childhood and adult glioma in The Netherlands, 1989-2003.
Acta oncologica 2006;45(3):272-9.
1
44 - Ichimura K, Pearson DM, Kocialkowski S, et al. IDH1 mutations are present in the majority of common adult gliomas but
rare in primary glioblastomas. Neuro-oncology 2009;11(4):341-7.
1
45 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
46 - Ius T, Isola M, Budai R, et al. Low-grade glioma surgery in eloquent areas: volumetric analysis of extent of resection and
its impact on overall survival. A single-institution experience in 190 patients: clinical article. Journal of neurosurgery
2012;117(6):1039-52.
1
47 - Jackson RJ, Fuller GN, Abi-Said D, et al. Limitations of stereotactic biopsy in the initial management of gliomas. Neuro-
oncology 2001;3(3):193-200.
1
48 - Jain, R. et al., Permeability estimates in histopathology-proved treatment-induced necrosis using perfusion CT: can these
add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol, 2011. 32(4):
p. 658-63.
1
49 - Jakola AS, Myrmel KS, Kloster R, et al. Comparison of a strategy favoring early surgical resection vs a strategy favoring
watchful waiting in low-grade gliomas. Jama 2012;308(18):1881-8.
1
50 - Jakola AS, Unsgard G, Myrmel KS, et al. Surgical strategy in grade II astrocytoma: a population-based analysis of survival
and morbidity with a strategy of early resection as compared to watchful waiting. Acta neurochirurgica 2013;155(12):2227-35.
1
51 - James, ND. Guerrero, D., Brada, M., (1994) Who should follow-up cancer patients? Nurse specialist based out-patients
care and the introduction of a phone clinic system Clin Oncol (R Coll Radiol) 6, 283-287
1
52 - Janda, M., Eakin, E. G., Bailey, L., Walker, D., & Troy, K. (2006). Supportive care needs of people with braintumours and
their carers. Support Care Cancer, 14(11), 1094-1103.
1
53 - Janda, M., Steginga, S., Langbecker, D., Dunn, J., Walker, D., & Eakin, E. (2007). Quality of life among patients with a
brain tumor and their carers. J PsychosomRes, 63(6), 617-623.
1
54 - Jansen J, van Weert J, van der Meulen N, et al. Recall in older cancer patients: measuring memory for medical
information. The Gerontologist 2008;48(2):149-57.
1
55 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
56 - Jansen J, van Weert JC, de Groot J, et al. Emotional and informational patient cues: the impact of nurses' responses on
recall. Patient education and counseling 2010;79(2):218-24.
1
57 - Jenkins RB, Blair H, Ballman KV, et al. A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a
better prognosis of patients with oligodendroglioma. Cancer research 2006;66(20):9852-61.
1
58 - Jeong, S.Y. et al., 3'-Deoxy-3'- 18F fluorothymidine and O-(2- 18F fluoroethyl)-L-tyrosine PET in patients with suspicious
recurrence of glioma after multimodal treatment: Initial results of a retrospective comparative study. Nucl. Med. Mol. Imaging,
2010. 44(1): p. 45-54.
1
59 - Jeremic B, Shibamoto Y, Grujicic D, et al. Hyperfractionated radiation therapy for incompletely resected supratentorial
low-grade glioma. A phase II study. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology
and Oncology 1998;49(1):49-54.
1
60 - Jung TY, Jung S, Moon JH, et al. Early prognostic factors related to progression and malignant transformation of low-
Gliomen
PDF aangemaakt op 
23-01-2025
960
/
971
grade gliomas. Clinical neurology and neurosurgery 2011;113(9):752-7.
1
61 - Juratli TA, Kirsch M, Geiger K, et al. The prognostic value of IDH mutations and MGMT promoter status in secondary
high-grade gliomas. Journal of neuro-oncology 2012;110(3):325-33.
1
62 - Juratli TA, Kirsch M, Robel K, et al. IDH mutations as an early and consistent marker in low-grade astrocytomas WHO
grade II and their consecutive secondary high-grade gliomas. Journal of neuro-oncology 2012;108(3):403-10.
1
63 - Karim AB, Maat B, Hatlevoll R, et al. A randomized trial on dose-response in radiation therapy of low-grade cerebral
glioma: European Organization for Research and Treatment of Cancer (EORTC) Study 22844. International journal of radiation
oncology, biology, physics 1996;36(3):549-56.
1
64 - Karunanithi, S. et al., Comparative diagnostic accuracy of contrast-enhanced MRI and 18F-FDOPA PET-CT in recurrent
glioma. Eur. Radiol., 2013. 23(9): p. 2628-2635.
1
65 - Karunanithi, S. et al., Prospective comparison of 99mTc-GH SPECT/CT and 18F-FDOPA PET/CT for detection of recurrent
glioma: A pilot study. Clin. Nucl. Med., 2013.
1
66 - Keime-Guibert F, Chinot O, Taillandier L et al. Radiotherapy for glioblastoma in the elderly. N Engl J Med
2007;356(15):1527-1535.
1
67 - Keles GE, Chang EF, Lamborn KR, et al. Volumetric extent of resection and residual contrast enhancement on initial
surgery as predictors of outcome in adult patients with hemispheric anaplastic astrocytoma. Journal of neurosurgery
2006;105(1):34-40.
1
68 - Kelly PJ. Gliomas: Survival, origin and early detection. Surgical neurology international 2010;1:96.
1
69 - Kerkhof M, Dielemans JC, van Breemen MS et al.(2013) Effect of valproic acid on seizure control and on survival in
patients with glioblastoma multiforme. Neuro Oncol 15(7):961-967
1
70 - Kerrigan S, Grant R (2011) Antiepileptic drugs for treating seizures in adults with brain tumours. Cochrane Database Syst
Rev (8), CD008586
1
71 - Khan, F., Amatya, B., Ng, L., Drummond, K., &Olver, J. (2013). Multidisciplinary rehabilitation after primar ybrain tumour
treatment. Cochrane Database Syst Rev, 1, CD009509.
1
72 - Khangembam, B.C. et al., 13N-Ammonia PET/CT for detection of recurrent glioma: A prospective comparison with
contrast-enhanced MRI. Nucl. Med. Commun., 2013. 34(11): p. 1046-1054.
1
73 - Kiebert GM, Curran D, Aaronson NK, et al. Quality of life after radiation therapy of cerebral low-grade gliomas of the
adult: results of a randomised phase III trial on dose response (EORTC trial 22844). EORTC Radiotherapy Co-operative Group.
European journal of cancer 1998;34(12):1902-9.
1
74 - Kim YH, Nobusawa S, Mittelbronn M, et al. Molecular classification of low-grade diffuse gliomas. The American journal of
pathology 2010;177(6):2708-14.
1
75 - Klein M, Heimans JJ, Aaronson NK, et al. Effect of radiotherapy and other treatment-related factors on mid-term to long-
term cognitive sequelae in low-grade gliomas: a comparative study. Lancet 2002;360(9343):1361-8.
1
76 - Klein M, Heimans JJ. The measurement of cognitive functioning in low-grade glioma patients after radiotherapy. Journal
of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(5):966-7; author reply 7-8.
1
77 - Klein M. Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities. Neuro-
oncology 2012;14 Suppl 4:iv17-24.
1
78 - Kondziolka D, Lunsford LD, Martinez AJ. Unreliability of contemporary neurodiagnostic imaging in evaluating suspected
adult supratentorial (low-grade) astrocytoma. Journal of neurosurgery 1993;79(4):533-6.
1
79 - Kong DS, Kim ST, Lee JIet al.Kim JH & Nam DH 2010 Impact of adjuvant chemotherapy for gliomatosis cerebri. BMC
cancer 10 424-2407-10-424
1
80 - Kongkham PN, Knifed E, Tamber MS, et al. Complications in 622 cases of frame-based stereotactic biopsy, a decreasing
procedure. The Canadian journal of neurological sciences Le journal canadien des sciences neurologiques 2008;35(1):79-84.
1
81 - Kotsarini C, Griffiths PD, Wilkinson ID et al. (2010) A systematic review of the literature on the effects of dexamethasone
on the brain from in vivo human based studies: implications for physiological brain imaging of patients with intracranial tumors.
Neurosurgery 67:1799-1815
1
82 - Kouwenhoven MC, Kros JM, French PJ, et al. 1p/19q loss within oligodendroglioma is predictive for response to first line
temozolomide but not to salvage treatment. European journal of cancer 2006;42(15):2499-503.
1
83 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
Gliomen
PDF aangemaakt op 
23-01-2025
961
/
971
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
84 - Kristiansen K, Hagen S, Kollevold T, et al. Combined modality therapy of operated astrocytomas grade III and IV.
Confirmation of the value of postoperative irradiation and lack of potentiation of bleomycin on survival time: a prospective
multicenter trial of the Scandinavian Glioblastoma Study Group. Cancer 1981;47(4):649-52.
1
85 - Kuhnhenn J, Kowalski T, Steenken S, et al. Procarbazine, carmustine, and vincristine (PBV) for chemotherapy pre-treated
patients with recurrent glioblastoma: a single-institution analysis. Journal of neuro-oncology 2012;109(2):433-8.
1
86 - Kunwar S, Chang S, Westphal M, et al. Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent
glioblastoma. Neuro-oncology 2010;12(8):871-81.
1
87 - Kunz M, Thon N, Eigenbrod S, et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected
WHO grade II gliomas. Neuro-oncology 2011;13(3):307-16.
1
88 - Kwaliteitscriteria neuro-oncologie: Diagnostiek, behandeling en begeleiding van patiënten met een glioom. Landelijke
Werkgroep Neuro-Oncologie (LWNO) december 2013.
1
89 - Kwaliteitscriteria, V. Kwaliteitscriteria voor de zorg, vanuit het perspectief van mensen met een hersentumor. Vereniging
Cerebraal. Maart 2011.
1
90 - Lacroix M, Abi-Said D, Fourney DR, et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis,
extent of resection, and survival. Journal of neurosurgery 2001;95(2):190-8.
1
91 - Laperriere N, Zuraw L, Cairncross G, et al. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic
review. Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology 2002;64(3):259-
73.
1
92 - Laperriere NJ et al. Randomizedstudy of brachytherapy in the initial management of patients with malignant astrocytoma.
1998 Int J Radiat Oncol Biol Phys. 1998;41:1005-11.
1
93 - Lassen U, Sorensen M, Gaziel TB, et al. Phase II study of bevacizumab and temsirolimus combination therapy for
recurrent glioblastoma multiforme. Anticancer research 2013;33(4):1657-60.
1
94 - Laurant M, Reeves D, Hermens R et al.Substitution of doctors by nurses in primary care. Cochrane Database syst. Review.
2005 Apr 18;(2):CD001271
1
95 - Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and
proton MR spectroscopic imaging compared with conventional MR imaging. AJNR American journal of neuroradiology
2003;24(10):1989-98.
1
96 - Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume
measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247(2):490-8.
1
97 - Laws ER, Jr., Taylor WF, Clifton MB, et al. Neurosurgical management of low-grade astrocytoma of the cerebral
hemispheres. Journal of neurosurgery 1984;61(4):665-73.
1
98 - Leavitt, MB., Lamb, SA., Voss, BS. (1996). Brain Tumour Support Group: content themes and mechanisms of support.
Oncol Nurs Rorum 23, 1247-1256
1
99 - Lebrun C, Fontaine D, Bourg V, et al. Treatment of newly diagnosed symptomatic pure low-grade oligodendrogliomas
with PCV chemotherapy. European journal of neurology : the official journal of the European Federation of Neurological
Societies 2007;14(4):391-8.
2
00 - Levin N, Gomori JM & Siegal T 2004 Chemotherapy as initial treatment in gliomatosis cerebri: results with temozolomide.
Neurology 63 354-356.
2
01 - Levin N, Lavon I, Zelikovitsh B, et al. Progressive low-grade oligodendrogliomas: response to temozolomide and
correlation between genetic profile and O6-methylguanine DNA methyltransferase protein expression. Cancer
2006;106(8):1759-65.
2
02 - Li, D.L. et al., 11C-methionine and 18F-fluorodeoxyglucose positron emission tomography/CT in the evaluation of
patients with suspected primary and residual/recurrent gliomas. Chin. Med. J., 2012. 125(1): p. 91-96.
2
03 - Liu, R., Page, M., Solheim, K., Fox, S., & Chang, S. M. (2009). Quality of life in adults with brain tumors: current
knowledge and future directions. Neuro Oncol, 11(3), 330-339.
2
04 - Louis DN, Ohgaki H, Wiestler OD, et al. The 2007 WHO classification of tumours of the central nervous system. Acta
neuropathologica 2007;114(2):97-109.
2
05 - Louis DN, Perry A, Burger P, et al. International Society Of Neuropathology--Haarlem consensus guidelines for nervous
system tumor classification and grading. Brain pathology 2014;24(5):429-35.
Gliomen
PDF aangemaakt op 
23-01-2025
962
/
971
2
06 - Louis E, Keime-Guibert F, Delattre JY & Sanson M 2003 Dramatic response to chemotherapy in oligodendroglial
gliomatosis cerebri. Neurology 60 151
2
07 - Madsen K., Poulsen H.S. (2011). Needs for everyday life support for brain tumour patients’ relatives: systematic literature
review.European Journal of Cancer Care 20, 33–43
2
08 - Malmstrom A, Gronberg BH, Marosi C et al. Temozolomide versus standard 6-week radiotherapy versus
hypofractionated radiotherapy in patients older than 60 years with glioblastoma: the Nordic randomised, phase 3 trial. Lancet
Oncol 2012;13(9):916-926.
2
09 - Mandl ES, Dirven CM, Buis DR, et al. Repeated surgery for glioblastoma multiforme: only in combination with other
salvage therapy. Surgical neurology 2008;69(5):506-9; discussion 9.
2
10 - Marantidou A, Levy C, Duquesne A et al. (2010) Steroid requirements during radiotherapy for malignant gliomas. J
Neurooncol 100:89-94
2
11 - Mattox AK, Lark AL, Adamson DC. Marked response of gliomatosiscerebri to temozolomide and whole brain
radiotherapy. ClinNeurolNeurosurg. 2012 May;114(4):299-306. doi: 10.1016/j.clineuro.2012.01.030. Epub 2012 Feb 17.
Review. PubMed PMID: 22341931.
2
12 - McAleese JJ, Stenning SP, Ashley S et al. Hypofractionated radiotherapy for poor prognosis malignant glioma: matched
pair survival analysis with MRC controls. Radiother Oncol 2003;67(2):177-182.
2
13 - McDonald MW, Shu HK, Curran WJ, Jr., et al. Pattern of failure after limited margin radiotherapy and temozolomide for
glioblastoma. International journal of radiation oncology, biology, physics 2011;79(1):130-6.
2
14 - McGirt MJ, Chaichana KL, Attenello FJ, et al. Extent of surgical resection is independently associated with survival in
patients with hemispheric infiltrating low-grade gliomas. Neurosurgery 2008;63(4):700-7; author reply 7-8.
2
15 - McGirt MJ, Chaichana KL, Gathinji M, et al. Independent association of extent of resection with survival in patients with
malignant brain astrocytoma. Journal of neurosurgery 2009;110(1):156-62.
2
16 - McGirt MJ, Woodworth GF, Coon AL, et al. Independent predictors of morbidity after image-guided stereotactic brain
biopsy: a risk assessment of 270 cases. Journal of neurosurgery 2005;102(5):897-901.
2
17 - Meyer FB, Bates LM, Goerss SJ, et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent
brain. Mayo Clinic proceedings 2001;76(7):677-87.
2
18 - Minniti G, Arcella A, Scaringi C, et al. Chemoradiation for anaplastic oligodendrogliomas: clinical outcomes and
prognostic value of molecular markers. Journal of neuro-oncology 2014;116(2):275-82.
2
19 - Minniti G, Scaringi C, Arcella A, et al. IDH1 mutation and MGMT methylation status predict survival in patients with
anaplastic astrocytoma treated with temozolomide-based chemoradiotherapy. Journal of neuro-oncology 2014;118(2):377-83.
2
20 - Mirimanoff RO, Gorlia T, Mason W, et al. Radiotherapy and temozolomide for newly diagnosed glioblastoma: recursive
partitioning analysis of the EORTC 26981/22981-NCIC CE3 phase III randomized trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2006;24(16):2563-9.
2
21 - Moiyadi AV, Shetty PM. Surgery for recurrent malignant gliomas: feasibility and perioperative outcomes. Neurology India
2012;60(2):185-90.
2
22 - Morris Z, Whiteley WN, Longstreth WT, Jr., et al. Incidental findings on brain magnetic resonance imaging: systematic
review and meta-analysis. Bmj 2009;339:b3016.
2
23 - Mukherjee D, Sarmiento JM, Nosova K, et al. Effectiveness of radiotherapy for elderly patients with anaplastic gliomas.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia 2014;21(5):773-8.
2
24 - Nakagawa K, Aoki Y, Fujimaki T, et al. High-dose conformal radiotherapy influenced the pattern of failure but did not
improve survival in glioblastoma multiforme. International journal of radiation oncology, biology, physics 1998;40(5):1141-9.
2
25 - National Comprehensive Cancer Network. Clinical Practice Guidelines in Oncology. Central Nervous System Cancers.
Version 2.2013 http://www.nccn.org/professionals/physician_gls/pdf/cns.pdf
2
26 - Nelson DF, Diener-West M, Horton J, et al. Combined modality approach to treatment of malignant gliomas--re-
evaluation of RTOG 7401/ECOG 1374 with long-term follow-up: a joint study of the Radiation Therapy Oncology Group and
the Eastern Cooperative Oncology Group. NCI monographs : a publication of the National Cancer Institute 1988(6):279-84.
2
27 - Neyns B, Tosoni A, Hwu WJ, et al. Dose-dense temozolomide regimens: antitumor activity, toxicity, and
immunomodulatory effects. Cancer 2010;116(12):2868-77.
2
28 - Nieder C. A thought-provoking retrospective study on survival and toxicity after reirradiation for recurrent high-grade
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(5):e121; author
Gliomen
PDF aangemaakt op 
23-01-2025
963
/
971
reply e2-3.
2
29 - Nihashi T, Dahabreh IJ, Terasawa T. Diagnostic accuracy of PET for recurrent glioma diagnosis: a meta-analysis. AJNR
American journal of neuroradiology 2013;34(5):944-50, S1-11.
2
30 - Nihashi T, Dahabreh IJ, Terasawa T. PET in the clinical management of glioma: evidence map. AJR American journal of
roentgenology 2013;200(6):W654-60.
2
31 - Niyazi M, Siefert A, Schwarz SB, et al. Therapeutic options for recurrent malignant glioma. Radiotherapy and oncology :
journal of the European Society for Therapeutic Radiology and Oncology 2011;98(1):1-14.
2
32 - North CA, North RB, Epstein JA, et al. Low-grade cerebral astrocytomas. Survival and quality of life after radiation
therapy. Cancer 1990;66(1):6-14.
2
33 - Oberndorfer S, Piribauer M, Marosi C et al. (2005) P450 enzyme inducing and non-enzyme inducing antiepileptics in
glioblastoma patients treated with standard chemotherapy.J Neurooncol 72(3):255-60
2
34 - O'Connor AM, Bennett CL, Stacey D, et al. Decision aids for people facing health treatment or screening decisions. The
Cochrane database of systematic reviews 2009(3):CD001431.
2
35 - Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta neuropathologica 2005;109(1):93-108.
2
36 - Olar A, Aldape KD. Biomarkers classification and therapeutic decision-making for malignant gliomas. Current treatment
options in oncology 2012;13(4):417-36.
2
37 - Olson RA, Brastianos PK, Palma DA. Prognostic and predictive value of epigenetic silencing of MGMT in patients with
high grade gliomas: a systematic review and meta-analysis. Journal of neuro-oncology 2011;105(2):325-35.
2
38 - Omuro A, Chan TA, Abrey LE, et al. Phase II trial of continuous low-dose temozolomide for patients with recurrent
malignant glioma. Neuro-oncology 2013;15(2):242-50.
2
39 - Omuro A, DeAngelis LM. Glioblastoma and other malignant gliomas: a clinical review. Jama 2013;310(17):1842-50.
2
40 - Omuro AM, Faivre S, Raymond E. Lessons learned in the development of targeted therapy for malignant gliomas.
Molecular cancer therapeutics 2007;6(7):1909-19.
2
41 - Orringer D, Lau D, Khatri S, et al. Extent of resection in patients with glioblastoma: limiting factors, perception of
resectability, and effect on survival. Journal of neurosurgery 2012;117(5):851-9.
2
42 - Ozsunar, Y. et al., Glioma Recurrence Versus Radiation Necrosis?. A Pilot Comparison of Arterial Spin-Labeled, Dynamic
Susceptibility Contrast Enhanced MRI, and FDG-PET Imaging. Acad. Radiol., 2010. 17(3): p. 282-290.
2
43 - Pace A, Vidiri A, Galie E, et al. Temozolomide chemotherapy for progressive low-grade glioma: clinical benefits and
radiological response. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO
2003;14(12):1722-6.
2
44 - Pallud J, Audureau E, Blonski M, et al. Epileptic seizures in diffuse low-grade gliomas in adults. Brain 2014;137(Pt 2):449-
62.
2
45 - Pallud J, Blonski M, Mandonnet E, et al. Velocity of tumor spontaneous expansion predicts long-term outcomes for
diffuse low-grade gliomas. Neuro-oncology 2013;15(5):595-606.
2
46 - Pallud J, Capelle L, Taillandier L, et al. Prognostic significance of imaging contrast enhancement for WHO grade II
gliomas. Neuro-oncology 2009;11(2):176-82.
2
47 - Pallud J, Fontaine D, Duffau H, et al. Natural history of incidental World Health Organization grade II gliomas. Annals of
neurology 2010;68(5):727-33.
2
48 - Pallud J, Taillandier L, Capelle L, et al. Quantitative morphological magnetic resonance imaging follow-up of low-grade
glioma: a plea for systematic measurement of growth rates. Neurosurgery 2012;71(3):729-39; discussion 39-40.
2
49 - Park JK, Hodges T, Arko L, et al. Scale to predict survival after surgery for recurrent glioblastoma multiforme. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(24):3838-43.
2
50 - Patil CG, Yi A, Elramsisy A, et al. Prognosis of patients with multifocal glioblastoma: a case-control study. Journal of
neurosurgery 2012;117(4):705-11.
2
51 - Pauleit D, Floeth F, Hamacher K et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic
assessment of cerebral gliomas. Brain 2005;128(Pt 3):678-687.
2
52 - Paulsson AK, McMullen KP, Peiffer AM, et al. Limited margins using modern radiotherapy techniques does not increase
marginal failure rate of glioblastoma. American journal of clinical oncology 2014;37(2):177-81.
2
53 - Pelletier, G., Verhoef, M. J., Khatri, N., & Hagen, N. (2002). Quality of life in brain tumor patients: the relative
contributions of depression, fatigue, emotional distress, and existential issues. J Neurooncol, 57(1), 41-49.
Gliomen
PDF aangemaakt op 
23-01-2025
964
/
971
2
54 - Perkins GH, Schomer DF, Fuller GN, Allen PK & Maor MH 2003 Gliomatosis cerebri: improved outcome with
radiotherapy. International journal of radiation oncology, biology, physics 56 1137-1146.
2
55 - Perry A, Brat D. Practical Surgical Neuropathology: A Diagnostic Approach. 2010
2
56 - Perry J, Chambers A, Spithoff K, et al. Gliadel wafers in the treatment of malignant glioma: a systematic review. Current
oncology 2007;14(5):189-94.
2
57 - Perry JR, Belanger K, Mason WP, et al. Phase II trial of continuous dose-intense temozolomide in recurrent malignant
glioma: RESCUE study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(12):2051-7.
2
58 - Perry JR, Rizek P, Cashman R, et al. Temozolomide rechallenge in recurrent malignant glioma by using a continuous
temozolomide schedule: the "rescue" approach. Cancer 2008;113(8):2152-7.
2
59 - Philippon JH, Clemenceau SH, Fauchon FH, et al. Supratentorial low-grade astrocytomas in adults. Neurosurgery
1993;32(4):554-9.
2
60 - Phuphanich S, Wheeler CJ, Rudnick JD, et al. Phase I trial of a multi-epitope-pulsed dendritic cell vaccine for patients
with newly diagnosed glioblastoma. Cancer immunology, immunotherapy : CII 2013;62(1):125-35.
2
61 - Pignatti F, van den Bent M, Curran D, et al. Prognostic factors for survival in adult patients with cerebral low-grade
glioma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2002;20(8):2076-84.
2
62 - Pinsker M, Lumenta C. Experiences with reoperation on recurrent glioblastoma multiforme. Zentralblatt fur
Neurochirurgie 2001;62(2):43-7.
2
63 - Potts MB, Smith JS, Molinaro AM, et al. Natural history and surgical management of incidentally discovered low-grade
gliomas. Journal of neurosurgery 2012;116(2):365-72.
2
64 - Prabhu RS, Won M, Shaw EG, et al. Effect of the addition of chemotherapy to radiotherapy on cognitive function in
patients with low-grade glioma: secondary analysis of RTOG 98-02. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2014;32(6):535-41.
2
65 - Puduvalli VK, Hashmi M, McAllister LD, et al. Anaplastic oligodendrogliomas: prognostic factors for tumor recurrence and
survival. Oncology 2003;65(3):259-66.
2
66 - Puts MT, Santos B, Hardt J et al. An update on a systematic review of the use of geriatric assessment for older adults in
oncology. Ann Oncol 2014;25(2):307-315.
2
67 - Quant EC, Drappatz J, Wen PY, et al. Recurrent high-grade glioma. Current treatment options in neurology
2010;12(4):321-33.
2
68 - Quillien V, Lavenu A, Karayan-Tapon L et al. Comparative assessment of 5 methods (methylation-specific polymerase
chain reaction, MethyLight, pyrosequencing, methylation-sensitive high-resolution melting, and immunohistochemistry) to
analyze O6-methylguanine-DNA-methyltranferase in a series of 100 glioblastoma patients. Cancer 2012;118(17):4201-4211.
2
69 - Quinn JA, Reardon DA, Friedman AH, et al. Phase II trial of temozolomide in patients with progressive low-grade glioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):646-51.
2
70 - Rajan B, Pickuth D, Ashley S, et al. The management of histologically unverified presumed cerebral gliomas with
radiotherapy. International journal of radiation oncology, biology, physics 1994;28(2):405-13.
2
71 - Reardon DA, Egorin MJ, Quinn JA, et al. Phase II study of imatinib mesylate plus hydroxyurea in adults with recurrent
glioblastoma multiforme. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2005;23(36):9359-68.
2
72 - Reardon DA, Herndon JE, 2nd, Peters KB, et al. Bevacizumab continuation beyond initial bevacizumab progression
among recurrent glioblastoma patients. British journal of cancer 2012;107(9):1481-7.
2
73 - Reardon DA, Nabors LB, Stupp R, et al. Cilengitide: an integrin-targeting arginine-glycine-aspartic acid peptide with
promising activity for glioblastoma multiforme. Expert opinion on investigational drugs 2008;17(8):1225-35.
2
74 - Recht LD, Lew R, Smith TW. Suspected low-grade glioma: is deferring treatment safe? Annals of neurology
1992;31(4):431-6.
2
75 - Reddy, K., D. Westerly, and C. Chen, MRI patterns of T1 enhancing radiation necrosis versus tumour recurrence in high-
grade gliomas. J. Med. Imaging Radiat. Oncol., 2013. 57(3): p. 349-355.
2
76 - Reijneveld JC, Bottomley A, Taphoorn M et. Health Related Quality of Life results from temozolomide chemotherapy vs.
radiotherapy in molecularly characterized (1p loss) low-grade glioma. A randomized phase III Intergroup study by the
EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC22033-26033). World Federation of Neuro-Oncology (WFNO): 2013, abstract.
Gliomen
PDF aangemaakt op 
23-01-2025
965
/
971
2
77 - Reijneveld JC, Sitskoorn MM, Klein M, et al. Cognitive status and quality of life in patients with suspected versus proven
low-grade gliomas. Neurology 2001;56(5):618-23.
2
78 - Richtlijn Handreiking slecht-nieuws gesprek oktober 2012
2
79 - Roa W, Brasher PM, Bauman G et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. J Clin Oncol 2004;22(9):1583-1588.
2
80 - Roa W, Brasher PM, Bauman G, et al. Abbreviated course of radiation therapy in older patients with glioblastoma
multiforme: a prospective randomized clinical trial. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2004;22(9):1583-8.
2
81 - Roldan Urgoiti GB, Singh AD, Easaw JC. Extended adjuvant temozolomide for treatment of newly diagnosed
glioblastoma multiforme. Journal of neuro-oncology 2012;108(1):173-7.
2
82 - Rooney, A. G., Carson, A., & Grant, R. (2011). Depression in cerebral glioma patients: a systematic review of observational
studies. J Natl Cancer Inst, 103(1), 61-76.
2
83 - Roth P, Wick W, Weller M. Anaplastic oligodendroglioma: a new treatment paradigm and current controversies. Current
treatment options in oncology 2013;14(4):505-13.
2
84 - Rudà R, Bertero L, Sanson M. Gliomatosiscerebri: a review. Curr Treat Options Neurol. 2014 Feb;16(2):273. doi:
10.1007/s11940-013-0273-2. PubMed PMID: 24390814.
2
85 - Ryan R, Booth S, Price S (2012) Corticosteroid-use in primary and secondary brain tumour patients: a review. J Neuro
Oncol 106:449-459
2
86 - Ryu CH, Yoon WS, Park KY et al.(2012) Valproic acid downregulates the expression of MGMT and sentisitizes
Temozolomide-resistant glioma cells. J Biomed Biotech
2
87 - Sabel M, Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of
clinical experience. Current medical research and opinion 2008;24(11):3239-57.
2
88 - Sahgal A, Ironside SA, Perry J, et al. Factors influencing overall survival specific to adult low-grade astrocytoma: a
population-based study. Clinical oncology 2013;25(7):394-9.
2
89 - Salander, P., (1996). Brain Tumour as a threat to life and personality: The spouse perspective. J. Psychosoc oncol 14, 1-18
2
90 - Salzberg M, Kirson E, Palti Y, et al. A pilot study with very low-intensity, intermediate-frequency electric fields in patients
with locally advanced and/or metastatic solid tumors. Onkologie 2008;31(7):362-5.
2
91 - Sanai N, Berger MS. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008;62(4):753-64;
discussion 264-6.
2
92 - Sanai N, Polley MY, McDermott MW, et al. An extent of resection threshold for newly diagnosed glioblastomas. Journal
of neurosurgery 2011;115(1):3-8.
2
93 - Sanson M, Cartalat-Carel S, Taillibert Set al.; ANOCEF group. Initial chemotherapy in gliomatosis cerebri. Neurology.
2004 Jul 27;63(2):270-5. PubMed PMID: 15277619
2
94 - Santra, A. et al., Comparison of glucoheptonate single photon emission computed tomography and contrast-enhanced
MRI in detection of recurrent glioma.Nucl. Med. Commun., 2011. 32(3): p. 206-211.
2
95 - Santra, A. et al., Detection of recurrence in glioma: A comparative prospective study between Tc-99m GHA SPECT and
F-18 FDG PET/CT. Clin. Nucl. Med., 2011. 36(8): p. 650-655.
2
96 - Santra, A. et al., F-18 FDG PET-CT in patients with recurrent glioma: Comparison with contrast enhanced MRI. Eur. J.
Radiol., 2012. 81(3): p. 508-513.
2
97 - Sardell, S., Sharpe, G., Ashley, D.et al. (2001) Evaluation of a nurse -led telephone clinic in the follow-up of patients with
malignant glioma. Clin. oncol (r Coll radiol), 12, 36-41
2
98 - Satoer D, Visch-Brink E, Smits M, et al. Long-term evaluation of cognition after glioma surgery in eloquent areas. Journal
of neuro-oncology 2014;116(1):153-60.
2
99 - Sayin MY, Kaya B, Bakkal BH, et al. The results of hypofractionated radiotherapy in 31 patients with high-grade gliomas.
Medical oncology 2007;24(4):379-83.
3
00 - Schmidt F, Fischer J, Herrlinger U, et al. PCV chemotherapy for recurrent glioblastoma. Neurology 2006;66(4):587-9.
3
01 - Schomas DA, Laack NN, Brown PD. Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic. Cancer
2009;115(17):3969-78.
3
02 - Schomas DA, Laack NN, Rao RD, et al. Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-
up at Mayo Clinic. Neuro-oncology 2009;11(4):437-45.
Gliomen
PDF aangemaakt op 
23-01-2025
966
/
971
3
03 - Schubart, J. R., Kinzie, M. B., & Farace, E. (2008). Caring for the brain tumor patient: family
caregiverburdenandunmetneeds. Neuro Oncol, 10(1), 61-72.
3
04 - Scott JG, Suh JH, Elson P, et al. Aggressive treatment is appropriate for glioblastoma multiforme patients 70 years old or
older: a retrospective review of 206 cases. Neuro-oncology 2011;13(4):428-36.
3
05 - Scott JN BP, Sevick RJet al. How often are nonenhancing supratentorial gliomas malignant? A population study. .
Neurology 2002;59((6)):947-9.
3
06 - Senft C, Bink A, Franz K, et al. Intraoperative MRI guidance and extent of resection in glioma surgery: a randomised,
controlled trial. The Lancet Oncology 2011;12(11):997-1003.
3
07 - Shah AH, Madhavan K, Heros D, et al. The management of incidental low-grade gliomas using magnetic resonance
imaging: systematic review and optimal treatment paradigm. Neurosurgical focus 2011;31(6):E12.
3
08 - Shaw E, Arusell R, Scheithauer B, et al. Prospective randomized trial of low- versus high-dose radiation therapy in adults
with supratentorial low-grade glioma: initial report of a North Central Cancer Treatment Group/Radiation Therapy Oncology
Group/Eastern Cooperative Oncology Group study. Journal of clinical oncology : official journal of the American Society of
Clinical Oncology 2002;20(9):2267-76.
3
09 - Shaw EG, Berkey B, Coons SW, et al. Recurrence following neurosurgeon-determined gross-total resection of adult
supratentorial low-grade glioma: results of a prospective clinical trial. Journal of neurosurgery 2008;109(5):835-41.
3
10 - Shaw EG, Wang M, Coons SW, et al. Randomized trial of radiation therapy plus procarbazine, lomustine, and vincristine
chemotherapy for supratentorial adult low-grade glioma: initial results of RTOG 9802. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 2012;30(25):3065-70.
3
11 - Shields LB, Choucair AK. Management of low-grade gliomas: a review of patient-perceived quality of life and
neurocognitive outcome. World neurosurgery 2014;82(1-2):e299-309.
3
12 - Siesling SS, G.; De Raaf, A.; Jansen M. . Kankerzorg in beeld 2014.
3
13 - Simo M, Velasco R, Graus F et al. (2013) Impact of antiepileptic drugs on thrombocytopenia in glioblastoma patients
treated with standard chemoradiotherapy. J Neurooncol DOI 10.1007/s11060-012-0836-1
3
14 - Sizoo E, Braam L, Postma TJ et al (2010) Symptoms and problems in the end-of-life phase of high-grade glioma patients.
Neuro Oncol 12:1162-1166
3
15 - Sizoo EM, Pasman HRW, Buttelo J et al (2012) Decision-making in the end-of-life phase of high-grade glioma patients.
Eur J Cancer 48:226-232
3
16 - Sizoo EM, Pasman HRW, Dirven L et al (2014) The end-of-life phase of high-grade glioma patients: a systematic review.
Support Care Cancer 22:847-857
3
17 - Slotman BJ, Kralendonk JH, van Alphen HA, et al. Hypofractionated radiation therapy in patients with glioblastoma
multiforme: results of treatment and impact of prognostic factors. International journal of radiation oncology, biology, physics
1996;34(4):895-8.
3
18 - Smets T1, Lawson TM, Grandin C et al. Immediate post-operative MRI suggestive of the site and timing of glioblastoma
recurrence after gross total resection: a retrospective longitudinal preliminary study. Eur Radiol. 2013 Jun;23(6):1467-77. doi:
10.1007/s00330-012-2762-1. Epub 2013 Jan 12.
3
19 - Smith JS, Chang EF, Lamborn KR, et al. Role of extent of resection in the long-term outcome of low-grade hemispheric
gliomas. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(8):1338-45.
3
20 - Soffietti R, Baumert BG, Bello L, et al. Guidelines on management of low-grade gliomas: report of an EFNS-EANO Task
Force. European journal of neurology : the official journal of the European Federation of Neurological Societies
2010;17(9):1124-33.
3
21 - Soffietti R, Trevisan E, Bertero L, et al. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO
(Italian Association of Neuro-Oncology). Journal of neuro-oncology 2014;116(3):533-41.
3
22 - Sohlberg, M. M., & Mateer, C. A. (2001). Cognitive rehabilitation: An integrative neuropsychological approach. New
York: Guilford Press.
3
23 - Solheim O, Gulati S, Jakola AS. Glioblastoma resection: in search of a threshold between worthwhile and futile. Neuro-
oncology 2014;16(4):610-1.
3
24 - Souhami L, Seiferheld W, Brachman D, et al. Randomized comparison of stereotactic radiosurgery followed by
conventional radiotherapy with carmustine to conventional radiotherapy with carmustine for patients with glioblastoma
multiforme: report of Radiation Therapy Oncology Group 93-05 protocol. International journal of radiation oncology, biology,
Gliomen
PDF aangemaakt op 
23-01-2025
967
/
971
physics 2004;60(3):853-60.
3
25 - Spetz, A., Hendriksson, R., Bergenheim, AT.et al. (2005) A specialist nurse-function in neurooncology: a qualitative study
of possibilities, limitations, and pittfalls. Palliat Support Care, 3 121-130
3
26 - Stege EM, Kros JM, de Bruin HG, et al. Successful treatment of low-grade oligodendroglial tumors with a chemotherapy
regimen of procarbazine, lomustine, and vincristine. Cancer 2005;103(4):802-9.
3
27 - Stummer W, Pichlmeier U, Meinel T, et al. Fluorescence-guided surgery with 5-aminolevulinic acid for resection of
malignant glioma: a randomised controlled multicentre phase III trial. The Lancet Oncology 2006;7(5):392-401.
3
28 - Stummer W, Reulen HJ, Meinel T, et al. Extent of resection and survival in glioblastoma multiforme: identification of and
adjustment for bias. Neurosurgery 2008;62(3):564-76; discussion -76.
3
29 - Stupp R, Hegi ME, Gorlia T, et al. Cilengitide combined with standard treatment for patients with newly diagnosed
glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label,
phase 3 trial. The Lancet Oncology 2014;15(10):1100-8.
3
30 - Stupp R, Hegi ME, Mason WP et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol 2009;10(5):459-466.
3
31 - Stupp R, Mason WP, van den Bent MJ et al. Radiotherapy plus concomitant and adjuvant temozolomide for
glioblastoma. N Engl J Med 2005;352(10):987-996.
3
32 - Stupp R, Mason WP, Van den Bent MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor
and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma.N Engl J Med. 2005 Mar 10;352(10):987-96.
3
33 - Stupp R, Wong ET, Kanner AA, et al. NovoTTF-100A versus physician's choice chemotherapy in recurrent glioblastoma: a
randomised phase III trial of a novel treatment modality. European journal of cancer 2012;48(14):2192-202.
3
34 - Taal W, Brandsma D, de Bruin HG et al. Incidence of early pseudo-progression in a cohort of malignant glioma patients
treated with chemoirradiation with temozolomide. Cancer 2008;113(2):405-410.
3
35 - Taal W, Oosterkamp HM, Walenkamp AM, et al. Single-agent bevacizumab or lomustine versus a combination of
bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial. The
Lancet Oncology 2014;15(9):943-53.
3
36 - Taillibert S, Chodkiewicz C, Laigle-Donadey Fet al.Gliomatosiscerebri: a review of 296 cases from the ANOCEF database
and the literature. J Neurooncol. 2006 Jan;76(2):201-5. PubMed PMID: 16200347.
3
37 - Takahashi Y, Nakamura H, Makino K, et al. Prognostic value of isocitrate dehydrogenase 1, O6-methylguanine-DNA
methyltransferase promoter methylation, and 1p19q co-deletion in Japanese malignant glioma patients. World journal of
surgical oncology 2013;11:284.
3
38 - Takano S, Tian W, Matsuda M, et al. Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry
and sequencing. Brain tumor pathology 2011;28(2):115-23.
3
39 - Talacchi A, Santini B, Savazzi S, et al. Cognitive effects of tumour and surgical treatment in glioma patients. Journal of
neuro-oncology 2011;103(3):541-9.
3
40 - Tanaka S, Meyer FB, Buckner JC, et al. Presentation, management, and outcome of newly diagnosed glioblastoma in
elderly patients. Journal of neurosurgery 2013;118(4):786-98.
3
41 - Taphoorn, M. J., & Klein, M. (2004). Cognitive deficits in adult patients with braintumours. Lancet Neurol, 3(3), 159-168.
3
42 - Thon N, Eigenbrod S, Kreth S, et al. IDH1 mutations in grade II astrocytomas are associated with unfavorable progression-
free survival and prolonged postrecurrence survival. Cancer 2012;118(2):452-60.
3
43 - Tremont-Lukats IW, Ratilal BO, Armstrong T et al. (2008) Antiepileptic drugs for preventing seizures in people with brain
tumors. Cochrane Database Syst Rev (2), CD004424.
3
44 - Triebels VH, Taphoorn MJ, Brandes AA, et al. Salvage PCV chemotherapy for temozolomide-resistant
oligodendrogliomas. Neurology 2004;63(5):904-6.
3
45 - Tsai HC, Wei KC, Tsai CN, Huang YC (2012) Effect of valproic acid on the outcome of glioblastoma multiforme. Br J
Neurosurg 26(3):347-54.
3
46 - Tsitlakidis A, Foroglou N, Venetis CA, et al. Biopsy versus resection in the management of malignant gliomas: a
systematic review and meta-analysis. Journal of neurosurgery 2010;112(5):1020-32.
3
47 - Ullrich RT KL, Brunn A et al. Methyl-L-11C-methionine PET as a diagnostic marker for malignant progression in patients
Gliomen
PDF aangemaakt op 
23-01-2025
968
/
971
with glioma. J Nucl Med 2009;50((12)):1962-8.
3
48 - Valtonen S, Timonen U, Toivanen P, et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade
gliomas: a randomized double-blind study. Neurosurgery 1997;41(1):44-8; discussion 8-9.
3
49 - Van Breemen MS, Wilms EB, Vecht CJ (2007) Epilepsy in patients with brain tumors: epidemiology,mechanisms and
management. Lancet Neurol 6:421-430
3
50 - van den Bent MJ, Afra D, de Witte O, et al. Long-term efficacy of early versus delayed radiotherapy for low-grade
astrocytoma and oligodendroglioma in adults: the EORTC 22845 randomised trial. Lancet 2005;366(9490):985-90.
3
51 - van den Bent MJ, Brandes AA, Taphoorn MJ, et al. Adjuvant procarbazine, lomustine, and vincristine chemotherapy in
newly diagnosed anaplastic oligodendroglioma: long-term follow-up of EORTC brain tumor group study 26951. Journal of
clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(3):344-50.
3
52 - Van den Bent MJ, Carpentier AF, Brandes AA et al.2006. Adjuvant procarbazine, lomustine, and vincristine improves
progression-free survival but not overall survival in newly diagnosed anaplastic oligodendrogliomas and oligoastrocytomas: a
randomized European Organisation for Research and Treatment of Cancer phase III trial. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 24 2715-2722.
3
53 - van den Bent MJ, Dubbink HJ, Marie Y, et al. IDH1 and IDH2 mutations are prognostic but not predictive for outcome in
anaplastic oligodendroglial tumors: a report of the European Organization for Research and Treatment of Cancer Brain Tumor
Group. Clinical cancer research : an official journal of the American Association for Cancer Research 2010;16(5):1597-604.
3
54 - van den Bent MJ, Erdem-Eraslan L, Idbaih A, et al. MGMT-STP27 methylation status as predictive marker for response to
PCV in anaplastic Oligodendrogliomas and Oligoastrocytomas. A report from EORTC study 26951. Clinical cancer research :
an official journal of the American Association for Cancer Research 2013;19(19):5513-22.
3
55 - Van den Bent MJ, Keime-Guibert F, Brandes AA et al. 2001. Temozolomide chemotherapy in recurrent
oligodendroglioma. Neurology 57 340-342.
3
56 - Van den Bent MJ, Kros JM, Heimans JJ et al. Response rate and prognostic factors of recurrent oligodendroglioma
treated with procarbazine, CCNU, and vincristine chemotherapy. Dutch Neuro-oncology Group. Neurology 1998;51(4):1140-
1145.
3
57 - van den Bent MJ, Snijders TJ, Bromberg JE. Current treatment of low grade gliomas. Memo 2012;5(3):223-7.
3
58 - van den Bent MJ, Taphoorn MJ, Brandes AA, et al. Phase II study of first-line chemotherapy with temozolomide in
recurrent oligodendroglial tumors: the European Organization for Research and Treatment of Cancer Brain Tumor Group
Study 26971. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(13):2525-8.
3
59 - van den Bent MJ, Wefel JS, Schiff D, et al. Response assessment in neuro-oncology (a report of the RANO group):
assessment of outcome in trials of diffuse low-grade gliomas. The Lancet Oncology 2011;12(6):583-93.
3
60 - van der Sanden GA, Schouten LJ, van Dijck JA, et al. Incidence of primary central nervous system cancers in South and
East Netherlands in 1989-1994. Neuroepidemiology 1998;17(5):247-57.
3
61 - Van Nifterik KA, Van den Berg J, Slotman BJ (2012) Valproic acid sensitizes human glioma cells for temozolomaide and ?-
irradiation. J Neurooncol 107:61-67
3
62 - van Veelen ML, Avezaat CJ, Kros JM, et al. Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation,
and the issue of early versus late surgery. Journal of neurology, neurosurgery, and psychiatry 1998;64(5):581-7.
3
63 - Vecht CJ, Kerkhof M, Duran-Pena A (2014) Seizure prognosis in brain tumors: new insights and evidence-based
management. The Oncologist 19:1-9
3
64 - Veeravagu A, Jiang B, Ludwig C, et al. Biopsy versus resection for the management of low-grade gliomas. The Cochrane
database of systematic reviews 2013;4:CD009319.
3
65 - Verhaak RG, Hoadley KA, Purdom E, et al. Integrated genomic analysis identifies clinically relevant subtypes of
glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer cell 2010;17(1):98-110.
3
66 - Verhoef, MJ., Hagen, N., Pelletier, G., Forsyth, P., (1999). Alternative therapy use in neurologic disease. Use in brain
tumour patients. Neurology 52, 617-622
3
67 - Vlassenbroeck I, Califice S, Diserens AC et al. Validation of real-time methylation-specific PCR to determine O6-
methylguanine-DNA methyltransferase gene promoter methylation in glioma. J Mol Diagn 2008;10(4):332-337.
3
68 - Vogelbaum MA, Jost S, Aghi MK, et al. Application of novel response/progression measures for surgically delivered
therapies for gliomas: Response Assessment in Neuro-Oncology (RANO) Working Group. Neurosurgery 2012;70(1):234-43;
discussion 43-4.
Gliomen
PDF aangemaakt op 
23-01-2025
969
/
971
3
69 - Vordermark D, Kolbl O, Ruprecht K, et al. Hypofractionated stereotactic re-irradiation: treatment option in recurrent
malignant glioma. BMC cancer 2005;5:55.
3
70 - Vos, M.J. et al., Systematic review of the diagnostic accuracy of 201Tl single photon emission computed tomography in
the detection of recurrent glioma. Nucl Med Commun, 2007. 28(6): p. 431-9.
3
71 - Vuorinen V, Hinkka S, Farkkila M, et al. Debulking or biopsy of malignant glioma in elderly people - a randomised study.
Acta neurochirurgica 2003;145(1):5-10.
3
72 - Walbert T, Khan M (2014) End-of-life symptoms and care in patients with primary malignant brain tumors: a systematic
review. J Neurooncol 117: 217-224
3
73 - Walker MD, Alexander E, Jr., Hunt WE, et al. Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic
gliomas. A cooperative clinical trial. Journal of neurosurgery 1978;49(3):333-43.
3
74 - Walker MD, Strike TA, Sheline GE. An analysis of dose-effect relationship in the radiotherapy of malignant gliomas.
International journal of radiation oncology, biology, physics 1979;5(10):1725-31.
3
75 - Wang M, Cairncross G, Shaw E, et al. Cognition and quality of life after chemotherapy plus radiotherapy (RT) vs. RT for
pure and mixed anaplastic oligodendrogliomas: radiation therapy oncology group trial 9402. International journal of radiation
oncology, biology, physics 2010;77(3):662-9.
3
76 - Wefel, J. S., Armstrong, T. A., & Kohli, S. (2011). Neuropsychological function and quality of life. In A. D. Norden & D. A.
Reardon (Eds.), Primarycentralnervous system tumors: Pathogenesisandtherapy (pp. 143-161). New York: Springer.
3
77 - Weitzner, M. A., Jacobsen, P. B., Wagner, H., Jr., Friedland, J., & Cox, C. (1999). The Caregiver Quality of Life Index-
Cancer (CQOLC) scale: development and validation of an instrument tomeasurequality of life of the family caregiver of patients
with cancer. Qual Life Res, 8(1-2), 55-63.
3
78 - Weller M, Cloughesy T, Perry JR, et al. Standards of care for treatment of recurrent glioblastoma--are we there yet?
Neuro-oncology 2013;15(1):4-27.
3
79 - Weller M, Felsberg J, Hartmann C, et al. Molecular predictors of progression-free and overall survival in patients with
newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network. Journal of clinical oncology :
official journal of the American Society of Clinical Oncology 2009;27(34):5743-50.
3
80 - Weller M, Gorlia T, Cairncross JG (2011) Prolonged survival with valproic acid use in the EORTC/NCIC temozolomide
trial for glioblastoma. Neurology 77(12):1156-64.
3
81 - Weller M, Stupp R, Hegi ME, et al. Personalized care in neuro-oncology coming of age: why we need MGMT and 1p/19q
testing for malignant glioma patients in clinical practice. Neuro-oncology 2012;14 Suppl 4:iv100-8.
3
82 - Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for high-grade gliomas: response
assessment in neuro-oncology working group. Journal of clinical oncology : official journal of the American Society of Clinical
Oncology 2010;28(11):1963-72.
3
83 - Wensing M, Grol R. Patients’ views on health care. A driving force for improvement in disease management. Dis Manag
Outcomes 2000;7:117-25.
3
84 - Westphal M, Hilt DC, Bortey E, et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers
(Gliadel wafers) in patients with primary malignant glioma. Neuro-oncology 2003;5(2):79-88.
3
85 - Whittle IR. What is the place of conservative management for adult supratentorial low-grade glioma? Advances and
technical standards in neurosurgery 2010;35:65-79.
3
86 - Wick W, Hartmann C, Engel C, et al. NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic
glioma with procarbazine, lomustine, and vincristine or temozolomide. Journal of clinical oncology : official journal of the
American Society of Clinical Oncology 2009;27(35):5874-80.
3
87 - Wick W, Platten M, Meisner C et al. Temozolomide chemotherapy alone versus radiotherapy alone for malignant
astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial. Lancet Oncol 2012;13(7):707-715.
3
88 - Wick W, Puduvalli VK, Chamberlain MC, et al. Phase III study of enzastaurin compared with lomustine in the treatment of
recurrent intracranial glioblastoma. Journal of clinical oncology : official journal of the American Society of Clinical Oncology
2010;28(7):1168-74.
3
89 - Willems PW, Taphoorn MJ, Burger H, et al. Effectiveness of neuronavigation in resecting solitary intracerebral contrast-
enhancing tumors: a randomized controlled trial. Journal of neurosurgery 2006;104(3):360-8.
3
90 - Wong ET, Hess KR, Gleason MJ et al. Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase
II clinical trials. J Clin Oncol 1999;17(8):2572-2578.
Gliomen
PDF aangemaakt op 
23-01-2025
970
/
971
3
91 - Wu AS, Trinh VT, Suki D et al. (2013) A prospectieve randomized trial of perioperative seizure prophylaxis in patients with
intraparenchymal brain tumors. J Neurosurg 118:873-883
3
92 - Wu JS, Zhou LF, Tang WJ, et al. Clinical evaluation and follow-up outcome of diffusion tensor imaging-based functional
neuronavigation: a prospective, controlled study in patients with gliomas involving pyramidal tracts. Neurosurgery
2007;61(5):935-48; discussion 48-9.
3
93 - Xu JF, Fang J, Shen Y, et al. Should we reoperate for recurrent high-grade astrocytoma? Journal of neuro-oncology
2011;105(2):291-9.
3
94 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and radiation injury using MR diffusion tensor imaging.
Neuroradiology, 2010. 52(12): p. 1193-1199.
3
95 - Xu, J.L. et al., Distinction between postoperative recurrent glioma and delayed radiation injury using MR perfusion
weighted imaging. J. Med. Imaging Radiat. Oncol., 2011. 55(6): p. 587-594.
3
96 - Yan H, Parsons DW, Jin G, et al. IDH1 and IDH2 mutations in gliomas. The New England journal of medicine
2009;360(8):765-73.
3
97 - Yin AA, Cai S, Dong Y et al. A meta-analysis of temozolomide versus radiotherapy in elderly glioblastoma patients. J
Neurooncol 2014;116(2):315-324.
3
98 - Yin AA, Cheng JX, Zhang X, et al. The treatment of glioblastomas: a systematic update on clinical Phase III trials. Critical
reviews in oncology/hematology 2013;87(3):265-82.
3
99 - Yin AA, Zhang LH, Cheng JX et al. Radiotherapy plus concurrent or sequential temozolomide for glioblastoma in the
elderly: a meta-analysis. PLoS One 2013;8(9):e74242.
4
00 - Yin AA, Zhang LH, Cheng JX et al. The Predictive but Not Prognostic Value of MGMT Promoter Methylation Status in
Elderly Glioblastoma Patients: A Meta-Analysis. PLoS One 2014;9(1):e85102.
4
01 - Yip S, Miao J, Cahill DP, et al. MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate
temozolomide resistance. Clinical cancer research : an official journal of the American Association for Cancer Research
2009;15(14):4622-9.
4
02 - Yordanova YN, Moritz-Gasser S, Duffau H. Awake surgery for WHO Grade II gliomas within "noneloquent" areas in the
left dominant hemisphere: toward a "supratotal" resection. Clinical article. Journal of neurosurgery 2011;115(2):232-9.
4
03 - Yoshii Y, Tominaga D, Sugimoto K, et al. Cognitive function of patients with brain tumor in pre- and postoperative stage.
Surgical neurology 2008;69(1):51-61; discussion
4
04 - Youland RS, Schomas DA, Brown PD, et al. Changes in presentation, treatment, and outcomes of adult low-grade
gliomas over the past fifty years. Neuro-oncology 2013;15(8):1102-10.
4
05 - Young, R.J. et al., Potential utility of conventional MRI signs in diagnosing pseudoprogression in glioblastoma.Neurology,
2011. 76(22): p. 1918-24.
4
06 - Yung WK, Albright RE, Olson J, et al. A phase II study of temozolomide vs. procarbazine in patients with glioblastoma
multiforme at first relapse. British journal of cancer 2000;83(5):588-93.
4
07 - Yung WK, Prados MD, Yaya-Tur R, et al. Multicenter phase II trial of temozolomide in patients with anaplastic
astrocytoma or anaplastic oligoastrocytoma at first relapse. Temodal Brain Tumor Group. Journal of clinical oncology : official
journal of the American Society of Clinical Oncology 1999;17(9):2762-71.
4
08 - Zaidi HA, Chowdhry SA, Wilson DA et al. The dilemma of early postoperative magnetic resonance imaging: when
efficiency compromises accuracy: case report. Neurosurgery. 2014 Mar;74(3):E335-40. doi: 10.1227/NEU.0000000000000191.
4
09 - Zucchella, C., Capone, A., Codella, V. et al. (2013). Cognitive rehabilitation for early post-surgery inpatients affected by
primary brain tumor: a randomized, controlled trial. J Neurooncol, 114(1), 93-100.
Gliomen
PDF aangemaakt op 
23-01-2025
971
/
971
